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Summary  
Background and aims 
Underactive thyroid function during pregnancy and its effects on offspring intelligence, 
general cognition and behaviour have long been researched and reported on. Some of the 
differences found for the offspring are so apparent, that is has warranted authors to suggest 
universal thyroid function screening during pregnancy. The current study was the world’s 
first randomised controlled trial to investigate the effects of treatment for suboptimal 
gestational thyroid function (SGTF) on offspring. The aims of this thesis are, 1) to re-analyse 
the intelligence scores for the offspring at age 3 years, 2) to clarify any SGTF effects by 
cognitive testing and behavioural questionnaires completed at offspring age 9, and 3) 
compare and contrast wave one and two findings. 
Methods and analysis 
1) Data was previously collected for this analysis. Treated and untreated SGTF groups were 
compared by unadjusted and adjusted models. 2) I conducted the intelligence, additional 
cognitive testing, and collection of the completed behavioural questionnaires. All data were 
analysed separately (per chapter) by multivariate analysis models. 3) Comparison of 
intelligence results were explored by correlations and a repeated measures multivariate 
analysis.  
Results and conclusions 
Re-analysis of the age 3 intelligence scores revealed that the untreated SGTF group 
performed worse compared to the treated SGTF group (p = .008 for scores below 85). No age 
9 differences in intelligence or additional cognitive tests were found. The behavioural 
questionnaires revealed that treatment for SGTF may have had a detrimental effect for the 
offspring. Intelligence score comparisons revealed no differences between the groups. These 
results suggest that any intelligence effects from the mother not being treated for SGTF may 
be present at age 3 but have disappeared by age 9. However, treatment for SGTF appeared 
to significantly increase behaviour problems for offspring at age 9; though not clinically 
significant.  
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1. Controlled Antenatal Thyroid Screening Study II; cognitive and 
behavioural data 
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1.1. General introduction 
1.1.1. Chapter Overview 
The aim of this thesis is to add to the knowledge base of psychological effects for children 
born to mothers who have had an underactive thyroid during their pregnancies. The focus 
of this first chapter is to review the literature pertaining to maternal thyroid function and its 
impact on the offspring. Firstly there is a brief overview of thyroid function, how this can 
change during pregnancy and subsequently may become deficient. The potential effects to 
offspring intelligence are discussed, then memory, motor coordination, language and 
hearing difficulties, as well as behaviour and brain morphology. This literature review closes 
with a discussion of universal screening for treatment of an underactive thyroid during 
pregnancy.  
1.1.2. Thyroid Function 
The thyroid gland is located in the neck, is often described as a butterfly shape, and forms 
two lobes connected by an isthmus. The thyroid is the main site for iodine uptake in the body 
(1). Thyroid peroxidase (TPO) (produced by the thyroid gland) incorporates iodine into two 
hormones, thyroxine (T4) and triiodothyronine (T3). These thyroid hormones are involved in 
the regulation of basal metabolic rate and macronutrient metabolism (2, 3). In the central 
nervous system, thyroid hormones also regulate cell migration, differentiation and 
myelination (4). T3 is the active form of the hormone and has a shorter half-life (one day) 
than T4 (5). T3 binds to three thyroid hormone receptors, one that is largely restricted to the 
pituitary, and the other two are widely distributed throughout the body. T4 is converted to 
T3 in most tissues by two enzymes; deiodinase type 1 and type 2; deiodinase type 3 converts 
T4 to the inactive form of T3. Specific transporters identified in carrying thyroid hormones 
across cell lines, are organic anion co-transporting polypeptide 1C1 for T4 across the blood-
brain barrier, and mono-carboxylate transporter 8 for moving T3 into brain neurones (6). 
Free T4 is unbound thyroxine in the bloodstream which is available for uptake and use by 
cells, whereas T4 is also circulating in the bloodstream, but is bound to proteins by thyroxine-
binding globulin. T3 and T4 are stored in the form of thyroglobulin and are released when 
thyroid stimulating hormone (TSH), from the pituitary, stimulates the thyroid. TSH maintains 
circulating levels of thyroid hormones, iodine uptake and thyroid growth (7) and its secretion 
is regulated by T4/T3 in a negative feedback loop. Replacement of thyroid hormones with T4 
only, provides an individual with a long-lasting store of thyroid hormone that is gradually 
converted to T3 (5).  
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Thyroid dysfunction occurs when there is an excess (hyperthyroidism) or limited levels of 
thyroid hormones (hypothyroidism). This thesis is concerned with the latter only, and 
hyperthyroidism will not be discussed. Deficient thyroid function has a higher prevalence in 
females than males, with a proposed ratio of 4:1 (8). Chronic autoimmune thyroiditis is the 
most common cause of spontaneous hypothyroidism in iodine-sufficient regions (5). If TPO 
antibodies are present (Ab+), this might also inhibit the function of TPO and (9) and can be 
viewed as a ‘precursor’ for future underactive thyroid problems. Iodine deficiency is also a 
prevalent catalyst to thyroid dysfunction and is discussed below. Some hypothyroid 
symptoms include fatigue, weight gain, muscle cramps and/or joint pain. These symptoms 
can also be viewed by some as common characteristics to pregnancy, which is one of the 
reasons an underactive thyroid is often overlooked during pregnancy.  
As mentioned, iodine deficiency can also be seen as a precursor for hypothyroid issues, as it 
is essential for the production of T4 and T3 (10). The general population of the United 
Kingdom (UK) is iodine deficient (11) (which may be due to diet), and an iodine deficiency 
disrupts the metabolism of thyroid hormones (10) as 70-80% of an individual’s iodine is 
located in the thyroid gland (1). The recommended iodine intake for adults is 150-300 µg, 
hypothyroidism is a risk when iodine intake falls below 50 µg/day (5). When iodine supplies 
are severely inadequate, TSH increases as a compensation mechanism. With the cumulative 
demands of thyroid hormones during pregnancy (12, 13), iodine requirements also increase 
for the mother.  
1.1.2.1. Thyroid function in pregnancy 
Thyroid dysfunction occurs in around 2.5% of pregnancies (14). T3 and T4 are essential for 
early brain development, and maternal thyroid hormones are required by the foetus, before 
it can produce its own (15-17). Thyroid physiology of the mother is altered during pregnancy 
due to an increase in thyroid-binding globulin and increased thyroid hormone requirements 
from the foetus (18). During normal pregnancy, the high-oestrogen environment causes the 
concentration of thyroxine-binding globulin to rise. As a result, total T4 and T3 
concentrations increase in early pregnancy, peak in mid-pregnancy, and consequently 
remain elevated throughout the remainder of the pregnancy (5). At the beginning of second 
and third trimesters, T4 and T3 concentrations are 30-100% higher than before pregnancy 
(12, 13), as blood volume also increases. Inadequate supply of thyroid hormones from the 
mother could disrupt the brain development of the foetus (19). Mono-carboxylate 
transporter 8 is expressed in the placenta (6), and T3 uptake is mediated by L-type amino 
acid transporter 1 in the placental cell line (20). Severe maternal hypothyroidism during the 
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first two trimesters may result in irreversible neurological deficits, whereas later in 
pregnancy the foetus may be able to compensate for any lack of maternal thyroid hormones, 
but not achieving full function until term (21). The tiny gland first appears at the base of the 
tongue of the foetus at around 20 days gestation, and migration to the neck is complete by 
seven weeks (22). Thyroid hormones in the foetal brain are known to be of maternal origin 
(23, 24). At about 12 weeks gestation, the foetal thyroid begins to trap iodine and by 18-20 
weeks it is working almost to full capacity (5). Rovet (22) illustrates proposed brain 
development timings for different neuropsychological aspects for the foetus (based upon 
previous work by Rovet (21, 25)). If thyroid hormones are disrupted during certain phases of 
gestation, it is concluded that these could then affect the proposed domains. Evidence of the 
importance of thyroid hormones for the foetus can be illustrated by congenital 
hypothyroidism, the foetus can intake the necessary hormones during gestation, but 
following birth it is reliant upon its own. Untreated neonates with congenital hypothyroidism 
display effects to growth, cognitive difficulties and language deficits (26). Early treatment for 
their hypothyroidism can suppress some of the effects, but mild disruptions to cognition may 
persist (27); new-born screening occurs for the baby at around 8-14 days old (28).  
1.1.2.1.1. Iodine Deficiency 
During pregnancy, the iodine requirement also increases because of the high renal iodide 
clearance by the mother and foetal thyroid requirement (5). Iodine is essential for 
neurodevelopment in utero (29). The World Health Organisation recommends an additional 
50 µg of iodine supplementation for pregnant women (compared to adults), if suspected of 
being iodine deficient. In women with chronic iodine deficiency during pregnancy, their 
depleted iodine stores are not able to compensate for enlarged iodine demands leading to 
increased risk of maternal goitre and hypothyroidism (30). 
In places with iodine-poor diets, cognitive deficits associated with maternal thyroid 
dysfunction in offspring have been studied for more than a century (31). It is recognised that 
a low maternal urinary iodine concentration of < 150 µg/L has led to poorer scores for verbal 
functioning for the offspring compared to those born to mothers whom had concentrations 
> 150 µg/L (32, 33), likewise deficits for neurobehavioural performance delays (34) and 
psychomotor development (35) have also been identified. However, there may be an 
inverted ‘U’ associated with treatment for iodine deficiency during pregnancy, as Murcia et 
al. (36) found that if mothers were over-supplemented with iodine, their children’s scores 
were rated lower on Bayley Scales of development (also confirmed by (37)).  
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1.1.2.1.2. Gestational subclinical hypothyroidism 
Subclinical hypothyroidism, defined as an elevated level of TSH with normal circulating levels 
of T4 and T3 (38), affects 3-6% of the UK population (39, 40). Subclinical hypothyroidism is 
more prevalent in females, (8%) than males (3%), and cases diagnosed increase with age, 10-
20% of women and 5-10% of men over 65 years old are reported to have an elevated TSH 
(5). Gestational subclinical hypothyroidism (GSH) in pregnancy is defined as a TSH 
concentration higher than the upper limit of the pregnancy related reference-range with 
normal T4 (and, if measured, normal T3). The upper limit of TSH is now defined as 2.5 mIU/l 
in the first trimester and 3 mIU/l in the second and third trimesters (41, 42). Subclinical 
hypothyroidism is a biochemical diagnosis as symptoms may be mild, non-specific and mimic 
typical symptoms occurring in pregnancy (43).  
1.1.2.1.3. Maternal Hypothyroxinaemia 
Women with euthyroid function displaying a transient and mild decrease in T4 hormone 
levels during pregnancy without a rise in TSH (44), are reported to have maternal 
hypothyroxinaemia (45). Maternal hypothyroxinaemia has been identified in 4-10% of 
pregnant women (46-48). Though not as common as GSH, this lowering of T4 is attracting 
interest in recent studies, and evidence is mounting for adverse effects on the offspring (34, 
49-53).  
1.1.3. Intelligence 
There is some evidence that neuropsychological and intellectual development of offspring 
can be adversely affected by GSH (49, 54-57) or an iodine deficiency during pregnancy (10, 
32, 58). The suggested mechanism for these effects of iodine deficiency and GSH is that 
although the brain is very dependent on thyroid hormones for normal development, active 
secretion of thyroid hormone in the foetus does not start until about 18-20 weeks gestation 
so the foetus is dependent on the mothers’ circulating hormones for growth and 
development up until this point (59).  
1.1.3.1. What is ‘intelligence’? 
There is no widely accepted definition of intelligence. There is an identified link between how 
broad the definition should be to how broad the intelligence domain should be (60). Further 
to this, Boeck also adds (pp. 6): 
“…must a definition be based on research or should research be based on a definition?” 
Intelligence is stated as requiring a flexibility in responding to challenging situations and 
actively shaping our environment (61). It is argued that intelligence could be referred to the 
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commonly coined ‘g’ (for ‘general-intelligence’), or could be described as being driven by 
domain-specific faculties (62-65). Intelligence has been defined as an individual’s ability to 
understand and reason correctly with concepts and solve problems (66, 67). 
Intelligence testing can be viewed as a desire to quantify intelligence, as assessment 
batteries attempt to measure this fluid concept. As Jensen (pp. 76) (68) stated, 
“Intelligence…is what intelligence tests measure”. Intellect, as measured by Intelligence 
Quotient (IQ) tests, has been shown to predict a range of life outcomes such as academic 
performance, job performance, years in education, quality of life and even physical health 
(69-77). IQs measured on standardised tests are normally distributed with an average IQ 
score falling in the range of 90-109; with a percentile ranking of 50 for an IQ of 100 (78). Very 
young children are frequently assessed by development scales, and the most recent Bayley 
Scale of Development can assess from as young as 16 days (79). These scales are primarily 
used to identify any possible developmental delays for the child (80), and are not necessarily 
IQ measurements.  
Genes are also acknowledged to play a role in an individual’s intelligence; heritability 
accounts for around 50% of intelligence, therefore the environment is accepted to construct 
the rest of the variance (81). It has been identified that the environmental effects on 
intelligence are important in childhood, but are negligible in adulthood (82). There appears 
to be an overlap between gene interplay and cortical thickness that could influence 
intelligence (83). Different brain morphology is apparent in individuals with differing 
intelligence levels; those with superior intelligence levels show more intense and prolonged 
cortical thickening followed by more rapid thinning (84). This thickening and thinning has 
been suggested to occur in an extended sensitive period, during which the brain is responsive 
to environmental input (85). More recent cortical thickness studies support McGue (82), that 
heritability increases in childhood and adolescence, whilst environmental influences 
decrease in importance (86-89).  
1.1.3.2. Underactive thyroid function in pregnancy and the effect on offspring 
intelligence 
The number of studies investigating the impact of an untreated GSH on an offspring’s IQ are 
growing, but the findings are equivocal. In one retrospective study, untreated GSH was 
shown to lower an offspring’s IQ by a mean of 7 points (54), and of the 48 GSH offspring nine 
children had an IQ of < 85 compared to only six of the 124 matched control children (7-9 year 
old offspring assessed by a Wechsler Intelligence Scale for Children- third edition). 
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Interestingly, in this study by Haddow and colleagues there was a small group of women that 
were treated for their GSH (n = 14), but significant differences were only found between the 
untreated and matched controls (see Table 1 and Table 2 for further details).  
Table 1 
Summary of Results from Haddow et al.  
IQs (WISC-III) p (treated GSH vs. untreated 
GSH) 
p (Untreated GSH vs. matched 
controls) 
Verbal IQ .30 .006 
Performance IQ .30 .01 
Full scale IQ .20 .005 
Notes. Adapted from Haddow et al. (1999). Maternal thyroid deficiency during 
pregnancy and subsequent neuropsychological development of the child. The New 
England Journal of Medicine, 341 (8), pp. 549-555. Table extracted and edited from pp. 
553.  
IQ=intelligent quotient, WISC-III=Wechsler intelligence scale for children-third edition, 
GSH=gestational subclinical hypothyroidism. 
 
Li et al. (49) detected this impact on IQ in children as young as 25- 30 months using Bayley 
Scales of development (compared to controls, mean intelligence scores were found to be 
significantly lower p = 0.008). However, even though Li et al. included a large sample (n = 
1,268) with serum samples taken at 16-20 weeks gestation, there were only 18 mothers 
identified with GSH, with others being euthyroid. Klein et al. (90) found evidence for offspring 
cognitive deficits for increasing maternal TSH values measured at 17 weeks gestation (124 
GSH mothers from a sample of 25,000 women). It was found that the higher the percentile 
ranking of TSH, the lower the IQ measurement would be for the offspring. Furthermore, IQs 
below 1 standard deviation (SD) were more frequent in children born to mothers with GSH 
compared to controls with gestational euthyroid function (p = .006). In a large population 
cohort in China, it has also been identified that GSH is associated with poorer 
neurodevelopment and also poor vision of offspring (91). Finally, Smit et al. (56) identified 
effects of GSH (identified during the first trimester) on offspring at ages 6 and 12 months 
measured by Bayley Scales, but no significance was achieved with the child at 2 years of age. 
Again, caution is advised as Smit et al.’s research was on a very small number of mother-child 
pairs consisting of 20 in total; specifically, only seven identified as having GSH and six with 
normal gestational euthyroid function. Henrichs et al. (53) included a much larger sample of 
women (n = 3,659) and also found no effect of GSH (as well as measuring for 
hypothyroxinaemia at 13 weeks gestation) for offspring language impairment, verbal and 
nonverbal functioning.  
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Maternal hypothyroxinaemia has also been linked to lower intelligence for the offspring. In 
a study by Ghassabian et al., hypothyroxinaemia was measured around 18 weeks, and was 
defined as T4 in the lowest 5th percentile of the cohort. IQ was then measured in the children 
at age 6 from the large sample (n = 3,727). It was found that nonverbal IQ was 4.3 points 
lower in the maternal hypothyroxinaemic children (p = .001), compared to children born to 
mothers who had normal thyroid function (52). Henrichs et al. (53) confirmed similar findings 
and identified a nonverbal cognitive developmental delay for offspring born to such women. 
Higher percentile cut-off as a definition for maternal hypothyroxinaemia has also been found 
to be detrimental to the children. Suárez-Rodriguez et al. (51) had a cut-off for maternal 
hypothyroxinaemia at the 10th percentile (measured at 37 weeks gestation) and found using 
McCarthy Scales of Children Abilities when offspring were age 38 to 60 months, that the 
general cognitive index score was lower compared to controls (p < .01). However, the 
research included a very small sample size of only 70 children being assessed. Also, Pop et 
al. (50) measured thyroid function at 12 weeks gestation and classified women as being 
hypothyroxinaemic when their T4 was below the 10th percentile (with normal TSH). The 
offspring were followed up at two stages, 1 year of age (63 case, 62 control) and 2 years of 
age (57 case, 58 control). Even with the small sample sizes, there were significant differences 
on measurements by Bayley Scales for mental processing and motor function (all p’s < .02). 
Li et al. (49) also found differences using Bayley Scales of Infant Development and found in 
their small sample (study details as above and in Table 2) that children born to 
hypothyroxinaemic mothers performed 9.30 points lower (p = .004) compared to children 
born to euthyroid mothers during their pregnancies. The final study to discuss was by Berbel 
et al. (34), they had a sample (n = 345) of three groups of women, those with normal thyroid 
function, those classed as having maternal hypothyroxinaemia at 12-14 weeks gestation and 
those with the same classification at full-term. It was found that the offspring in the latter 
two groups compared to the normal group had lower cognitive function measured at 18 
months old (p < .05 and p < .001).  
As with GSH, the evidence is conflicting on the impact maternal hypothyroxinaemia has on 
the offspring’s cognitive function. Su et al. (91) identified in their research that GSH had a 
detrimental cognitive effect for the offspring, but for those children born to mothers with 
hypothyroxinaemia during their pregnancies, no difference was found compared to maternal 
euthyroid controls. Bayley Scales were again a popular choice of assessment tool for the 
research as young children were being assessed. Craig et al. (92) assessed using Bayley Scales 
in a large sample (n = 5,734) and found that of the 198 children born to mothers with 
9 
 
gestational hypothyroxinemia, there were no significant differences to those born to 
euthyroid mothers (p = .14). Chevrier et al. (93) assessed children (n = 287) with Bayley Scales 
at 6, 12 and 24 months of age and found no difference compared to offspring born to 
euthyroid women. The children in the study also underwent a Wechsler Preschool and 
Primary Scale of Intelligence (94) at 60 months of age and again, found no differences. Grau 
et al. (95) recently assessed neuropsychological outcome in offspring born to mothers 
measured to have hypothyroxinaemia (T4 below the 10th percentile) at the end of their first 
trimester. Children were assessed at two time points, 1 year of age (n = 455) and between 6-
8 years (n = 289) with a Wechsler intelligence scale. No differences were found between the 
case children compared to the controls, furthermore there was no difference in intelligence 
when compared to free T4 in each trimester. Finally, Oken et al. (96) used a visual recognition 
memory test, which was stated to be as good a predictor of development as Bayley Scales, 
in children (n = 500) aged 6 months and 3 years of age and also found no difference between 
those born to mothers who were hypothyroxinaemic during their pregnancies and those 
with normal thyroid function.   
So in summary, the evidence is conflicting as to whether an underactive thyroid during 
pregnancy could have a negative impact on a child’s intelligence and cognition. There seems 
a great discontinuity between studies on a number of aspects: TSH and T4 classification cut-
off points, when the mothers have their thyroid function measured during their pregnancy, 
the age of the offspring assessment and also the type of assessments all vary from study to 
study. The following sections explore the evidence concerning potential areas of specific 
impairments to the offspring; memory function, motor coordination, language delay, hearing 
ability and behavioural observations. 
1.1.4. Further cognitive effects 
In addition to effects on intelligence, effects on specific areas of cognitive function for 
offspring born to mothers who had gestational deficient thyroids are also reported. As with 
the intelligence research, evidence was conflicting and studies tended to focus on either GSH 
or maternal hypothyroxinemia. Four domains are to be covered in relation to human studies 
(selected due to their evidence); memory, motor coordination, language delays and reading 
ability, and the offspring’s hearing.  
1.1.4.1. Memory 
It has been proposed that memory is affected in a child born to a mother who has 
underactive thyroid function. Memory deficits are suggestive of possible hippocampal 
10 
 
damage in the brain (97, 98): the hippocampus  has been shown to require an adequate 
supply of thyroid hormone during development (15) and insufficient exposure to thyroid 
hormones in utero has been shown to affect hippocampal structure and function (99, 100). 
It is suggested that the insufficiency will affect the transcription of specific thyroid hormone 
dependent genes resulting in hippocampal functional abnormalities (15, 27). Episodic 
autobiographical memory is the recall of past events using many different types of episodic 
details, such as emotions, who, what was present etc. (101).  
The hippocampus was also implicated in episodic autobiographical memory retrieval (102), 
and this memory system has been evidenced to be impaired for those children born to 
mothers with GSH. Willoughby et al. (103) had a small group (n = 17) of children aged 10-14 
years of age born to mothers whom were treated for GSH. Compared to the controls, the 
GSH children performed significantly worse and relayed less details of the event, including 
perceptual and place details. Also in an exploratory analysis, severe thyroid hormone 
deficiency in the third trimester was associated with lower proportion accuracy scores 
compared to the controls. This confirmed previous findings by Willoughby et al.’s (104) that 
controls performed better on autobiographical memory tasks. More recently in 2014, 
Willoughby et al. (105) identified that individuals (n = 24) born to mothers who had GSH and 
were treated for such, scored significantly lower on memory indices compared to euthyroid 
controls (n = 30). All of these studies used children born to mothers that were treated for 
GSH. It would have been interesting if there was a sample in all of the small studies that 
included children from mothers that were untreated.  
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Table 2 
Ten Summarised Studies Frequently Referred to Throughout This Thesis 
Reference 
(Country) 
Gestational 
age 
measurement 
Participants 
/ controls 
T4 TSH Treatment Offspring 
assessment 
age 
Offspring 
assessment 
domain / 
tool 
Blinded 
testing 
Results (p) Adjustments 
Berbel et 
al. (34) 
(Spain) 
1) 4-6 wks & 
f/t 
2) 12-14 wks & 
f/t 
3) f/t 
1) 12 
2) 19 
/ 13 
Free T4 
Cases: 
1) 0-10th 
percentile, 
(0.71-0.82 
ng/dL)  & > 
20th 
percentile 
at f/t 
(>0.91 
ng/dL) 
2) 0-10th 
percentile 
Controls: 
> 20th 
percentile 
 
Normal 
range for 
all groups: 
0.38-4.80 
µIU/mL 
Iodine from 
time of 
consent for 
all groups, 
200 microg 
KI per day 
18 months Cognition, 
motor, 
language / 
Brunet-
Lezine scale 
Yes Cognition: 
<.05 
Motor: 
<.05 
Language: 
>.05 
None 
Craig et al. 
(92) 
(America) 
2nd-3rd 
trimester 
99 / 99 
(matched) 
Free T4 
Cases: <3rd 
percentile 
(0.92 
ng/dL). 
Normal 
range for 
both 
groups: 
None 2 years Cognition, 
motor, 
language / 
Bayley Scale 
of Infant 
Yes Unadjusted; 
cognition 
and motor: 
=.05 
Language: 
Gestational 
age, child 
age, 
,maternal 
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Controls: 
10-90th 
percentile 
(1.00-1.34 
ng/dL). 
0.26-3.34 
mLU/liter 
Developmen
t-III 
>.05. 
Adjusted: all 
>.05 
weight and 
education 
Haddow et 
al. (54) 
(America) 
2nd-3rd 
trimester 
1) 48 
2) 14 
/ 124 
T4 
Cases: 
<7.75 
µg/dL 
Controls: 
>threshold 
 
Cases: 
>98th 
percentile 
Controls: 
<threshold 
 
1) None 
2) Treated 
from time 
of consent 
with 
thyroid 
hormone. 
7-9 years Intelligence / 
WISC-III. 
Language / 
Test of 
Language 
Developmen
t-II & The 
Peabody 
Individual 
Achievement 
Test-R. 
Motor / The 
Developmen
t Test of 
Visual-motor 
Integrations 
& The 
Grooved 
Pegboard 
Yes Intelligence: 
1) <.05 2) 
>.05 
Language: 1) 
<.05 2) >.05 
Motor: 1) 
<.05 2) >.05 
None 
Henrichs et 
al. (53) 
(Netherlan
ds) 
13.3 weeks Total: 3659 
(cases not 
specified) 
Free T4 
Cases: 
<10th 
(<11.76 
pmol/liter) 
and < 5th 
Normal 
range for 
all groups: 
0.03-2.5 
mU/liter 
None A) 18 
months 
(n=3411) 
B) 30 
months 
(n=2819) 
A) Language 
/ McArthur 
Communicati
ve 
Developmen
t Inventory 
N/A Both free T4 
percentiles; 
Language 
and 
nonverbal 
Maternal age 
& education, 
prenatal 
distress, 
prenatal 
smoking, 
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(<10.96 
pmol/liter) 
percentiles. 
Controls: > 
10th 
percentile 
(11-25 
pmol/liter) 
B) Cognition 
/ Parent 
Report of 
Children’s 
Abilities 
(verbal and 
nonverbal) 
Language / 
Language 
Developmen
t Survey. 
cognition: 
<.05 
TSH: >.05 
birth weight, 
gestational 
age at 
sampling, 
child 
ethnicity. 
Klein et al. 
(90) 
(America) 
17 weeks 1) 28 
2) 20 
/ 124 
(matched) 
Not 
disclosed 
Cases: 
1) 98-
99.85th 
percentile 
2) > 99.85th 
percentile 
Controls: 
< 98th 
percentile 
None 8 years old Intelligence 
/WISC-III 
Not 
disclose
d 
1) >.05 
2) <.05 
Socioecono
mic status, 
parental 
education 
and 
occupation 
Li et al. 
(49) 
(China) 
16-20 weeks 1) 18 
2) 19 
/ 142 
(matched) 
T4 
Cases: 
1) 2.5th-
97.5th 
percentile 
(101.79-
218.49 
nmol/I) 
2) <2.5th 
percentile 
1) >97.5th 
(>4.21 
mIU/I) 
2) 2.5th-
97.5th 
percentile 
(0.12-4.21 
mIU/I) 
Controls: 
None 25-30 
months old 
Cognition & 
Motor / The 
Bayley Scale 
of Infant 
Developmen
t 
Yes Cognition 
and motor 1) 
& 2) <.05 
None 
14 
 
(<101.79 
nmol/I) 
Controls: 
2.5th-97.5th 
percentile 
2.5th-
97.5th 
percentile 
Pop et al. 
(50) 
(Netherlan
ds) 
12 weeks 1) 63 / 62 
(matched) 
2) 57 / 58 
(matched) 
T4 
Cases: 
<10th 
percentile 
(<12.14 
nmol/I) 
Controls: 
>10th 
percentile 
Normal 
range for 
groups: 
0.15-2.0 
mIU/I 
None 1) 1 year 
old 
2) 2 years 
old 
Cognition 
and motor / 
The Bayley 
Scale of 
Infant 
Developmen
t 
Yes 1) & 2) 
cognition & 
motor: <.05 
 
None 
Saurez-
Rogriguez 
et al. (51) 
(Spain) 
37 weeks 37 / 33 
(matched) 
T4 
Cases: 
<10th 
percentile. 
Controls: 
9.5-23.9 
pmol/I 
Normal 
range for 
groups: 
0.2-5 
µU/mL 
None 3-5 years 
old 
Cognition, 
memory, 
motor/ 
McArthuy 
Scales of 
Children’s 
Abilities 
N/A Cognition & 
memory: 
<.05, motor: 
>.05 
None 
Smit et al.  
(56) 
(Netherlan
ds) 
<20 weeks 7 / 6 T4 
Cases and 
controls: if 
1st 
trimester 
7.4-24.2 
pmol/I. If 
2nd 
trimester 
Cases: 1st 
trimester 
>2.0 
µU/mL. 2nd 
trimester 
>2.3 µU/mL 
Controls: 
below 
thresholds 
None 6, 12 & 24 
months 
Cognition / 
The Bayley 
Scale of 
Infant 
development 
Yes 6 & 12 
months, 
<.05. 24 
months, >.05 
Maternal 
ethnicity and 
education. 
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5.1-14.3 
pmol/I 
Su et al. 
(91) 
(China) 
<20 weeks 1) 41 
2) 43 
/ 845 
T4 
Cases: 
1) 5-95th 
percentile 
2) <5th 
percentile 
Controls: 
5-95th 
percentile 
Cases: 
1) >95th 
percentile 
2) 5th-95th 
percentile 
Controls: 
5th-95th 
percentile 
 
None A) before 6 
months 
B) 42 days 
& 3 
months 
A) Cognition 
/ The Bayley 
Scale of 
Infant 
Developmen
t 
B) Hearing / 
Auditory 
Brain Stem 
Response 
Not 
disclose
d 
1) Cognition: 
<.05, 
Hearing: >.05 
2) Cognition 
& Hearing: 
>.05 
Maternal age 
and body 
mass index 
Note. T4=thyroxine, TSH=thyroid stimulating hormone, WISC-III=Wechsler intelligence scale for children third edition. 
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There are a few studies that have identified specific working (short term) memory deficits 
for the offspring; rather than those in the long term memory system, episodic and 
autobiographical. By using a test investigating a string of numbers, it was identified that 
children born to mothers who had hypothyroxinaemia during their pregnancies performed 
significantly worse compared to controls (106). Suárez-Rodriguez et al. (51) explored 
differences in their sample of children born to mothers with gestational hypothyroxinaemia 
and found that memory was recorded as significantly lower (p < .01) compared to controls 
(see Table 2 for further study details). Finally, an interesting study investigating T4 from the 
umbilical cord shortly after birth, identified that those whom had low levels of T4 performed 
better on the memory domain of the McCarthy Rating Scales at age 5 and a half years (n = 
542) (107). This latter study is in direct contrast to most other research available, as it implies 
a positive affect for the child when the mother has an underactive thyroid during her 
pregnancy. A reason for this may be due to T4 being measured post-delivery from the 
umbilical cord, whereas other studies discussed in this chapter relate to serum samples 
collected during gestation.  
1.1.4.2. Motor Coordination 
Motor coordination of children born to women whom had an underactive thyroid during 
their pregnancies has also been identified in the literature. It was first identified in the 1960s 
(108) that 12-29 weeks of pregnancy could be a critical period for the visuospatial system 
including some aspects of motor coordination, and that these are affected by thyroid 
hormone insufficiency. Fine and gross motor skills appear to be sensitive to thyroid hormone 
after 16 weeks of gestation (90, 109) and declining levels of T4 in the third trimester result 
in poor motor skills of preterm babies (110).  
GSH has been linked to a poorer motor coordination for the offspring. In Li et al.’s (49) study 
motor coordination was poorer in those born to mothers who had GSH compared to controls 
(p < .001) (see Table 2 for further study details). Haddow et al. (54) found that children born 
to mothers who were treated for their GSH, showed no significant difference between motor 
scores at ages 7-9 years (p = .30). However, when Haddow et al. compared the untreated to 
the matched controls, significance was reached (p = .04) with the untreated GSH group 
performing worse; caution is advised however, as significance was only reached for fine 
motor coordination of the non-dominant hand of the children (see Table 2 for further study 
details). Radetti et al. (111) conducted thyroid screening between the 8th and 10th gestational 
week (n = 691) and identified eight women with GSH who were treated swiftly following 
17 
 
diagnosis. The children were assessed for their psychomotor abilities at 9 months of age, but 
no differences between the case and control children were found.  
Maternal hypothyroxinaemia has also been linked to reduced performance in psychomotor 
skills (112). Pop et al. (50) found that those born to mothers who were hypothyroxinaemic 
during their pregnancies performed worse for motor coordination compared to controls (p’s 
< .02, see Table 2 for further study details). Li et al.’s (49) study also included a subset of 
mothers who were hypothyroxinaemic, and confirmed Pop et al.’s findings (p = .007, see 
Table 2). Pop et al. (113) assessed 220 children at 32 weeks of age by Bayley Scales and found 
that there were no differences to controls. The children were assessed again at the later time 
point of 10 months, and those born to mothers who had gestational hypothyroxinaemia 
performed worse on psychomotor measurements at this older age point.  
Some of the pregnancy studies have revealed no significant effects of maternal 
hypothyroxinaemia on the offspring. Berbel et al. (34), Craig et al. (92) and Suárez-Rodriguez 
et al. (51) did not identify a difference for motor function between the case and controls in 
their studies (see Table 2).  
1.1.4.3. Language Delay and Reading Ability 
A language and reading impairment may also be measureable in children born to mothers 
who had an underactive thyroid function during their pregnancies. Reading ability has been 
shown to be sensitive to thyroid hormone levels after 16 weeks gestation (90, 109).  
Specifically, GSH has been shown to affect the offspring’s language and reading ability. 
Henrichs et al. (53) found that those offspring born to mothers who had GSH were more 
likely to be at a higher risk for an expressive language delay compared to controls born to 
euthyroid mothers. Li et al. (49) confirmed findings and identified that the child’s language 
capabilities would be affected by GSH. Furthermore, Haddow et al. (54) found that between 
the treated to untreated GSH children there were no differences for language ability (p = 
.90), however when the untreated GSH were compared to control children, significance was 
achieved (p = .02) with the untreated performing worse (see Table 2 for further study details 
of all three studies).  
Maternal hypothyroxinaemia has also been linked to a language delay for the offspring (44), 
however most of the research suggests that there is no deficit for this domain. Berbel et al. 
(34) and Craig et al. (92) did not identify this link in their samples (see Table 2 for details). 
Noten et al. (114) recently assessed language in 5 year old children (n = 1,196) between those 
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born to mothers who had maternal hypothyroxinaemia, and euthyroid controls measured at 
around 13 weeks gestation, no differences were found between the groups (a 1.61 increased 
odds of poorer arithmetic was identified for the case group however). However, Li et al. (49) 
did identify a language deficit for children born to mothers with gestational 
hypothyroxinaemia compared to controls (see Table 2 for study details).  
1.1.4.4. Hearing Ability 
There is little evidence that low thyroid function (especially during pregnancy) could affect 
the offspring’s hearing. Cognition and hearing deficits have been shown to both occur in 
iodine-deficient areas (115-117). Furthermore, maternal hypothyroidism brought on in 
iodine-deficient areas has been linked to deaf-mutism and low cognitive function for the 
offspring (118, 119). Hearing difficulties have consistently been reported to be linked to 
individuals with congenital hypothyroidism (120-123).  
As mentioned, TPO is an enzyme that plays a role in the production of thyroid hormones, if 
antibodies are present (Ab+), these could inhibit the function of TPO (9) and can be viewed 
as a ‘precursor’ for future underactive thyroid problems. Wasserman et al. (124) investigated 
TPO-Ab+ in mothers in their third trimester of pregnancy. The children were assessed using 
a Wechsler Intelligence Scale for Children at 7 years of age and their auditory levels were 
evaluated at age 8. The children’s hearing was reported to be significantly worse in the case 
group compared to the controls, and these hearing difficulties were associated with their IQ 
levels (this hearing association was identified Wasserman et al. (31)).  
Su et al. (91) identified a link between thyroid function during pregnancy and offspring 
hearing deficits, but this was only significant in the children born to women who had 
hyperthyroidism during their pregnancies (See Table 2 for details). Radetti et al. (111) had a 
small sample of children born to mothers who were treated for their GSH, and assessed at 9 
months of age for audiology proficiency. No differences were found compared to the 
controls; furthermore, maternal T4 was identified as not being associated to audiological 
outcome for the offspring.  
1.1.5. Behavioural Observations 
1.1.5.1. Attention Deficit Hyperactivity Disorder 
Attention Deficit Hyperactivity Disorder (ADHD) is characterised by symptoms of inattention, 
hyperactivity and impulsivity (125, 126) with prevalence rates ranging from 1-5.29% 
worldwide (127, 128), with an increasing trend (129). The cause of ADHD is still unclear and 
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it appears to be an accumulation of factors which contribute to an individual displaying ADHD 
(130). Twin studies have shown a high heritability for ADHD of around 71-90% (131-133). 
Adoption studies allow a focus on separation of the environment and genetics by 
investigating the degree of similarities between individuals with ADHD and their biologically 
related or adopted relatives; studies have found a genetic, inherited contribution to ADHD 
(134-137). There have been specific studies searching for candidate genes for ADHD (138-
140), but no definitive genetic link has yet been identified (130, 141). However, we must be 
mindful that genetics and the environment are intertwined and cannot exclude 
environmental influences when discussing special educational needs (SEN) (142).  
1.1.5.1.1. ADHD and the Thyroid 
It has long been evidenced that some individual’s with ADHD may have a thyroid disruption 
of their own. Hauser at al. (143) found that in individual’s with resistance to thyroid hormone 
(RTH) (defined as mutations in thyroid receptor ß-gene and characterised as a reduced 
responsiveness of the peripheral and pituitary tissues to the action of thyroid hormone), 
were significantly more likely to exhibit symptoms of ADHD compared to those without RTH 
(significant differences were applicable to adult and child groups p < .001). However, others 
have struggled to find a link between RTH and ADHD (144-146). Furthermore, there have 
also been identified links between an individual’s lower concentrations of T4 and ADHD-
predominantly Inattentive, but not ADHD Combined type (147).   
There is conflicting evidence related to gestational thyroid function and the possible ADHD 
consequences for the offspring. Andersen et al. (19) assessed at the population level (n = 
857,014) in Danish nationwide registers between 1991-2004 and identified maternal 
hypothyroidism posed no association to ADHD to the offspring. However, this included 
mothers who were treated for their underactive thyroid and no consistent T4 or TSH 
classifications were used, as the population was nationwide. Some studies with a strict GSH 
definition have also found no association. Modesto et al. (45) recently identified in a large 
population sample from the Netherlands that GSH measured at around the end of the first 
trimester (mean = 13.9 weeks gestation) was not associated with higher ADHD scores. 
Pakkilla et al. (148) identified that for female offspring of mothers with GSH, inattention and 
total ADHD symptoms increased with increases of maternal TSH concentrations; but the 
results were not replicated with boys. In contrast, Ghassabian et al. (44) reviewed findings 
from the Generation R study and identified that maternal GSH was related to ADHD 
symptoms in the offspring. Prior to this, Ghassabian et al. (149) investigated TPO-Ab+ during 
early pregnancy and found that, if present, there was an increased risk of externalising 
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problems in preschool children: in particular, ADHD problems. The significant effect 
remained when maternal TSH was controlled for, the authors concluding that TSH has an 
effect on offspring ADHD.  
Further conflicting evidence was identified for individuals who experienced maternal 
hypothyroxinaemia. In Pakkilla et al.’s (148) study, no association to maternal low T4 (or TPO-
Ab+) was identified to offspring ADHD symptoms. In the Generation R cohort, Ghassabian et 
al. (44) identified that for those born to mothers who had gestational hypothyroxinaemia 
there were no offspring behaviour difficulties at age 3 but by age 6, the children were 
significantly more likely to display ADHD symptom behaviours compared to controls (p = .03); 
however, this significance disappeared after controlling for maternal age and maternal 
education. Modesto et al. (45) found in their study that maternal hypothyroxinaemia was 
associated with higher ADHD symptom scores for the child at age 8 years compared to those 
born to normal GTF mothers. Furthermore, treatment for hypothyroxinaemia made little 
influence to the results.  Mathew et al. (150) investigated maternal hypothyroxinaemia 
(measured at a mean of 13.6 weeks gestation) in 3,873 mother-child pairs from the 
Generation R study in the Netherlands. ADHD was assessed around age 8 years of age in the 
offspring by Conners Parent Rating Scale- revised short form, it was also identified that 
maternal hypothyroxinaemia was associated with higher scores for ADHD; these results 
remained unchanged when TPO-Ab were excluded. Finally, in iodine deficient areas, 
hypothyroxinaemic mothers during their pregnancies reported children with an abnormally 
high frequency of ADHD (151).  
1.1.5.2. Autism Spectrum Conditions 
Autism Spectrum Conditions (ASCs) is an umbrella term used to describe Autism, Asperger’s 
Syndrome and Pervasive Developmental Disorders Not Otherwise Specified. There is some 
evidence of prenatal and early-life ‘critical periods’ for possible susceptibility to developing 
ASCs and other neurodevelopmental disruptions (152, 153).  
The most common traits of those with ASCs is some form of communication difficulty (154). 
There may also be an over dependence on routines, fixations on items and/or being highly 
sensitive to changes in a particular environment (see the Diagnostic and Statistical Manual 
of the American Psychiatric Association (DSM) fifth edition, 2013 (155) for further details). 
The terminology ASCs was preferred for this thesis, rather than the more commonly used 
‘Autism Spectrum Disorders’, as it was less stigmatising and it reflects that these individuals 
may have cognitive strengths rather than just viewing a person with a ‘disorder’ which can 
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imply a negative label of a SEN (156). The prevalence in the UK for ASCs was last noted from 
the 2011 Census (157) to be 1.1% (n = 695,000).  
There is much about ASCs that remains unknown with many questions still unanswered; why 
is the prevalence higher in boys than in girls? Why is this umbrella term so wide? Why is 
there no ‘one size fits all model’? Are the reasons for this developmental disorder genetic? 
Numerous studies have focused on this latter question (158-163). The environment is now 
also coming under scrutiny as its links to ASCs are becoming clearer in the recent literature. 
Additionally, there is a growing body of evidence linking ASCs and non-genetic factors such 
as the environment, for example, proximity to air pollution (164). Moreover, there is 
evidence of maternal influences on the risk of ASCs with affects from prenatal maternal 
antidepressant use (165), maternal infections (166) and low periconceptional folic acid 
intake (167). 
1.1.5.2.1. ASCs and the Thyroid 
Without knowing the cause of autism, it is difficult to begin to understand the complex role 
the thyroid may play in increasing the risk of offspring developing ASCs or, the role the 
thyroid may play in individuals who already have a label of an ASC. As mentioned above, it is 
documented how thyroid hormones are critical for normal human brain development (168), 
additionally, how thyroid hormones can influence myelination and also gene expression 
(169), which could help begin to address this possible link between thyroid and the genetic 
basis identified for ASCs. Hoshiko et al. (170) identified low T4 levels in newborns to be 
associated with a high risk for ASCs, whereas Soldin et al. (171) found no association between 
neonatal thyroid hormone levels and ASCs; the dependency of thyroid hormones may then 
be before this, during pregnancy.  
Few studies have investigated thyroid function during pregnancy and the possible impact it 
can have on offspring developing an ASC. As well as a small group of studies finding a link 
between ASCs (as below), there are also at least three studies where no link was identified. 
Firstly, a study published in 1980 suggested there is no link between thyroid hormones and 
diagnoses of ASCs (172). However, 35 years and multiple studies later, a systematic review 
and meta-analysis has been conducted that identified a positive association between 
maternal autoimmune diseases and risk of ASCs in the offspring; though no detail was 
covered in respect to classifications of the autoimmune conditions included (173). Croen et 
al. (174) with 407 participants with ASCs and 2,095 controls found that when maternal 
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autoimmune disorders were present around the time of their pregnancies, these were 
unlikely to contribute to the offspring developing an ASC.  
Brown et al. (175) found that the prevalence of maternal TPO-Ab+  increased the odds of ASC 
in offspring by 80% (p = .009) compared to mothers negative for this antibody. Adding validity 
to these findings is the large sample size of the study; 1,132 individuals with ASCs and 967 
matched controls.  
Román et al. (176) identified in their large study sample of 4,039, that severe maternal 
hypothyroxinaemia (measured at 13.4 weeks gestation) was significantly (p = .001) 
associated with an almost four fold increase in odds of the child developing an ASC. Transient 
hypothyroxinaemia of prematurity (THOP) is defined as low thyroid hormone levels and 
normal TSH during a critical period of brain development in infants born prematurely (177). 
Korzeniewski et al. (178) identified that individual born with THOP were at a 2.5-fold greater 
risk of having an ASC. Whilst Román (179) postulates that the presence of THOP may increase 
the risk of ASCs in the offspring.   
Whilst hypothyroxinaemia is linked to normal TSH levels, Yau et al. (180) identified a 
difference in maternal TSH levels being lower in their ASCs group (n = 78) compared to the 
gender and age matched controls (n = 149), though not significant (p = .18). It was concluded 
that the higher the TSH levels the less chance there was of the child having an ASC. However, 
there were no measurements of T3 or T4; therefore it would not be possible to conclude that 
the mothers were hyperthyroid during their pregnancy. Further to this, TSH was only 
measured once during mid pregnancy, and if levels were high this has been associated to 
decreased odds of the offspring having an ASC; therefore low TSH was concluded to be 
associated ASCs for the offspring (180). However the study was unable to conclude if the 
mothers had GSH as no measurements of T3 or T4 were taken, also it was unclear whether 
the low TSH measurements were a product of high T3/T4 for the mothers. Andersen et al. 
(19) assessed at the population level (n = 857,014) and identified maternal hypothyroidism 
posed an increased risk for the offspring to be vulnerable to ASCs. However, this included 
mothers whom were treated for their underactive thyroid and no consistent T4 or TSH 
classifications were used; it was unfortunate that those with maternal thyroid deficiencies 
were not included, but as a retrospective study these individuals would have been difficult 
to include.  
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1.1.6. Brain Structure and Development 
There is emerging evidence in a few studies that brain morphology may be affected by 
thyroid hormones. Children with congenital hypothyroidism have affected brain regions, for 
example one study has demonstrated areas of cortical thinning and thickening that were 
significantly different compared to controls (181). Furthermore, adolescents with congenital 
hypothyroidism have been shown to have an increased magnitude of hippocampal activation 
and bilateral activation compared to controls, and this was associated with the severity of 
hypothyroidism the individual experienced early in life (182). It is also well recognised that 
T4 and T3 are required for brain and neurological development of the foetus (17), and these 
hormones may be in insufficient supply during pregnancy.  
Corpus callosum development occurs in the brain of the foetus during pregnancy (183-185), 
and it is vulnerable to early thyroid hormone deficiency (186). Samadi et al. (187) 
investigated a small sample of women and found that those born to hypothyroid mothers 
during their pregnancy (some were treated), had smaller anterior and larger posterior sub-
regions of the corpus callosum compared to healthy controls. Significantly larger splenium 
and a smaller genu (at the trend level) was also observed. Samadi et al. concluded that 20% 
of variance in the genu size was explained by maternal TSH levels; suggesting mothers with 
a long period of TH insufficiency had smaller genua. One of the limitations of this study, aside 
from the small sample size, was that there was little detail about the treated underactive 
thyroid function of the mothers, and no comparison was made between those whom were 
treated or untreated for the duration of their pregnancies. However, building on the 
evidence of the importance of maternal TSH levels, Si et al. (188) identified children with 
‘abnormal brain results’ were more likely to be born to mothers with high levels of TSH during 
their pregnancies, compared to those with a ‘normal brain result’. It is difficult to discuss this 
research further as little detail about which brain regions were viewed as ‘abnormal’ or in-
fact, what specific measurements of the brain were taken in the children.  
Some studies have investigated the effect of GSH on offspring brain morphology. Willoughby 
et al. (103) investigated 68 children (ages 10-14 years), 17 of whom were born to mothers 
that were treated for GSH. It was found that the controls accurately relayed more details 
from a staged event; including more perceptual details and more accurate places than the 
case group. A reason for this, could have been that the children born to the treated GSH 
mothers had smaller hippocampal volumes, and this finding was specific to the right anterior 
hippocampal volumes; although the result was non-significant (103). In a second study, 
Willoughby et al. (105) studied the hippocampus again with a group of 54 children (30 
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controls and 24 born to mothers with GSH that were treated), the case children showed 
significantly smaller right and left hippocampal volumes compared to the controls. This was 
particularly evident in the right posterior and left anterior segments. Similar to the previous 
research (103), the children born to treated GSH mothers performed significantly lower than 
controls on memory indices, furthermore, these results correlated to the smaller 
hippocampal volumes identified (105).  
Ghassabian et al. (52) investigated hypothyroxinaemia during pregnancy, and as mentioned 
above, measured IQ at age 6 in the offspring, but also conducted brain imaging scans on the 
children when they were around 8 years of age. The scans investigated specific brain 
volumes, cortical thickness and brain surface area. Even though a significant difference was 
identified for nonverbal IQ between those born to mothers whom were hypothyroxinaemic 
during their pregnancies, and those who had euthyroid function, no differences were found 
between any of the brain measurements. Conversely, T4 has been recognised as having an 
effect on offspring brain morphology. Korevaar et al. (37) investigated maternal thyroid 
function at 9-18 weeks gestation, and similarly to Ghassabian et al. (52) (as participants were 
drawn from the same cohort), IQ was measured at age 6 with brain morphology assessed (n 
= 646) at around 8 years of age. It was identified that an inverted ‘U’ was evident for the 
association of T4 to offspring nonverbal IQ (p = .0044), grey matter (p = .0062) and cortex 
volume (p = .0011). The finding of the inverted ‘U’ implies that either a high or low maternal 
T4 measurement could have equally detrimental effects on brain development for the foetus 
(37). Furthermore, Korevaar et al. identified that TSH was not associated to brain 
morphology of the offspring, there was also no association between T4 to white matter, 
corpus callosum or hippocampal volume (conflicts to the above discussed literature (103, 
105, 187)).  
1.1.7. Should we screen for underactive thyroid function in pregnancy? 
If there is a significant consequence of a pregnant mother having a deficient thyroid on the 
child’s development, this could potentially be widespread. To test and treat for low thyroid 
function in pregancy is reasonably “low-cost” (189, 190), thus the argument of ‘should we 
treat’ is debated.  
In response to the detrimental findings for the offspring, there are those who propose 
screening during pregnancy to help determine the circulating thyroid hormone levels in the 
mothers (189, 191-195). Miscarriages, premature births and gestational hypertension have 
all been related to overt and mild maternal hypothyroidism (196), and treatment has been 
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shown to reduce these complications (197). Women at a low risk for thyroid dysfunction 
during their pregnancy and who received treatment for such had a smaller chance of adverse 
pregnancy outcomes than matched women who did not receive treatment (197). Jouyandeh 
et al. (190) executed a systematic review and meta-analysis across 3 databases. Articles were 
identified that demonstrated universal screening would lead to less miscarriages and adverse 
pregnancy outcomes. The meta-analysis confirmed that case-finding screening, rather than 
universal screening missed around 49% of pregnant women who had a thyroid dysfunction. 
Reid et al. (198) also conducted a systematic review and concluded that the treatment of 
euthyroid women with TPO-Ab+ showed a reduction in preterm births and also a trend to 
reduced miscarriages with levothyroxine treatment.  
Some suggest only performing thyroid function tests in pregnant women with a previous 
history of thyroid dysfunction and do not recommend universal screening (199). 
Furthermore, few have investigated the neuropsychological outcomes of the offspring, 
rather than obstetric outcomes. Thung et al. (189) investigated a treatment model of 
hypothyroidism in women based on the IQ outcome of the offspring. It was concluded that 
screening would be cost effective, as there was a low cost initially from thyroid screening 
tests and treatment. If IQs were to be improved, money would be saved from the “…large 
additional lifetime costs that [would be] incurred by individuals with neurodevelopmental 
impairment” (pp. 267).  
Before the decision of universal screening can be made, the evidence needs to be more 
robust and based on longitudinal large-scale randomised trials including women with treated 
and untreated GSH and their offspring. The Controlled Antenatal Thyroid Screening (CATS) 
study (200) was the first randomised controlled trial (RCT) to investigate the effects of 
treatment of women with deficient thyroid function during their pregnancies on their 
offspring’s neuropsychological abilities. Thyroid function was measured at a mean of 12 
weeks gestation with IQ measurements at age 3 and 9 (discussed in this thesis), with the 
latter age also including additional cognitive assessments. More details of the study can be 
found in the following chapter.  
As mentioned in the above literature, there are varying times when maternal thyroid 
function has been measured during pregnancy and some believe that thyroid testing should 
not only be at the start of pregnancy, but perhaps continue until the end of the second 
trimester (201). However, adverse effects on both mother and child appear more apparent 
if thyroid dysfunction occurs within the first trimester of pregnancy (202). It is proposed that 
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there needs to be consistency for reference ranges of TSH and T4 (201, 203), and that this 
should occur before the decision to make screening universal is taken or not.  
1.1.8. Conclusions 
Thyroid function during pregnancy has been discussed including definitions for GSH and 
maternal hypothyroxinaemia. There have been a wide variety of studies conducted that have 
assessed the offspring for any differences compared to those born to mothers who had 
normal thyroid function during their pregnancies. Throughout this chapter, the literature has 
been contradictory. For GSH, some intelligence differences were identified for the offspring 
(49, 54, 56, 90, 91), whilst others struggled to find a difference (53, 56). Similarly, for 
maternal hypothyroxinaemia, differences were reported (34, 49-53) and also not reported 
(91, 92, 95, 96). On a more general level of cognitive deficits from a gestational underactive 
thyroid function, memory difficulties have been identified (51, 103-106), as well as motor 
(49, 50, 54, 110, 112), language difficulties (49, 53) and hearing difficulties (91, 124); but 
there are conflicting studies reported in the literature (34, 51, 54, 92, 111, 113, 114). As well 
as these possible cognitive deficits, behaviour has also been debated in the literature. ADHD 
difficulties have been identified in those born to mothers with an underactive thyroid 
compared to those born to those with euthyroid function (44, 45, 143, 148-151), but no 
differences have been found (19, 45, 144-146, 148). ASCs are similar with differences being 
identified (19, 170, 175-180) and challenged (171, 172, 174) in the literature. It is difficult to 
draw conclusions as to why there was conflicting evidence from the studies, as the studies 
vary on a number of factors: where the sample was from, gestational age, age of offspring at 
testing, and also assessment conducted on the offspring. The aims formulated from this 
general introduction can be found at the end of the following chapter.  
1.1.9. Chapter Summary 
This chapter has outlined some of the key areas in the literature relating to thyroid function 
during pregnancy and the outcomes for the offspring. Specifically, the chapter has covered 
different types of underactive thyroid function during pregnancy, GSH and maternal 
hypothyroxinaemia and also briefly explored the literature on iodine deficiency and how this 
can affect a pregnant woman’s thyroid function. The offspring outcomes are varied for such 
women, the main effect reported in the literature is on the child’s intelligence. In addition 
there are further possible deficits experienced by the child such as effect to memory, motor 
coordination, language and reading difficulties, and hearing abilities. More recently, studies 
are emerging of brain morphological differences for children born to women with an 
underactive thyroid function during their pregnancies. Based on the research outcomes, 
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arguments were proposed for the treatment or non-treatment of such women. This chapter 
prepares the ground for the following chapter in which wave one of the controlled antenatal 
thyroid screening study is described and the results are re-analysed using the UK cohort.  
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1.2. Re-analysis of intelligence at age 3; UK CATS I cohort 
1.2.1. Chapter Overview 
This chapter presents the analysis of the UK cohort CATS I data that I have conducted. This 
analysis is the precursor of the CATS II analysis, the description of the CATS I study sets the 
scene for the CATS II data collection and the data demonstrates how these children 
performed at a younger age. The chapter contains an introduction which describes how 
participants were recruited into CATS I, the methodology of the first cognitive assessments 
of the offspring, the statistical analysis I have conducted, the results and the discussion of 
those results. 
1.2.2. Introduction 
Lazarus et al.’s (200) CATS I work was a benchmark study as it was the first large prospective 
RCT to investigate the impact of treatment for deficient thyroid function during pregnancy 
on intelligence of the offspring. The CATS I study contributed to the growing literature of 
possible effects of thyroid dysfunction on child intelligence, including studies which have 
found an effect (34, 49-57, 90, 91), and those which found no difference compared to 
controls (53, 56, 91-93, 95, 96). 
Women were invited to take part in CATS I at their first hospital antenatal appointment. The 
median gestation at recruitment was 12 weeks and 3 days. Women were excluded if they 
were < 18 years old, had a gestational age of > 15 weeks and 6 days, had a twin pregnancy 
or a known thyroid disease. A total of 21,846 women were recruited (16,349 women in ten 
centres in the UK, 5,497 women in one centre in Turin, Italy). At recruitment, blood samples 
were taken from the participants for measurement of TSH and T4 and women were randomly 
assigned with the use of a computer-generated block design to either the screening or 
control group.  
Screening group participants had serum samples assayed immediately for a thyroid function 
result. Women were classified as having suboptimal gestational thyroid function (SGTF) if 
their TSH concentration was above the 97.5th percentile of the cohort, the T4 below the 2.5th 
percentile, or both (based on international guidelines (41, 204, 205), and also the same as a 
large cohort study based in the Netherlands that started recruitment the same year as CATS 
I; (37)). If a screen group participant had a positive result for SGTF, they were treated with 
levothyroxine at a starting dose of 150 µg per day (recommended amount), treatment was 
initiated at a median of 13 weeks and 3 days. These participants had their TSH and T4 
checked 6 weeks after the start of the therapy, and at 30 weeks gestation; treatment 
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adjustments were made if required. The women in the screen group with a positive result 
for SGTF were advised to see their family doctor after delivery of their baby to determine 
whether levothyroxine therapy should be continued or not. Women in the control group had 
their bloods (taken at the same time as the screen women) assayed after delivery of their 
baby. If they had a positive serum result for SGTF were also advised to visit their family doctor 
to see whether treatment should be initiated or not.  
The primary outcome for CATS I was an IQ measurement in the offspring. IQ was measured 
at a mean age of 3.2 years and only those participants who had a positive serum result were 
included (i.e. not offspring born to mothers who had a normal thyroid function during their 
pregnancy, the normal GTF group). The Wechsler Preschool and Primary Scale of Intelligence 
third edition, UK version (WPPSI-III) (206) was administered by two psychologists at the 
children’s homes. The psychologists were unaware of whether the child was born to either a 
mother from the screen (treated) or the control (untreated) group. As reported by Lazarus 
et al., the mean IQ scores for the analysis were corrected to a score of 100. For the current 
chapter, IQs have been left in their ‘uncorrected’ form to ease comparisons in chapter 2.2. 
(IQ comparison between ages 3 and 9; children from the CATS sample). There was a non-
significant difference between the groups (p = .40) with the mean treated SGTF full scale IQ 
being 99.2 compared to the mean untreated SGTF full scale IQ of 100.0. To see whether there 
was an effect with more children scoring lower IQs, percentages of IQs below 1 SD were also 
calculated. The treated SGTF group had 12.1% of children scoring below 85 compared to the 
untreated SGTF group having 14.1% (p = .39).  
As these results were from CATS I, and this thesis discusses findings from the second wave 
of the project, I decided to re-calculate the CATS I findings. The purpose of this was three-
fold, firstly it acted as a pilot data set for the statistical analysis I would use for this thesis. 
Secondly, as CATS II only recruited from the UK, I wanted to establish if there would be any 
major difference found from excluding the Italian sample. Finally, I was interested to re-run 
the data with the IQs in their ‘uncorrected’ form, i.e. not corrected to the mean of 100.  
Based on the CATS I results of there being no significant IQ differences between the treated 
and untreated SGTF groups, the current hypothesis was to fail to reject the null hypothesis; 
i.e. there would be no difference between IQs of those offspring from the treated or 
untreated SGTF groups.  
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1.2.3. Methods 
As reported by Lazarus et al. (200), between 2002 and 2006, a total of 21,846 women were 
recruited to the CATS I study (see Figure 1 for the participant flow chart). Within this cohort, 
16,349 women were recruited from the UK and 609 mother and child pairs from the treated 
(n = 302) and untreated (n = 307) SGTF groups were revisited at a mean offspring age of 3.2 
years for measurements of their IQ. 
As stated, the WPPSI-III (206) generates a full scale IQ, verbal IQ and also a performance IQ. 
Similar to the CATS II IQ test, the verbal IQ was a measure of “acquired knowledge, verbal 
reasoning, and comprehension”, whilst the performance IQ was “a measure of fluid 
reasoning, spatial processing, attentiveness to detail, and visual-motor integration” ((94) pp. 
135-136). The WPPSI was first developed in 1967 (207), and was an extension to the 
Wechsler adult and child intelligence scales. The WPPSI-III was published in 2002 (94) with 
the UK standardised version, as used in CATS I, published in 2003 (206) (and the current 
fourth UK edition released in 2013 (208)). The WPPSI-III was standardised on a sample of 
1,700 children divided into 9 age groups of 200 each (except the 7 years 0 to 7 years 3 months 
composed of 100 children) (206). There was high internal-consistency coefficients reported 
with all IQs r ≥ 0.93 and test-retest coefficients were above r = 0.86 for verbal, performance 
and the full scale IQs (209). The WPPSI-III was also demonstrated to display good validity as 
it had correlations to the WPPSI-R and Wechsler Intelligence Scale for Children third edition 
of r = 0.80-0.89 (206).  
The WPPSI-III could be used to assess children between the ages of ≥ 2 years 6 months to ≤ 
7 years 3 months. For children aged between ≥ 2 years 6 months to ≤ 3 years 11 months a 
shortened version was administered as children were anticipated to have a shorter attention 
span at this age. For CATS I, the aim was to test children around the age of 3 years so only 
the shorted version (25-35 minutes) was used. As can be seen in Figure 2, the children in 
CATS I completed four subtests for the WPPSI-III. The ‘block designs’ and ‘object assembly’ 
subtests comprised the performance IQ score. For block design, children were required to 
reproduce patterns made from one or two coloured blocks from a stimulus book. Object 
assembly required the child to fit puzzle pieces together to form a meaningful whole. The 
verbal IQ score was made up of the scores from the sub-tests of ‘information’ and ‘receptive 
vocabulary’. For information, the child had to either point to a picture, or verbally answer a 
brief question presented orally to them by the examiner; the pictures, questions and 
concepts were about commonplace objects and events. Receptive vocabulary required the 
child to look at a group of four images and point to the one that the examiner was orally 
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describing. The raw scores from the four tests were converted into scaled scores, which in 
turn were converted to the composite IQs. The verbal and performance IQs equally 
contributed to the full scale IQ.  
Data for the current analysis was retrieved from the CATS I Excel documents as IQs were in 
their ‘uncorrected’ form (i.e. not adjusted by 5 points as used for the Lazarus et al. (200)  
publication).  
 
Figure 1: Randomisation and Follow-up of the Study Participants from CATS I  
Adapted from Lazarus et al. (2012). Antenatal thyroid screening and childhood cognitive 
function. The New England Journal of Medicine, 366 (6), pp. 493-501. SGTF=suboptimal 
gestational thyroid function. 
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Figure 2: Wechsler Preschool and Primary Scale of Intelligence (WPPSI)-III, UK breakdown of 
subtests  
IQ=intelligent quotient. 
 
1.2.4. Statistical Analysis 
The statistical analysis for this chapter was executed after the collection of all CATS II data to 
eliminate the potential bias from un-blinding, a possibility as the CATS I IQs were stored by a 
CATS ID number which was retained in CATS II.  
The CATS I data was cleaned on a blinded dataset to avoid any further bias. No checks of 
nominal data for input errors was undertaken as all data was cleaned previously as part of 
the CATS I analysis. IQ cleaning occurred as it was an analysis of the UK only cohort, i.e. 
potential outliers from the UK cohort may have been ‘masked’ by the Turin, Italy IQ results. 
Descriptive statistics were used for the three IQs initially to check the ranges and for missing 
data. Z-scores were computed to identify any outliers in the data set. It was found for the 
verbal IQ that three individuals achieved z-scores < -3 and one had a z-score > 3. For 
performance IQ, only one participant had a z-score < -3, none achieved scores > 3. Finally, 
for the full scale IQ, two participants had z-scores < -3. Two participants had z-scores below 
the -3 threshold twice; these participants were removed as they could have skewed the 
dataset. See Figures 3 and 4 below to show how the histograms changed with the identified 
outliers removed. In total, there were 609 participants who had completed age 3 IQ 
assessments that were used for the re-run of the CATS I data analysis, UK cohort only. 
  
 Receptive Vocabulary   Verbal IQ    
 Information 
Full Scale IQ 
 Block Design 
 Object Assembly    Performance IQ 
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Figure 3: Verbal, performance and full scale Intelligent quotients (IQs) of complete 
dataset (n=609) of Wechsler Preschool and Primary Scale of Intelligence- third 
edition, UK (WPPSI-III) in the Controlled Antenatal Thyroid Screening study I 
Y axis shows frequency, X axis, IQ scores.  
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All Kolmogorov-Smirnov (and Shapiro-Wilk) normality tests were generated with all p’s < 
.001 for the IQ measures. However, means and medians appeared close and skewness and 
kurtosis ranges were all within the -1 - +1 range and thus were normal (see Table 3 below). 
The IQ data were analysed by parametric tests as the variables were continuous, and based 
on the means, medians, skewness, kurtosis and histograms (see Figures 3 and 4) the data 
was accepted as being normally distributed.  
  
Figure 4: Verbal, performance and full scale Intelligent Quotients (IQs) of dataset 
(n=607) of Wechsler Preschool and Primary Scale of Intelligence- third edition, UK 
(WPPSI-III) in the Controlled Antenatal Thyroid Screening study I  
Y axis shows frequency, X axis, IQ scores. 
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Table 3 
Means, Medians, Skewness and Kurtosis for Verbal, Performance and Full Scale 
Intelligent Quotients (IQs)  
IQ Domain Mean Median Skewness Kurtosis 
WPPSI Verbal IQ 108.18 
(11.60) 
110.00 -.354 .161 
WPPSI Performance IQ 106.14 
(13.62) 
105.00 -.025 -.390 
WPPSI Full Scale IQ 108.25 
(12.30) 
109.00 -.220 -.203 
Note. Standard deviations appear in parentheses below means. 
WPPSI=Wechsler preschool and primary scale of intelligence- third edition, UK 
version. 
 
The data was analysed using IBM SPSS Statistics version 20. The data collected by the two 
psychologists was amalgamated into one dataset and no analysis was conducted to 
investigate possible differences between the two datasets as this was investigated during 
the CATS I publication analysis, and no differences were found. For the current CATS I re-
analysis, comparisons between the treated and untreated SGTF groups were executed by t-
tests as it was continuous data. Similar to the CATS I publication (200), the data was analysed 
firstly in its unadjusted form, i.e. not controlled for any covariates. This was executed in the 
paper as the study was an RCT. To develop the work, and in keeping with this thesis, the 
second model of analysis included controlling for three covariates; child gender, mother age 
at time of consent into CATS I, and a measure of the participants’ social deprivation (further 
details of how this was calculated can be found on page 58). Therefore, model two included 
a multivariate analysis of covariance (MANCOVA) to examine the variation of these 
confounders on the dependent variables.  
The portion of children with a full scale IQ ≤ 85 (1 SD below the mean of 100 (206)) was also 
re-assessed by use of chi-square; this was also analysed firstly with the data in its 
‘uncorrected’ form, and secondly by controlling for covariates by a multinomial logistic 
regression. It was predicted that the screening, treated SGTF group would contain 5% (n = 
15) with IQ ≤ 85 and the control, untreated SGTF group would contain 15% (n = 46) with IQ 
≤ 85. This prediction was based on the results of Haddow et al.’s work (54), however, for the 
published CATS I findings, Lazarus et al. (200) adopted Haddow et al.’s percentage calculation 
of children born to normal thyroid function mothers, for the treated SGTF group.  These two 
analysis designs (t-test and chi-square) were adopted here. The power to detect a difference 
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in full scale IQ from the UK cohort sample was greater than 95% at the 5% significance level 
(two-sided test) (200).  
Regression models were also used in CATS I to assess the risk of lower IQ based on SGTF 
classification. As CATS I analysed by TSH and T4 measurements during pregnancy, this 
allowed this type of analysis; however, I adopted group coding and therefore omitted this 
specific re-analysis. The CATS I study was an RCT, so covariates did not need to be controlled 
for (randomisation meant that conditions should have contained participants with similar 
characteristics), therefore there was only one model of analysis adopted for the publication’s 
regression; unadjusted.  
Further analyses were conducted as exploratory investigations of overt hypothyroidism, 
subclinical hypothyroidism, and maternal hypothyroxinaemia (see appendix 9). These were 
conducted to explore whether the broad definition of SGTF was potentially ‘masking’ any 
significant results or effects of, for example, low maternal T4 with a normal TSH.  
1.2.5. Results 
1.2.5.1. General attendance information 
As mentioned in Lazarus et al. (200), there was around a 20% drop-out rate from time of 
pregnancy for children from the SGTF groups completing the WPPSI-III. In total, 607 (300 
treated SGTF and 307 untreated SGTF) children’s assessments were included in the current 
analysis.    
1.2.5.2. Analysis 
Below in Table 4, are the adjusted and unadjusted group means and SDs for the verbal, 
performance and full scale IQs. The graph (Figure 5) displays the means achieved by the 
groups pictorially (unadjusted model); error bars have also been included. 
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Table 4 
Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI)-III, UK at Age 3 
 CATS GROUP Unadjusted data Adjusted Data 
N Mean N Mean 
WPPSI Verbal IQ Treated SGTF 300 108.68 
(10.96) 
300 108.68 
(10.96) 
Untreated 
SGTF 
307 107.72 
(12.20) 
306* 107.75 
(12.21) 
WPPSI Performance 
IQ 
Treated SGTF 300 106.35 
(13.48) 
300 106.35 
(13.48) 
Untreated 
SGTF 
307 105.94 
(13.78) 
306 105.96 
(13.80) 
WPPSI Full scale IQ Treated SGTF 300 108.64 
(11.76) 
300 108.64 
(11.76) 
Untreated 
SGTF 
307 107.88 
(12.82) 
306 107.91 
(12.83) 
Note. *n has dropped due to a participant who resided in Northern Ireland: no social 
deprivation score available. Standard deviations appear in parentheses below means.  
 
 
 
Figure 5: Means per group achieved on the Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK  
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SGTF=suboptimal gestational thyroid function, CI=confidence interval. X axis=WPPSI 
domain, Y axis=mean of scores per group. 
 
For the unadjusted data comparison, on average participants from the treated group had 
higher IQs than those from the untreated SGTF group (as can be seen in Table 4 above). The 
difference for verbal IQ was 0.954, 95% CI [-.897, 2.804], and was not significant t(605) = 
1.012, p = .312. The difference for performance IQ was 0.409, 95% CI [-1.765, 2.582], and 
was not significant t(605) = .369, p = .712. Finally the difference for full scale IQ was 0.761, 
95% CI [-1.201, 2.722], and was also not significant t(605) = .761, p = .447.  
When the data was controlled for covariates (child gender, mother age at time of consent 
into CATS I, and a measure of the participants social deprivation), the participants from the 
treated group still had higher IQs than those from the untreated SGTF group (as can be seen 
in Table 4 above). The MANCOVA also yielded non-significant results, using Roy’s largest root 
(most powerful multivariate statistic (210)), ROY = .002, F (3, 599) = .492, p = .688, p2 = .002. 
As the multivariate analysis was non-significant, no further investigations of univariate 
effects were completed. 
Percentages of IQ scores ≤ 85 (unadjusted) were calculated and compared using Pearson Chi-
square significance test. Table 5 below shows the significance values, and that full scale IQ 
was the only IQ that was significantly different between the treated and the untreated SGTF 
groups (p = .008).  
Table 5 
Percentage of Intelligent Quotients (IQ) Falling Below 1 Standard Deviation (≤ 85) 
 IQs ≤ 85 (%) 
Verbal IQ Performance IQ Full scale IQ 
Treated SGTF  
(n = 300) 
7  
(2%) 
25  
(8%) 
7  
(2%) 
Untreated SGTF  
(n = 307) 
12  
(4%) 
25  
(8%) 
21  
(7%) 
Pearson Chi-Square p=.265 p=.932 p=.008* 
Note. Scores were from the Wechsler Preschool and Primary Scale of Intelligence 
(WPPSI)-III, UK and Intelligent Quotients (IQs) from the Controlled Antenatal Thyroid 
Screening study I UK only cohort. Percentages of scores per group are appear in 
parentheses below totals. *Significance < .05.  SGTF=suboptimal gestational thyroid 
function. 
 
The significant statistic of full scale IQ between the groups was explored further by 
adjustments for the covariates child gender, mother age at time of consent into CATS I and 
social deprivation score. The multinomial logistic regression revealed that children born to 
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mothers who were not treated for SGTF during their pregnancies were 3.335 times more 
likely to have a full scale IQ ≤ 85 at age 3 compared to those born to mothers who were 
treated for SGTF. The regression also revealed that as mother age increased and social 
deprivation score improved, the chance of achieving an IQ ≤ 85 decreased. It also was 
apparent that females were less likely to have an IQ ≤ 85 compared to males. See Tables 6 
and 7 for further details.  
Table 6 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
115.821    
Final 86.924 28.897 4 .000 
Note. See improved figure for -2 Log Likelihood. 
Df=degrees of freedom. 
 
Table 7 
Main Output from Multinomial Logistic Regression, Full Scale Intelligent Quotient (IQ) ≤ 
85 
full scale IQ 
≤ 85 
B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
       Lower Upper 
Gender -1.063 .454 5.482 1 .019* .345 .142 .841 
Mother age -.433 .219 3.900 1 .048* .648 .422 .997 
Social 
deprivation 
-.348 .145 5.770 1 .016* .706 .531 .938 
[Untreated 
SGTF] 
1.204 .453 7.070 1 .008* 3.335 1.372 8.103 
[Treated 
SGTF] 
0 . . 0 . . . . 
Note. The reference category was full scale Intelligent Quotient (IQ) ≥ 85. *Significance < 
.05. SGTF=suboptimal gestational thyroid function, B=beta, df=degrees of freedom. 
 
1.2.6. Discussion 
Based on the CATS I findings, the working hypothesis for this section was that the results 
would fail to reject the null hypothesis and that there would be no differences between IQ 
at age 3 of those offspring from either the treated or untreated SGTF groups (UK cohort only). 
Even though the treated SGTF group performed better than the untreated group for all three 
IQ scores, the results did not reach significance. Based on the findings for verbal IQ p = .312, 
performance IQ p = .712 and full scale IQ p = .447, the null hypothesis was not rejected.  
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Secondly, I investigated whether the treated SGTF group would contain the expected 5% 
with IQs ≤ 85 and the untreated SGTF would have 15%. For verbal IQ the treated SGTF group 
had 2% ≤ 85 whilst the untreated SGTF children had 4%. For performance IQ, the treated and 
untreated SGTF groups both had 8% of individuals with ≤ 85 scores. Finally, for full scale IQ 
the treated SGTF group had 2% ≤ 85 compared to 7% from the untreated SGTF group. These 
findings were different to Lazarus et al.’s (200) results for full scale IQ, 12.1% treated SGTF 
to 14.1% from the untreated SGTF group, as the IQs had been corrected to average around 
100 rather than their true results of between 106-109. It was concluded that the 12.1% 
identified in the complete CATS I cohort (200) was higher than expected as treatment may 
have been initiated too late (discussed further in ‘limitations’ page 42). The full scale IQ 
differences were significant by a Chi-square test (p = .008), when adjusted in a multinomial 
regression, significance was sustained and it was identified that the untreated SGTF group 
were 3.335 times more likely to score a full scale IQ ≤ 85 at age 3. However, only three 
covariates were controlled for and there may have been more effects to have made 
adjustments for. Furthermore, IQ is a continuous measure, and thus comparisons of means 
are preferred as binary calculations can simplify the statistical analysis as well as 
underestimate the extent of variability in a sample (211, 212). It has also been reported that 
changing continuous data to binary has an increased risk of generating a type one error (213), 
which may have occurred here.  
The results in the current chapter were not surprising as they supported the CATS I findings. 
CATS I only tested those from the treated and untreated SGTF groups at age 3 of offspring. 
As CATS I was the first study to investigate the effects of treatment for SGTF, comparing it to 
studies of euthyroid mothers was important. If there was no difference to IQ of offspring 
born to a mother who was treated or untreated for SGTF, then would there be any difference 
for IQ compared to offspring born to a euthyroid mother? Furthermore, if there was no 
difference in childhood IQ from being born to a mother with SGTF compared to normal GTF 
then, why would treatment have made a difference? 
Gestational underactive thyroid function has also been reported to have no effect on 
neuropsychological outcomes for the offspring. As stated, CATS I included women with either 
T4 in the lowest 2.5th percentile, TSH in the highest 2.5th percentile, or both. This meant 
including women with SGTF that were maternally hypothyroxinaemic (low T4), had GSH (high 
TSH) or had maternal overt hypothyroidism (combination of both). As mentioned, studies 
have highlighted no cognitive detriments to the child when born to a mother who had GSH 
(53, 56, 107, 214). Interestingly, Smit et al. (56) identified effects of GSH on offspring at ages 
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6 and 12 months, but no significance was seen with the child at 2 years of age. This was 
confirmed by Henrichs et al. (53) who identified no difference between offspring aged 18 
and 30 months for language impairment who were born to euthyroid mothers and those that 
had GSH. Similarly, there is evidence that children born to mothers who had maternal 
hypothyroxinaemia do not have any cognitive deficits when compared to those born to 
euthyroid mothers (91-96, 215).  
However, there have been articles where a lower thyroid function in pregnancy has been 
reported to have a detrimental cognitive affect for the child, for GSH (49, 54, 56, 90, 91), and 
also maternal hypothyroxinaemia (34, 49-53, 57). As CATS I did not assess any of the children 
born to mothers who had normal GTF, this was important to explore in the second wave of 
the study as there could have been a difference between the normal GTF and untreated SGTF 
children; alike to the studies cited here.  
There may have been some issues with the WPPSI-III measure itself and reasons as to why 
the mean IQs were so high follows. To help aid recruitment for the cognitive assessments, 
children were visited in their homes for the WPPSI-III. This could have affected the IQs scored 
by the children, because their home environment could have been filled with distractions 
which are discussed as having an adverse effect for cognitive assessments (216). Within the 
previous research around thyroid function and childhood intelligence testing, some did 
assess within the home environment (such as Pop et al. (50)), whereas others did not 
mention the testing environment (for example Haddow et al. (54)). However, in CATS I 
distractibility from assessing in the home environment was not an issue as mean scores were 
higher than anticipated. The WPPSI-III results could have been subject to the ‘Flynn Effect’; 
this is a phenomenon of increasing IQ scores over the years; i.e. as time goes on, people 
appear to perform better on such tests (217-223). The WPPSI-III used in CATS I was published 
in 2003 (206), and the assessments were conducted by two psychologists between 2006 and 
2010. It would be unlikely that the Flynn Effect would have occurred in the earlier 
assessments, but it was possible it could have had an effect on the latter assessments. There 
was also the possibility that those more able to help research studies participated, i.e. more 
able to give up their time, to comfortably welcome a test examiner into their home, and 
therefore may possibly have a better social background which could also explain the high 
mean IQs.  
From Table 4 above, it is clear that for verbal, performance and full scale IQs, the treated 
group achieved higher IQ results compared to the untreated SGTF group. If the IQs were 
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rounded up or down to full numbers, the verbal and full scale IQs for the treated SGTF group 
were one point higher; which was not clinically significant, nor a statistically significant result. 
It would be interesting to see whether with larger groups, this difference may have been 
bigger, or in-fact statistically significant.  
Appendix 9 contains supplementary analyses exploring maternal overt hypothyroidism, 
subclinical hypothyroidism, and hypothyroxinaemia in the CATS I UK only cohort. No 
differences were identified between the treated and untreated SGTF groups, concluding 
that, within this cohort, treatment with levothyroxine was of no benefit to these offspring at 
age 3 years.  
1.2.6.1. Limitations 
One of the limitations was that the treatment during pregnancy may have been initiated too 
late. The CATS I cohort had a median of 13 weeks and 3 days for blood samples from the 
mothers. Lazarus et al. (200) executed an exploratory analysis to see whether using the 
mothers who were recruited earlier during their pregnancies would yield different results, 
but it was non-significant; possibly as the groups were small and thus, underpowered to see 
any affects (200). One of the reasons for samples being extracted around the end of the first 
trimester was that women were recruited into CATS I by first appointment at the antenatal 
clinic in a hospital. To have enabled the study to recruit from earlier in pregnancy would have 
meant perhaps recruiting women from the first visit to their GP to confirm the pregnancy.  
A further limitation that was highlighted by Lazarus et al. (200), was that the IQ testing at age 
3 may not have been that reliable and IQ tests in older children have been found to be more 
accurate (224-226). Specifically, childhood IQ testing at ages 5-12 years generates a good 
stability into later adult life, thus are perceived as more of a true reflection of an individual’s 
capabilities (86). Furthermore (as discussed below in chapter 1.4., Intelligence measured at 
age 9; CATS II data), IQ test outcomes are dependent on a number of examinee factors such 
as motivation, shyness, and rapport with the examiner (227-229).  
The final critique would be that the CATS I study recruited women as having an SGTF if their 
TSH was above the 97.5th percentile, if their T4 was below the 2.5th percentile, or both (only 
consisting of 5% of both SGTF groups). This mixture of differing underactive thyroid functions 
may have clouded the results. Lazarus et al. (200) did investigate this further as an 
exploratory analysis. Non-significant results were found between the six groups (TSH above 
the 97.5th percentile, T4 below the 2.5th percentile or a combination of both, and then 
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whether the mothers were treated or not). It was argued that the groups were too small 
however and thus underpowered to find any statistically significant results.  
1.2.6.2. Conclusions 
The current analysis indicated that within the UK only CATS I cohort, there was no significant 
difference between the mean IQs of children from either the treated SGTF or untreated SGTF 
mothers at age 3 years. The CATS I published findings, when including the Turin sample, 
found p = .40 compared to the identified p = .447 for full scale IQ in the current chapter. This 
indicated that the Italian sample did not make any difference to the reported findings 
between the treated and untreated SGTF groups. Conversely, when the IQs ≤ 85 are 
considered, for full scale IQ I identified that there was a significant difference between the 
UK only cohort of CATS I, but the published findings including the Italian sample were non-
significant. A regression revealed that those children from the untreated SGTF group were 
3.335 times more likely than those from the treated SGTF group, to obtain a full scale IQ ≤ 
85.  
As discussed, one of the major limitations of CATS I was that the children were young, thus 
a speedy intelligence test was desirable. Also, none of the offspring from the normal GTF 
were examined. CATS II secured funding to revisit children from both of the SGTF groups, 
and also some from the normal GTF group. As the children were older (around 7-10 years), 
a more in-depth intelligence battery was administered as well as the option to explore 
further cognitive domains. With older children, a measurement of the child’s behaviour was 
also attainable, and the study also collected vast physical measurements (not discussed in 
this thesis).  
1.2.7. Thesis aims of section 1: CATS II data 
Based on the literature reviewed and the re-analysis of the CATS I findings, the following 
research aims were developed: 
i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at age 
3, would any differences to the normal GTF group be measurable; as there is a wealth 
of studies displaying that an underactive thyroid during pregnancy does not affect a 
child’s cognition (53, 56, 91-93, 95, 96).  
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
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For the data I collected for CATS II, specific hypotheses grounded in theory were also 
developed and can be found in the respective results chapters; for intelligence see page 62, 
for additional cognitive domains see page 85 and for the behaviour see page 103.  
1.2.8. Chapter Summary 
This chapter has covered the CATS I UK only cohort analysis; it contained a study overview 
and in-depth description of how mothers were recruited into the project during their 
pregnancies. A brief methodology of the WPPSI-III measure was included in the methods 
section, as well as how the WPPSI-III was administered. The statistical analysis conducted for 
this re-run of the data was discussed followed by the main t-test results. The chapter 
concluded with the discussion of the non-significant results between the treated and 
untreated SGTF groups. The aim of this chapter was to aid the reader to grasp a better 
understanding of the project, and how CATS I had developed before I began the data 
collection in CATS II. The following chapter reviews the protocol for the cognitive and the 
behavioural data collected for CATS II and discusses the analysis of my data that I adopted 
for this thesis.   
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1.3. Methods for the cognitive and behavioural data collection for the 
CATS II study 
1.3.1. Chapter Overview 
The current chapter identifies the methods and methodology that were undertaken for the 
data collection for CATS II and, in-turn, this thesis. Before I began work on CATS II, the IQ test 
was pre-selected for data collection, in addition to the child behaviour questionnaires. Some 
of the questionnaires had already been administered to mothers who participated before 
my employment. The specific assessment battery used to investigate further cognitive 
domains was suggested as I began my journey on the project, however I did have direct input 
into which tests were to be selected from the battery.  
CATS II was the follow-on study from CATS I, a large multi-centre RCT that aimed to 
investigate the possible long term effects of exposure to SGTF (see Appendix 1: Timeline of 
the CATS project). In CATS II cognitive assessments were administered to children aged 
between 7 and 10 years to ascertain their overall development. The study aimed to recruit a 
total of 480 participants from August 2011 over 4 years, and to complete the cognitive 
assessments in the latter 28 months of the project. Participants were seen either at the 
research centre (a clinical environment) or visited at their homes. If the participants 
preferred they had the choice to provide a reduced data set using a postal pack. The study 
was approved by the Wales Research Ethics Committee 2 and Caldicott Guardian.  
I disaggregated this thesis from the CATS II project by adopting a different statistical analysis 
plan; briefly described in this chapter and more detail can be found in the following relevant 
results chapters. The different analyses were adopted to illustrate how this body of work was 
separate from the planned CATS II analysis. The results of the three groups of participants 
were analysed (normal GTF, treated and untreated SGTF) with no further investigations into 
pregnancy thyroid function to focus this work on psychological outcomes. 
1.3.2. Population, eligibility and sample size 
Participants were included if they were involved in CATS I and originally recruited in the UK. 
The CATS I sample did include a subset of participants from Turin, Italy (n = 5,497); these 
were not included in CATS II. As mentioned CATS II began recruiting before the cognitive 
assessments commenced as physical aspects of the mother-child pairs were investigated in 
the UK only. As funds were secured later for the cognitive assessments, it was logistically 
easier to keep to the UK only and not revisit those from Italy. Potential participants were 
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approached for CATS II when the child involved in the study was ≥7 years 0 months to ≤ 10 
years 11 months. Participants were excluded from the study if they had moved overseas.   
With a 5% two-sided significance level and 90% power, a sample of 120 from both treated 
and untreated SGTF groups would have allowed a detection of a difference of 6 points in 
mean IQ (assuming mean IQ to be 100 with a SD of 15 (78)) for a statistically significant result. 
In addition 240 participants (1.5%) from the normal GTF group were randomly selected from 
the UK cohort of CATS II; 15,744. These participants were used to assess whether there was 
an interaction with maternal thyroid status on offspring IQ as a baseline comparison. 
Therefore, three groups were re-visited at offspring age 9; normal GTF, treated and 
untreated SGTF.  
1.3.3. Measures 
To be able to address the aims of CATS II, an IQ test (a) and additional cognitive tests (b) were 
administered to the children in the study. Questionnaires (c) were also completed by the 
mothers to quantify if any behavioural problems were evident in the children.  
a) The Wechsler Intelligence Scale for Children- Fourth Edition UK (WISC-IV). The WISC-
IV (78) provided subtest and composite scores that represented intellectual 
functioning across specific cognitive domains: Verbal Comprehension (VC); 
Perceptual Reasoning (PR); Working Memory (WM); and Processing Speed (PS). The 
IQs generated from these areas equally contributed to the Full Scale (FS) IQ. 
b) Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-II). Possible 
delays in long term memory (LTM), WM and fine-motor skills were investigated by 
selected subtests from the NEPSY-II (230): List Memory and List Memory Delayed 
(combined score) (LTM), Memory for Designs (WM), Memory for Designs Delayed 
(LTM), Fingertip Tapping (motor) and Narrative Memory (WM). 
c) Questionnaires: 
i. Strengths and Difficulties Questionnaire (SDQ) (231) 
ii. Child ADHD Questionnaire (modified by Thapar et al. (232)) 
iii. Social Communication Questionnaire (SCQ) (233)  
iv. General CATS questionnaire (administered to gather demographic 
information) 
A brief overview of the study procedure follows the discussion of each measure, more detail 
regarding the administration of the specific measures can be found in the following three 
results chapters (pages 62-104). As I was the only examiner and sole person scoring the 
questionnaires for CATS II, there was good consistency; training was completed prior to 
cognitive test administration. A randomly selected 10% of completed cognitive assessments 
were double scored to ensure accuracy by an educational psychologist on the research team. 
Stability was ensured by reviewing means fortnightly to check no scaled or composite scores 
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were well above or below the average which may have indicated skewed testing. The 
cognitive tests were administered in a set order with standardised verbal instructions given 
to each child. The WISC-IV was administered first, followed by the NEPSY-II. All behavioural 
questionnaires were completed by the child’s mother.  
a) 1.3.3.1. WISC-IV 
The WISC-IV used for the data collection of CATS II, was the UK standardised fourth edition 
(78). As mentioned in the General introduction (chapter 1.1.), it was reported in the literature 
that a deficit to a child’s intelligence may be measurable if the mother had SGTF (34, 49-57, 
90, 91). The WISC-IV was adopted as the Wechsler scales are the most widely used tests of 
intelligence in the world (234-238). Furthermore, the WISC-IV generated a FSIQ as a 
representation of an individual’s general intelligence functioning, as well as yielding four 
domain scores (VCIQ, PRIQ, WMIQ and PSIQ). Thus if there were any specific deficits, the 
assessment could be interrogated to investigate where these might be.   
1.3.3.1.1. Development of the WISC-IV 
As well as the Wechsler scales being the most widely used intelligence batteries, they have 
led development and research into intelligence for more than 50 years (239). Conversely, 
WISCs have been criticised for lacking a firm grounding in theory (234, 240) with studies 
scrutinising their higher order structure (240, 241).   
The WISC-IV began its development over 60 years prior to its use in the CATS II research. The 
very first of the Wechsler tests was called the Wechsler-Bellevue Intelligence Scale (242), 
with Form-II released in 1946 (243). Soon after, the first Wechsler intelligence scale for 
children (ages 5-15 years) was published (244), and subsequently revised in 1974 (245). The 
third edition was published 17 years later (246), the fourth edition (current research) in 2003 
(78) and the most recent, fifth edition, in 2014 (247). Versions II, III, IV and V assessed 
children within the range of 6 years 0 months to 16 years 11 months.  
The WISC-IV included more items than its predecessor to enable it to test lower functioning 
in younger children; ceilings had also been improved on certain subtests (240). It contained 
15 tests, with ten constituting the core battery of the assessment. These ten core subtests 
were selected for the CATS II data collection and none of the additional five tests were used, 
to help aid continuity between participants. The WISC-IV was the first to measure on four 
factor indices: VC, PR, WM and PS. Around 60% of the core subtests from the WISC-IV were 
new or revised from the third edition (241). The WISC-V has been published in the United 
States (US), but at time of writing this thesis is awaiting UK standardisation. The fifth edition 
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is a major revision of the fourth (248), which now includes a larger five-factor model where 
PR has been divided to measure visual spatial and fluid reasoning as two separate entities 
(similar to what was suggested by Kaufman et al. (234) in their review of the WISC-IV). 
Furthermore, the FSIQ from the WISC-V can be calculated by seven core subtests instead of 
the ten used in CATS II, which is a positive aspect with regard to testing time, but could invite 
criticism for reliability (i.e. if a child performs badly on one subtest, it will have a higher 
impact on the FSIQ (249)).  
One of the reasons the WISCs are popular intelligence measures, is that all of the editions 
have undergone extensive norming and standardisation. The WISC-IV used in the current 
research, was standardised from a stratified sample of 2,200 individuals: 200 children per 
year of birth within the specified WISC-IV age range, with equal numbers of males and 
females (78). For the UK standardisation (250); 800 British children in 110 schools were 
examined within the space of six months concluding that some of the language had to be 
altered for the UK version. Norming the WISC-IV would have been complex as the battery 
assessed a wide age range of children with differing levels of ability. Norming was also 
important to ensure that older children would not get frustrated by answering questions that 
were too simple, likewise that younger children would begin a subtest at an appropriate 
level.   
1.3.3.1.2. Reliability and Validity 
The reliability of a test refers to the accuracy, consistency and stability of the test scores 
across multiple situations (251). Test-retest stability was assessed using a sample of 243 
children with 18-27 participants comprising each of the 11 age groups. The WISC-IV was 
administered twice with test intervals ranging from 13-63 days (mean = 32 days), it was found 
that there was adequate stability for all age groups (correlations between tests at time one 
and time two were high r = .80) (78), which demonstrated good consistency of the scores. 
The validity of the WISC-IV invited scrutiny due to the two new radical composite scores (WM 
and PS) and introduction of five new subtests. The three new subtests on the PR domain 
were added to enhance the measurement of fluid reasoning, with the additional two 
subtests assisting measurements of the WM and PS domains (78). A number of inter-
correlational studies were conducted and displayed that the WISC-IV correlated well to other 
child Wechsler scales (r = .89, see Kaufman for further details (234)), including its previous 
version.  
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b) 1.3.3.2. NEPSY-II 
Being the most common IQ test (234-238), the WISC-IV was simple to select for the CATS II 
study. Deciding on which additional tests to administer was grounded in theory (see chapter 
1.1., General introduction). As the child cognitive assessments were conducted in one 
session, it was not feasible to test all possible domain deficits. Based on the literature, the 
most frequent deficits investigated were memory and motor coordination. Therefore I 
helped guide the decision process to assess across these domains.  
Subtests from the NEPSY–II (230) were selected and administered in an identical manner. 
The NEPSY-II was chosen for the measure of the additional tests because this assessment 
battery was commonly adopted in the UK and contained the widest variety of subtests to 
choose from on a domain level. As well as suggesting the cognitive domains to assess (see 
Appendix 2: The decision process for additional tests for CATS II), I had direct input into which 
subtests were selected from the NEPSY-II. One of the NEPSY-II subtests, list memory and list 
memory delayed (LM), I suggested adding latterly to testing; this was to aid any evidence 
found for a LTM deficit.  
1.3.3.2.1. Development of the NEPSY 
Korkamn et al. (252) argued the uniqueness of the NEPSY as being solely based on childhood 
assessment, unlike other neuropsychological measures that appeared as ‘add-ons’ to adult 
cognitive scales. Ahmad and Warriner (253) discussed the four main purposes for the 
development of the NEPSY: 
1. To provide an instrument to detect deficits that interfere with learning. 
2. To offer a tool for identifying and assessing brain damage and dysfunction and to 
measure the extent to which they may affect operations and development. 
3. To provide researchers and clinicians with a tool for long-term follow-up. 
4. An instrument that would deliver an assessment that was standardised, reliable and 
valid for investigating normal and atypical neuropsychological assessment.  
The NEPSY was developed in 1998 by Korkman et al. (252) and originally only assessed 
children between the ages of 3 and 12. Prior to this, Korkman published a version in Finish 
for children aged between 5 and 6 years, and the 1998 version followed for a wider age group 
in English. The first edition NEPSY was used to assess across five domains: 
attention/executive function, language, visual-spatial processing, sensorimotor and memory 
and language. The second edition (used in the current research) additionally included the 
domain of social perception (230): this would aid assessments for individuals suspected of 
having an ASC.  
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One of the reasons the NEPSY was so popular was because of the vast norming and 
standardisation completed. For the first and second editions, 100 children of each age group 
and of equal gender were used to make a complete cohort of 1000; for the second edition, 
these were split further by age, half born in the first six months of the year, and the other 
half in the latter (230). The second edition included many subtests from the first edition. 
However, some of these were not re-normed during the standardisation phase (including LM 
among others) (254). The rationale given for this was that these particular tests were not 
expected to be subject to the Flynn effect; however, there was no empirical basis to support 
this decision (255).  
1.3.3.2.2. Reliability and Validity 
The reliability of the NEPSY-II was tested and it was identified that fingertip tapping dominant 
hand (FTDH), fingertip tapping non-dominant hand (FTNDH) and LM were amongst the 
subtests with the highest reliability coefficient, and the lowest were found on some subtests 
including memory for designs (MD) spatial and total scores, and memory for designs delayed 
(MDD) total score (230). It was expected that the lowest reliability tests would mainly belong 
to the memory and learning domain as they would have been influenced by practice effects. 
However, some subtests were not included in the reliability testing, and no rationale was 
provided as to why this would be or why some stability estimates were reused (255).  
The validity was assessed in the NEPSY-II by a number of correlational studies. Validity of 
intellectual functioning was assessed using the WISC-IV (78), Differential Abilities Scales-
Second Edition (256) and the Wechsler Nonverbal Scale of Ability (257). Correlations 
between these scales demonstrated the NEPSY-II to be predictive of cognitive performance 
for both verbal and nonverbal domains (comparisons between the NEPSY-II and WISC-IV are 
evaluated further in chapter 2.4., Memory score comparisons; data from the WISC-IV and 
NEPSY-II assessments). Nine further scales were adopted to test other aspects from the 
NEPSY-II (see Korkman et al. (230) for details).  
c) 1.3.3.3. Questionnaires 
Based on the literature cited in the General introduction (chapter 1.1.), it was apparent that 
possible deficits from SGTF may stretch beyond the cognition of the child and could also 
affect different behavioural aspects (19, 44, 45, 143, 148-151, 170, 175-180). The SDQ was 
adopted for CATS II as it could report across multiple domains. As discussed on pages 19-22, 
there was some evidence that children born to mothers with SGTF may be more vulnerable 
to ADHD and ASC symptoms than those born to euthyroid mothers. As a consequence the 
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Child ADHD Questionnaire (232) and the SCQ (233) were used, selected as measures being 
widely used, familiar to the research team and for ease of administration to minimise the 
burden on the mother (e.g. the SCQ takes approximately ten minutes to answer and less than 
five minutes to score (258)).  
The behavioural questionnaires were given to the mothers of the children in CATS II and were 
completed independently by them. Where possible, participants were asked, after 
completion, if they had any queries regarding the questionnaires and they were also checked 
by a member of the CATS II data collection team that they were filled in correctly (see chapter 
1.6., Behavioural questionnaires at age 9; CATS II data, for further information about missing 
data). No feedback was offered to families for questionnaires. 
i. 1.3.3.3.1. Strengths and Difficulties Questionnaire (SDQ) 
The Strengths and Difficulties Questionnaires (SDQ) (231) used in the CATS II data collection, 
is a brief behavioural screening questionnaire. It was developed as an extension of Rutter’s 
parent questionnaire (259, 260) and has been rated as one of the most commonly used tools 
for measuring psychopathological symptoms in children aged 4-17 years (261) with over 
3,000 research citations (262). Reasons for this include its availability in 40 languages (263), 
it is quick to fill in and cost effective (264). It has been frequently used by the ‘Children and 
Young People’s Improving Access to Psychological Therapies’ (CYP IAPT) programme 
delivered by the national health service in England. Multiple versions are available for the 
parent, teacher and also a self-report form for 11-16 year olds (265); CATS II administered 
the parent version. As the SDQ is so widely used it is constantly under scrutiny. Recently, 
Curvis et al. (266) found that younger children (6-10 years) could self-report the assessment 
tool when items were read aloud to them. This self-reporting could be seen as more accurate 
as it would more eloquently reflect the child’s voice (although changing the mode of delivery 
would inherently change the nature of the tool).  
The SDQ consisted of 25 items grouped into five subscales; hyperactivity-inattention, 
emotional symptoms, conduct problems, peer problems and (a subscale of strength) pro-
social. The five subscales were found to be internationally validated and appeared to have 
good psychometric properties (263, 267-269).  
ii. 1.3.3.3.2. Child ADHD Questionnaire 
The Child ADHD Questionnaire was a combination of two scales that had been modified by 
Thapar et al. (232), a version of the DuPaul scale (270) and Conners’ abbreviated parent 
questionnaire (271). The questionnaire was originally devised to include 14 items from the 
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DSM-III revised ((272)), and it was modified and updated to also include four further items 
to match symptoms from the DSM-IV (125) and ICD-10 criteria (232). There were 18 items 
for scoring out of a possible 26 questions; this included eight ‘dummy’ questions from 
Conners’ questionnaire (271), which were not included in the final score. There were three 
subscales measured by this ADHD tool, inattention (nine items), overactivity (four items) and 
impulsivity (five items). A total ADHD score was obtained by combining all of the three 
subscales together, which would generate a score within the range of 0-54. The higher the 
score obtained on the questionnaire, the higher the presence of ADHD symptoms would be 
for that individual (232).  
The DuPaul scale was rated as having good internal consistency for the subscales and for the 
total score, as test-retest scores over four weeks displayed good coefficient alphas in the 
range of r = .86-.92. (273). There was a moderate correlation between parent-teacher 
agreement scoring the scale (r = .53) (270); which would have been expected for this type of 
scale (273).  
iii. 1.3.3.3.3. Social Communication Questionnaire (SCQ) 
The SCQ had undergone substantial development prior to its use in CATS II. The Autism 
Diagnostic Interview (ADI) was developed by Le Couteur et al. (274), was revised (ADI-R) by 
Lord et al. (275), and was a common tool for screening for ASCs (276). The Autism Screening 
Questionnaire (ASQ) (276) included 40-questions that were based on the ADI-R and provided 
a score across three areas of functioning: reciprocal social interaction (e.g. interest in other 
children), language and communication (e.g. use of conventional gestures) and repetitive 
and stereotyped patterns of behaviour (e.g. unusual preoccupations). The ASQ was 
developed further into the SCQ (233), and its criteria used for screening for a diagnosis of an 
ASC is comparable to the DSM-IV (125).  
The SCQ has been reported to be one of the most widely adopted screening tools for ASCs 
(277) and can screen from 4-40 years of age. Currently, there are two versions of the SCQ 
available; ‘SCQ lifetime’ (used in CATS II) which specifies an individual’s entire developmental 
history and secondly, ‘SCQ current’ which only specifies an individual’s behaviour in the past 
three months (278). The SCQ comprised of 40 yes-no questions with scores of ≥ 15 being an 
indication of the individual possibly having an ASC (for verbal and nonverbal children) (258). 
It has been found that by perhaps lowering the cut off to scores if ≥ 12, there would be an 
increased sensitivity (279), but this could lead to incorrectly identifying children as having an 
ASC when they could be typically developing (258). 
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Correlations between the ASQ and the ADI were highly significant across all domains (276).  
A problem with Berument et al.’s research into the ASQ was that all of the parents in the 
sample had previously completed the ADI-R, which may have affected the validity rates as 
the parents would have been used to similar questioning. However, the revised SCQ version 
was shown to have good external validity (278). Caution was still warranted, as Eaves et al. 
(258) identified that higher functioning children with ASCs were less likely to be identified by 
screening from the SCQ.  
iv. 1.3.3.3.4. General CATS Questionnaire 
The general CATS questionnaire was used to gather demographic information about the 
participants (see Appendix 3: CATS II general questionnaire). The questionnaire was divided 
in two sections; the first to gather information on the mother and the second on the child 
around pregnancy and birth. The former section gathered demographic information and 
some paternal information; occupation and height. There was also a brief section on the 
mothers’ medical history and any current drug therapy. The child section of the 
questionnaire gathered information on medical complications during pregnancy, 
breastfeeding, gestational age and also language spoken at home, school and the child’s 
handedness. This questionnaire collated key information when controlling for certain 
covariates in the data. Most of the data generated was descriptive (i.e. medical history), and 
thus was not used in the main analysis here. Quantitative data such as breastfeeding, 
handedness of the child and language at home and school was used in the current research.  
1.3.4. Recruitment and options for participation 
An initial contact pack inviting the CATS I mothers to participate in the research was mailed 
to all in the SGTF groups; including those who did not participate in CATS I (See Appendix 4:  
Initial contact pack). Re-involvement in CATS II was centred on the age of the child; those 
born earliest during CATS I were contacted first in a rolling recruitment process over the 49 
months of the project. When recruitment began in 2011 there was a very low response rate, 
consequently ethical amendments and approval was sought to make use of the Welsh 
Demographics Service; this enabled telephone calls to prompt responses from potential 
participants. The Patient Data Register was also used to ensure up-to-date addresses for 
individuals from the SGTF groups.  
A slightly different protocol was adopted when contacting individuals from the normal GTF 
group who consented to participate in CATS I but did not participate in the cognitive 
assessments at age 3. There were 15,744 potential participants that could have been 
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contacted from the UK CATS I cohort; 240 participants were required from this group. As 
participants were contacted by year of registration into the study a random selection were 
mailed from each of the four years CATS I recruited for, totalling 5,000 packs being sent to 
mothers from the normal GTF group. Many participants mailed their response forms back 
from the initial contact packs indicating their willingness to take part in the study. See Hales 
et al. (280) for a flow chart of the recruitment process and overview of participation options 
including the data collected. 
There were three options for re-involvement in the CATS study:   
1. Post Packs 
These packs contained a cover letter, specific consent, mother and child information sheets, 
a questionnaire pack, information on how to provide a saliva sample using the spit tubes 
(Oragene•DNA (OG-500) manufactured by DNA Genotek), two spit tubes and a freepost label 
(see Appendix 5: Information sheets from the post packs). From this information, the project 
could obtain samples of the mother and child’s DNA, an indication of the child’s behaviour, 
child pregnancy and delivery information and also a snapshot of the mother’s medical 
history.  
2. Remote/Home Visit 
On successful booking of a remote/home visit, a confirmation letter was mailed out which 
included a copy of the specific consent and information letters for that visit (See Appendix 6: 
Appointment letters); and a text reminder was sent the day before. 
Once at the visit, participants firstly had the opportunity to discuss the research and raise 
any initial questions if they wished. The mothers were reminded not to reveal which study 
group they belonged to so that assessments could be conducted blindly. The order of the 
visit was as follows, consent was taken from the mother, and then she was handed the 
behavioural questionnaires for completion. As the mothers were sent the appointment 
letters in advance, they would already have been made aware about an optimal test 
environment and whether or not they should stay present for the assessment. If any mothers 
did stay in the testing room, they were prompted that they were free to leave the child to 
the assessment. The WISC-IV and NEPSY-II items were subsequently administered to the 
child and the visit would finish upon completion of the spit tube DNA samples.  
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Following the visit, parents were mailed a report of the WISC-IV results (as generated by 
PsychCorp WISC Scorer software). If they had any questions, they could telephone or email 
to make an enquiry. 
3. Research Centre Visit  
A ‘complete dataset’ was obtained from the participants if they attended the research centre 
for a morning visit. Similar to the remote/home visits, a confirmation letter was mailed out 
which included a copy of the specific consent and information letters for that visit (See 
Appendix 6: Appointment letters), and a text reminder was also sent the day before. 
The visits were either at 9am or 10.45am and lasted for around 2-2.5 hours (see Table 8 
below for a detailed breakdown of how the morning visits were constructed, note the 
additional data collected at these appointments for the CATS II project which are not used in 
the current thesis). As can be seen in the table, the research centre visits were under strict 
time constraints. Appointments could not have been offered later to participants as children 
were fasted for the blood sample collection; to enable lipid and blood sugar measurements. 
As can be seen in Table 8, there was a cross over between the two appointments which often 
led to minor practical difficulties when, for example, participants arrived late for their 9am 
appointment. Two appointments were offered per day to try and get as many people re-
involved to CATS as possible. Therefore, up to three cognitive assessments could be 
conducted in a day, as most of the home visits commenced from 3.30pm onwards.  
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Table 8 
Research Centre Visit Appointment Breakdown 
Time slot one Time slot two 
9.00  
PARTICIPANTS ARRIVE 
10.45 
PARTICIPANTS ARRIVE 
9.00-9.20 
Consents, blood/saliva collection and 
pregnancy testing in Clinical Research 
Facility 
10.45-11.05 
Consents, blood/saliva collection and 
pregnancy testing in Clinical Research 
Facility 
9.20-9.40 
Breakfast 
11.05-11.25 
Breakfast 
9.40-10.10 
Medical Physics Dept.: height, weight, 
blood pressure, arterial stiffness and bone 
density scans. Child measurements taken 
in current timeslot. 
11.25-11.55 
Medical Physics Dept.: height, weight, 
blood pressure, arterial stiffness and bone 
density scans. Child measurements taken 
in current timeslot. 
10.10-10.40 
Medical Physics 
Dept.: mother’s 
measurements 
taken.  
10.10-11.40 
Child cognitive 
testing 
11.55-12.25 
Medical Physics 
Dept.: mother’s 
measurements 
taken. 
11.55-13.25 
Child cognitive 
testing 
10.40-11.00 
Mother completion 
of questionnaires 
12.25-12.45 
Mother completion 
of questionnaires 
11.40 FINISH 13.25 FINISH 
 
1.3.5. General Analysis 
As stated in the current chapter overview, this thesis used the same data that I collected for 
the CATS II research project. Details of how the CATS II data was analysed (for publication), 
can be found on the study protocol (280). Different analysis techniques were adopted for 
CATS II and were similar to the exploration design found in the CATS I paper: i.e. looking at 
IQs below a threshold (200). All of the data was cleaned then kept for the current analysis, 
and a copy also passed to the designated statistician for the CATS II project.  
Data was analysed in IBM SPSS Statistics, version 20. The initial analysis included re-running 
the CATS I data for the UK cohort only (see previous chapter, 1.2., Re-analysis of the 
intelligence at age 3; UK CATS I cohort). This served as the pilot study for the subsequent 
analyses. The cognitive measures were scrutinised for dataset accuracy by using histograms, 
z-scores and cross tabulations to identify any outliers and errors in the data set. Descriptive 
statistics were presented as means and SDs.  
1.3.5.1. WISC-IV 
The data collected from the WISC-IV (intelligence measure) attempted to answer two (in 
bold) of the four research aims: 
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i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at 
age 3, would any differences to the normal GTF group be measurable; as there is a 
wealth of studies displaying that an underactive thyroid during pregnancy does not 
affect a child’s cognition (53, 56, 91-93, 95, 96). 
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
Based on the literature reviewed in General introduction (chapter 1.1.), it was hypothesised 
that there would be a significant difference between the normal GTF and untreated SGTF 
groups (34, 49-57, 90, 91), but there would not be a significant difference between the 
treated and untreated SGTF groups (based on the CATS I findings of offspring intelligence 
measured at age 3 (200) and chapter 1.2., Re-analysis of intelligence at age 3; UK CATS I 
cohort). 
The primary analysis for CATS II and this thesis (based on the main deficits reported in the 
literature), was assessing the five IQs between all three groups of participants by a 
MANCOVA. This multivariate analysis was followed by subsequent univariate analysis of 
variances (ANOVA) dependent upon statistically significant results. The multivariate analysis 
of variances (MANOVA) was chosen as the data required a model to fit all three groups 
(between-subjects factor) and multiple dependent variables into one analysis. The MANOVA 
also allowed manipulation for adjustments of several covariates and included four models of 
analysis, analysed in a step-by-step manner controlling for a total of six covariates. Thus the 
final output for the WISC-IV was analysed by a MANCOVA (see Figure 6 below for the four 
models of analysis used in the current research from the CATS II cognitive study protocol 
(280)). These models of analysis were adopted so that the work here would be comparable 
to the CATS II analysis. As mentioned, most of the covariate information was obtained from 
the General CATS questionnaire; of note, mother age at time of consent into CATS I was 
quartiled but mean ages were calculated for the reader’s information. Furthermore, the 
social deprivation score was calculated from postcode scores from StatsWales (281) and 
OpenDataCommunities (282) (England). The Welsh and English ranked scores were changed 
into quintiles to make the data comparable. See Tables 9 and 10 for further information on 
the scoring; the higher the score, the less socially deprived the ranking was. 
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Table 9 
StatsWales Social Deprivation Scores Converted into Quintiles 
Social Deprivation StatsWales Score CATS II Ranking 
Most deprived 
 
 
 
Least deprived 
1-382 1 
383-764 2 
765-1,146 3 
1,147-1,528 4 
1,529-1,909 5 
Note. CATS=Controlled Antenatal Thyroid Screening. 
 
Table 10 
OpenDataCommunities (England) Social Deprivation Scores Converted into Quintiles 
Social Deprivation  OpenDataCommunities Score CATS II Ranking 
Most deprived 
 
 
 
Least deprived 
1-6,497 1 
6,498-12,994 2 
12,995-19,489 3 
19,490-25,986 4 
25,987-32,482 5 
Note. CATS=Controlled Antenatal Thyroid Screening. 
 
The WISC-IV and NEPSY-II results were not compiled into one main MANOVA for two reasons. 
Firstly, the MANOVA would only include those participants who had completed all testing (as 
discussed in chapter 1.5., Additional cognitive assessments at age 9; CATS II data, there were 
multiple reasons why there was a decreased number of participants who completed the 
NESPY-II). Secondly, as this thesis’ findings aimed to be comparable to the CATS II findings, 
the WISC-IV was analysed separately as IQ was the primary outcome of CATS II and the 
NEPSY-II served as additional cognitive assessments.  
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Figure 6: Models of Analysis  
CATS=controlled antenatal thyroid screening. 
 
1.3.5.2. NEPSY-II 
The data collected from the NEPSY-II (additional cognitive domains) aimed to cover two 
(bold) of the four research aims:  
i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at 
age 3, would any differences to the normal GTF group be measurable; as there is a 
wealth of studies displaying that an underactive thyroid during pregnancy does not 
affect a child’s cognition (53, 56, 91-93, 95, 96). 
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
Based on the literature reviewed in the General introduction (chapter 1.1.) and similar to the 
IQ hypotheses, it was predicted that there would be a cognitive deficit for the untreated 
SGTF group compared to the normal GTF group (as supported by (10, 32, 49, 54-58)). 
Similarly, that the treated SGTF and untreated SGTF groups would have non-significant 
differences between their scores (alike to the CATS I findings (200) and chapter 1.2., Re-
analysis of intelligence at age 3; UK CATS I cohort).  
Model 1: Unadjusted 
Model 2: Adjusted for child 
gender 
Model 3: Adjusted for model 2, 
age of mothers at 1st consent 
into CATS I and whether the 
child was breastfed ≥ 1 month 
Model 4: Adjusted for model 3, 
child’s language at school and 
home, where assessed and 
social deprivation 
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This secondary analysis was to explore the additional cognitive assessments administered to 
the children, i.e. the NEPSY-II tests. Similar to the IQ analysis, this took the form of a MANOVA 
before the relative adjustments were made for a MANCOVA. The MANOVA also included all 
three groups of participants and investigated the differences between the scaled scores for 
the MD, MDD, FTDH, FTNDH and narrative memory (NM) tests. The subtest of LM was 
investigated separately (by ANOVA) as the test was introduced latterly into the CATS II study, 
thus it was administered to fewer participants. Therefore, if it had been included in the main 
NEPSY-II MANCOVA, the group numbers would have dropped as the MANCOVA would only 
include those participants that had a complete set of data.  
1.3.5.3. Questionnaires 
The data collected from the questionnaires (behaviour) attempted to answer one of the four 
thesis research questions: 
i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at age 
3, would any differences to the normal GTF group be measurable; as there is a wealth 
of studies displaying that an underactive thyroid during pregnancy does not affect a 
child’s cognition (53, 56, 91-93, 95, 96).  
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
As the null hypothesis was adopted for the WISC-IV and NEPSY-II that there would be no 
differences between the treated and untreated SGTF groups, similarly it was proposed that 
there would be no differences between behaviour either (supported by (19, 45, 144-146, 
148, 171, 172, 174)). It was predicted that there would be a behaviour deficit for the 
untreated SGTF group compared to the normal GTF group; as has been suggested in the 
literature (19, 44, 45, 143, 148-151, 170, 175-180).  
Therefore, a third main analysis was conducted to explore the behavioural questionnaires. 
This was undertaken by using total scores of domains by a MANOVA (model one), and 
MANCOVA by models two and three of the analysis (here, model three also included 
controlling for social deprivation and child age). School and home language and where the 
child was assessed were not taken into consideration as these were proposed not have 
affected the questionnaire outcomes.  
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1.3.5.4. Exploratory Analysis (section 2) 
In the second section of this thesis (from page 125), multiple exploratory analyses were 
undertaken. Briefly, this section comprises of the following: 
i) Investigations of the effects of the covariates on the dependent variables of 
CATS II; explored by t-tests and MANOVAs.   
ii) IQs of CATS I and CATS II were compared by correlations and a repeated 
measures MANCOVA.  
For further details of the specific analyses completed, please see the relevant results 
chapters.  
1.3.6. Chapter Summary 
This chapter described the methodology behind the assessment measures used for this 
thesis and attempted to disaggregate the separable work for this thesis and the CATS II 
research publication. This chapter described the population of CATS II, eligibility for re-
participation and the desired group sizes that were worked towards. The development, 
reliability and validity of the cognitive assessments I conducted for the study and also the 
questionnaires, were discussed. Further detail of what each tool consisted of can be found 
in the following three chapters, as well as a brief overview of how they were scored. This 
chapter concluded with how the participants took part in the study, and highlighted how the 
cognitive assessments only took place for those who attended the research centre or opted 
for a remote/home visit. As the cognitive assessment data collection period lasted for around 
28 months with a maximum of three assessments being conducted in a day, every effort was 
made to maximise recruitment into CATS II. The following chapter details the WISC-IV data 
analysis.  
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1.4. Intelligence measured at age 9; CATS II data  
1.4.1. Chapter Overview 
This chapter contains the work relating to the IQ test assessments and statistical analysis 
between the three groups of participants. Within this chapter, there is a brief overview of 
the topic as the main literature identified is described in detail in the General introduction 
(chapter 1.1.). The methods section describes the process of the assessment administration, 
there is a statistical analysis plan and explanation of how the data was prepared. The results 
section follows, then a discussion of the results including the limitations and main 
conclusions.  
1.4.2. Introduction 
The aim of the work presented in this chapter was to investigate whether there were 
differences in IQ measurements between the three groups of participants (treated SGTF, 
untreated SGTF and normal GTF). Based on previous research, it was hypothesised that there 
would be a significant difference between the normal GTF and untreated SGTF groups (34, 
49-57, 90, 91), but no difference between the treated and untreated groups based upon the 
CATS I findings of IQs at age 3 ((200) and chapter 1.2., Re-analysis of intelligence at age 3; UK 
CATS I cohort).  
1.4.3. Method 
The anticipated sample size for CATS II was 480 participants to address the null hypothesis 
that there would be no difference of IQs between all three participant groups. The 
participants were assessed for IQ by the WISC-IV (78), UK version. The WISC-IV was 
administered in a standardised format and I was the sole examiner on the study which 
provided consistency. I was blinded to the participant groups as not to introduce any bias to 
the testing (or scoring) and 10% of packs were double scored by an educational psychologist 
on the project team to ensure reliability.  
The WISC-IV can be used to assess children between the ages of 6 years 0 months and 16 
years 11 months. No hints or help for the examinee were allowed during testing as this could 
have incurred a ‘spoilt’ answer. Attempting to build rapport before the assessment was 
important to help maximise effort from the participant. Administration time of the core ten 
subtests took between 65-80 minutes. The more intelligent a child was, the longer the 
assessment was; as more items were administered per test. The order of the tests were, 
blocks design, similarities, digit span, picture concepts, coding, vocabularly, letter-number 
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sequencing, matrix reasoning, comprehension and symbol search. See Table 11 for further 
information of each subtest, as organised by their respective domains.  
Table 11 
Descriptions of the Wechsler Intelligence Scale for Children- Fourth Edition, UK Subtests 
IQ Domain Subtest Description 
VCIQ: 
A measure 
of an 
individual’s 
verbal 
capabilities 
Similarities The child was presented with two words that had a 
common object or concept and was requested to describe 
orally how they were similar. 
Vocabulary The child was requested to give verbal definitions of 
words. 
Comprehension This item required the child to answer questions based on 
their understanding of social situations and general 
principles. 
PRIQ: 
An 
individual’s 
non-verbal 
and fluid 
reasoning 
capabilities 
Block Design All items required the child to view a constructed model or 
picture from the stimulus book and then use red-and-
white blocks to re-create the pattern within a specified 
time limit. 
Picture 
Concepts 
The child was presented with two or three rows of pictures 
and was requested to choose one picture from each row 
to form a group with a common characteristic. 
Matrix 
Reasoning 
The child was presented with an incomplete matrix and 
was requested to select the missing portion from five 
options. 
WMIQ: 
Identified an 
individual’s 
short term 
memory 
capacity 
Digit Span Digit span was comprised of two components: digit span 
forwards and digit span backwards. Digit span forwards 
required the child to repeat numbers in the same order as 
they were read aloud to them. Digit span backwards 
required the child to repeat the numbers in reverse order 
to how they were said to them. 
Letter-number 
Sequencing 
The child was read a sequence of numbers and letters and 
was required to recall the numbers in ascending order and 
then the letters in alphabetical order. 
PSIQ: 
Measured 
the 
individual’s 
processing 
speed. 
Coding The child was required to copy symbols that were paired 
with numbers. 
Symbol Search The child was required to scan a search group and indicate 
whether the target symbol(s) matched any symbols in the 
search group within a specified time limit of two minutes. 
Note. VCIQ=verbal comprehension intelligence quotient, PRIQ=perceptual reasoning 
intelligence quotient, WMIQ=working memory intelligence quotient, PSIQ=processing speed 
intelligence quotient. 
 
The average for a scaled score was 10 and SDs were ± 3 points, whereas IQs had a mean of 
100 and SDs were ± 15 points. The design of the scale is such that about 68% of children 
obtain IQs between 1 SD above and below the mean, 96% in the 2 SD range and 99.8% in the 
3 SD range (IQs: 55-145) (78). Percentile ranks were also calculated, the ranks would range 
from 0.1-99.9 with 50 being the mean and median.  
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The WISC-IV raw scores were calculated by hand and then inputted into an-automated WISC-
IV scorer to generate age-equivalent scaled scores. The automatic scorer calculated the sum 
of scaled scores for a domain to produce the IQ. The FSIQ would be calculated by the 
software adding the total sum of ten scaled scores. The WISC-IV scorer also generated a 
parent-report which detailed the IQ scores, percentile ranks and classifications (e.g. average, 
high average etc.). The percentile ranks were useful to parents as they quantified how their 
child theoretically performed against a group of 100 ‘typically developing’ children. If the 
participants had any questions regarding their child’s results, they were able to directly 
contact me. 
1.4.4. Statistical Analysis 
Data entry and data cleaning was completed on a blinded dataset (i.e. the participants were 
still all grouped as one complete cohort, as they had been during the data collection phase 
of the study. This method of ‘blinding’ meant a reduction in any potential research bias 
between groups, for example when removing outliers from the dataset.  
Checks were executed to investigate whether the correct child was re-recruited into CATS. 
This was completed by comparing child date of birth against the estimated delivery date. 
This was also completed during the data collection phase and subsequently six participants 
were removed prior to data cleaning. As stated in the protocol paper for CATS II (280), the 
age ranges were ≥ 7 years 0 months to ≤ 10 years 11 months. Based on this, one set of data 
was removed for the child being 6.5 years and five datasets were removed for the children 
being ≥ 11 years to 11 years and 5 months. Further to this, in the original CATS I study (200), 
participants were excluded if they were carrying twins. A set of twins were assessed in CATS 
II and thus, were also removed.  
The following nominal data was checked for miss-inputting by range checks: how participants 
took part in the study (i.e. attending research centre or home/remotely), child gender, dates 
of participation and assessment, age at testing, and school and home language for the child.  
WISC-IV scaled scores, followed by the IQs and percentile ranks, were checked for input 
errors by frequency analysis to ensure none of the values were outside the plausible ranges. 
Following this, the distributions (floor/ceiling effects were explored) and outliers were 
examined. From this method, nine IQs were flagged as input errors, and corrected by pulling 
hardcopy data.  
Histograms and z-scores were computed for all IQs. The histograms (Figures 7 and 8) 
indicated how there may have been a possible outlier in the dataset. Z-scores were 
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computed, which confirmed this individual as having four out of five IQ z-scores < -3; none 
were > 3. After this individual had completed cognitive testing, a note had been added to the 
dataset: 
“NB: concept of PS tasks for WISC not grasped. No effort on matrix 
reasoning.” 
Based on this, this participant was removed from all subsequent CATS II analyses. There were 
four other individuals that could have been classified as outliers based on their z-scores for 
VCIQ and WMIQ. These individuals were not removed as they only presented an abnormal 
z-score on one IQ score. Further to this, for our study population to be representative of the 
general population, we would still require some individuals to fall within the ‘tail-ends’ on 
the bell-curves in order to represent our sample pragmatically and to allow variability. 
Moreover, if these four individuals had been removed, then it could be argued that you could 
reanalyse the z-scores to search for more possible outliers and also analyse z-scores for the 
ten subtests; in which participant numbers would decrease and decrease. Therefore the total 
CATS II sample was 452 with complete IQ data. 
With the identified removed participants, the final 452 participants’ histograms were 
recalculated and were as follows (Figure 9 and 10): all ten histograms calculated show the 
data fitting well into a normal distribution curve with little skewness or kurtosis effects.  
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Figure 7: Histograms of Verbal Comprehension Intelligent Quotient (IQ), 
Perceptual Reasoning IQ, Working Memory IQ and Processing Speed IQ (n=461) in 
the Controlled Antenatal Thyroid Screening study II with removed participants  
WISC=Wechsler intelligence scale for children-fourth edition, UK. X axis=IQ scores, 
Y axis=frequency. 
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Figure 8: Histogram of Full Scale Intelligent Quotient (IQ) (n=461: complete dataset) in 
the Controlled Antenatal Thyroid Screening study II  
WISC=Wechsler intelligence scale for children-fourth edition, UK. X axis=IQ scores, Y 
axis=frequency. 
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Figure 9: Histograms of Verbal Comprehension Intelligent Quotient (IQ), Perceptual 
Reasoning IQ, Working Memory IQ and Processing Speed IQ (n=452) in the Controlled 
Antenatal Thyroid Screening study II with removed participants  
WISC=Wechsler intelligence scale for children-fourth edition, UK. X axis=IQ scores, Y 
axis=frequency. 
 
Figure 10: Histogram of Full Scale Intelligent Quotient (IQ) (n=452) in the Controlled 
Antenatal Thyroid Screening study II with removed participants  
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WISC=Wechsler intelligence scale for children-fourth edition, UK. X axis=IQ scores, Y 
axis=frequency. 
All Kolmogorov-Smirnov (and Shapiro-Wilk) normality tests were generated with all p’s < .044 
for the IQ measures. However, means and medians appeared close and skewness and 
kurtosis ranges were all within the -1 - +1 range and thus were normal (see Table 12 below). 
The WISC-IV data was analysed by parametric tests as the variables were continuous, and 
based on the means, medians, skewness, kurtosis and the histograms (see figures 9 and 10), 
the data was accepted as being normally distributed.  
Table 12 
Means, Medians, Skewness and Kurtosis for all 5 Intelligent Quotients (IQs) 
IQ Domain Mean Median Skewness Kurtosis 
WISC-IV VCIQ 99.19 
(11.32) 
99.00 .303 .376 
WISC-IV PRIQ 104.94 
(12.57) 
104.00 -.025 -.299 
WISC-IV WMIQ 99.86 
(11.93) 
99.00 .233 .599 
WISC-IV PSIQ 103.00 
(12.73) 
103.00 .133 -.507 
WISC-IV FSIQ 102.54 
(12.12) 
102.00 -.103 -.317 
Note. Standard deviations appear in parentheses below means. WISC-
IV=Wechsler Intelligence Scale for Children- fourth edition, UK, VC=verbal 
comprehension, PR=perceptual reasoning, WM=working memory, 
PS=processing speed. 
.  
. 
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Table 13  
Wechsler Intelligence Scale for Children- Fourth Edition, UK (WISC-IV) Participant Group 
Demographics 
 Group 
 Normal GTF 
(n=233) 
Treated SGTF 
(n=118) 
Untreated 
SGTF (n=101) 
Participated 
(n) 
Research Centre 
(n=assessed at 
home) 
191 (79) 78 (51) 47 (29) 
Remote/Home 42 (18%) 40 (33.9%) 54 (53.5%) 
Total home visits (n) 121 (52%) 91 (77.1%) 83 (82.2%) 
Mean Age (yrs) 9.66 9.40 9.46 
Gender (n) Male 117 65 50 
Female 116 53 51 
Child’s 
language at 
school and 
home (n) 
English School and 
English at Home 
181 (77.7%) 94 (79.7%) 88 (87.1%) 
Welsh School and 
English at Home 
42 (18%) 20 (16.9%) 11 (10.9%) 
Welsh School and 
Welsh at Home 
7 (3%) 3 (2.5%) 1 (1%) 
English School and 
Other Language at 
Home (not Welsh 
or English) 
2 (.98%) 1 (.8%) 1 (1%) 
Welsh School and 
Other Language at 
Home (not Welsh 
or English) 
1 (.4%) 0 0 
Whether the 
mother 
breastfed over 
1 month 
Yes 150 (64.6%) 72 (61.5%) 56 (56%) 
No 82 (35.3%) 45 (38.5%) 44 (44%) 
Missing 1 1 1 
Mother age at time of consent into 
CATS I 
Mean of quartile (mean, years) 
2.5 (31.82) 2.2 (30.26) 2.3 (30.99) 
Social deprivation score (Mean of 
quintile) 
3.7 3.8 3.3 
Note. Further information appears in parentheses following n’s were applicable. 
SGTF=suboptimal gestational thyroid function, CATS=controlled antenatal thyroid 
screening. 
 
Table 13 shows the group demographics of each participant group. How the participants 
opted to take part in CATS II varied between the groups. More than 80% of the normal GTF 
group opted to attend the research centre for a visit, compared to around 60% of the treated 
and 45% of the untreated SGTF groups. ‘Participant group’ and ‘where the child was 
assessed’ were compared by a Chi-square and confirmed to be significantly different; X2 (2, 
n = 452) = 36.765, p < .001. This decreasing attendance between the groups could be a 
product of individuals from the SGTF groups having participated previously and perhaps, not 
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wanting to sacrifice as much time to the project again. This was also reflected in the number 
of home visits that were a consequence of shortened research centre visits. The ages of the 
children were compared by an ANOVA, and significance was identified: F (2, 449) = 6.182, p 
= .002, p2 = .027. The treated SGTF were significantly younger than the normal GTF group: p 
= .004, 95% CI [-.4623, -.0664]. Conversely, this should not have affected the IQ testing as 
the WISC-IV takes account of child age (described further in the discussion). Gender of the 
offspring and child’s language at school and home appeared to be equal between groups, as 
did breastfeeding, mother age at time of consent into CATS I and social deprivation score. By 
having any of these differences between the groups, it could indicate compromised 
randomisation. I attempted to overcome these effects by controlling for six covariates; child 
gender, age of mother at time of consent into CATS I, whether the mother breastfed over 
one month, where the child was assessed, child’s language at school and home and social 
deprivation score (see Figure 6 page 59. chapter 1.3., Methods for the cognitive and 
behavioural data collection for the CATS II study, for further information).  
The data cleaning process resulted in 15 children being removed and leaving the final sample 
at 452. The WISC-IV data was analysed using a MANCOVA in IBM SPSS Statistics version 20. I 
decided to replicate the proposed four models of analysis from the CATS II protocol (280) so 
that the findings would be comparable (see chapter 1.3., Methods for the cognitive and 
behavioural data collection for the CATS II study, for further information). The participant 
group information was added to the database after data cleaning was complete. A blinded 
analysis could not have been undertaken as, from the start of the data collection phase, 
those responsible for recruitment were aware of the target numbers for each group and thus 
it was deducible which was which group based on the frequency of participants in each. Any 
significant differences identified at the multivariate level were followed up with post hoc 
tests (Bonferroni was selected as one of the most ‘strict’ post hoc corrections to control the 
overall type one error rate when multiple testing is carried out (210)), to investigate where 
the significant differences were. 
As shown in chapter 1.3. (Methods for the cognitive and behavioural data collection for the 
CATS II study), the analysis included four models to adjust for all covariates (see Figure 6). 
Information for models two to four was mainly generated by the ‘General CATS 
Questionnaire’ (see Appendix 3: CATS II general questionnaire). Age of mothers at time of 
first consent (recruitment) into CATS I, i.e. age during their pregnancy, was collated from 
CATS I. Social deprivation was assessed by postcode scores from StatsWales (281) and 
OpenDataCommunities (282). The Welsh and English ranked country scores were separated 
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into quintiles to allow all participants to have their social deprivation controlled as a 
covariate for the analysis. 
Similar to the CATS I UK only cohort analysis (chapter 1.2., Re-analysis of intelligence at age 
3; UK CATS I cohort), percentages of participants scoring IQs of ≤ 85 (1 SD from the mean) 
were computed, to enable comparisons to be drawn from the main CATS II findings to the 
work completed for this thesis. The frequency of participants scoring ≤ 85 were tested by a 
Chi-Square and any significant values were followed up and adjusted for covariates by a 
multinomial logistic regression. This was explored in CATS I as there was an attempt to 
replicate the findings from Haddow et al.’s (54) benchmark study which identified 
significantly more children with IQ scores below 85 if they were born to mothers with high 
TSH compared to those with normal thyroid function. Lazarus et al. (200) proposed that the 
15% of the untreated SGTF group would score ≤ 85 (Haddow et al.) and that there would be 
5% from the treated SGTF; comparable to Haddow et al.’s normal thyroid group. In line with 
the WISC-IV (78), it was anticipated that 16% of the normal GTF would score ≤ 85.  
1.4.5. Results 
1.4.5.1. General attendance information 
As can be seen in the bar chart below (Figure 11), those recruited back into CATS II were very 
close to the targets of 240 for the normal GTF group, and 120 into each treated and untreated 
SGTF group.  The smallest group recruited back into CATS II were those from the untreated 
SGTF group. A reason for this differential attrition may be that mothers from this group did 
not receive treatment from us during their pregnancy and subsequently might view the study 
team as ‘not helping/helpful’. As we did not ‘help them’ during their pregnancies to correct 
for their SGTF, why would they now help us with the continued study?  Further recruitment 
frequencies and demographics are displayed by participant group in Table 13.   
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Figure 11: Graph to show participants with completed cognitive assessments in the 
Controlled Antenatal Thyroid Screening study II (n = 452)  
SGTF=suboptimal gestational thyroid function. X axis= study groups, Y axis = count of 
participants. 
 
1.4.5.2. Analysis 
Table 14 shows the means and SDs for all study IQs as per group and adjusted for by model 
four (see Figure 6) (NB total n has decreased due to missing data for breastfeeding (n = 3)). 
The graph (Figure 12) displays the means achieved by the groups pictorially (unadjusted 
model); error bars have also been included.  
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Table 14 
Intelligent Quotient (IQ) means by study group and model 4 
 Participant Group Mean N 
WISC-IV 
VCIQ 
normal GTF 99.81 
(11.256) 
232 
treated SGTF 97.62 
(10.002) 
117 
untreated SGTF 99.74 
(12.841) 
100 
Total 99.22 
(11.339) 
449 
WISC-IV 
PRIQ 
normal GTF 105.37 
(12.298) 
232 
treated SGTF 104.32 
(12.219) 
117 
untreated SGTF 104.83 
(13.653) 
100 
Total 104.98 
(12.571) 
449 
WISC-IV 
WMIQ 
normal GTF 99.91 
(11.236) 
232 
treated SGTF 99.61 
(13.128) 
117 
untreated SGTF 100.04 
(12.294) 
100 
Total 99.86 
(11.964) 
449 
WISC-IV 
PSIQ 
normal GTF 103.66 
(12.748) 
232 
treated SGTF 102.99 
(12.688) 
117 
untreated SGTF 101.68 
(12.806) 
100 
Total 103.04 
(12.741) 
449 
WISC-IV 
FSIQ 
normal GTF 103.10 
(11.683) 
232 
treated SGTF 101.66 
(11.978) 
117 
untreated SGTF 102.42 
(13.315) 
100 
Total 102.57 
(12.127) 
449 
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Note. Standard deviations appear in parentheses below means. WISC-IV=Wechsler 
Intelligence Scale for Children- fourth edition, UK, IQ=intelligent quotient, VC=verbal 
comprehension, PR=perceptual reasoning, WM=working memory, PS=processing speed, 
FS=full scale, SGTF=suboptimal gestational thyroid function. 
 
 
 
Figure 12: Means per group from the Intelligent Quotient (IQ) testing  
WISC-IV=Wechsler Intelligence Scale for Children- fourth edition, UK, VC=verbal 
comprehension, PR=perceptual reasoning, WM=working memory, PS=processing speed, 
FS=full scale, SGTF=suboptimal gestational thyroid function, CI=confidence interval. X axis= 
IQ domain, Y axis= mean of score. 
 
As stated, the WISC-IV data was investigated by four models of analysis (see chapter 1.3., 
Methods for the cognitive and behavioural data collection for the CATS II study, and the CATS 
II protocol (280)). The unadjusted model of analysis by MANOVA found no significant 
differences between the normal GTF, treated SGTF and untreated SGTF groups on IQ 
measures using Roy’s largest root (most powerful multivariate statistic (210)), ROY = .012, F 
(5, 446) = 1.087, p = .367, p2 = .012. The second model of analysis controlled for child gender 
and also identified a non-significant effect between groups: ROY = .013, F (5, 445) = 1.201, p 
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= .308, p2 = .013. Model three adjusted for model two plus age of mothers at first consent 
into CATS I (i.e. age at which they were pregnant) and whether their child was breastfed for 
more than one month. Similarly, by Roy’s largest root, no significance was reached: ROY = 
.012, F (5, 440) = 1.088, p = .366, p2 = .012. The final model of analysis controlled for models 
two, three, school and home language of the child, where the cognitive assessments took 
place, and also the social deprivation of the mother and child (based on their postcode). 
There was a non-significant effect between groups for IQ measures, ROY = .013, F (5, 437) = 
1.112, p = .353, p2 = .013. There were no main effects or interactions found from the data. 
As the multivariate analysis was non-significant, no further investigations of univariate 
effects were completed. Partial Eta Square results indicated that the effect size in CATS II 
were small (283), which was in keeping with the small sample sizes in the study. Thus the 
study may have lacked power to detect a significant effect, if one existed.  
For the secondary analysis, IQs were analysed for the percentage per group scoring ≤ 85 and 
tested for significance by use of a Chi-Square. Results can be found in Table 15 below. This 
was computed as it was initially investigated in CATS I. This was a further exploratory analysis 
as, if there was no significant difference for the continuous outcome of IQ, there may have 
been a binary outcome measurable by lower IQ scores. As can be seen in Table 15, the PRIQ 
was almost significantly affected, it appeared that the untreated SGTF children had many 
more scoring ≤ 85. This was investigated further with a multinomial logistic regression to 
enable the adjustments of covariates to the dependent variable.  
Table 15 
Intelligent Quotients (IQs) ≤ 85 (%) 
 IQs ≤ 85 (%) 
VCIQ PRIQ WMIQ PSIQ FSIQ 
Normal GTF 
(n = 233) 
28 
(12%) 
11 
(5%) 
18 
(8%) 
22 
(9%) 
15 
(6%) 
Treated 
SGTF  
(n = 118) 
19 
(16%) 
7 
(6%) 
14 
(12%) 
8 
(7%) 
10 
(8%) 
Untreated 
SGTF  
(n = 101) 
12 
(12%) 
12 
(12%) 
10 
(10%) 
10 
(10%) 
12 
(12%) 
Pearson Chi-
Square 
p=.520 p=.051 p=.438 p=.648 p=.247 
Note. Percentages of scores per group are appear in parentheses below totals. VC=verbal 
comprehension, PR=perceptual reasoning, WM=working memory, PS=processing speed, 
FS=full scale, SGTF=suboptimal gestational thyroid function. 
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A multinomial logistic regression was only executed for the PRIQ, as this was the only 
dependent variable that was close to significance (p = .051) as calculated by the Chi-square. 
The regression controlled for all six covariates that were also adjusted for in the MANCOVA, 
and revealed that, following adjustments, non-significance was sustained and there were no 
differences between the groups for PRIQ ≤ 85 between the normal GTF, treated and 
untreated SGTF groups. See Tables 16 and 17 for further details of beta values, significance 
and -2 log likelihood comparing (comparison of normal GTF to treated SGTF was also non-
significant, p = .884).  
Table 16 
Table Displaying the Regression Model’s Fit for the Data 
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
187.870    
Final 156.443 31.428 8 .000 
Note. See improved figure for -2 Log Likelihood. Df=degrees of 
freedom. 
 
  
78 
 
Table 17 
Main Output from the Multinomial Logistic Regression, Perceptual Reasoning Intelligent 
Quotient (PRIQ) ≤ 85 
PRIQ ≤ 85 B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
Lower Upper 
Gender -
.029 
.408 .005 1 .944 .972 .436 2.164 
Where 
Assessed 
-
.607 
.503 1.452 1 .228 .545 .203 1.462 
Language -
.576 
.500 1.328 1 .249 .562 .211 1.497 
Mother 
Age 
-
.422 
.227 3.450 1 .063 .656 .420 1.024 
Breast Fed 
1mns 
-
.397 
.424 .877 1 .349 .672 .293 1.544 
Social 
Deprivation 
-
.464 
.143 10.538 1 .001* .629 .475 .832 
[Normal 
GTF] 
-
.532 
.484 1.209 1 .271 .587 .227 1.516 
[Treated 
SGTF] 
-
.504 
.535 .889 1 .346 .604 .212 1.723 
[Untreated 
SGTF] 
0b . . 0 . . . . 
Note. The reference category was PRIQ ≥ 85. *Significance < .05. SGTF=suboptimal 
gestational thyroid function, B=beta, df=degrees of freedom. 
 
1.4.6. Discussion 
The aim of this chapter was to test the null hypothesis that there would be no difference 
between the three groups of participants (those who were treated during their pregnancies 
for SGTF, those who were not treated, and those who had normal GTF; total n = 452) for 
childhood IQ measures at a mean age of 9 years 7 months. Based on p = .353, we failed to 
reject this null hypothesis. Therefore, no specific differences in the IQs were found between 
the normal GTF and untreated SGTF group, as well as the treated to untreated SGTF groups.  
Percentages of participants with IQs ≤ 85 were also computed as a secondary, exploratory 
analysis. It was found that the untreated SGTF group scored ≤ 85 more frequently than the 
normal GTF group, and it can be inferred that with much larger participant groups 
significance may have been found. The most notable chi-square statistic was on the PRIQ 
domain. The results were extremely close to reaching significance, with the untreated SGTF 
group achieving a much greater number of IQ scores ≤ 85 compared to the treated SGTF 
group and the normal GTF group. These percentages for the PRIQ are the closest to those 
predicated by Haddow et al. (54). The PRIQ scores ≤ 85 were investigated further by a 
multinomial logistic regression, once adjusted for covariates, the effect was lost.  
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There were no significant differences found between the three groups of participants for the 
four models of specified analysis. One of the reasons for this may be that CATS II was 
underpowered. This was indicated by the small Partial Eta Square results. Furthermore, by 
looking for differences between the mean IQs as a continuous outcome, a six IQ point 
difference would have been needed to reach significance (as based on original CATS II study 
calculations to identify sample sizes for the project (280)). There could be many explanations 
why a non-significant result was identified here in contradiction to many other studies that 
have found an underactive thyroid to have a detrimental effect to a child’s intelligence (34, 
49-57, 90, 91). The following discussion is around the reliability of intelligence testing and 
the fluidity of the concept of intelligence itself and explored the mean IQs identified in the 
current dataset. 
1.4.6.1. IQ testing challenges, in the context of CATS II 
IQ testing has been widely criticised in the literature for not being a good representation of 
an individual’s capabilities for a number of reasons, these all tend to focus around the fact 
that an IQ test, is a test, and thus occurs at a single time point. The WISC-IV, like numerous 
other assessments, only measures how a child performs on a particular day at a particular 
time (a ‘snapshot’ of a child’s development (78)). The child’s motivation to complete the IQ 
test is also an important factor to consider as those less motivated to complete the 
assessment would not have performed as well compared to those who were (227-229). 
Intelligence tests tend to rely on the notion that the assessment was the most important 
thing the individual had to do at that particular point in time (284). ‘Stage-fright’ for the child 
was also important to consider; when beginning the WISC-IV, it was stated how establishing 
and maintaining a rapport with the child was key to elicit cooperation and effort during 
testing (78). Rapport was always sought before all of the assessments were conducted. This 
was easier with participants who were seen in the research centre as there was more time 
for the child to see me, the examiner, whilst other data collection aspects for the project 
were underway, e.g. the bone density scans. When the child was assessed in at their home, 
a discussion about the child’s day and/or upcoming festivities was used to help build an initial 
examiner-examinee relationship. Those children who kept their concentration levels high, 
inevitably had quicker assessments as less time was spent attempting to keep them on-task 
and motivated. This point was eloquently illustrated by Young (285) [pp. 105],  
“…intelligent children were those who were obedient…” 
80 
 
At all times, use of the words ‘intelligence’ and ‘intelligent’ were avoided as it could have left 
the child feeling anxious (286). Trying to ease any anxious tendencies for the individuals was 
important, as Moutafi (287) found that under anxiety-provoking instructions, individuals 
performed significantly worse than participants in a non-stressful condition. Having an 
additional adult viewing a cognitive assessment would not induce optimal testing (216). This 
was pertinent to the home assessments as frequently parents would opt to ‘watch’ the 
testing, therefore ‘where the child was assessed’ was viewed as a potential covariate and 
controlled for.  
As well as the problems of the child sitting to take the assessment, there are also general 
problems of the IQ tests themselves. Intelligence tests evaluate an individual’s ability to do 
or say something meaningful during the assessments (288), thus it could be argued that 
these tests are verbally dependent. Furthermore, an individual could score different ranges 
of IQs dependent on which IQ test was administered (289). Kranzler and Floyd (290) agree 
with Kaufamn (289) and discussed how different intelligence tests can produce a range of 
results. As an individual could display discrepancies between IQ tests; revisiting the definition 
of ‘intelligence’ would be beneficial. However, there is no widely accepted definition of 
intelligence. It can be summarised then, that it would be difficult to design a test to assess a, 
somewhat, fluid concept; let alone being able to examine an assessment’s statistical validity 
(291). Fiedman et al. (292) argued and evidenced that some executive functions (processes 
that control and regulate thought and action) were not measured by traditional IQ tests. 
Intelligence testing is (and has been) closely correlated with academic performance, but 
conscientiousness and openness do play a role also (293, 294) and are not accounted for in 
IQ testing. To try and overcome these problems, the WISC-IV was selected as it is one of the 
most commonly used IQ measures (234-238), however as with any cognitive measure, it 
carries limitations. In intelligence tests, an individual’s ‘IQ’ is observed, recorded and scored; 
whereas intelligence is one’s performance and has been argued to be unobservable (227). 
Young (285) discusses how using record forms during the testing measures the outcome 
result rather than the process of the assessment, i.e. how the individual is performing; that 
it quantifies an individual. Whilst this is beneficial for research, more in-depth assessments 
may be required if investigating an individual’s needs.  
As discussed, during the blinded cleaning of the WISC-IV dataset, an outlier was removed. 
This individual had four IQ z-scores < -3 and was clearly observable on histograms of the CATS 
II cohort (see Figures 7 and 8). The WISC-IV had a floor effect in so far as it does not allow IQs 
below 40 (78). If an individual’s raw score was zero for a subtest, the scaled score became 
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one (295) which could have masked a floor effect; this occurred in the removed participant. 
During the Symbol Search subtest (for PSIQ), the examinee was required to select ‘yes’ or 
‘no’ depending on whether a target symbol was located in a fixed number of presented 
symbols. If a child scored an incorrect ‘yes’ or ‘no’ on an item, the score was taken away from 
the total correct answers (e.g. if an individual marked 15 correct and 1 incorrectly, the total 
raw score would have been 14). The removed participant answered extremely quickly and 
selected ‘yes’ or ‘no’ without looking at any symbols- this was evident by the speed in which 
the task was completed. Consequently, this individual ended up with a minus score (as more 
selections were incorrectly marked than correctly marked). However, the raw score had to 
be reported as zero as the WISC-IV was not equipped for taking minus scores. Orsini et al. 
(296) found that this hidden floor effect could artificially increase an individual’s IQ, they 
summarised that those with IQs around the score of 40 may in fact be overestimates of that 
persons true ability.  
1.4.6.2. CATS II mean IQs 
As can be seen in Table 14, the mean IQs for the groups were all close to the desired 
normative mean of 100. As the WISC-IV was UK standardised over a decade ago, it could be 
argued that the means in CATS II were subject to the Flynn effect (see chapter 2.2., IQ 
comparisons between ages 3 and 9; children from the CATS sample, for further discussion). 
The IQ that appeared to be ‘pulling away’ from the others was the PRIQ (normal GTF 105, 
treated SGTF 104, untreated SGTF 105 and total group 105). Higher IQs in non-verbal 
(perceptual reasoning) compared to verbal were first identified in 1942 (297). It was 
recognised that over the course of a decade, there would be a six IQ point increase for non-
verbal, and only 2.6 point increase for verbal; this had been confirmed in many subsequent 
studies (222, 298-300). By looking at multiple studies, it was concluded that in the UK 
between 1979 to 2008, fluid IQ (nonverbal and reasoning) increased, but crystallised IQ 
(verbal and educational abilities) stayed the same (301). A proposed reason for this was the 
‘nutrition theory’ (71, 299, 302-306). This theory posits that the advancements of nutrition 
impacts on the foetus and also on the younger child when their brain is developing and 
growing. This explains why fluid intelligence has increased and verbal has not, and can help 
to explain why a higher PRIQ was found in the CATS II study as compared to the VCIQ.  
On an individual administration level, the PRIQ to VCIQ differences were difficult to explain 
and quantify as the tests that were administered to measure an individual’s PRIQ are 
somewhat “black and white” in nature. For example, it was the same preliminary instructions 
given before each test and scoring was either zero or one. VCIQ would be open to more 
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scrutiny however as the scoring was based on the examiner’s judgement of answers given. 
The slightly low verbal scores may be due to a portion of the children in CATS II attending 
welsh schools (16.2%) and some speaking welsh at home (2.4%). 
Even though no significant differences were found for any of the IQs between the groups, it 
was visible in Table 14 that the means were consistently higher for the normal GTF group 
(except for WMIQ). These differences were slight, and may have reached significance with a 
much larger cohort. Looking closer at the differences between the SGTF groups, we can see 
that there was slight variance; the most notable was for PSIQ. WMIQ and FSIQ had virtually 
no difference between SGTF groups; for VCIQ and PRIQ treated SGTF group had slightly lower 
results compared to the untreated SGTF group. These results support CATS I showing that 
treatment had no effect on childhood cognition. One of the reasons for this may have been, 
as discussed, that the IQ tests were in some way flawed. However, if this was the case how 
have previous studies identified a difference in intelligence measured? It appears more likely, 
that treatment may not have been given at the optimal timing and perhaps initiated too late 
(200), or it may not have been complied with in some cases.  
1.4.6.3. Limitations 
One of the limitations of this data was that the findings were from small groups and thus 
were not generalisable to the general population. From the outset, the CATS II study design 
had attempted to avoid bias by having the cognitive assessments blinded by participant 
group, I continued this by also blinding myself during the data cleaning phase. Bias was 
introduced in other ways however, namely age of child when participating in CATS II (p = 
.002: see Table 13 above and chapter 2.1., Significant effects from the covariates; CATS II 
data, for further information). A possible reason for this may have been because of the way 
in which the children from the normal GTF group were recruited into CATS II. There were 
15,744 possible participants to approach for the 240 required for the normal GTF group. 
Participants were contacted by year of registration into CATS I and invited to take part in the 
research (280).  Participants from both SGTF were recruited in smaller groups as and when 
they were needed, thus not based on their age like the normal GTF children. This method of 
recruitment may explain the age differences, but does not help with understanding why the 
difference was only significant between the treated SGTF group and the normal GTF group 
(p = .004). However, this would not define the IQ results in CATS II as the WISC-IV will have 
taken account of child age, by year and four month intervals.  
83 
 
The WISC-IV used in CATS II was the most recent version available at the time, but it was still 
a decade since standardisation and therefore could be regarded as out of date. On an 
assessment level, this was apparent on a few images in picture concepts (e.g. black board, 
stamp, type writer) and one of the questions from the comprehension test (referred to 
stamps on letters).  For picture concepts, this was overcome by prompting the child that they 
could ask what an image was if they were not sure; this will not have affected the validity of 
the test as it examines the relationships between the objects presented, rather than what 
the objects were. Furthermore, it was stipulated in the administration manual that the 
examiner could have named the pictures if requested (78).  
1.4.6.4. Conclusions 
This results chapter has answered two (bold) of the four research aims: 
i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at 
age 3, would any differences to the normal GTF group be measurable; as there is a 
wealth of studies displaying that an underactive thyroid during pregnancy does not 
affect a child’s cognition (53, 56, 91-93, 95, 96).  
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
The results reported identified that thyroid function during pregnancy did not have a 
negative impact on childhood IQ; there were no significant differences between intelligence 
scores between offspring born to the normal GTF, treated or untreated SGTF groups. This 
was contradictory to some literature available, but was in keeping with CATS I that also found 
no significant differences between children for IQ measured at an earlier time point. As there 
was no difference found between results of CATS I and CATS II, this added validity to the 
cognitive assessments conducted (CATS I incorporated 2 examiners, and I was the only 
examiner for CATS II). A secondary analysis exploring the IQs ≤ 85 revealed no differences 
between the three groups. A repeated study with a larger population might have yielded 
different results, however CATS I was not underpowered to see effects.  
1.4.7. Chapter Summary 
This chapter has discussed the main findings from the WISC-IV IQ testing on the three groups 
of participants; children born to mothers that were treated for their SGTF, untreated for their 
SGTF and those born to mothers who had a normal GTF. No significant differences were 
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identified between any of the three groups on any of the five IQ scores. Significance was 
almost achieved for the PRIQ domain between the groups for a score ≤ 85, but caution was 
advised interpreting this result as no adjustments for the covariates were taken for this 
calculation. This chapter covered the hypotheses for the data, details of the WISC-IV and how 
the children were assessed, how the data was cleaned, statistical analysis, the results and 
the discussion of the results in the context of the IQ test. The discussion also included a 
section on the criticisms noted in the literature of IQ testing as a whole, as it is important to 
consider these when interpreting the main findings. The following chapter details the 
additional cognitive assessments from the NEPSY-II; long term memory, working memory 
and fine motor coordination.   
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1.5. Additional cognitive assessments at age 9; CATS II data  
1.5.1. Chapter Overview 
This chapter contains the data arising from the additional cognitive assessments 
administered in CATS II. There is a brief introduction and methods overview (further 
information on the development of the assessment tool can be found in chapter 1.1. 
(General introduction) and chapter 1.3. (Methods for the cognitive and behavioural data 
collection for the CATS II study). Information about the participants, demographics for the 
three groups and reasons for the differing numbers of completed subtests, are explained. 
The four model statistical analysis is highlighted in the results section. Finally, the chapter 
closes with a discussion including limitations and main conclusions. The data presented in 
this chapter was also used in the main CATS II project; however, the statistical package and 
analysis selected were different to the project to emphasise the separate work undertaken 
for this thesis. 
1.5.2. Introduction 
As well as effects on intelligence for offspring born to mothers that had an underactive 
thyroid during their pregnancy, there was literature available that also investigated 
additional possible deficits on specific cognitive domains; memory and motor-coordination 
(27, 34, 49-51, 54, 92, 97, 103-106, 110-113, 307-312).  
The aim of the work presented in this chapter was to investigate whether being born to a 
mother who had normal GTF, was treated for SGTF or was untreated for SGTF, would have 
had an effect on specific cognitive domains. The specific cognitive domains were working 
memory, long term memory and fine-motor coordination. Further deficits in reading ability 
(49, 53) and hearing loss (91, 124) were not investigated as part of CATS II because of time 
constraints of the assessment structure.  
Similar to the IQ hypotheses, it was predicted that there would be a cognitive deficit for the 
untreated SGTF group compared to the normal GTF group (as supported by (10, 32, 49, 54-
58)). Also, the treated SGTF group and untreated SGTF would have non-significant 
differences between their scores; similar to the CATS I IQ findings (200) and chapter 1.2., Re-
analysis of intelligence at age 3; UK CATS I cohort. 
1.5.3. Method 
Similar to the WISC-IV, a total of 480 participants were required to address the null 
hypothesis that there would be no difference of mean scores between the additional 
cognitive measures and all three participant groups. The NEPSY-II (230) was adopted to 
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explore any possible differences between long term memory, fine motor coordination and 
also further working memory tests amongst the participants. I was blinded to the participant 
group for the NEPSY-II assessments as the NEPSY-II followed the WISC-IV testing. Subtests 
were administered in the same order for participants and as the NEPSY-II was placed second 
it was as a whole (or specific tests were) subject to being ‘dropped’ dependent on the child’s 
fatigue, testing environment issues etc. If a subtest (or subtests) were removed, this did not 
affect the order of the remaining subtests. 
The NEPSY-II was standardised for children between the ages of ≥ 3 years 0 months to ≤ 16 
years 11 months. The complete NEPSY-II included 32 tests and assessed children across six 
domains: attention and executive functioning, language, memory and learning, 
sensorimotor, social perception and visuoperceptual processing. From the literature review, 
it was decided to assess across the memory and language, and sensorimotor domains. Similar 
to the WISC-IV administration, hints or helps were prohibited whilst assessing.  
Administration time of the selected five subtests (four memory, one sensorimotor) was 
about 30 minutes on average; in total the cognitive assessments would take around an hour 
and a half for participants. The order of the tests was list memory, memory for designs, 
fingertip tapping, narrative memory, memory for designs delayed, and finished with the 
delayed recall from list memory. See Table 18 for further information of each subtest, as 
organised by their respective domains.  
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Table 18:  
Descriptions of the Developmental Neuropsychological Assessment Second Edition 
(NEPSY) Subtests Used in the Controlled Antenatal Thyroid Screening study II 
NEPSY-II 
Domain 
Subtest Description 
Memory and 
Language 
List memory 
and list 
memory 
delayed (LM) 
The child was presented with a list of 15 words and 
asked to immediately recall the words. After a delay of 
25-35 minutes, the child was asked to recall the 15 
words from memory 
Memory for 
designs (MD) 
The child was shown a grid with four to ten designs on 
a page, and then it was removed. The child would then 
be required to select designs from a set of cards and 
place the cards in a grid in the same location as shown 
to them. 
Memory for 
designs 
delayed (MDD) 
15-25 minutes after MD was administered, the child 
would attempt the final grid again.  
Narrative 
memory (NM) 
The child was required to listen to a story and then 
repeat the story back. Prompt questions were 
administered for any missing information. The subtest 
would finish with recognition questions. 
Sensorimotor Fingertip 
tapping 
dominant hand 
& non-
dominant hand 
(FTDH & 
FTNDH) 
The first trial was in the dominant hand and required 
the individual to tap the tip of their index finger on 
their thumb as quickly as they could 20 times. This was 
then repeated for the non-dominant hand. Next, the 
child would have to tap their index fingertip against 
their thumb, middle, ring and little fingertip in the 
dominant hand followed by their non-dominant hand.  
Note. LM=list memory, MD=memory for designs, MDD=memory for designs delayed, 
NM=narrative memory, FTDH=fingertip tapping dominant hand, FTNDH=fingertip 
tapping non-dominant hand. 
 
The NEPSY-II generated six scaled scores for comparison. The raw scores were calculated first 
by hand, then using age-derived scales, scaled scores were finally calculated. Similar to the 
WISC-IV scaled scores, a mean was 10 within the range of 1-19, and SDs were ± 3 points from 
the mean. No feedback of the NEPSY-II was made available to parents. As there was no 
feedback, no percentile ranks were calculated for the NEPSY-II as the scores were for the 
project purposes only.  
1.5.4. Statistical Analysis 
The NEPSY-II was cleaned blind similar to the WISC-IV. As the NEPSY-II was administered 
secondary to the WISC-IV, if there were any administration issues (such as environment 
problems, child fatigue issues, child requesting to stop etc.) the NEPSY-II or some of its tests 
were omitted to ease testing. For example, if the child showed signs of great fatigue following 
the WISC-IV, the NEPSY-II results would not have been a true reflection of that child’s ability. 
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Furthermore, if the testing environment contained multiple distractions, this would have 
also affected the results. Therefore, only 416 children completed the WISC-IV and aspects of 
the NEPSY-II (see Table 20 for breakdown).  
In total, there were 36 participants who did not complete any of the NEPSY-II subtests. I 
made qualitative notes for all of these participants on the data set, and reasons for non-
completion of the NEPSY-II fell into eight broad themes: 
1. Long WISC assessment (any over 1 hr and 20)    n=14 
2. Mother requested quick visit      n=7 
3. Unsuitable test environment      n=4 
4. Child ill         n=3 
5. Child was difficult to assess      n=3 
6. Two families attended the research centre the same day n=2 
7. Child refused NEPSY and requested to finish cognitive testing  n=2 
8. Child distressed       n=1 
Along with the 14 participants who were noted as having long WISC-IV assessments, nine of 
these also included the child appearing visibly tired (n = 5) or the child wanting to finish and 
not being able to sit and concentrate (n = 4). In particular, had these 14 completed a NEPSY-
II assessment it may have included a large measurement error (the difference between an 
individual’s true score and the individual’s obtained score (230)). There were two further 
participants who generated small amounts of data from the NEPSY-II:  one who only 
completed FTDH and FTNDH and one other who completed both fine motor coordination 
tasks and NM only. In both cases the mothers requested to finish the assessments early.  
Ranges of scores were initially checked and searches for missing values were executed. As 
covered by the WISC-IV cleaning, the following demographic information had already been 
checked and thus was ready for the secondary cognitive analysis: how participants took part 
in CATS II, child gender, where the child was assessed, age of child at cognitive assessment, 
child’s language at school and home, age quartiles for the mother, whether the child was 
breastfed over one month and also the social deprivation score quintiles (as calculated by 
StatsWales (281) and OpenDataCommunities (282)).   
As explained in chapter 1.4. (Intelligence measured at age 9; CATS II data), nine individuals 
were removed from the complete dataset; one as an outlier, two as they were twins, one 
child for being aged ≤ 7 years old and finally, five children who were ≥ 11 years old. Similar 
to the WISC-IV data cleaning procedures (see chapter 1.4., Intelligence measured at age 9; 
CATS II data), z-scores were computed for target items for the NEPSY-II. It was identified that 
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all participants for LM, MD and MDD achieved z-scores between -3 to +3. On the FTD test, 
three individuals had z-scores < -3. Likewise, on FTND there was one individual < -3 and NM 
observed three participants with scores < -3. None of these individuals presented low z-
scores on more than one test measure, had outside normal z-score ranges on any of the 
WISC-IV items, or had z-scores > 3. The individual from the WISC-IV who presented extremely 
low scores on four out of the five IQs was the only removed participant based on z-scores, 
and the decision was made not to remove others who were outside normal ranges on only 
one IQ measure. Likewise, with the NEPSY-II, it was argued not to remove these seven 
individuals as that would mean looking at domains separately rather than a whole, i.e. an 
individual scoring a < -3 z-score on VCIQ was not removed, so then, why should a different 
individual be removed for low scoring on FTD/FTND tasks?  
All Kolmogorov-Smirnov (and Shapiro-Wilk) normality tests were returned as all p’s < .001 
for all additional NEPSY-II tests. However, means and medians appeared close and skewness 
and kurtosis ranges were all within the -1 - +1 range and thus were normal (see Table 19 
below). The NEPSY-II data was analysed by parametric tests as the variables were continuous, 
and based on the means, medians, skewness and kurtosis the data was accepted as being 
normally distributed.  
Table 19 
Means, Medians, Skewness and Kurtosis for the Developmental Neuropsychological 
Assessment (NEPSY)-II Tests 
NEPSY-II Subtest Mean Median Skewness Kurtosis 
NEPSY-II List Memory and List Memory 
Delayed Scaled Score 
10.79 
(2.85) 
11.00 -.134 -.338 
NEPSY-II Memory for Designs Total Scaled 
Score 
10.01 
(3.05) 
10.00 -.382 -.512 
NEPSY-II Memory for Designs Delayed Total 
Scaled Score 
10.09 
(2.74) 
10.00 .216 -.120 
NEPSY-II Fingertip Tapping Dominant 
Combined Scaled Score 
12.11 
(1.54) 
12.00 -.356 -.032 
NEPSY-II Fingertip Tapping Non-Dominant 
Combined Scaled Score 
12.39 
(1.40) 
12.00 -.211 -.675 
NEPSY-II Narrative Memory Free and Cued 
Recall Scaled Score 
11.32 
(2.76) 
12.00 -.367 .239 
Note. Standard deviations appear in parentheses below means.  
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Table 20  
Developmental neuropsychological assessment (NEPSY)-II participant group 
demographics 
 Normal GTF 
(n=219) 
Treated SGTF 
(n=109) 
Untreated 
SGTF (n=88) 
Participated 
(n) 
Research centre 
(n=assessed at 
home) 
180 (79) 74 (51) 41 (26) 
Remote/Home 39 (17.8%) 35 (32%) 47 (53%) 
Total home visits (n) 118 (53.9%) 86 (78.9%) 73 (82.9%) 
Mean Age (yrs) 9.67 9.41 9.44 
Gender (n) Male 109 59 41 
Female 110 50 47 
Child’s 
language at 
school and 
home (n 
& %) 
English School and 
English at Home 
169 (77.2%) 85 (78%) 76 (86.4%) 
Welsh School and 
English at Home 
41 (18.7%) 20 (18.3%) 11 (12.5%) 
Welsh School and 
Welsh at Home 
7 (3.2%) 3 (2.8%) 0 
English School and 
Other Language at 
Home (not Welsh or 
English) 
1 (0.5%) 1 (0.9%) 1 (1.1%) 
Welsh School and 
Other Language at 
Home (not Welsh or 
English) 
1 (0.5%) 0 0 
Whether 
the mother 
breastfed 
for over 1 
month 
Yes 139 (63.8%) 67 (62%) 48 (54.5%) 
No 79 41 40 
Missing 1 1 0 
Mother age at time of consent into 
CATS I 
Mean of quartile (mean, years) 
2.5 (31.72) 2.2 (30.40) 2.3 (30.74) 
Social deprivation score (mean of 
quintile) 
3.7 3.8 3.3 
NEPSY-II 
Subtests (n 
& missing n) 
LM 170 (49) 77 (32) 70 (18) 
MD  218 (1) 109 87 (1) 
MDD  218 (1) 109 87 (1) 
FTDH  219 109 88 
FTNDH  218 (1) 109 88 
NM  218 (1) 109 87 (1) 
Note. Further information appears in parentheses following n’s were applicable. 
SGTF=suboptimal gestational thyroid function. CATS=controlled antenatal thyroid 
screening, LM=list memory, MD=memory for designs, MDD=memory for designs 
delayed, NM=narrative memory, FTDH=fingertip tapping dominant hand, 
FTNDH=fingertip tapping non-dominant hand.  
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Table 20 shows the group demographics of each participant group. As mentioned in chapter 
1.4. (Intelligence measured at age 9, CATS II data), the untreated SGTF group consisted of far 
more home visits and assessments at home compared to the treated SGTF and normal GTF 
groups. ‘Participant group’ and ‘where the child was assessed’ were compared by a Chi-
square and confirmed to be significantly different; X2 (2, n = 416) = 33.913, p < .001. The ages 
of the children were compared by ANOVA, and alike to the findings in the previous chapter, 
a significant difference persisted: F (2, 413) = 5.998, p = .003, p2 = .028. However, the normal 
GTF group were significantly older than both the treated (p = .007, 95% CI [.0565, .4595]) and 
untreated (p = .043, 95% CI [.0051, .4390]) SGTF groups. This will not have affected the 
NEPSY-II scores, as like to the WISC-IV this assessment battery also takes account of age. The 
other covariates were similar to what was discussed in the chapter 1.4. (Intelligence 
measured at age 9; CATS II data). By controlling for six covariates, I have attempted to 
overcome potential biased effects of recruitment. 
The NEPSY-II data was analysed in IBM SPSS version 20 by the four models of analysis 
proposed in the published CATS II protocol (280) and chapter 1.3. (Methods for the cognitive 
and behavioural data collection for the CATS II study).  As can be seen in Table 20, there was 
a shortfall in LM tests across all three groups of participants. One of the reasons for this 
deficit was that the LM test was introduced later in the data collection phase. Furthermore, 
it was placed at the beginning (working memory aspect) and at the end of the NEPSY-II 
assessments (the long term memory aspect), and thus was easy to exclude if the child was 
not coping well with the long battery of assessments. If the data was analysed in a grouped 
MANCOVA, this would have only included those individuals who participated in every subtest 
of the NEPSY-II. As there was a large amount of data missing for the LM subtest, this would 
have yielded a small cohort; and even smaller participant groups. Therefore, the decision 
was made to analyse the LM test by a separate Analysis of Covariance (ANCOVA) and the 
remaining five subtests by a larger MANCOVA. Any significant differences at the multivariate 
level were followed up with post hoc tests to investigate where the significant differences 
were, and to control for multiple testing; a Bonferroni correction was chosen. The different 
models for the analysis were the same as the WISC-IV (see Figure 6).  
Similar to the CATS I UK only cohort analysis (chapter 1.2., Re-analysis of intelligence at age 
3; UK CATS I cohort) and WISC-IV analysis (chapter 1.4., Intelligence measured at age 9; CATS 
II data), percentages of participants scoring ≤ 1 SD from the mean (≤ 7) were computed and 
tested by Chi-Square for significance as a secondary, exploratory analysis. This was executed 
to allow comparisons to be drawn from the main CATS II findings to the work completed for 
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this thesis. Any significant values were followed up by a multinomial logistic regression to 
allow for adjustments of the six covariates: child gender, mother age at time of consent into 
CATS I, whether the mother breastfed over one month, where the child was assessed, 
language at school and home, and social deprivation. This was explored in CATS I as there 
was an attempt to replicate the findings from Haddow et al.’s (54) benchmark study which 
identified significantly more children with IQ scores below 1 SD if they were born to mothers 
with high TSH compared to those with normal thyroid function. It was predicted that 
individuals from the normal GTF groups would have 16% with scaled scores ≤ 7 (as 
anticipated by the NEPSY-II (230)), whereas those in the treated SGTF group would contain 
5% of scaled scores ≤ 7 compared to the untreated SGTF group achieving 15% (this 
predication was based on the work by Haddow et al. (54)).  
1.5.5. Results 
1.5.5.1. General attendance information 
As stated in the chapter 1.3. (Methods for the cognitive and behavioural data collection for 
the CATS II study), CATS II aimed to recruit a total of 480 participants back into the study. 
This consisted of 120 from the treated and untreated SGTF groups, and 240 from the normal 
GTF group. The WISC-IV analysis contained a final cohort of 452 individuals. As previously 
stated, the NEPSY-II was dropped in 8% of cases and thus a reduced dataset was generated. 
The treated SGTF group fell short by 9.2% of target (n = 109), the untreated group were 
26.7% behind the recruitment target (n = 88) and the normal GTF were 8.8% below target (n 
= 219). See Table 20 for group demographic information.  
1.5.5.2. Analysis 
Table 21 shows the means and SDs for all study NEPSY-II scores and was adjusted for by the 
fourth model of analysis (see Figure 6). The graph (Figure 13) displays the means achieved 
by the groups (unadjusted model); error bars have also been included. 
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Table 21 
Developmental Neuropsychological Assessment (NEPSY)-II Means by Study Group 
and Model Four of Analysis 
 Participant Group Mean N 
NEPSY-II List Memory and List 
Memory Delayed Scaled Score 
Normal GTF 10.94 
(2.837) 
170 
Treated SGTF 10.53 
(3.079) 
76 
Untreated SGTF 10.70 
(2.628) 
70 
Total 10.78 
(2.849) 
316 
NEPSY-II Memory for Designs 
Total Scaled Score 
Normal GTF 10.36 
(2.916) 
215 
Treated SGTF 9.56 
(3.259) 
108 
Untreated SGTF 9.85 
(2.979) 
87 
Total 10.04 
(3.036) 
410 
NEPSY-II Memory for Designs 
Delayed Total Scaled Score 
Normal GTF 10.34 
(2.646) 
215 
Treated SGTF 9.74 
(2.793) 
108 
Untreated SGTF 10.00 
(2.889) 
87 
Total 10.11 
(2.743) 
410 
NEPSY-II Fingertip Tapping 
Dominant Combined Scaled Score 
Normal GTF 12.24 
(1.596) 
215 
Treated SGTF 11.88 
(1.406) 
108 
Untreated SGTF 12.02 
(1.532) 
87 
Total 12.10 
(1.539) 
410 
NEPSY-II Fingertip Tapping Non-
Dominant Combined Scaled Score 
Normal GTF 12.51 
(1.370) 
215 
Treated SGTF 12.19 
(1.391) 
108 
Untreated SGTF 12.31 
(1.465) 
87 
Total 12.38 
(1.399) 
410 
NEPSY-II Narrative Memory Free 
and Cued Recall Scaled Score 
Normal GTF 11.56 
(2.764) 
215 
Treated SGTF 10.94 
(2.741) 
108 
Untreated SGTF 11.21 
(2.783) 
87 
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Total 11.32 
(2.768) 
410 
Note. Standard deviations appear in parentheses below means. SGTF=suboptimal 
gestational thyroid function. 
 
 
Figure 13: Means per group for scores obtained on the Developmental neuropsychological 
assessment (NEPSY)-II  
CI=confidence interval. X axis=NEPSY-II subtest, Y axis=mean of scores per participant 
group.  
 
The LM test was analysed by an ANOVA for the unadjusted, first model of analysis (see Figure 
6). It was found that there were no significant differences between the three participant 
groups, F (2, 314) = .482, p = .618, p2 = .003.  By adjusting for child gender (model two), the 
ANCOVA was still non-significant, F (2, 313) = .498, p = .608, p2 = .003. Model three of the 
analysis and thus controlling for model two and age of mother at recruitment into CATS I and 
whether the child was breastfed, it was also found that there was no significant differences 
between the groups, F (2, 310) = .354, p = .702, p2 = .002. The final model of analysis 
controlled for model two, three and the child’s language at school and home, where the child 
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was assessed and the social deprivation of the family, significance was still not achieved: F 
(2, 307) = .489, p = .613, p2 = .003. Therefore, by all models of analysis, there were no 
significant differences between the groups on the joint working memory and long term 
memory task: LM; the covariates made little differences to the probability values.  
There were no significant differences between the normal GTF, treated SGFT and untreated 
SGTF groups on the other five NEPSY-II measures, all p’s > .078. For the unadjusted, first 
model of analysis, MANOVA, using Roy’s largest root, there was a non-significant effect 
between groups for NEPSY-II measures, ROY = .025, F (5, 406) = 1.999, p = .078, p2 = .024. 
Model two yielded a similar non-significant MANCOVA result: ROY = .024, F (5, 405) = 1.973, 
p = .082, p2 = .024. Model three also generated a non-significant result ROY = .021, F (5, 
401) = 1.660, p = .143, p2 = .020. Finally, model four which controlled for all covariates also 
produced a non-significant result between the three groups of participants: ROY = .018, F (5, 
398) = 1.431, p = .212, p2 = .018. As no significant differences were revealed by 
ANOVA/ANCOVA and MANOVA/MANCOVA, no discriminate analyses were undertaken. 
The secondary analysis involved analysing scaled scores per group scoring ≤ 7 and tested for 
significance by use of a Chi-Square. Results can be found in Table 22 below. The only result 
that achieved significance was the MD subtest. This was explored further by a multinomial 
logistic regression.  
Table 22 
Scaled Scores ≤ 7 (%) from the Developmental Neuropsychological 
Assessment (NEPSY)-II 
 Scaled Scores ≤ 7 (%) 
LM MD MDD FTDH FTNDH NM 
Normal 
GTF  
18/170 
(11%) 
42/218 
(19%) 
32/218 
(15%) 
2/219 
(1%) 
1/218 
(0.5%) 
16/218 
(7%) 
Treated 
SGTF  
16/77 
(21%) 
36/109 
(33%) 
25/109 
(23%) 
0/109 
(0%) 
0/109 
(0%) 
10/109 
(9%) 
Untreated 
SGTF  
9/70 
(13%) 
17/87 
(12%) 
16/87 
(18%) 
1/88 
(1%) 
0/88 
(0%) 
9/87 
(10%) 
Pearson 
Chi-
Square 
p=.094 p=.014* p=.178 p=.572 p=.636 p=.662 
Note. *Significance < .05. Percentages of scores per group are appear in 
parentheses below totals. LM=list memory, MD=memory for designs, 
MDD=memory for designs delayed, NM=narrative memory, 
FTDH=fingertip tapping dominant hand, FTNDH=fingertip tapping non-
dominant hand, SGTF=suboptimal gestational thyroid function. 
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A multinomial logistic regression was executed to explore the differences between the 
groups for the subtest MD. The regression, controlled for all six covariates that were adjusted 
for in the MANCOVA, revealed that those offspring from the treated SGTF group were 2.257 
times more likely to achieve a scaled score for the MD subtest ≤ 7 compared to those from 
the untreated SGTF group. It was also apparent that breastfeeding had a significant effect, 
suggesting that if the child was breastfed there was a decreasing chance of scoring ≤ 7 MD 
subtest. See Tables 23 and 24 for further details of beta values, significance and -2 log 
likelihood. 
Table 23 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
361.038    
Final 341.965 19.073 8 .014 
Note. See improved figure for the -2 Log Likelihood. 
Df=degrees of freedom. 
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Table 24 
Main Output from Multinomial Logistic Regression, Memory for Designs (MD) ≤ 7 
MD ≤ 7 B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
Lower  Upper  
Gender -
.060 
.242 .061 1 .805 .942 .586 1.514 
Where 
Assessed 
-
.467 
.280 2.773 1 .096 .627 .362 1.086 
Language -
.204 
.240 .726 1 .394 .815 .510 1.304 
Mother Age -
.113 
.119 .908 1 .341 .893 .708 1.127 
Breast Fed 
1mns 
-
.517 
.249 4.314 1 .038* .596 .366 .971 
Social 
Deprivation 
-
.007 
.089 .006 1 .938 .993 .835 1.181 
[normal 
GTF] 
.181 .335 .293 1 .589 1.199 .621 2.314 
[treated 
SGTF] 
.814 .349 5.448 1 .020* 2.257 1.139 4.472 
[untreated 
SGTF] 
0b . . 0 . . . . 
Note. The reference category was MD ≥ 7. *Significance < .05. SGTF=suboptimal 
gestational thyroid function, B=beta, df=degrees of freedom. 
 
To enable to account for differences between the treated SGTF and the normal GTF groups, 
a further regression was executed. It was found that the normal GTF group were 1.899 times 
less likely to score ≤ 7 for the MD subtest compared to the treated SGTF group (p = .024). 
Further information for the regression model can be found in Tables 25 and 26.  
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Table 25 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
343.982    
Final 327.911 16.070 7 .024 
Note. See improved figure for the -2 Log Likelihood. 
Df=degrees of freedom.  
 
Table 26 
Main Output from Multinomial Logistic Regression, Memory for Designs (MD) ≥ 7 
MD  ≥ 7 B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
Lower Upper 
Gender .106 .275 .149 1 .699 1.112 .649 1.906 
Where 
Assessed 
.542 .308 3.091 1 .079 1.720 .940 3.147 
Language .099 .250 .155 1 .693 1.104 .676 1.801 
Mother Age .114 .133 .739 1 .390 1.121 .864 1.454 
Breast Fed 
1mns 
.474 .282 2.832 1 .092 1.606 .925 2.790 
Social 
deprivation 
.000 .000 .069 1 .793 1.000 .999 1.000 
[normal 
GTF] 
.641 .283 5.119 1 .024* 1.899 1.090 3.310 
[treated 
SGTF] 
0b . . 0 . . . . 
Note. The reference category was MD ≤ 7. *Significance < .05. SGTF=suboptimal 
gestational thyroid function, B=beta, df=degrees of freedom. 
 
1.5.6. Discussion  
The aim of this chapter was to test the null hypothesis that there would be no difference 
between the three groups of participants (those who were treated during their pregnancies 
for SGTF, those who were not treated, and those who had normal GTF; total n = 416) for 
working memory, long term memory and fine motor coordination measures at a mean age 
of 9 years 7 months. We failed to reject the null hypothesis on all subtests from the NEPSY-
II. Therefore, no specific differences were found between the normal GTF and untreated 
SGTF group, as well as the treated to untreated SGTF groups. 
The secondary analysis of percentages of participants with scaled scores ≤ 7 was also 
computed. The normal GTF group scored ≤ the untreated SGTF group for LM, MDD, FTDH 
and NM. We could infer from this trend, that having SGTF during pregnancy could potentially 
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have a slight negative impact on the offspring across these domains. Furthermore, it could 
be inferred that with much larger participant groups, significance may have been found. The 
most interesting result was on the MD domain. The Pearson chi-square statistic reached 
significance with a large number of participants (33%) from the treated SGTF group scoring 
≤ 7 for this working memory subtest on the NEPSY-II. The mean score for MD from the 
treated SGTF group was not too dissimilar to the untreated SGTF group. This was explored 
further by a multinomial logistic regression which confirmed that those from the treated 
SGTF were 2.257 times more likely to score ≤ 7 compared to the untreated SGTF group. 
Furthermore, the normal GTF group were 1.899 times less likely to score ≤ 7 for the MD 
subtest compared to the treated SGTF group (p = .024). However, WMIQ scores ≤ 85 were 
non-significant (i.e. at a domain level) as well as the other WM subtests from the NEPSY-II, 
so this result for the MD subtest may be yielding a type one error; this has been reported as 
being commonplace when converting continuous variables to binary outcomes (213). 
The findings of the NEPSY-II tests were contradictory to some research that has found an 
underactive thyroid having an effect on specific neuropsychological processes (long term and 
working memory (51, 97, 103-106, 307-312) and motor coordination (27, 49, 50, 54, 110, 
112)), but also add to the validity of findings from other studies that found thyroid function 
did not affect these various aspects of cognition (34, 51, 92, 93, 111, 113, 200, 215). 
The results identified from the NEPSY-II were comparable to the results from the WISC-IV in 
the previous chapter. As the analysis from the WISC-IV revealed no WMIQ differences 
between groups, it was not surprising then that no differences were found on the working 
memory tasks of the NEPSY-II (LM, MD and NM), as these two cognitive scales appear to 
support each other. Before the NEPSY-II was available, concurrent validity of its intellectual 
functioning was assessed by the WISC-IV. The correlation of the WISC-IV to other intellectual 
functioning measures suggested that the NEPSY-II was sufficiently predictive of cognitive 
performance for verbal and nonverbal domains (230).  
The ‘population’ that comprises the current results chapter was not as well-ordered as the 
WISC-IV results. Testing was very much completed on an individual basis, i.e. the NEPSY-II 
items were in addition to the complete WISC-IV; thus aspects of, or the complete assessment 
were dropped in some instances to either ease the experience for the child and keep rapport 
high, the test environment conditions were insufficient or based on parental requests. No 
participants were removed based on variable z-scores (± 3). No participants had z-scores ≥ 3 
for any subtests and no ≤ -3 scores were recorded for LM, MD or MDD tests. Three ≤ -3 z-
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scores were recorded for FTDH, one ≤ -3 for FTNDH and a further three ≤ -3 for NM. The 
seven ≤ -3 scores were obtained by seven different participants and none of these seven had 
outlier z-scores on the WISC-IV. The decision was reached not to remove these seven 
participants as this was a pragmatic study to include a varying population. Further to this, 
the NEPSY-II was reported to have developed its floors and ceilings to encompass those of 
all abilities (255) (NB: floor effects were reported to arise when a test was too difficult and a 
large portion of the normative sample would then perform poorly, whereas ceiling effects 
occurred when a test was too easy for the normative sample (254)). Some subtests of the 
NEPSY-II were specifically developed to address the lower limits of ability at the youngest 
ages (230) which was an additional reason for keeping the seven participants in the main 
analysis. 
The NEPSY-II assessment included multiple drawbacks. Some of the criticisms were similar 
to the WISC-IV assessment, such as being reliant on motivation, rapport, the individual’s 
obedience and the effects of a ‘snapshot’ view, (see chapter 1.4., Intelligence measured at 
age 9; CATS II data, for further information). A further issue with the NEPSY-II was that it was 
not UK standardised. Kline (313) explored the importance of standardisation, even though 
the NEPSY-II was standardised, it may have benefitted from the UK cohort standardisation 
similar to the WISC-IV used in the current research. Further differences between these two 
cognitive measures was that unlike the WISC-IV with its’ ten subtest order, the NEPSY-II was 
left free to the examiner to decide on order and test selection; this was aided by the NEPSY-
II tests being alphabetically ordered in the scoring manual (254). The order that was decided 
for CATS II was guided by the time required for delayed tasks (LM and MDD).  
1.5.6.1. Limitations 
With the NEPSY-II being placed after the WISC-IV, the children were often fatigued when the 
testing occurred. This led to some decisions to drop certain tests and therefore has led to a 
somewhat, fragmented dataset. With the NEPSY-II being ‘tagged’ on to the WISC-IV, this led 
to long assessment times for the participants: a couple reached just over two hours. As the 
NEPSY-II was always viewed as secondary to the WISC-IV for main outcomes, the WISC-IV 
was always viewed as the first priority. The incomplete datasets lead to the LM subtest being 
analysed in a separate ANCOVA and has left the research open to scrutiny because of 
multiple testing. A MANCOVA would have been more appropriate to use for all of the NEPSY-
II subtests, however this would have meant losing statistical power from the dwindling 
participant groups. With separate testing, the small group numbers still made the research 
difficult to generalise to the wider population.  
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As mentioned, the NEPSY-II was not UK standardised and certain subtests within it were not 
re-normed from the original assessment in 1998.  Even though the NEPSY-II used in the 
current research was developed in 2007, it was out of date and this was particularly visible 
in the FTDH and FTNDH. The mean scores for the groups, and cohort, were all well above the 
expected result of 10. With the means for both tests being at 12, this put the groups at a 75th 
percentile rank, instead of being placed around the norm of 50. The reasoning for such a high 
mean could be that the children were affected by their technology use, i.e. a high number of 
children now have access to mobile phones, computers, laptops, iPad/tablets etc., and thus 
must have had a proficient level of finger dexterity to enable them to adequately use these 
products.  
1.5.6.2. Conclusions  
This results chapter has answered two (bold) of the four research aims: 
i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at 
age 3, would any differences to the normal GTF group be measurable; as there is a 
wealth of studies displaying that an underactive thyroid during pregnancy does not 
affect a child’s cognition (53, 56, 91-93, 95, 96).  
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
Whilst the project tried to seek further answers from the IQ only CATS I study, investigations 
into long term memory, additional working memory and fine motor coordination appeared 
to have no mean significant differences between those from the normal GTF, treated SGTF 
or untreated SGTF groups. Larger studies would be needed to investigate the theory that 
CATS II was underpowered and that levothyroxine therapy was started too late for the 
treated SGTF group to be able to see any discrepancies to the untreated SGTF group.  
1.5.7. Chapter Summary 
The current chapter has attempted to explore the possibility that there may have been 
further deficits from children exposed to SGTF. By investigating the three groups of 
participants, no significant differences were identified by use of the NEPSY-II subtests. There 
was, however, a significant difference between the treated and untreated SGTF groups on 
the MD subtest for scores below 1 SD from the mean; the treated group contained more 
children in this category. This was concluded as a type one error as no such differences were 
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identified on the other memory subtests of the NEPSY-II, or on the domain level in the WISC-
IV. This chapter covered the hypotheses for the data, details of the NEPSY-II and why there 
were differing group sizes compared to the WISC-IV, data cleaning, statistical analysis, the 
results and the discussion of the results. The following chapter contains the final data that I 
collected for the CATS II project, and my analysis of it; the child behavioural questionnaires.   
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1.6. Behavioural questionnaires at age 9; CATS II data  
1.6.1. Chapter Overview 
The current chapter describes and discusses findings from the child behavioural 
questionnaires completed by the mothers who took part in CATS II. There is a brief 
introduction and methods overview (further information can be found chapters 1.1., General 
introduction and 1.3., Methods for the cognitive and behavioural data collection for the CATS 
II study), which lead into the analysis plan for the data. The results are discussed in respect 
of the primary and secondary analyses.  
1.6.2. Introduction 
Behavioural differences between individuals that have been affected by gestational 
underactive thyroid function are emerging in the literature; specifically, in respect to ADHD 
(44, 45, 143, 147-151) and ASCs (19, 170-172, 174-180). The aim of the analysis presented in 
this chapter was to test the null hypothesis that there would be no difference between the 
normal GTF, treated SGTF and untreated SGTF groups on any of the behavioural 
questionnaires administered to the mothers in respect of their offspring in CATS II. The null 
hypothesis was adopted as no cognitive differences were displayed between the treated and 
untreated SGTF at age 3 and 9 and thus, similarly, it was proposed that no differences 
between groups in regard to behaviour would be identified either. In the alternate 
hypothesis, it was predicted that there would be a behaviour deficit for the untreated SGTF 
group compared to the normal GTF group; as had been suggested in the literature.  
This chapter details the participants and demographics for the three groups. It also discusses 
replacing missing items on the questionnaires as well as the three-models of statistical 
analysis, results and discussion section.  
1.6.3. Method 
A total of 480 participants were needed to address the null hypothesis that treatment for an 
underactive thyroid during pregnancy would have no effect on the offspring’s behaviour as 
compared to those who were born to mothers who were untreated; with the normal GTF 
group acting as a baseline comparison. This recruitment aim was the same as the cognitive 
assessment goal as the questionnaires were completed at the same time by the mothers. 
Four questionnaires were administered to the mothers, of which three relate to the 
behavioural analysis of the offspring; SDQ, Child ADHD Questionnaire and SCQ. As with the 
cognitive assessments, I scored the questionnaires blind to avoid any group bias.  
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The SDQ questionnaire generated scores for emotional symptoms, conduct problems, 
hyperactivity, peer problems, a total difficulties score and also a prosocial rating. Higher 
scores on a subscale indicated a problem behaviour, except for the prosocial scale where 
higher scores indicated positive behaviour (proposed 80% scoring ‘close to average’: 8-10). 
The total difficulties ranged from 0-40 (proposed 80% scoring ‘close to average’: 0-13) and 
were obtained by summing the scores from hyperactivity (proposed 80% scoring ‘close to 
average’: 0-5), emotional symptoms (proposed 80% scoring ‘close to average’: 0-3), conduct 
problems (proposed 80% scoring ‘close to average’: 0-2) and peer problems (proposed 80% 
scoring ‘close to average’: 0-2). From the SDQ, 6 scores were used in the current analysis.  
The Child ADHD Questionnaire generated four scores for analysis: inattention, overactivity, 
impulsivity and a total ADHD score. Subscale scores were generated by adding all items in a 
subscale together; inattention 0-27, overactivity 0-12, impulsivity 0-15. Based on the 
modified DuPaul rating scale (232), the following means and SDs (in brackets) were 
developed based on a general population: inattention 6.05 (6.21), overactivity 2.17 (2.74) 
and impulsivity 3.59 (3.44).  
The final behavioural questionnaire was the SCQ investigating symptoms synonymous with 
ASCs. The SCQ generated a total score, if it was ≥ 15, this would indicate a possible ASC. The 
first item (of 40 questions) enquired about the level of language of the child and thus was 
not included in the total score. The SCQ only generated a total score for the current analysis.  
The questionnaires were scored soon after completion; all notes added by the mothers were 
also stored electronically. Participants were mailed requesting further completion if large 
sections or sides of a questionnaire were missing. No feedback to the parents was generated 
for the questionnaires, unless requested.  
1.6.4. Statistical Analysis 
A total of 483 participants completed the questionnaires and a total of 18 participants were 
removed from this analysis. As a result of the WISC-IV cleaning (see chapter 1.4., Intelligence 
measured at age 9; CATS II data) nine were excluded; one was identified as an outlier, six 
children for ages outside the specified target (see study protocol (280)) and two participants 
were a set of twins. On the questionnaire dataset, one participant was the sibling of the child 
who was in CATS II and therefore was removed, and three participants did not complete the 
behavioural questionnaires; this left 471 participants who had completed the 
questionnaires. A final six participants were excluded from the analysis due to not having 
answered one of the three questionnaires (four participants), and two others due to missing 
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information for adjustments; no breastfeeding data, and no social deprivation score was 
available for a participant who now lived in France. Therefore, 465 participants’ data were 
used in the final analysis.  
Data were cleaned without the participants coded to their groups to help minimise any 
researcher bias. As CATS II was a pragmatic study, we included a wide range of IQs and SENs 
as we wanted to achieve variability in our study so that it would be more generalisable to 
the wider population. This meant, not computing z-scores, as those likely to achieve ± 3 score 
would be those individuals who were recognised as, for example, having some autistic traits 
or ADHD related difficulties. This in-turn could have skewed the data and thus not have been 
a true representation of behaviour difficulties expressed within our three groups.  
Nominal data was investigated for miss-input by range checks; this included how participants 
took part in the study, child gender, child date of birth. The ordinal scores from the SDQ 
questionnaire were first checked for correct ranges (0-2), then the total and rankings for each 
domain. This was also completed for the child ADHD questionnaire domains (desired range 
0-3) and the SCQ (0 or 1).  
Missing values were commonplace throughout a number of questionnaires. Replacing 
missing values by ‘series mean’ in SPSS was adopted to overcome the problem (seen as one 
of the better methods for dealing with this problem (314)). For the SDQ, there was only ever 
a maximum of three missing scores for the questionnaire, and for all of the difficulty 
subscales, if participants did omit an item it was only ever the one item. One individual did 
not answer any items on the SDQ. The replacing of missing values was not conducted across 
the entire SDQ, but on the domain level (i.e. the new score for the missing item on the 
emotional scale, was averaged by scores the individual received on the emotional questions 
only and thus there was no ‘item interference’ from how they performed in a different 
domain). One participant omitted answering the child ADHD questionnaire and also the SCQ. 
The missing data for the child ADHD questionnaire was completed in much the same way as 
the SDQ; i.e. by domain level. Eight participants missed scoring the back page of the 
questionnaire (items 19-26: 23-26 were needed for the analysis). For these eight individuals, 
it meant that 25% of the overactivity items were missing (one question) and 33% of the 
inattention items were missing (three questions). As the amount of missing data was low, 
mean items to generate a ‘missing value’ were still used. Finally for SCQ, two individuals had 
omitted this questionnaire, one participant only completed 50%, and another had around 
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40% missing. Based on these high levels of omissions, all four participants were removed 
from the SCQ analysis.  
All Kolmogorov-Smirnov (and Shapiro-Wilk) normality tests were returned as p < .001 for all 
questionnaires on every totalled domain. However, means and medians appeared close and 
skewness and kurtosis ranges were largely just above ± 1 and thus were returned as normal 
with caution (see Table 27 below). The prosocial SDQ received a Kurtosis value of 4.535, this 
was because there was a high peak around participants receiving the top score for the scale 
(i.e. they were rated by their mothers to have a high prosocial demeanour). The 
questionnaire data was analysed by parametric tests as the total scores were continuous, 
and based on the means, medians, skewness and kurtosis, the data was accepted as being 
normally distributed with caution.  
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Table 27 
Means, Medians, Skewness and Kurtosis of Behavioural Questionnaires 
Questionnaire Mean Median Skewness Kurtosis 
SDQ Emotion Total 2.30 
(2.14) 
2.00 .896 .229 
SDQ Conduct Total 1.37 
(1.60) 
1.00 1.345 1.705 
SDQ Hyperactivity Total 3.38 
(2.71) 
3.00 .590 -.456 
SDQ Peer Problems Total 1.38 
(1.71) 
1.00 1.485 1.972 
SDQ Total Difficulties Total 8.43 
(6.02) 
7.00 .854 .158 
SDQ Prosocial Total 8.79 
(1.75) 
9.03 -1.962 4.535 
ADHD Inattention Mean 6.24 
(5.70) 
5.00 1.228 1.210 
ADHD Overactivity Mean 2.39 
(2.64) 
1.43 1.364 1.403 
ADHD Impulsivity Mean 3.38 
(3.01) 
3.00 1.140 .986 
ADHD Total Mean 12.01 
(10.17) 
9.00 1.254 1.384 
SCQ Total Mean 4.51 
(3.86) 
4.00 1.349 2.326 
Note. Standard deviations appear in parentheses below means. SDQ=strengths and 
difficulties questionnaire, ADHD=attentional deficit hyperactivity disorder, SCQ=social 
communication questionnaire. 
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Table 28 
Questionnaire Participant Group Demographics 
 Normal GTF 
(n=245) 
Treated SGTF 
(n=120) 
Untreated 
SGTF (n=106) 
Mean Age (yrs) 9.66 9.43 9.43 
Gender (n) Male 123 (50.2%) 64 (53.3%) 50 (47.2%) 
Female 122 56 56 
Whether the 
mother 
breastfed for 
over 1 month 
Yes 160 (65.3%) 71 (59.2%) 58 (54.7%) 
No 85 49 47 
Missing 0 0 1 
Mother age at time of consent into 
CATS I 
Mean of quartile (mean, years) 
2.51 (31.74) 2.22 (30.32) 2.31 (30.89) 
Social deprivation score (mean of 
quintile) 
3.68 3.83 (missing 
1) 
3.38 
Questionnaires 
(n & missing n) 
SDQ 244 (1) 120 106 
Child ADHD 
Questionnaire  
244 (1) 120 106 
SCQ 242 (3) 120 105 (1) 
Note. Further information appears in parentheses following n’s were applicable. 
SGTF=suboptimal gestational thyroid function, CATS=controlled antenatal thyroid 
screening, SDQ=strengths and difficulties questionnaire, ADHD=attentional deficit 
hyperactivity disorder, SCQ=social communication questionnaire. 
 
Table 28 shows the group demographics of each participant group for the analysis of the 
questionnaires. The ages of the children were compared by an ANOVA, and as with to the 
cognitive findings, there was a significant difference identified: F (2, 468) = 5.426, p = .005, 
p2 = .023. Again, it was the normal group who were older than the treated (p = .019, 95% CI 
[.0283, .4349]) and the untreated (p = .029, 95% CI [.0177, .4420]) SGTF groups. This should 
not have affected the questionnaire results as the inventories were designed to be 
completed by a wide age range (231-233). The characteristics (gender, whether the mother 
breastfed over one month, age of mother at time of consent into CATS I and social 
deprivation rating), appeared to have equal spread across the groups. However, as bias could 
have been introduced by these subtle differences, these covariates were controlled for.  
The questionnaire data was analysed in IBM SPSS Statistics version 20 by a MANCOVA. 
Models one and two of the analysis were adopted (see the published CATS II protocol (280), 
and chapter 1.3., Methods for the cognitive and behavioural data collection for the CATS II 
study) and also model three, but adjusted to include social deprivation. Child age was also 
taken into consideration in model three, as the questionnaires could assess across a wide 
age range and were not as age stringent in scoring compared to the WPPSI-III, WISC-IV and 
NEPSY-II. Data was analysed by use of total scores for domains only, and it did not include 
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any ordinal data or classifications. Univariate analysis commenced dependent on significant 
multivariate results. 
The second exploratory analysis investigated questionnaire outcomes by a binary cut-off. For 
SDQ, the scores for each domain were classified as either ‘close to average’, ‘high average’, 
‘high’ or ‘very high’ (apart from the prosocial domain which were ‘close to average’, ‘low 
average’, ‘low’ or ‘very low’) (231). Scores resulting in a ‘high’ (/’low’ for the prosocial 
domain) classification or above were selected for the SDQ cut-off. Thapar et al. (232) had 
established SDs for the Child ADHD Questionnaire, thus individuals scoring ≥ 1 SD were 
included; similar to the binary analyses of the WISC-IV and NEPSY-II with scores 1 SD from 
the mean. SCQ had a cut-off of 15 points to warrant further investigation for a possible ASC 
(233), therefore scores ≥ 15 were included here.  Unadjusted models were firstly compared 
by Pearson Chi-square, with adjusted multinomial logistic regressions completed secondly 
(as with the MANCOVA, these controlled for child gender, whether the mother breastfed 
over one month, age of mother at time of consent into CATS I, social deprivation score and 
also child age).  
Exploratory analyses of maternal T4 and TSH levels in respect of offspring behaviour 
questionnaire results can be found in appendix 10. As discussed in chapter 1.2., those women 
randomised to the treatment branch of CATS I who had SGTF, began levothyroxine therapy 
at 150 µg. As a consequence, mean T4 values at 6 weeks post consent and at 30 weeks 
gestation (when women were visited to check whether levothyroxine adjustments were 
required) were reasonably high, and some women were classified as being ‘over-treated’ (T4 
> 17.7 pmol/L). The offspring questionnaire results of such women were compared against 
others in the study. Prevalence rates of undesirable behaviour were also explored in this 
appendix.  
1.6.5. Results  
1.6.5.1. General attendance information 
As stated in the chapter 1.3. (Methods for the cognitive and behavioural data collection for 
the CATS II study), CATS II aimed to recruit a total of 480 participants back into the study. 
This consisted of 120 from the treated and untreated SGTF groups, and 240 from the normal 
GTF group. The questionnaires were completed by a total of 471 participants. The treated 
SGTF group achieved the target (n = 120), the untreated group were 11.7% behind the 
recruitment target (n = 106) and the normal GTF above the desired target (n = 245). See Table 
28 for group demographics.  
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1.6.5.2. Analysis 
Table 29 shows the means and SDs for all study behavioural questionnaires as per group and 
adjusted for by model three (see Figure 6) (NB total n decreased due to missing data for 
questionnaires, breastfeeding > 1 month and a participant living abroad). The graphs (Figures 
14, 15 and 16) display the means achieved by the groups pictorially (unadjusted model), error 
bars have also been included.  
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Table 29 
Behavioural Questionnaires Descriptive Statistics by Study Group and Model Four of 
Analysis 
Questionnaire 
Domain 
PARTICIPANT GROUP 
CODE 
Mean N 
SDQ Emotion Total Normal GTF 2.30 
(2.23) 
242 
Treated SGTF 2.40 
(2.05) 
119 
Untreated SGTF 2.22 
(2.00) 
104 
Total 2.31 
(2.13) 
465 
SDQ Conduct Total Normal GTF 1.23 
(1.50) 
242 
Treated SGTF 1.65 
(1.84) 
119 
Untreated SGTF 1.28 
(1.42) 
104 
Total 1.35 
(1.58) 
465 
SDQ Hyperactivity 
Total 
Normal GTF 3.12 
(2.51) 
242 
Treated SGTF 3.79 
(2.94) 
119 
Untreated SGTF 3.43 
(2.73) 
104 
Total 3.36 
(2.69) 
465 
SDQ Peer Problem 
Total 
Normal GTF 1.55 
(1.87) 
242 
Treated SGTF 1.20 
(1.61) 
119 
Untreated SGTF 1.19 
(1.34) 
104 
Total 1.38 
(1.70) 
465 
SDQ Total 
Difficulties Total 
Normal GTF 8.20 
(5.95) 
242 
Treated SGTF 9.04 
(6.46) 
119 
Untreated SGTF 8.12 
(5.44) 
104 
Total 8.40 
(5.98) 
465 
SDQ Prosocial Total Normal GTF 8.77 
(1.77) 
242 
Treated SGTF 8.81 
(1.80) 
119 
Untreated SGTF 8.77 
(1.70) 
104 
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Total 8.78 
(1.76) 
465 
ADHD inattention 
Mean 
Normal GTF 6.10 
(5.64) 
242 
Treated SGTF 6.91 
(6.12) 
119 
Untreated SGTF 5.74 
(5.22) 
104 
Total 6.23 
(5.68) 
465 
ADHD overactivity 
Mean 
Normal GTF 2.08 
(2.29) 
242 
Treated SGTF 2.90 
(3.06) 
119 
Untreated SGTF 2.47 
(2.70) 
104 
Total 2.38 
(2.62) 
465 
ADHD impulsivity 
Mean 
Normal GTF 3.17 
(2.81) 
242 
Treated SGTF 3.85 
(3.43) 
119 
Untreated SGTF 3.28 
(2.83) 
104 
Total 3.37 
(2.99) 
465 
ADHD Total Mean Normal GTF 11.36 
(9.49) 
242 
Treated SGTF 13.66 
(11.66) 
119 
Untreated SGTF 11.48 
(9.44) 
104 
Total 11.97 
(10.11) 
465 
SCQ Total Mean Normal GTF 4.31 
(3.68) 
242 
Treated SGTF 5.13 
(4.68) 
119 
Untreated SGTF 4.07 
(2.93) 
104 
Total 4.47 
(3.83) 
465 
Note. Standard deviations appear in parentheses below means. SDQ=strengths and 
difficulties questionnaire, ADHD=attentional deficit hyperactivity disorder SCQ=social 
communication questionnaire, SGTF=suboptimal gestational thyroid function. 
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Figure 14: Means of scores achieved per group for the Strengths and Difficulties 
Questionnaire (SDQ) 
SGTF=suboptimal gestational thyroid function, CI=confidence interval. X axis=domains from 
the SDQ, Y axis=mean of participant groups.   
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Figure 15: Means of scores achieved per group for the Child Attention Deficit Hyperactivity 
Disorder (ADHD) Questionnaire  
SGTF=suboptimal gestational thyroid function, CI= confidence interval. X axis=domains 
from the ADHD questionnaire, Y axis=mean of participant groups.   
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Figure 16: Means of scores achieved per group for the Social Communication Questionnaire 
(SCQ)  
SGTF=suboptimal gestational thyroid function, CI= confidence interval. X axis=domains 
from the SCQ, Y axis=mean of participant groups.   
 
The first model of analysis identified a significant effect of group on the behavioural 
questionnaires: ROY = .057, F (9, 457) = 2.902, p = .002, p2 = .054. When adjusted for gender 
(model two), the significant result persisted: ROY = .057, F (9, 456) = 2.886, p = .003, p2 = 
.054, and by the final analysis of model three there was also a significant difference: ROY = 
.052, F (9, 450) = 2.587, p = .006, p2 = .049. The univariate tests revealed that the following 
questionnaires (and domains within a specified questionnaire) were significant; SDQ Peer 
Problems (F (2, 458) = 3.623, p = .027, p2 = .016) and SCQ Total (F (2, 458) = 3.099, p = .046, 
p2 = .013). The rest of the questionnaires yielded non-significant results when compared 
between the three groups, all p’s > .062; SDQ Emotion, SDQ Conduct, SDQ Hyperactivity, SDA 
Total Difficulties, SDQ Prosocial, ADHD Inattention, ADHD Overactivity, ADHD Impulsivity and 
ADHD Total.   
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Post hoc analysis was executed by Bonferroni testing. Bonferroni was a much more 
conservative test so that it can take account of multiple testing, and has been described as 
the most robust of the univariate techniques (210). With this in mind, upon post hoc analysis, 
SDQ Peer Problems had lost significance between the groups. For SCQ Total, those children 
from the treated SGTF group had significantly higher scores than those from the untreated 
SGTF group (p = .047, 95% CI [.012, 2.412]).  
The second exploratory analysis investigated questionnaire outcomes by a binary cut-off. For 
SDQ, scores were included if above the ‘high’ classification (‘low’ for prosocial), the ADHD 
questionnaire included those ≥ 1 SD and the SCQ included those ≥ 15 (258). Results for the 
unadjusted chi-square can be found in Table 30 (significant results were highlighted **). 
Multinomial logistic regressions were executed to explore any differences between the 
groups for the significant questionnaire results from the preliminary unadjusted chi-square; 
SDQ emotion, ADHD Overactivity, ADHD Impulsivity and SCQ. There was a non-significant 
regression for SDQ emotion (p’s > .189). 
For ADHD Overactivity, the normal GTF group were 2.027 times less likely to score ≥ 1SD 
compared to the treated SGTF group (p = .017), all other interactions were non-significant. 
For ADHD Impulsivity, the normal GTF group were 2.060 times less likely to score above 1 SD 
compared to the treated SGTF group (p = .038), all other interactions were non-significant. 
Finally, for SCQ, the normal GTF group were 4.132 times less likely to score above the 
threshold compared to the treated SGTF group (p = .031), all other interactions were non-
significant. Further information about the goodness of fit and parameter estimates for the 
multinomial logistic regressions can be found in Appendix 7: Behavioural questionnaires, 
additional regression models.   
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Table 30 
Chi-Square (Unadjusted) Statistics for Participants Scoring Above the Specified Threshold for the Questionnaires 
 Higher scores indicating worse behaviour* 
SDQ 
emotion 
SDQ 
Conduct 
SDQ 
Hyperactivity 
SDQ Peer 
problems 
SDQ 
Total 
SDQ 
Prosocial 
ADHD 
Inattention 
ADHD 
Overactivity 
ADHD 
Impulsivity 
SCQ 
Normal 
GTF 
33/244 
(13%) 
21/244 
(7%) 
17/244  
(7%) 
40/244 
(16%) 
29/244 
(12%) 
28/244 
(11%) 
30/244 
(12%) 
33/244 
(13%) 
20/244 
(8%) 
4/242 
(2%) 
Treated 
SGTF 
31/120 
(26%) 
19/120 
(16%) 
17/120 
(14%) 
14/120 
(12%) 
17/120 
(14%) 
14/120 
(12%) 
22/120 
(18%) 
31/120 
(26%) 
21/120 
(17%) 
7/120 
(6%) 
Untreated 
SGTF 
26/106 
(24%) 
8/106 
(7%) 
12/106 
(11%) 
9/106 
(8%) 
9/106 
(8%) 
10/106 
(9%) 
11/106 
(10%) 
26/106 
(24%) 
12/106 
(11%) 
1/105 
(1%) 
Pearson 
Chi-
square 
p=.005** p=.060 p=.079 p=.111 p=.412 p=.830 p=.165 p=.005** p=.031** p=.030** 
Note. Percentages of scores per group are appear in parentheses below totals. ‘High’ (*Strengths and Difficulties Questionnaire (SDQ) 
scores ≥ ‘High’ classification, Child attention deficit hyperactivity disorder questionnaire (ADHD) scores ≥ 1 SD, Social Communication 
Questionnaire (SCQ) scores ≥ 15 point threshold for possible autism spectrum conditions). **Significance < .05. SGTF=suboptimal 
gestational thyroid function. 
:. 
. 
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1.6.6. Discussion  
The aim of this chapter was to explore the null hypothesis of there being no difference 
between the treated SGTF, untreated SGTF and normal GTF groups on any of the behavioural 
questionnaires at the sub-domain, total-scored level.  Based on the p = .006 from the 
multivariate analysis, the null hypothesis was rejected. Post hoc analysis indicated that the 
treated SGTF group had significantly higher mean scores for the SCQ questionnaire 
compared to the untreated SGTF group (p = .047). The mean scores of the groups do not 
infer a clinical significance, and as can be seen in the Table 29 and on page 111, the scores 
were still within the average range and were below clinical significance (for example, the 
treated SGTF group mean for SCQ was not above the threshold of 15 to warrant further 
investigation for ASCs).  
The secondary exploratory analysis of binary outcomes from the behavioural questionnaires 
identified that for SCQ, the normal GTF were 4.132 times less likely to score above the 
threshold (≥ 15) compared to the treated SGTF group (p = .031). It was interesting that by 
investigating above the threshold for binary outcomes rather than continuous, this changed 
the significant difference between the treated SGTF group to the normal GTF group, rather 
than the untreated SGTF group (seen in the continuous analysis); still inferring that the 
treated SGTF group presented more ASC symptoms however. On the Child ADHD 
Questionnaire, the normal GTF group were less likely to score ≥ 1 SD compared to the treated 
SGTF group for Overactivity and Impulsivity (2.027 OR p = .017 and 2.060 OR p = .031, 
respectively). However, as can be seen in Appendix 7: Behavioural questionnaires, additional 
regression models, the significant logistic regressions mentioned here do contain wide 
confidence intervals suggesting a larger amount of variability. Furthermore, the adjusted 
regressions all suggest that the treated SGTF group have more ADHD and ASC traits 
compared to the normal GTF group. Although this analysis was not the primary outcome but 
was executed for comparative purposes to the main CATS II analysis, similar to the 
MANCOVA, it has demonstrated the treated SGTF group to be significantly higher (indicating 
more behaviour problems) on the behavioural questionnaires. Caution has been advised 
when interpreting binary outcomes from continuous data however (211, 212), as there 
would be an increased risk of a type one error (213). 
As CATS I was the first study to look at treatment for SGTF, there was little literature available 
that investigates those whom were treated during their pregnancies and the behavioural 
outcomes of their offspring compared to those who were not treated. Treatment for 
congenital hypothyroidism has been evidenced to have a negative effect on the child’s 
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behaviour if it was inadequate (315). Also, the authors identified that behaviour problems 
such as aggression and poor attention were more frequent in children with congenital 
hypothyroidism compared to controls (rated by their teachers, not parents). This was 
contradictory to the findings here as no (specific) deficits in attention were identified and 
aggression was not investigated.  
CATS I used a definition of ‘sub-optimal’ thyroid function for recruitment of an underactive 
thyroid (200, 280): this was T4 in the lowest 2.5th percentile, TSH in the highest 2.5th 
percentile, or both. In essence, CATS has a mixture of mothers who were either 
hypothyroxinaemic during their pregnancies (low T4, normal TSH), or who had GSH (high 
TSH, normal T4). Ghassabian et al. (316) found that GSH resulted in higher externalising 
scores in children aged 1 and a half and 3 years old. It was also found that hypothyroxinaemia 
during pregnancy was not associated with internalizing or externalising scores for the 
children.  However, in iodine insufficient areas, hypothyroxinaemic mothers during their 
pregnancies reported children with an abnormally high frequency of ADHD (151). Children 
exposed to hypothyroxinaemia in early pregnancy (measured at a mean of 13.6 weeks 
gestation) were more likely to express ADHD symptoms at age 8; independent of 
confounders (45). Furthermore, it was identified in Modesto et al.’s study that those born to 
mothers with GSH did not express any ADHD symptoms, also a small portion of the maternal 
hypothyroxinaemic mothers did receive a low levothyroxine treatment, but this had no effect 
to the high ADHD outcomes measured in the offspring. We could infer from this that by 
subdividing our SGTF groups into low T4 or high TSH could indicate differing results to what 
had been identified. There may be more mothers who had GSH in the untreated group 
compared to the treated which would affect the results. However, this would generate small 
study groups and would not be representative of the wider population.  
Ghassabian et al. (149) also investigated TPO-Ab+ during early pregnancy and found that, if 
present, there was an increased risk of externalising problems in preschool children: in 
particular, ADHD problems. Brown et al. (175) found that the prevalence of maternal TPO-
Ab+ increased the odds of ASC in offspring by 80% (p = .009) compared to mothers negative 
for this antibody. These maternal TPO studies are interesting, as akin to CATS II, deficits for 
ASCs and ADHD were identified. Unfortunately TPO was not measured during the CATS I 
pregnancies, making comparisons and comments difficult. Some studies have found no link 
between gestational thyroid disorders and ASCs in children (171, 172, 174), whilst others 
have found a link (19, 170, 175-180) which supports the current finding that one of the SGTF 
groups had significantly higher scores on the SCQ compared to the normal GTF group.  
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As noted in chapter 1.1. (General introduction), Stein and Weiss (147) did identify a link 
between thyroid function and ADHD. The study investigated the thyroid function in the child 
however, so caution is advised in comparing to the CATS II cohort; although CATS II will 
eventually have thyroid function status for some of the children which may be a useful 
analysis. Furthermore, deficits were only found with low FT4 for inattentive ADHD types and 
no link to hyperactivity (/overactivity) or impulsivity were identified. This contradicts the 
current binary findings as no links were identified between any of the three groups for 
inattention. There was literature that suggested there is no link at all between thyroid 
hormone function and ADHD (19, 45, 144-146, 148), which the MANCOVA analysis in the 
current chapter also confirmed. 
The question as to why the treated SGTF performed worse on the behavioural questions 
compared to the other two groups is one that is difficult to answer. As discussed, it does 
indicate that an underactive thyroid during pregnancy does have some effect on the 
offspring; and that levothyroxine treatment in some way may be affecting the offspring’s 
behaviour. Regarding the cognitive testing for CATS II, it was identified that there were no 
differences between the three groups for IQ, long term memory or fine motor coordination. 
The treated SGTF mothers were followed-up during their pregnancies to check for the correct 
dosage of levothyroxine (200) to ensure none of them had been overprescribed the 
hormone. It could be suggested that this regular checking, assessment and prescription of 
drugs may have induced a certain level of stress in the mothers. It has been evidenced in the 
literature that stress during pregnancy could lead to emotional and behavioural problems 
for the child (317). The behaviour focus appears to be around ADHD; maternal stress was 
found to be linked to hyperactivity and inattention in boys and total behavioural and 
emotional problems in both boys and girls (318), as well as a modest contribution being 
identified between maternal stress and ADHD (319). However, further investigation is 
needed as stress for the mothers should have been kept to a minimum by study team 
members, i.e. we have identified that you have sub-optimal thyroid function, but we are 
correcting this for you.  
Out of the 11 behavioural questionnaire domains inputted to the MANCOVA, only five 
outputs yielded means where the normal GTF had the lowest problem behavioural score (see 
Table 29 for group means). It can be inferred from this, that an underactive thyroid during 
pregnancy has some effect on the offspring’s behaviour; with treatment making the 
behaviour more pronounced.   
121 
 
The supplementary analyses in appendix 10 identified that, within the CATS II cohort, 
treatment for underactive thyroid function during pregnancy resulted in offspring having 
more ADHD Overactivity and autism-type behaviours, though not clinically significant. One 
of the reasons could be that around a third of the mothers in CATS II were over-treated with 
levothyroxine during their pregnancies, which identified a need for clinicians to closely 
monitor dosage levels during the gestation period.  
Although treatment for SGTF has not been previously investigated (by an RCT), there has 
been recent research that has suggested higher levels of T4 being detrimental to the 
offspring in respect of intelligence and brain morphology (37). CATS II was the first study to 
show that treatment could have a detrimental effect to the offspring behaviour at age 9. 
Adjustment of levothyroxine dosage in CATS II was centred on TSH levels, rather than T4. TSH 
levels were within the normal range for the treated SGTF group during pregnancy (200). The 
mean of T4 decreased between 6 weeks post consent and at 30 weeks gestation, indicating 
that there was an attempt to correct the over-treatment. 
One of the explanations of the treated SGTF group expressing more behavioural difficulties 
may be due to the placental transfer of thyroid hormones. During the first trimester, the 
foetus is completely surrounded by the placenta, and it regulates the uptake of all types of 
thyroid hormone for the foetus (320). Fetal T4 is correlated to maternal circulating T4, but is 
lower compared to maternal serum values, which indicates the placental barrier system (59). 
D2 and Deiodinase 3 (D3, inactivating thyroid-hormone enzyme), are expressed in the 
placenta. D3 metabolises the majority of the maternal T4 from the placenta; placental D2 
decreases as pregnancy continues (321), whereas placental D3 activity increases (322). 
Placental D3 may therefore have a more substantial role in the placental barrier system of 
protecting the foetus from excessive maternal T4 levels (323). However, if there is excessive 
circulating maternal T4, the placental barrier may become ‘saturated’ and unable to fully 
regulate the maternal T4 transfer sufficiently (324). This could explain how excess levels of 
maternal T4 are able to reach the foetus.  
The implications of these findings are that maternal T4 levels have more of an influence on 
offspring behaviour then maternal TSH levels. The research also suggested that higher levels 
of maternal T4 were more detrimental than lower levels of maternal T4 to offspring. 
Furthermore, treatment of pregnant women with levothyroxine may need to be monitored 
more closely during pregnancy.  
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1.6.6.1. Limitations 
Small participant groups make the research difficult to generalise to the wider public. To 
ascertain a broader picture of the children’s functioning, teacher questionnaires could have 
been gathered. However, the time frame for this to be completed may have been 
challenging. The NEPSY-II and WISC-IV both allowed behaviour observations throughout the 
assessments which were not adopted as part of the CATS II protocol. If the study was being 
repeated, it may be beneficial to gather this information from the examiner and see if it could 
confirm findings from the behavioural questionnaires completed by the mothers.  
A problem with the data and with questionnaires in general, was ensuring a 100% completion 
rate. As mentioned, the team attempted to overcome this by ‘spot-checking’ the 
questionnaires filled out by the mothers; for remote/home visits and post packs, this was 
inevitably more difficult. By accepting a low percentage of missing data for calculating mean 
scores, I ensured accuracy in the missing items as the means generated were from the vast 
majority of completed items.  
1.6.6.2. Conclusions 
This results chapter has answered one (bold) of the four research aims for this section: 
i. By reassessing the children at the older age of 9, would there be a continued non-
significant difference identified for intelligence. 
ii. Would there also be non-significant findings at age 9 in other potential areas of 
cognition.  
iii. As there were no differences between the treated and untreated SGTF groups at age 
3, would any differences to the normal GTF group be measurable; as there is a wealth 
of studies displaying that an underactive thyroid during pregnancy does not affect a 
child’s cognition (53, 56, 91-93, 95, 96).  
iv. Would there also be non-significant differences between the groups that extend 
beyond cognition, i.e. behaviour. 
The hypothesis that there would be differences between the normal GTF and untreated SGTF 
group was not identified in either the primary or secondary analyses. The second hypothesis 
was that the treated SGTF group would display less behavioural problems than the untreated 
SGTF groups. This was unfounded as on the SCQ, the treated group were identified as scoring 
significantly higher. Furthermore, the treated SGTF group displayed more behaviour issues ≥ 
specified cut-offs compared to the normal GTF group for the SCQ and ADHD Overactivity and 
Impulsivity in the secondary analysis. Investigating different types of maternal thyroid 
dysfunction (i.e. hypothyroxinaemia and subclinical hypothyroidism), with treatment 
beginning earlier in the pregnancy, in larger groups, may in the future yield different results. 
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Within this study, treatment for SGTF had no effect on cognition in the group as a whole, but 
it did appear to affect the child’s behaviour.  
1.6.7. Chapter Summary 
The current chapter outlined the results from the data collection of the child behavioural 
questionnaires completed by the mothers from the normal GTF and treated and untreated 
SGTF groups. The results indicated that the treated SGTF group offspring had higher scores 
(indicating more behaviour difficulties) on the SCQ, ADHD Overactivity and ADHD Impulsivity 
(compared to the normal GTF and for SCQ they also had higher scores than the untreated 
SGTF group). The results suggested that treatment for an underactive thyroid during 
pregnancy may increase the chances of ADHD and ASC type behaviours for the offspring; 
although it is important to note that the overall means do not suggest a clinical significance 
of a SEN as means were all within the ‘average’ range for the behavioural questionnaires. 
This work concludes the first section of this thesis, the following includes more exploratory 
investigations from both the CATS I and II data. The next chapter investigated the significant 
effects the covariates had on the dependent variables from the WISC-IV (chapter 1.4., 
Intelligence measured at age 9; CATS II data), NEPSY-II (chapter 1.5., Additional cognitive 
assessments at age 9; CATS II data) and behavioural questionnaires (current chapter).   
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2. Exploratory Analysis of the Controlled Antenatal Thyroid Screening 
Study II; cognitive and behavioural data 
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2.1. Significant effects from the covariates; CATS II data 
2.1.1. Chapter Overview 
There were a total of six covariates that were adjusted in the analyses of section one of this 
thesis; these were selected as they may have had an effect on the dependent variables 
measured. This chapter reports on the covariates from the final model MANCOVAs that were 
shown to have a significant effect on the WISC-IV, NEPSY-II and the behavioural 
questionnaire outcomes. Child age was also adjusted in the behavioural questionnnaire 
analysis (presented in chapter 1.6., Behavioural quesitonnaires at age 9; CATS II data), but 
was not investigated here. Undesirable behaviour is not restricted to a specifc age range, and 
the final MANCOVA from the quesionnaire chapter revealed a non-significant effect of child 
age on mean questionnaire scores (p = .221).  
The introduction section is organised by the six covariates accounted for by order of the four-
model statistical analysis (see Figure 6). Model one was the unadjusted analysis and model 
two adjusted for the first covariate, child gender. Model three adjusted for model two plus 
the age of the mother when she first consented into CATS I during her pregnancy and 
whether she breastfed for longer than one month. The final model of analysis, model four, 
adjusted for model three plus where the child was assessed (i.e. home or at the research 
centre), the language spoken at the child’s school and home, and social deprivation. The 
hypotheses and results are then organised by the data collection tools. 
2.1.2. Introduction 
2.1.2.1. Gender (model 2) 
Gender differences in cognitive domains have captured the interest of many researchers 
over the decades. With the WISC-IV being so widely adopted for intelligence testing, it has 
attracted scrutiny of possible gender differences. There appears to be a trend for gender-
specific abilities on specific cognitive domains (325). Females have been reported to obtain 
higher mean scores in the verbal domain, whilst males perform best in the domains of spatial 
and mathematical reasoning abilities (326). For example, males performed significantly 
better on the Mazes subtest from the first edition WPPSI compared to females (327, 328).  
Males have been evidenced to show advantages in verbal domains, quantitative reasoning 
and visual-spatial ability (240, 329-331). Camarata and Woodcock (332) analysed gender 
differences across three cognitive assessment batteries in a total of 5,602 females and 4,863 
males from America, they identified that males significantly outperformed females for verbal 
abilities. Goldbeck et al. (333) analysed males and females on the WISC-IV (German version) 
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and found that males outperformed females in the VC and PR domains. Conversely, Halpern 
et al. (326) and Weiss et al. (334) found that females had a superior VC domain, whereas 
Chen and Zhu (335) found no differences between genders for this domain. Camarata and 
Woodcock (332) but there were no gender differences for long-term retrieval, visual-spatial 
abilities, fluid reasoning (latter two are similar to the concepts behind the PRIQ domain) and 
working memory (332); this latter finding has been supported elsewhere (333). 
Goldbeck et al. (333) discussed how tasks involving PS, memory skills or the comparison of 
symbols (similar to the concept behind the symbol search WISC-IV subtest), favours females 
and the reason may be akin to an advantage in phonological coding (336). Goldbeck et al. 
found that females outperformed males in PSIQ (p < .001); with sex differences being 
significant in both subtests (coding and symbol search). Camarata and Woodcock (332) found 
that PS differences were significant (p < .001) with females scoring more than eight IQ points 
higher than males, however this difference was found in adolescence and appeared to 
diminish in young adulthood. It appears well documented that females outperform males in 
PS abilities, (240, 329-331); and the superiority of female performance on PS tasks compared 
to males has been recognised since the mid-80s (328). However, recently Chen and Zhu (335) 
identified no gender differences for the PS domain from the large norming sample for the 
American WISC-IV.  
Studies have also found no differences between males and females for IQ. Chen and Zhu 
(335) analysed the WISC-IV US standardisation responses from the 2,200 sample (1,100 
males, 1,100 females). No significant differences were found and it was concluded that WISC-
IV scores for males and females should be interpreted in the same way; no differences for 
FSIQ has also been supported by Goldbeck et al. (333). It was also identified in the research 
that females performed less well on letter-number sequencing and symbol search as males 
appeared better at spatial perception, mental rotation and spatial visualisation, and Chen 
and Zhu concluded that females would have required extra cognitive capacity for these two 
subtests. Mulenga et al. (337) also found evidence of males outperforming females in the 
visual-spatial domain; in the NEPSY assessment rather than the WISC-IV. However, caution 
is advised in generalisation as this data was from the first edition NEPSY (252) and was from 
a small sample in Zambia. As mentioned in chapter 1.3. (Methods for the cognitive and 
behavioural data collection for the CATS II study), there is now a newer version of the WISC 
available- the fifth edition (247). Chen et al. (248) again assessed the factor invariance 
between genders for this scale and found no differences between male and females 
outcomes (based on the 2,200 US standardisation sample, 1,009 males, 1,101 females). Chen 
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identified, however, that male children performed slightly better on the visual spatial 
domain, and females on PS domain: though not significant. 
Gender differences have also been examined on the SDQ. It was found in a large Norwegian 
sample (n = 29,631) on the self-report version of the SDQ, that females exhibited more 
emotional problems compared to males, and that males were reported to have higher means 
for the conduct and peer problem domains (338). Conversely, more recently in a smaller 
sample from the Netherlands (n = 2,185), it was found that males expressed more difficulties 
on the emotion domain compared to females, as well as scoring worse for peer problems, 
hyperactivity/inattention and on the prosocial domain (all p’s < .001) (339). Becker and 
Rothenberger (340) found gender also had a significant influence on the scales hyperactivity-
inattention and emotional symptoms. Males had a significantly higher risk for hyperactivity-
inattention and females had a significantly higher risk for emotional problems compared to 
males. 
Any findings of gender differences from the hyperactivity/inattention domain from the SDQ 
would be comparable to any found on the Child ADHD Questionnaire. It has been widely 
researched that males may present more symptoms of ADHD compared to females (341-
345) with the prevalence being as much as 3-4:1 male: female ratio (128). It has also been 
identified that males may express ADHD-typical behaviour differently to females; males may 
squirm and fidget, whilst females may talk excessively or act angry/resentful (346). As well 
as ADHD, ASCs are also viewed as being more prevalent amongst males compared to females 
(347-350). ASCs are four to five times more common in males than females with prevalence 
rates of one in 42 males compared to one in 189 females (351, 352).  
2.1.2.1.1. Gender summary for hypotheses formulation 
The literature mentioned offers conflicting findings as to whether males or females would 
perform better on the VCIQ domain. Even though Chen (335) found no differences between 
the sexes for the VCIQ domain in the large US normative sample for the WISC-IV, the current 
hypothesis follows Goldbeck et al. (333) who found that males performed better than 
females for the VCIQ domain. Goldbeck et al.’s research was selected as favourable as it too 
was based on a European sample using a WISC-IV that had been re-normed for the 
population. For PRIQ and WMIQ it was hypothesised that there would be no significant 
differences (332) and for PSIQ, it was predicted that females would outperform the males 
(328, 332). As the literature appeared in equipoise for which sex was outperforming which, 
it was predicted that gender differences would not reject the null hypothesis for the FSIQ. 
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Similarly, for the NEPSY-II subtests it was predicted there would be no significant differences 
between the genders as the majority of the testing was related to the WM domain. For the 
behavioural questionnaires, males were predicted to score higher on the Child ADHD 
questionnaire and SCQ compared to females (128, 341-345, 347-350). For the SDQ it was 
hypothesized that there would be no gender differences for domains except for conduct and 
peer problems with males scoring higher (338, 339).  
2.1.2.2. Mother age (model 3) 
The average age of mothers has increased over the years from 26.4 years in 1974 to 29.3 
years in 2002 (353). A reason for the increase in age of the first time mother may be a societal 
trend to delay beginning a family for a career or financial reasons (354). Increased maternal 
age can lead to increased risks for the foetus (355-357), and although the offspring’s 
development has not been widely researched (358, 359), literature is starting to appear. It 
has been identified that increased maternal age has a direct linear association with a superior 
performance on intelligence tests (360, 361). A reason for this linear trend could be the social 
advantage of these mothers, i.e. economic security and increased education (362).  
Edwards and Roff (363) had a large US sample (n = 23,717) and FSIQ WISC-III measurement 
data of 7 year old children and data on their mothers’ age at birth. The graph on page five of 
the article shows that as maternal age increases, so does the offspring’s IQ. With respect to 
more general cognitive abilities, it has been identified in the literature that young maternal 
age was negatively associated to children’s mathematics and reading abilities at age 10 (364), 
however the statistically significant results diminished once maternal background covariates 
were controlled for.  
Edwards and Roff (363) also plotted findings from the Bayley Motor scale for a slightly 
inflated sample, including the previous WISC-III, of 26,529 children at 8 months old. For 
maternal age on motor outcomes, there appears little effect after the age of 20 until the 
mother was > 40 years old and then there was a dramatic drop in the mean motor results 
(graph can also be found on page five of the article). A possible reason for this could have 
been that older mothers may not be as involved in upcoming technology and consequently 
not invest as much time improving finger dexterity. 
As well as maternal age having an effect on the child’s cognition, it was also reported that it 
can affect the child’s behaviour. There was varying evidence for mothers who gave birth at 
younger ages to be more likely to have children with disruptive behaviours (361, 365-367). 
Furthermore, children born second or thirdly to young mothers were reported to have much 
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greater disruptive behaviours compared to the first born, and still worse when compared to 
older mothers (368); adjusted for covariates including social background. Saha et al. (369) 
studied a large cohort of 55,908 pregnancies in the early 60s in the US, and identified that 
with every five year increase in maternal age, there was a 12% decreased risk for 
externalising behaviours in the offspring; however, it was difficult to generalise from this 
study as only one culture was examined and the children were all aged 7 years (361). 
Externalising behaviours of aggression, opposition and overactivity have been reported to 
decrease as mother age increases (367), which is linked to ADHD like symptoms. A study that 
included the SDQ, found that male adolescent children born to mothers < 20 years of age 
had a higher prevalence of poor social functioning and that a ‘U-curve’ of performance was 
identified that meant that mothers ≥ 40 years of age were also more likely to have children 
who would exhibit poor social functioning, compared to those offspring born to mothers 
between aged 25-29 years old (370). Autism has also been found to be more prevalent 
amongst offspring born to older mothers compared to younger ones (371-376), but some 
studies have found contradictory findings (377-379).  
2.1.2.2.1. Mother age summary for hypotheses formulation 
It was predicted that the older the mothers were at time of consent into CATS I (i.e. during 
their pregnancy), the higher the scores would be for the WISC-IV (based on the above 
mentioned literature, (360, 361, 363, 364)). This hypothesis was also adopted for the NEPSY-
II WM and long-term memory tasks. Conversely, for fine-motor coordination scores on the 
NEPSY-II, it was predicted that there would be no maternal age effect (based on the work by 
Edwards and Roff’s (363)). There was reported literature that ‘disruptive behaviours’ were 
more common in children born to younger mothers; it was hypothesised for the SDQ and 
child ADHD questionnaire results that the older the mothers were, the less disruptive 
behaviours would have been reported (361, 365-367, 370). However, for the SCQ, the older 
the mothers were, the higher the questionnaire scores would be (371-376). 
2.1.2.3. Breastfeeding (model 3) 
There is a reported link between breastfeeding and cognitive development for offspring in 
early to middle childhood (380-383). It has been found that if the child was breastfed, they 
would perform better on scales of nonverbal ability, mathematics and reading ability 
compared to those who were not breastfed (384). It has also been evidenced that the length 
of breastfeeding is crucial (385-389). Mortensen et al. (386) found a non-linear relationship 
between length of time being breastfed and later adult intelligence (as measured on a 
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Wechsler scale). It was identified that the longer an infant was breastfed (by month), the 
higher the intelligence was, but any breastfeeding for longer than nine months incurred a 
slight drop in verbal, performance and FSIQ. Furthermore, it was identified in their sample 
that the verbal and performance IQ difference for those breastfed for less than one month 
(which also included those who were not breastfed at all), compared to those in the seven 
to nine month category, were 6 IQ points lower. Ruiz et al. (390) used the WISC-IV in their 
modest (n = 103) Spanish sample and found that for the VC, PR, WM and PS IQs all were 
significantly higher (p < .001) for those children that were breastfed for six months compared 
to those who were not. There does appear to be a reported trend of longer breastfeeding to 
a higher IQ, but it has been found to be non-significant in some cases (391-393); all three 
studies adjusted for multiple covariates, including social deprivation.  
Controlling for covariates for maternal breastfeeding has been stated to be of importance, 
as after controlling, results may be non-significant (380). Der et al. (394) found that the 
positive association between breastfeeding and offspring IQ was not significant when 
controlling for maternal IQ; this has been supported elsewhere in the literature (393, 395, 
396). Jacobson et al. (397) also found similar results that when controlling for the mothers’ 
intelligence, previous significant results for breastfeeding were no longer significant on 
specific vocabulary domains. However, a very recent publication by Kanazawa (398) has 
identified that in a British sample, differences in IQ dependent on breastfeeding were still 
significant when controlling for maternal IQ. Maternal education is also important to 
consider when exploring the effects of breastfeeding. A study by Bertini et al. (399) identified 
there was an association between a lack of breastfeeding and low level maternal education 
(n = 900 mothers). Maternal education has also been positively associated to performance 
on cognitive tests within the context of breastfeeding (400). Skafida (401) identified that 
maternal education was a more robust predictor of breastfeeding compared to social 
deprivation, and that mothers less socially deprived with more educational qualifications 
were more likely to breastfeed (n = 5012 babies). This identified literature highlights how 
breastfeeding is somewhat mediated by maternal education 
There is some evidence that motor coordination is affected by breastfeeding. Leventakou 
(402) recently identified that in a sample of Greek children assessed at 18 months of age, by 
Bayley scales, there was a positive linearly associated relationship between breastfeeding 
and all Bayley scales, except for gross motor; with fine motor coordination significantly 
related. Similarly, Dee (403) found that mothers who had not initiated breastfeeding were 
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more likely to report concerns about their child’s fine-motor coordination than those who 
did initiate breastfeeding. 
As well as the cognitive performance of children being affected by breastfeeding, child 
behaviour has also been reported. Infant feeding could influence behaviour by the nutrients 
within the milk (404), for example it has been shown that the increased fatty acid intake from 
breast milk has led to improved neurological development and fewer behavioural problems 
for the child (405). Data from the UK Millennium Cohort Study, > 10,000 mothers completed 
the SDQ about their child in the study (404), found that abnormal SDQ scores were less 
common in those children that were breastfed; the most accentuated effects were around 
those that were breastfed for > 4 months. In term babies who breastfed for > 4 months, this 
was associated with lower odds of emotional and conduct scores.  
As well as the reported effects on cognition, breastfeeding has also been shown to have an 
impact on white matter development in the brain (406, 407). In 8 year old children, the 
breastfeeding factor has also been shown to have a significant effect on specific white matter 
tracts (408) and these tracts are similar to those altered in 8 year olds with ADHD (409). 
Breastfeeding has been identified to not be associated with ADHD, but there appears an 
association when a shortened duration of breastfeeding occurred (410).  
Hong et al. (411) report on the conflicting evidence for whether breastfed or bottle fed 
infants may exhibit more ASC characteristics. Children who were not breastfed have been 
shown to be more likely to develop ASCs (412) and that even down to late initiation (> one 
hour) after birth has shown increased risk of developing ASCs (413). Further links to brain 
development can be identified in Steinman and Mankuta’s review (414), it was discussed 
how ASCs can be affected by dysmyelination which can be brought on by an inadequate 
supply of insulin-like growth factors in newborns. They concluded that breastfeeding was a 
method for increasing insulin like growth factor and thus may ease symptoms of ASCs.  
In 2000, it was reported that 69% of women began breastfeeding (415), currently 81% of 
mothers initiate breastfeeding (416). Although the CATS II prevalence was around 61-62% 
breastfeeding over one month during the period of 2003-2007, it has been identified that 
Welsh rates of breastfeeding are generally lower to that found in the UK (417). In 2005, 48% 
of mothers were breastfeeding at 6 weeks, and 25% continued to six months (418), therefore 
the CATS II breastfeeding rates being lower than the 2000 prevalence, could be due to CATS 
II focusing on those breastfeeding over one month.  
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2.1.2.3.1. Breastfeeding summary for hypotheses formulation 
The literature appears united that breastfeeding would be best when considering the child’s 
intelligence and cognition (380-384, 386-390, 402, 403). As the CATS II study did not collect 
maternal IQ data or maternal education, this important covariate could not be controlled 
for. It was hypothesised that children who were breastfed for over one month would have 
higher IQs and NEPSY-II memory and fine-motor coordination scaled scores, compared to 
those who were breastfed less than one month (as these also include those who were bottle 
fed). A similar hypothesis was adopted for the results from the behavioural questionnaires, 
that those whom were breastfed over one month would have lower SDQ, ADHD and ASC 
scores from the three questionnaire tools (based on the above literature (404, 410, 412-
414)). 
2.1.2.4. Where the child was assessed (model 4) 
Where the child was assessed was not adjusted in the behavioural questionnaire analysis as 
this was proposed not to affect the scoring by the mothers. Therefore, no literature search 
or hypothesis generation was conducted to investigate any possible effects on the behaviour 
of the children.  
There was little research available detailing any possible effects of the testing environment 
on cognitive assessments. Both the WISC-IV (250) and NEPSY-II (230) manuals denote the 
importance of a distraction, noise-free environment to ensure optimal testing. To my 
knowledge (by extensive literature searching), no articles had explored the possibility of a 
significant effect of the testing environment on assessment outcome.  
In a book by Kamphaus (216), he noted what extraneous factors psychologists should 
attempt to control for during cognitive testing. Kamphaus provided a list of the ideals of a 
testing room (pg. 96): 
“The testing room should; 
 Free from interruptions 
 Be pleasantly, but minimally decorated so as not to distract the child 
 Be well lit (…) 
 Have adequate ventilation 
 Be quiet (…) 
 Be a few degrees cooler than a room meant for adults (…)” 
It was further noted in Kamphaus’ book (216) that the optimal time for testing may be during 
the morning period. This was almost impossible for most home visits in CATS II, as the 
children were in school. A problem encountered was children being fatigued from their 
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school day by the time I arrived to conduct the assessment battery; this was sometimes 
mentioned by the mothers. Other activities preceding the assessment may have had an 
effect on the test outcome, for example whether they were preceding the test with calm 
story time, or high energetic play (419).  
All of the research centre tests occurred over the morning period, and only had the child and 
myself in the room, bar one assessment. The home visits contained a greater number where 
the mother was present during testing for part of or the whole of the assessment 
(unfortunately this was not noted after the assessments as this may have been an interesting 
covariate to investigate). The WISC-IV and NEPSY-II administration manuals both discussed 
the negative impact the presence of a parent or additional adult may have on the test 
outcome. If a child was ≤ 3 years of age, a parent could be present to aid the assessment 
(216). With the older child, and what I instinctively aimed to achieve if a parent was present 
during testing, was to have the adult sat away from the examinee’s line of sight to minimise 
the distraction (419).  
2.1.2.4.1. Place of assessment summary for hypotheses formulation 
As differences between scores on cognitive tests were not well reported in the literature, it 
was difficult to develop a hypothesis for this covariate. As the research centre cognitive 
assessments (clinical environment) were conducted in a controlled setting, where aspects 
such as distractions in the room could be more easily controlled for, it was predicted that 
those assessed at their home would perform worse that those assessed at the research 
centre.  
2.1.2.5. Child’s language at school and home (model 4) 
As previously mentioned, the covariate of child’s language spoken at school and home was 
controlled for. This was because the large majority of assessments occurred in Wales and 
many children attended Welsh-speaking schools. There were several combinations of school 
and home languages in the study; 
a. English school and English at home 
b. Welsh school and English at home 
c. Welsh school and Welsh at home 
d. English school and other language (not Welsh or English) spoken at home 
e. Welsh school and other language (not English or Welsh) spoken at home 
Further information can be found in Tables 13 and 20 about how many participants fell into 
which combination of languages. As those attending Welsh schools will have done-so in a 
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one-language format, i.e. solely in Welsh, for the purposes of this literature search, were 
seen as bilingual. Children from the categories d. and e., will have been trilingual; but few 
fell into these classifications, for example, only one child in CATS II attended a Welsh school 
and spoke an additional language at home, not Welsh or English. As the language of the 
child’s school or home-life were not controlled during the behavioural questionnaire data 
analysis, no literature search or hypothesis generation were conducted for differences 
between mono-and-bilingual children’s behaviour.  
The literature appeared conflicting for studies that had investigated specific cognitive 
differences between monolingual and bilingual children. Bilingual children had been 
reported to perform better on cognitive measures compared to monolingual children (420). 
However, bilingual children appeared to consistently perform worse for their VC domain 
when compared to monolingual children (420-422). There was research to suggest however, 
that on the PR domain of functioning (specifically investigating the demands of executive 
functioning tasks), bilingual children outperformed their monolingual peers (423-427). 
Specific to the WISC-IV, differences in favour of bilingual compared to monolingual 
individuals had been found on the Block Designs and Vocabulary subtests (428, 429). The 
possible reason for this ‘over performance’ in nonverbal abilities was that the bilingual mind 
would have required excellent executive resources to be able to select the correct language 
at the given time, and not make use of the other language (430, 431). However, others 
believed that both languages could be active in a bilinguals mind, when the intention was to 
only use one of them (432). 
Such studies looking at the different cognitive aspects of bilingual children have been 
criticised for not controlling for social deprivation factors whilst also having small sample 
sizes (430, 431, 433). Conversely when social deprivation factors were controlled for, 
consistent results of a lower VC to higher PR domain for bilingual compared to monolingual 
children has been identified  (433) (also supported by (420, 434)).  
Few studies have investigated any bilingual effects from the NEPSY-II. Korkman et al. (435) 
administered specific NEPSY-II subtests to bilingual and monolingual children and found no 
differences (including the NM subtest). This was replicated in a study administering all 14 
NEPSY-II subtests and found no differences on ten subtests (including FTDH, FTNDH and NM), 
but bilingual children outperformed on ‘Imitating Hand Positions’ and ‘Design Copy’, and 
performed worse on two of the verbal subtests (436). Recently, a study was conducted using 
the ten core subtests of the WISC-IV and nine selected NEPSY-II subtests (same versions as 
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current thesis), on a sample of Finnish bilingual children (n = 100) (437). The only significant 
difference that Karlsson et al. identified, was on the Symbol Search subtest of the WISC-IV, 
monolingual children outperformed their bilingual counterparts (p = . 003). It is unclear in 
the literature what the impact is of being educated in a language different, from an 
individual’s home language, in respect of test performance; for example would it be better 
to have an English test in a pupil’s school or home language? 
2.1.2.5.1. Child’s language at school and home summary for hypotheses formulation 
Based on the above literature, it was hypothesised that the mixed language children in CATS 
II would have a lower VCIQ compared to the monolingual children (420-422, 433, 434). It was 
also predicted that the bilingual children would have a higher PRIQ (420, 423-427, 433, 434) 
compared to the monolingual children. There would be no differences for WMIQ, PSIQ or 
FSIQ however, as this was sparsely reported upon in the literature. As no differences were 
identified for the NM subtest of the NEPSY-II (435-437), it was predicted that no further 
differences would be found between the participants for all of the NEPSY-II subtests. 
2.1.2.6. Social deprivation (model 4) 
There is a long established belief that those children from a higher rated social (and/or 
economic) backgrounds, exposed to luxuries of particular goods, services and social 
connections that could benefit them, are at an advantage compared to those children from 
a more socially deprived background (438). Social deprivation has been reported to be 
related to cognitive performance throughout an individual’s childhood (439-441). There is a 
reported mean cognitive decline with decreasing social class, which was more predominant 
in the VC domain (442).  
Differences of ability from social deprivation can be seen before the child begins schooling 
(440, 443). Once they get to school age, lower income families (therefore with a lower score 
of social deprivation) were more likely to send their child to a lower quality school (444, 445). 
However, if the child had a preschool enrolment before the age of 4 years, there was an 
association to reduced family-level influences on early reading and maths skills at age 5 years 
(443).  
Social deprivation may affect different ages of children in different ways. This effect had been 
found to be reduced on children aged 5 compared to those at aged 3 years (442). White (446) 
agreed that the link between the background of the child and school attainment diminished 
with age. However, it was been found that differences in cognitive and non-cognitive skills 
were apparent in children of different social deprivation at ages 4 and 6 years (447) and 
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Smith et al. (448) identified that there were no differences for achievement between 7 and 
3 year olds when controlling for social deprivation. Therefore, the impact of social 
deprivation may be more apparent during the first few years of schooling, longitudinal 
studies would be needed to investigate this further.  
As well as cognition, social deprivation has also been reported to affect the child’s behaviour, 
with those from a more socially deprived background exhibiting more behavioural difficulties 
(449, 450). It was noted in the literature that problems may begin to emerge in early 
childhood with externalising problems becoming apparent in middle childhood (451-453). In 
a large UK cohort sample, it was identified that those from lower socially deprived 
backgrounds were reported to have higher mean results on total SDQ scores for all domains, 
except for prosocial scale, compared to those from less socially deprived backgrounds (454). 
One possible reason for the correlation that has been suggested is diet (455).  
2.1.2.6.1. Social deprivation summary for hypotheses formulation  
Based on the above literature, it was hypothesised that the covariate of social deprivation 
(calculated by social-deprivation postcode scores from StatsWales (281) and 
OpenDataCommunities (282)) would have a significant effect on the child’s WISC-IV and 
NEPSY-II scores with those from a less socially deprived background performing better than 
those from a more socially deprived background (439-442). In relation to the three behaviour 
questionnaires, it was also predicted that social deprivation would have a statistically 
significant effect on the outcome scores, with more frequent indications of disruptive 
behaviours from those of a more socially deprived background (449, 450, 454).  
2.1.3. Hypotheses 
The section above described the rationale behind each hypothesis proposed of the possible 
significant effects of the covariates on the three main measures. Below are tables containing 
the grouped hypotheses by measure, i.e. the WISC-IV, followed by the NEPSY-II and then the 
behavioural questionnaires (Tables 31, 32 and 33). 
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Table 31 
Covariate Hypotheses for the Wechsler Intelligence Scale for Children- Fourth Edition, UK 
(WISC-IV) 
Covariates WISC-IV 
VCIQ PRIQ WMIQ PSIQ FSIQ 
Gender Males would 
score higher 
than females 
No difference Females 
would 
score 
higher 
than 
males 
No 
difference 
Mother age The older the mother was at time of pregnancy, the higher the IQs 
would be 
Breastfeeding If breastfed, there would be higher IQs compared to those who were not 
breastfed for over 1 month 
Where child 
was assessed 
Those assessed at the research centre would perform better than those 
assessed at their homes 
School and 
home 
language 
Bilingual 
children would 
have lower a 
VCIQ 
compared to 
monolingual 
children 
Bilingual 
children would 
have a higher 
PRIQ 
compared to 
monolingual 
children 
No difference 
Social 
deprivation 
score 
Lower rating* would yield lower IQs compared to those who had a 
higher social deprivation score 
Note. *lower ratings=more socially deprived. VCIQ=verbal comprehension intelligent 
quotient, PRIQ=perceptual reasoning intelligence quotient, WMIQ=working memory 
intelligent quotient, PSIQ=processing speed intelligent quotient, FSIQ=full scale 
intelligent quotient. 
 
  
139 
 
Table 32 
Covariate Hypotheses for the Developmental Neuropsychological Assessment (NEPSY)-II 
Covariates NEPSY-II 
Memory Motor-coordination 
Gender No difference 
Mother age The older the mother was at time of 
pregnancy, the higher the scaled scores 
would be compared to those born to 
younger mothers 
No difference 
Breastfeeding If breastfed, there would be higher scaled scores compared to those 
who were not breastfed over 1 month 
Where child 
was assessed 
Those assessed at the research centre would perform better than those 
assessed at their homes 
School and 
home 
language 
No difference 
Social 
deprivation 
score  
Lower rating would yield lower scaled scores compared to those whom 
had a higher social deprivation score 
  
Table 33 
Covariate Hypotheses for the Behavioural Questionnaires 
Covariates Questionnaires 
SDQ Child ADHD Questionnaire SCQ 
Gender No difference: except 
on conduct and peer 
problems where 
males would score 
higher 
Males to have higher mean scores than females 
Mother age The younger the mother was at time of pregnancy, 
the higher the mean scores would be 
The older the 
mother was, the 
higher the score 
Breastfeeding If breastfed over 1 month, there would be lower mean scores obtained 
compared to those who were not 
Social 
deprivation 
score 
A lower rating of social deprivation would yield higher scores on all 
questionnaires compared to a high rating 
Note. SDQ=strengths and difficulties questionnaire, ADHD=attention deficit hyperactivity 
disorder, SCQ=social communication questionnaire. 
 
2.1.4. Method and Statistical Analysis 
The data used in this chapter was from the CATS II study. Information about covariates was 
collected from the ‘CATS General Questionnaire’. The dependent variable data collection has 
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been previously described (for the WISC-IV see chapter 1.4., Intelligence measured at age 9; 
CATS II data, for the NEPSY-II see chapter 1.5., Additional cognitive assessments at age 9; 
CATS II data, and for the behavioural questionnaires see chapter 1.6., Behavioural 
questionnaires at age 9; CATS II data).   
The following statistical analyses were conducted in IBM SPSS statistics version 20. The 
indication that any of the six covariates were having a significant effect on the dependent 
variables was identified primarily from the MANCOVA outputs (primary analyses only). Once 
they had been identified, covariates were explored for their effects. If the covariates only 
had two groups of classification they were explored by t-test. This included gender (male or 
female), whether the child was breastfed for longer than one month (yes or no) and where 
the child was assessed (home or research centre). If the covariate had two or more groups, 
a MANOVA was adopted to enable investigation of either all WISC-IV, NEPSY-II or behaviour 
questionnaire scores in one main analysis. These included, mother age at time of consent 
into CATS I (data was in quartiles), the child’s language spoken at school and home (English 
school and English home, Welsh school and English home, Welsh school and Welsh home, 
English school and other home language or Welsh school and other home language) and also 
the social deprivation score (data was quintiled). Any significant MANOVA results were 
explored by Bonferroni corrected post hoc tests. As discussed in chapter 1.6. (Behavioural 
questionnaires at age 9; CATS II data), child age was also adjusted in the primary MANCOVA 
analysis. This covariate did not have a significant effect on the behavioural questionnaires (p 
= .221), and was not explored further.  
An ANOVA was used for exploring the LM subtest from the NEPSY-II to keep the analysis 
similar to chapter 1.5. (Additional cognitive assessments at age 9; CATS II data), this was 
because a smaller group completed the LM subtest and by adding it to the NEPSY-II 
MANOVA, it would have lost overall statistical power by only including those children who 
completed all six NEPSY-II subtests.  
2.1.5. Results 
The following results were organised by the data collection tools; WISC-IV, NEPSY-II and 
behavioural questionnaires.  
2.1.5.1. WISC-IV 
All of the covariates except for the location of where the child was assessed ( ROY = .022, F 
(5, 436) = 1.891, p = .095, p2 = .021) had a significant effect on the IQs.  
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 Gender 
As identified by the MANCOVA at the fourth level of analysis, child gender had a significant 
effect on IQs obtained: ROY = .083, F (5, 436) = 7.258, p < .001, p2 = .077. T-tests revealed 
that females performed significantly better than males for three IQs: WMIQ (p = .031, 95% 
CI [-4.612, -.216]), PSIQ (p = <.001, 95% CI [-8.554, -3.986]) and FSIQ (p = .029, 95% CI [-4.714, 
-.249]). VCIQ and PRIQ yielded results of p’s >.756. See Table 34 below for further 
information of the gendered mean IQs.  
Table 34 
Male and Female Intelligent Quotient (IQ) Means 
IQ domain Childs gender N Mean 
WISC-IV VCIQ male 232 99.22 
(12.08) 
female 220 99.17 
(10.49) 
WISC-IV PRIQ male 232 104.76 
(12.74) 
female 220 105.13 
(12.41) 
WISC-IV WMIQ male 232 98.68 
(11.79) 
female 220 101.10 
(11.98) 
WISC-IV PSIQ male 232 99.95 
(12.15) 
female 220 106.22 
(12.55) 
WISC-IV FSIQ male 232 101.33 
(12.24) 
female 220 103.81 
(11.89) 
Note. Standard deviations appear in parentheses below means. WISC-IV=Wechsler 
intelligence scale for children-fourth edition, UK, VCIQ=verbal comprehension 
intelligent quotient, PRIQ=perceptual reasoning intelligence quotient, WMIQ=working 
memory intelligent quotient, PSIQ=processing speed intelligent quotient, FSIQ=full scale 
intelligent quotient. 
 
 Mother age 
Mothers age at time of first consent into CATS I by Roy’s largest root at the MANCOVA fourth 
level of analysis revealed a significant effect on the children’s IQs, ROY = .056, F (5, 436) = 
4.912, p < .001, p2 = .053. The exploratory MANOVA of the covariate revealed a sustained 
significant affect, ROY = .119, F (5, 446) = 10.586, p < .001, p2 = .106. At the univariate level, 
all IQs were significantly affected by age of mother: VCIQ- F (3, 448) = 12.926, p < .001, p2 = 
.080, PRIQ- F (3, 448) = 6.573, p < .001, p2 = .042, WMIQ- F (3, 448) = 5.678, p = .001, p2 = 
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.057, PSIQ- F (3, 448) = 11.238, p < .001, p2 = .070 and FSIQ- F (3, 448) = 14.680, p < .001, p2 
= .090. The overall trend was that the older the mothers were at time of consent into CATS 
I, i.e. during their pregnancies, the higher the mean IQs were for the children (see Figure 17 
for the graph showing the means). The strongest significance was evident between quartile 
group one to all other ages. The CATS I sample was grouped so that group one included ages 
of 14-24, group two: 25-29, group three: 30-33 and group four was ages 34-49 years. From 
the graph it appeared that after the initial steep increase between groups one to two, the 
IQs did still increase, but the increase was no-where near as dramatic.  
 
Figure 17: Graph to show trend of mean Intelligent Quotients by mother age quartiles  
VCIQ=verbal comprehension intelligent quotient, PRIQ=perceptual reasoning intelligence 
quotient, WMIQ=working memory intelligent quotient, PSIQ=processing speed intelligent 
quotient, FSIQ=full scale intelligent quotient. X axis=mother age quartiles,1 lowest. Y 
axis=mean IQ scores.  
 
 Breastfeeding 
Whether the child was breastfed over one month also had a significant effect on the child’s 
IQ scores by the MANCOVA adjusted by model four of the analysis, ROY = .028, F (5, 436) = 
2.417, p = .035, p2 = .027. An exploratory t-test revealed that all IQs except for PSIQ (p = 
.060) were significantly affected by the covariate of breastfeeding (p’s < .006). On average, 
those who were breastfed had a 5 point higher means for VCIQ, PRIQ and FSIQ compared to 
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those who were not, and WMIQ yielded a 3 point advantage to the breastfed over one month 
group. See Table 35 for further details of p values and confidence intervals.  
Table 35 
Breastfeeding Significance and Confidence Intervals on the Dependent Variables from the 
Wechsler Intelligence Scale for Children-Fourth Edition, UK (WISC-IV) 
IQ Sig. (2-tailed) Mean 
Difference 
95% Confidence Interval of the 
Difference 
Lower Upper 
VCIQ .000* -4.837 -6.958 -2.716 
PRIQ .000* -5.042 -7.399 -2.684 
WMIQ .006* -3.202 -5.470 -.934 
PSIQ .060 -2.329 -4.756 .097 
FSIQ .000* -5.383 -7.647 -3.118 
Note. *Significance < .05. VCIQ=verbal comprehension intelligent quotient, 
PRIQ=perceptual reasoning intelligence quotient, WMIQ=working memory intelligent 
quotient, PSIQ=processing speed intelligent quotient, FSIQ=full scale intelligent quotient. 
 
 Child’s language at school and home 
The covariate of child’s language at school and home was also significant, ROY = .039, F (5, 
436) = 3.408, p = .005, p2 = .038. The exploratory MANOVA also revealed a significant effect 
of language of school and home on IQ, ROY = .060, F (5, 446) = 5.355, p <.001, p2 = .057. 
Conversely, under separate univariate analysis, none of the five IQs reached significance (all 
p’s >.084). A reason for this was that the multivariate test takes account of the correlation 
between the many dependent variables, therefore the data has more power to detect group 
differences; when compared to the univariate tests (210).  
 Social deprivation 
The final adjustment to the analysis was for social deprivation. Using Roy’s largest root, there 
was a large significant effect on IQs for social deprivation scores, ROY = .089, F (5, 436) = 
7.784, p < .001, p2 = .082. The exploratory MANOVA revealed a continued significance, ROY 
= .146, F (5, 446) = 12.999, p <.001, p2 = .127. At the univariate level, all IQs were still affected 
by the covariates (all p’s <.001). The overall trend was that the more socially deprived the 
participants were (i.e. those with a lower quintiled score, see Tables 9 and 10 for further 
information), the worse the child’s performance on the IQ domains was (see Figure 18). 
There did appear to be a spike of VCIQ for the social deprivation score classification two, but 
this may have been a type 1 error as it was only apparent on this domain.  
144 
 
 
Figure 18: Graph to show trend of mean Intelligent Quotients by social deprivation quintiles  
VCIQ=verbal comprehension intelligent quotient, PRIQ=perceptual reasoning intelligence 
quotient, WMIQ=working memory intelligent quotient, PSIQ=processing speed intelligent 
quotient, FSIQ=full scale intelligent quotient. X axis= social deprivation score quintiles, 1 
represents the most socially deprived, Y axis=mean IQs.  
 
2.1.5.2. NEPSY-II 
As can be seen in Table 36 for the LM ANCOVA (as adjusted for by model four of the analysis), 
only child gender and social deprivation had a significant effect on the combined working 
and LTM subtest from the NEPSY-II. Gender was investigated by an independent samples t-
test. Females performed significantly better than males, receiving a mean of 11.30 for LM 
compared to the males achieving 10.28 (p = .001, 95% CI [-1.643, -.403]. The effects of the 
social deprivation were investigated by ANOVA (as five groups of quintiled ratings), F (4, 312) 
= 3.802, p = .005, p2 = .046. The social deprivation scores revealed that the more deprived 
the participants were, the worse they performed (see Table 37 below).  
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Table 37 
Social Deprivation Quintiles and Means for the Subtest List 
Memory and List Memory Delayed, from the Developmental 
Neuropsychological Assessment (NEPSY-II) 
Social Deprivation 
Quintiles of English 
and Welsh. Score 1 
low-5 
N Mean 
1 44 9.59 
(3.00) 
2 40 10.30 
(2.80) 
3 48 10.52 
(3.22) 
4 63 11.08 
(2.65) 
5 122 11.34 
(2.62) 
Total 317 10.79 
(2.85) 
Note. Standard deviations appear in parentheses below means. 
 
For the MANCOVA analysis involving the other NEPSY-II tests, only gender ( ROY = .041, F (5, 
397) = 3.236, p = .007, p2 = .039) and language spoken at school and home ( ROY = .046, F 
(5, 397) = 3.675, p = .003, p2 = .044) had a significant effect on the participants. All other 
covariates did not have a significant effect on the NEPSY-II scores (p’s > .111); where the child 
was assessed, mother age at consent in CATS I, whether the child was breastfed for longer 
than one month, and the social deprivation score.  
 Gender 
Table 36 
Covariate Effects on List Memory and List Memory Delayed Subtest  
Source df (error=307) F Sig. Partial Eta 
Squared 
Child Gender 1 10.982 .001* .035 
Mother Age Quartiles 1 .398 .528 .001 
Social Deprivation 
Quintiles 
1 11.264 .001* .035 
Where Assessed 1 .009 .923 .000 
Language at school & 
home 
1 .004 .950 .000 
Breast fed ≥ 1month 1 1.020 .313 .003 
Note. *Significance < .05. NEPSY-II= developmental neuropsychological assessment, 
df=degrees of freedom. 
146 
 
Gender was assessed for the five NEPSY-II subtests by an independent samples t-test. Similar 
to the ANCOVA, it was females who outperformed males on FTDH (p =.043, 95% CI [-.599, -
.009]) with females achieving a mean of 12.26 compared to males achieving on average 
11.95. Additionally, the subtest NM was significant, p =.001, 95% CI [-1.447, -.395], with 
females generating a mean score of 11.79 to the males’ score of 10.87.  The t-test revealed 
non-significant differences for gender (p’s >.417) on the remaining NEPSY-II tests (MD, MDD 
and FTNDH).  
 Child’s language at school and home 
For language at school, a MANOVA was adopted to investigate the covariate for the five tests. 
Using Roy’s largest root significance was still seen across the CATS II group: ROY = .051, F (5, 
406) = 4.134, p = .001, p2 = .048. At the univariate level, it was found that it was the FTDH 
subtest that was significantly affected by the child’s language at school: F (4, 407) = 3.490, p 
= .008, p2 = .033 (other subtests generated p’s >.057). As can be seen in Table 38 below, the 
highest mean attained was from those that attended a Welsh school, and spoke Welsh at 
home. Separate (Bonferroni corrected) t-tests could not have been computed on this 
covariate as only one participant attended a Welsh school with other language (not English 
or Welsh) spoken at home.  
Table 38 
Mean Score of Fingertip Tapping Dominant Hand by Language Spoken at School and 
Home 
Language at school N Mean 
English school and English at home 330 11.97 
(1.55) 
Welsh school and English at home 72 12.51 
(1.41) 
Welsh school and Welsh at home 10 13.20 
(1.32) 
English school and other language (not Welsh or English) 
spoken at home 
3 12.67 
(1.15) 
Welsh school and other language (not English or Welsh) 
spoken at home 
1 11.00 
(*) 
Note. Standard deviations appear in parentheses below means. *no standard deviation 
available as only one participant with this language classification. NEPSY-II= 
developmental neuropsychological assessment.  
2.1.5.3. Behavioural questionnaires 
The MANCOVA revealed that child gender ( ROY = .158, F (9, 450) = 7.916, p < .001, p2 = 
.137) and social deprivation ( ROY = .065, F (9, 450) = 3.229, p = .001, p2 = .061) had a 
significant effect on the child behavioural questionnaires; the other covariates of mother age 
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at time of consent into CATS I and whether the mother breastfed over one month, were non-
significant (p’s > .052).  
 Gender 
The significant effect of gender on the child behaviour questionnaires was explored further 
by a t-test. There were significant interactions for all questionnaire outcomes except SDQ 
emotion and SDQ peer problems (p’s > .110).  Table 39 displays the means, significance and 
confidence intervals for the remaining questionnaires. As is seen in the table, males 
performed significantly worse than females across the board (a higher score indicated a 
greater behavioural difficulties).  
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Table 39 
Significant Differences Between Genders for the Behavioural Questionnaire 
Questionnaire Gender N Mean Sig. 95% Confidence Interval 
Lower Upper 
SDQ Conduct Male 236 1.59 
(1.75) 
.002 .166 .740 
Female 233 1.13 
(1.39) 
SDQ 
Hyperactivity 
Male 236 3.82 
(2.90) 
.001 .378 1.351 
Female 233 2.96 
(2.44) 
SDQ Total 
Difficulties 
Male 236 9.10 
(6.55) 
.023 .177 2.350 
Female 233 7.83 
 (5.37) 
SDQ 
Prosocial* 
Male 236 8.40 
(2.00) 
< .001 -1.092 -.472 
Female 233 9.18 
(1.36) 
ADHD 
Inattention 
Male 237 7.29 
(6.14) 
< .001 1.105 3.137 
Female 232 5.17 
(5.01) 
   
ADHD 
Overactivity 
Male 237 3.09 
(2.82) 
< .001 .932 1.855 
Female 232 1.70 
(2.23) 
ADHD 
Impulsivity 
Male 237 3.85 
(3.20) 
.001 .400 1.480 
Female 232 2.91 
(2.73) 
ADHD Total Male 237 14.24 
(11.06) 
< .001 2.655 6.254 
Female 232 9.78 
(8.65) 
SCQ Male 234 5.33 
(4.14) 
< .001 .960 2.336 
Female 232 3.68 
(3.38) 
Note. Standard deviations appear in parentheses below means. *females had a higher 
mean, prosocial scale was the only one with ‘reverse’ marking, i.e. a higher score indicated 
a more desirable outcome.  SDQ=strengths and difficulties questionnaire, ADHD=attention 
deficit hyperactivity disorder, SCQ=social communication questionnaire. 
 
 Social deprivation 
The significant effect of social deprivation was explored by a MANOVA; ROY = .106, F (9, 456) 
= 5.371, p = > .001, p2 = .096. It was identified that all, except three mean scores, were 
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significantly affected by social deprivation; only SDQ prosocial, ADHD inattention and ADHD 
total scores were not significantly affected (p’s > .075). See the graph below (Figure 19) for 
the general trend of the significantly affected questionnaire domain scores. 
 
Figure 19: Graph to show mean scores by social deprivation score  
NOTE: Only those questionnaire domains that were significantly affected by social 
deprivation score are presented. Scale on the Y axis is arbitrary as it includes the total scores 
of the three questionnaires. Reader is advised to look at one particular scale at a time for a 
true reflection of the relationship between social deprivation ratings to questionnaire 
outcome. SDQ=strengths and difficulties questionnaire, ADHD=attention deficit 
hyperactivity disorder, SCQ=social communication questionnaire. X axis= social deprivation 
score quintiles, a score of 1 represented a more socially deprived rating, Y axis= means of 
questionnaires. 
 
2.1.6. Discussion 
The current chapter investigated whether the covariates (child gender, whether the mother 
breastfed over one month, age of mother at time of consent into CATS I, where the child was 
assessed, language of the child’s school and home, and social deprivation) had any effect on 
the dependent variables from the WISC-IV, NEPSY-II and behavioural questionnaires. It was 
hypothesised that all of the covariates would have had some effect to the dependent 
variables, this was confirmed apart from the covariate of where the child was assessed. The 
biggest effects to the WISC-IV, NEPSY-II and behaviour questionnaires, were child gender and 
social deprivation. Discussions below are organised by the dependent variable measures. 
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It was hypothesised that the WISC-IV scores would be significantly affected by child gender. 
The hypotheses generated in Table 31 based on the literature, were all unfounded except 
for PSIQ, where females performed significantly higher compared to males (328, 332). This 
result was also identified for WMIQ and FSIQ. The hypotheses of breastfeeding over one 
month yielding higher IQs in offspring compared to those who were not breastfed (380-384, 
386-390, 402, 403), the older the mother at time of pregnancy the higher the IQs (360, 361, 
363, 364) and the less socially deprived the participants were, the higher the IQs (439-442), 
were all confirmed by the above analysis. It was predicted that those who were assessed in 
the research centre would have higher IQ scores than those assessed at their homes, as the 
home environment would include more distraction, and therefore not be an optimal testing 
space (216, 230, 250). The testing environment appeared to have no effect at the 
multivariate level to IQs measured on the WISC-IV (p = .095). The final hypothesis of the 
effects of bilingualism on IQ was not confirmed at the multivariate level. It was predicted 
that bilingual children would have lower VCIQs than monolingual children (420-422, 433, 
434), but perhaps have a higher PRIQ compared to monolingual children (420, 423-427, 433, 
434), with no difference between the other IQ scores. There was a difference at the 
multivariate level but not at the univariate level, a possible reason for this was that the data 
had more power to detect group differences at the multivariate level (210).  
Table 32 displayed the anticipated outcome of no gender differences for the NEPSY-II, as it 
was evidenced in the literature that no previous differences had been identified for memory 
or motor-coordination (332). Females outperformed the males on LM, FTDH and NM 
subtests. This added validity to the WISC-IV gender findings, as significant differences for 
WMIQ were identified with females outperforming males. As mentioned in chapter 1.5. 
(Additional cognitive assessments at age 9; CATS II data), the LM subtest was analysed 
separately, consequently the effects of the covariates on the NEPSY-II were also analysed 
separately in the current chapter. Social deprivation rating was predicted to have a 
significant effect on the NEPSY-II scores (439-442), this was confirmed in the LM analysis, but 
confirmed other literature of a null hypothesis in the main MANCOVA of the NEPSY-II 
subtests (442, 446-448). As the literature had only identified language differences for the 
NM subtest of the NEPSY-II (435-437), it was predicted that there would be no differences 
on the NEPSY-II; as the covariate was analysed at the multivariate level, a subtle difference 
would be undetectable unless pronounced. Upon analysis, I identified that those who 
attended Welsh schools and who spoke Welsh at home, had higher FTDH results than those 
from other language combinations. As mentioned in the results section, no post hoc analysis 
151 
 
could be completed as one of the groups only contained one participant, it could be inferred 
then that this result was a false positive as the analysis was not conducted on groups with 
close/equal numbers in. No significant effects of whether the mother breastfed over one 
month or where the child was assessed were identified here, which contradicted the 
literature ((380-384, 386-390, 402, 403) and (216, 230, 250), respectively). The covariate of 
mother age at time of consent into CATS I, was predicted to have no effect on motor 
coordination (363), this was confirmed in the current analysis. However for the memory 
tests, it was predicted that the older the mother was, the higher the scores would be for the 
offspring alike to the WISC-IV predictions; this was unfounded in the current analysis.  
Hypotheses for the child behavioural questionnaires can be found in Table 33. Gender had a 
significant effect on all of the questionnaires, and on every domain measured. The males 
received significantly higher scores, indicating ‘worse’ behaviour (except for SDQ prosocial 
where scoring was inverted), compared to females. This was confirmed in the literature for 
ADHD and ASCs (128, 341-345, 347-350), and subsequently was adopted as the hypothesis. 
For the SDQ, no differences for gender were anticipated, except for peer problems and 
conduct where males would score higher (338, 339). The current analysis confirmed the 
previous literature, but also found males presenting more difficulties across the domains of 
the SDQ. The only other covariate that had a significant effect was social deprivation. It was 
predicted that the lower the rating, the ‘worse’ the behaviours (i.e. higher scores) would be 
for all of the questionnaires (449, 450, 454). This was confirmed in the analysis, and Figure 
19 displays a graph to illustrate the trend of scores by social deprivation. The rating appeared 
to have no effect on SDQ prosocial, ADHD inattention or ADHD total scores. Mother age at 
time of consent into CATS I and whether the mother breastfed over one month did not have 
a significant effect on the behavioural questionnaires. This contradicted the literature, it had 
been found that if the mother was young at time of pregnancy, there would be more 
behavioural difficulties reported (361, 365-367, 370), but for ASC traits it was an inverse 
relationship, i.e. the older the mother, the more likely it was that the offspring would have 
ASC traits (371-376). Similarly the breastfeeding data contradicted the literature, studies 
showing that better behaviour would be seen in those who breastfed for a period (404, 410, 
412-414). However, it is worth noting that the measures here were questionnaires and 
perhaps further investigations of assessments for specific behaviour difficulties or SENs may 
yield a link to breastfeeding.  
The WISC-IV was the only measure in CATS II significantly affected by the covariates of age 
of mother at time of consent into CATS I and whether the mother breastfed over one month. 
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Given the literature discussed in the introduction evidencing effects from mother age and 
breastfeeding, this was surprising. One of the reasons no differences were identified could 
have been because the NEPSY-II comparison included subtests, rather than the WISC-IV 
which was analysed at the domain level (e.g. VCIQ takes account of three subtests). 
Conversely, the behavioural questionnaires were domain level as each domain took account 
of at least five items for a total score.  
As mentioned, gender appeared to be the covariate with the largest effect. For cognitive 
differences, it was always females scoring higher than males. Chen et al. (248) found no 
differences between males and females on the WISC-V whereas Camarata and Woodcock 
(332) did identify differences. These two studies were based on American data, thus we can 
compare findings, but with caution. The behavioural questionnaires completed by the 
mothers, had males rated as presenting worse behaviour than females. As ADHD and ASCs 
were measured as more prevalent in males than females (128, 341-345, 347-350), this was 
not surprising, but with the extension of the SDQ finding a similar discrepancy between the 
genders, male specific traits may extend into more generalised behaviour.  
2.1.6.1. Limitations 
One of the limitations of this chapter was that there was a lot of multiple testing. The WISC-
IV, NEPSY-II and behavioural questionnaire measures were analysed separately so that the 
work here would be more comparable to that found in the main CATS II analysis. However, 
multiple testing in this way could have falsely identified a difference as significant when it 
should not have been.  
If these analyses were conducted again, adjustments could have been made when exploring 
the six covariates. For example, social deprivation has been previously discussed as an 
important factor to control for when exploring the effects of maternal age (364), as 
previously significant findings may not be once adjusted. Furthermore, the covariates and 
the dependent variables have all been analysed as one complete cohort; analyses were not 
repeated for the three separate groups of participants. Whilst this has added power to the 
calculations from a larger cohort, any subtle differences between the groups will have been 
lost. The results cannot be generalised as the SGTF groups make up around half of the 
participants.  
A limitation of the breastfeeding findings was that maternal education was not controlled 
for in the analysis. This could have greatly affected the cognition findings (399-401); 
therefore, they can only be discussed with caution. I did note the importance of maternal 
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education when I was collecting the CATS II data; unfortunately, this was identified too late 
in the project and my modified version of the CATS General Questionnaire to include this 
data was not submitted as an ethical amendment (see appendix 8).  
2.1.6.2. Conclusions 
It was hypothesised that all of the covariates (child gender, mother age at time of consent 
into CATS I, whether the mother breastfed over one month, where the child was assessed, 
language at school and home, and social deprivation) would have some effect on the 
dependent measures of the WISC-IV, NEPSY-II and the behavioural questionnaires. Child 
gender was reported to have the biggest effect, with females outperforming males on the 
majority of the cognitive measures, and males scoring higher (indicating a ‘worse’ behaviour) 
on the questionnaires. Social deprivation was the second covariate that appeared to have 
the strongest effect (as displayed in the partial eta squared scores), with scores of being less 
socially deprived being associated to more desirable outcomes. Where the child was 
assessed was the only covariate that did not affect the dependent variables; this confounder 
was not included in the questionnaire analysis.  
2.1.7. Chapter Summary 
This chapter has discussed the findings from the exploratory analysis that investigated the 
extent to which the covariates had a significant impact on the dependent variables. The 
literature debating for effects or no effects for each covariate was discussed firstly, then 
based on the evidence, a series of hypotheses were devised. The analysis was based on the 
final model MANCOVAs from the WISC-IV (see chapter 1.4., Intelligence measured at age 9; 
CATS II data), the NEPSY-II (see chapter 1.5., Additional cognitive assessments at age 9; CATS 
II data), and the behavioural questionnaires (see chapter 1.6., Behavioural questionnaires at 
age 9; CATS II data); any significance noted from these were explored further by exploratory 
t-tests and MANOVAs. The results were discussed in respect of the data collection measure 
and closely tied to the literature. The following chapter explores the associations between 
the age 3 and age 9 IQs of the CATS treated and untreated SGTF offspring.  
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2.2. IQ comparison between ages 3 and 9; children from the CATS sample 
2.2.1. Chapter Overview 
This chapter contains the second exploratory analysis using data from the CATS cohort; the 
treated and untreated SGTF groups and the offspring’s IQ scores from age 3 (WPPSI-III) and 
age 9 (WISC-IV). The CATS study, as well as being the first to explore the effect of treatment 
on SGTF, was also the first to follow up the children assessing them at two time points which 
presents a unique dataset. The chapter contains a literature review of the development of 
intelligence over an individual’s lifespan, the stability of IQ in young childhood and also a 
study this chapter’s analysis can be compared to.  
2.2.2. Introduction 
2.2.2.1. Intelligence development over the life span 
When considering intelligence over an individual’s life span, as well as having an 
understanding of what intelligence is (see pages 5-6), it is important to review how different 
aspects of intelligence change with age (456). Furthermore, it is important to consider the 
estimated stability between the multiple IQ measures as this could affect the continuity IQ 
scores between two time points (457).  
2.2.2.1.1. Changes in intelligence 
The overall IQ measure from intelligence tests, FSIQ, is often referred to as a representation 
of ‘g’. This general intelligence factor can be subdivided into two categories, fluid intelligence 
(gf) where we make understandings amongst stimuli, consider the implications and draw our 
own conclusions/inferences, and crystallised intelligence (gc) which is the measure of the 
breadth and depth of knowledge about our culture, i.e. general knowledge (458). It has been 
proposed that the stability of gc maintains and (can) improve through adulthood (459). 
Conversely, gf peaks in late adolescence/early adulthood then declines, and this may be a 
result of maturation of the aging brain (460). Schroeders et al. (456) found evidence for this 
theory, with gc displaying stronger age related gains compared to gf (ages 11-19, n > 10,000). 
A steady decline in average scores on IQ tests after young adulthood has been identified 
(461). 
The age differentiation hypothesis postulates that general ability gradually breaks down into 
a group of fairly distinct aptitudes as age increases, i.e. verbal and performance IQ would, 
with age, become less correlated (462). Studies have identified that as ages increase (> 3 
years), correlations decline, suggestive that there was a continuous reduction of the ‘g’ factor 
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across ages (463, 464). However, others have struggled to identify this ‘loss’ in association 
with increasing age (465, 466).  
2.2.2.1.2. The Flynn Effect 
As mentioned firstly in chapter 1.2. (Re-analysis of intelligence at age 3; UK CATS I cohort), 
the ‘Flynn Effect’ is a phenomenon of increasing IQ scores over the years; i.e. as time goes 
on, people appear to perform better on IQ tests (217-223); the average increase appears to 
be 3 IQ points per decade, although a recent meta-analysis of 285 studies found an average 
mean increase of 2.31 points per decade (467). Beaujean and Sheng (468) investigated the 
Flynn Effect in all versions of the WPPSI and WISC from the norming samples and found larger 
effects (0.61 and 0.73 increase of points per year, respectively). Caution has been advised 
when comparing decade increases of IQ as some studies may include children of slightly 
below or above average intelligence; as Lynn (301) found greater IQ increases in the lower 
range of ability (fifth percentile) when compared to those in the 95th percentile. There is no 
one cause for the Flynn Effect and many papers have tried to explain this in relation to: the 
general environment (e.g., (469)), specific environmental aspects such as education (e.g., 
(470)) or nutrition (e.g., (306)) or to biological factors (e.g., (471)) and the idea of ‘heterosis’ 
whereby genetically unrelated parents have children with IQs that are slightly higher than 
those born to the general population (472). This has been critiqued recently as not the 
leading cause as developmental status has also been discussed as important, such as 
demographic mobility, family structure, education and health (473).  
A reversal of the Flynn Effect is now being measured. Teasdale and Owen (474) found a 
reversal of the Flynn Effect in their study based on primarily Danish men. It was found that 
between time points 1988-1998 IQ increased by roughly 1.5 IQ points, but from 1998-2003/4 
IQ points dropped by 1.5 points. Similarly, a decline was also reported in Finland; 25,000 
males were assessed and from 1988-97 an average increase of 4 IQ points per decade was 
found, but from 1997-2009 a decline of 2 IQ points per decade was recorded (475). In France, 
79 participants were measured using adult Wechsler scales and a drop of 3.8 points was 
identified between 1999 and 2008-9 (476). Shayer (477) found in the UK a decline in IQ 
amongst 11-12 year olds of 12 IQ points from 1975-2003, which represents an average of 4.3 
IQ points per decade. These four studies could indicate that across Western Europe, the 
Flynn Effect is being called into question.  
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2.2.2.2. Stability of Childhood IQ measurement 
Testing the stability of childhood IQ measurements is important for the validity for the test 
scores (478), and also the consistency of the scores over time (479). Long-term stability of IQ 
scores are critical as ‘high-stake’ decisions are based upon the results, i.e. long term SEN 
placements (480), therefore it is essential that the initial placement decisions are based upon 
stable IQ results, as an incorrect SEN placement could be harmful to some (481). Intelligence 
is critiqued as a stable construct (482, 483), but of these studies few have measured IQ in 
infancy.  
However, some argue that the ‘g’ factor is not identifiable in young children/infants (465, 
484), due to an increase in stability of intelligence as individuals make the transition from 
childhood to adolescence (485). In one study children aged 2-5, 5-8 and 9-12 years were 
compared with an increasing correlation strength identified (r = .32, .70, .85 respectively) 
(486). Other early studies also identified little to no associations between IQ measured in 
infancy to those measured in early-middle childhood (487). Yang et al. (488) assessed 313 
pre-school children twice with delayed cognitive profiles (FSIQ < 85) with a follow-up mean 
of 38.6 months. A mean difference of 7.4 points from time point one to two was found which 
was significant (r = .43-.5). However, this was only a moderate correlation and participants 
weren’t all administered the same intelligence measure (a total of three were used to collect 
the data).  
Other studies have found a good stability in childhood to adulthood IQ measurements. IQs 
measured at age 11 have been associated to those at age 77 in a sample of 101 (r = .63) (489), 
and up to age 90 (r = .54) (490). Mortensen et al. (491) assessed slightly younger children at 
age 9.5 (n = 26) with the WISC-III and again at age 23.5 with the WAIS and identified stability 
estimates of r = .86, .86 and .89 (for verbal, performance and FSIQs respectively). Testing at 
age 6 compared to age 11 in a larger sample (n = 717) and also with a Wechsler scale, found 
very strong correlations (r = .85) (492). Testing at similar ages with the WISC-II (test interval 
2.83 years, n = 642) also yielded good stability (493). Finally, Watkins and Smith (480) 
analysed within this age group with the WISC-IV identifying coefficients ranging from r = .65-
.82 (FSIQ was the highest). However, 25% has FSIQs varying by ≥ 10 points and the VCIQ, 
PRIQ, WMIQ and PSIQ also varied (29%, 39%, 37% and 44% respectively, mixture of ± mean 
scores). It could be concluded that WISC-IV scores are not consistent with long test-retest 
intervals. This latter study highlighted how investigating the means may not provide the ‘full 
picture’ of IQ stability.  
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The causes of IQ change in childhood (beyond unreliability) remain unclear (492). Cherney et 
al. (494) have proposed age appropriate explanations as to why IQ during young childhood 
might not be stable. Firstly, that the transition from infancy to early childhood is where 
cognitive ability rapidly changes as the individual’s language develops. Secondly, the period 
covering early to middle childhood (around age 7) is where an individual develops concrete 
operational thoughts coupled with an increase in formal academic tasks undertaken. 
2.2.2.3. Comparative Study 
As part of the validation of WISC-IV, it was compared against scores on the WPPSI-III ((78), 
pp. 64). Both assessment measures were administered to 182 children aged 6-7 years with a 
testing interval of 9-62 days (mean of 22 days). It was found that the mean FSIQ had a small 
difference of 0.2 points: the WISC-IV scores were higher. The verbal IQ from the WPPSI-III 
and the VCIQ from the WISC-IV had a significant positive strong association (r = .76). The 
performance IQ from the WPPSI-III and the PRIQ from the WISC-IV had a similar association, 
(r = .74) and the FSIQs were very strongly associated (r = .85). The difference between the 
tests was non-significant: (F[1, 163] = 1.0, p = .32) based on a 2 (test: WISC-IV, WPPSI-III) X 3 
(scale: VCIQ-VCIQ, PRIQ-performance IQ, FSIQ-FSIQ) X 2 (test order) MANOVA; and (F[1, 169] 
= .25, p = .62) based on a 2 (test: WISC-IV, WPPSI-III) X 3 (scale: VCIQ-VCIQ, PRIQ-performance 
IQ, PSIQ-PSIQ) X 2 (test order) MANOVA (78). It was also identified that the two norms from 
the batteries were highly consistent with one another.   
2.2.3. Aims/hypothesis 
The aim of the current analysis was to explore how similar and associated the scores from 
the WPPSI-III and the WISC-IV were from the CATS cohort. Based on the literature that 
cognitive measures administered to younger children may not be good predictors of later 
outcomes (465, 484-488), the chapter aim and hypotheses were; 
i. There would be a weak-moderate association between the IQs (VCIQ, PRIQ and 
FSIQ): based on (480, 486, 488, 490) 
ii. Age 3 IQ would be significantly different to age 9 IQ: based on (465, 484-488) 
2.2.4. Method and statistical analysis 
The data used in the current chapter was taken from the CATS I and CATS II IQ tests. The 
collection method of the data can be found on pages 30-32 for the age 3 IQs (WPPSI-III), and 
pages 53-56 and 62-64 for the IQ data I collected at around age 9 of offspring (WISC-IV). All 
of the data was collected using Wechsler scales, and the WPPSI-III and the WISC-IV had 
similar structures. The FSIQs and verbal IQ (WPPSI-III) and VCIQ (WISC-IV) were similar, the 
WPPSI-III also generated a performance IQ, and for the analysis here this was compared to 
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the WISC-IV’s PRIQ. For the rest of this chapter, the verbal domain IQs from the WISC-IV and 
WPPSI-III will be referred to as VCIQ, and similarly, the performance domain IQs will be 
referred to as PRIQ.  
The analysis for the current chapter was completed after the data was collected for the CATS 
II project; this was to avoid any potential bias by unblinding the treated and untreated SGTF 
groups. The WPPSI-III and WISC-IV data had been cleaned previously (pages 32-35 and 64-
71, respectively) and checks for normality conducted alongside. Whilst no differences were 
identified between the cognitive outcomes for the treated and untreated SGTF groups, the 
groupings were included as the between-subjects factor.  
The data was analysed in IBM SPSS Statistics Version 20. In total, there were 196 participants 
(114 treated SGTF, 82 untreated SGTF). The analysis was two-fold to explore the chapter’s 
hypotheses. 
The first analysis was to explore the first hypothesis (i) by Pearson correlations, and adjusted 
partial correlations were executed to explore the associations whilst taking account of the 
following covariates: corrected for child gender, mother age at time of consent into CATS I, 
whether the mother breastfed over one month and social deprivation. These four covariates 
were selected for adjustments out of the possible six CATS II confounders as ‘place of 
assessment’ would not have been relative to the WPPSI-III assessments as all were 
conducted at home. Similarly, ‘language at school and home’ at age 3 was not collected (see 
page 59 for further information on the covariates used in this thesis which were the same as 
used in CATS II (280)). The correlations were carried out separately for both of the SGTF 
groups.  
The second analysis was to explore the significant results from the correlations, and also the 
second hypotheses (ii). The unadjusted model was analysed firstly by a repeated measures 
MANOVA; the within-subjects factor was the IQ test (i.e. WPPSI-III and WISC-IV), with 
measures being VCIQ, PRIQ and FSIQ. The main analysis reported in this chapter was the 
findings from the repeated measures MANCOVA; adjusted by the above four covariates used 
in the partial correlations.  
2.2.5. Results 
Descriptive statistics for the groups can be found in Table 40; output from the repeated 
measures MANCOVA. Note that total number has dropped (from 196 to 194) due to 
adjustments and missing data.  
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Table 40 
Means and Standard Deviations of Intelligent Quotient (IQ) Scores for the Treated 
and Untreated Suboptimal Gestational Thyroid Function (SGTF) Groups from Wave 
One and Wave Two 
 Participant Group Mean N 
WPPSI-III VCIQ Treated SGTF 109.91 
(11.37) 
113 
Untreated SGTF 110.10 
(11.47) 
81 
Total 109.99 
(11.38) 
194 
WISC-IV VCIQ Treated SGTF 97.74 
(10.02) 
113 
Untreated SGTF 100.46 
(13.24) 
81 
Total 98.88 
(11.52) 
194 
WPPSI-III PRIQ Treated SGTF 108.96 
(13.64) 
113 
Untreated SGTF 109.68 
(13.16) 
81 
Total 109.26 
(13.41) 
194 
WISC-IV PRIQ Treated SGTF 104.56 
(12.28) 
113 
Untreated SGTF 106.40 
(13.29) 
81 
Total 105.32 
(12.71) 
194 
WPPSI-III FSIQ Treated SGTF 110.84 
(12.09) 
113 
Untreated SGTF 111.38 
(11.47) 
81 
Total 111.07 
(11.80) 
194 
WISC-IV FSIQ Treated SGTF 101.90 
(12.02) 
113 
Untreated SGTF 103.74 
(13.07) 
81 
Total 102.67 
(12.47) 
194 
Note. Standard deviations appear in parentheses below means. WPPSI-
III=Wechsler preschool and primary scale of intelligence-third edition, UK, WISC-
IV=Wechsler intelligence scale for children-fourth edition, UK, VCIQ=verbal 
comprehension intelligent quotient, PRIQ=perceptual reasoning intelligence 
quotient, FSIQ=full scale intelligent quotient, SGTF=suboptimal gestational thyroid 
function. 
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2.2.5.1. Correlations 
The initial analysis explored the unadjusted (n = 114) and adjusted (n = 113, with 107 degrees 
of freedom) associations between the treated SGTF group for the VC, PR and FS IQs (see 
Table 41). All associations were positive and significant, r’s were > .293, with the majority 
displaying moderate relationships; the FSIQs had the strongest relationships (r’s > .635). 
Table 41 
Correlations for the Treated Suboptimal Gestational Thyroid Function Group of IQs from 
wave one (WPPSI) and wave two (WISC) 
 WISC VCIQ WISC PRIQ WISC FSIQ 
 Unad.* Ad.** Unad. Ad. Unad. Ad. 
WPPSI 
VCIQ 
Correlation .575** .546 .424** .381 .585** .543 
Sig.  .000 .000 .000 .000 .000 .000 
WPPSI 
PR IQ 
Correlation .326** .293 .561** .550 .552** .518 
Sig.  .000 .002 .000 .000 .000 .000 
WPPSI 
FSIQ 
Correlation .530** .497 .588** .562 .676** .635 
Sig.  .000 .000 .000 .000 .000 .000 
Note. *Unad. = unadjusted model, Pearson correlation. **Ad. = adjusted model, partial 
correlation. WPPSI=Wechsler preschool and primary scale of intelligence-third edition, 
UK, WISC=Wechsler intelligence scale for children-fourth edition, UK, VCIQ=verbal 
comprehension intelligent quotient, PRIQ=perceptual reasoning intelligence quotient, 
FSIQ=full scale intelligent quotient, SGTF=suboptimal gestational thyroid function. 
 
The untreated SGTF group’s associations were calculated for the IQs measured by the WPPSI-
III and the WISC-IV with an unadjusted, Pearson correlation (n = 82) and adjusted partial 
correlation (n = 81, with 75 degrees of freedom) to take account of the covariates. Table 42 
displays the associations, again the strongest correlated was the FSIQ (r’s > .595) with all 
associations being significant and positive.  
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Table 42 
Correlations for the Untreated Suboptimal Gestational Thyroid Function Group of 
Intelligent Quotients (IQs) from Wave One (WPPSI) and Wave Two (WISC) 
 WISC VCIQ WISC PRIQ WISC FSIQ 
 Unad.* Ad.** Unad. Ad. Unad. Ad. 
WPPSI 
VCIQ 
Correlation .536** .479 .396** .300 .497** .392 
Sig.  .000 .000 .000 .008 .000 .000 
WPPSI 
PR IQ 
Correlation .445** .365 .684** .633 .624** .548 
Sig.  .000 .001 .000 .000 .000 .000 
WPPSI 
FSIQ 
Correlation .585** .522 .661** .603 .678** .595 
Sig.  .000 .000 .000 .000 .000 .000 
Note. *Unad. = unadjusted model, Pearson correlation. **Ad. = adjusted model, partial 
correlation. WPPSI=Wechsler preschool and primary scale of intelligence-third edition, 
UK, WISC=Wechsler intelligence scale for children-fourth edition, UK, VCIQ=verbal 
comprehension intelligent quotient, PRIQ=perceptual reasoning intelligence quotient, 
FSIQ=full scale intelligent quotient, SGTF=suboptimal gestational thyroid function. 
 
2.2.5.2. Repeated measures analysis 
For the unadjusted, repeated measures MANOVA, there were no significant differences 
between the treated and untreated SGTF groups (p = .616).  IQ tests taken at age 3 and age 
9 were significantly different; ROY = 1.024, F (3, 192) = 65.510, p < .001, p2 = .506. Univariate 
analysis revealed the VCIQ had significantly changed; F (1, 194) = 188.948, p < .001, p2 = 
.493, the PRIQ was significantly different; F (1, 194) = 21.069, p < .001, p2 = .098, and also 
the FSIQ had significantly changed; F (1, 194) = 132.961, p < .001, p2 = .407. As can be seen 
in Table 40, the IQs had all dropped over time. The repeated measures MANOVA also took 
account of the change between each IQ test for the groups and calculated to see if there was 
any difference, i.e. a group and IQ test interaction; no significance was identified (p = .300). 
The adjusted analysis took account of the four covariates. Similar to the unadjusted model, 
there were no significant differences between the groups (p = .378). The IQ tests were again 
significantly different; ROY = .111, F (3, 186) = 6.870, p < .001, p2 = .100. Univariate analysis 
revealed the VCIQ had significantly changed; F (1, 188) = 4.619, p = .033, p2 = .024, PRIQ was 
not significantly different between age 3 and age 9 (p = .288), but FSIQ was; F (1, 188) = 
13.720, p < .001, p2 = .068. Figures 20 and 21 below show the drops in mean IQ over the two 
time points for first the treated and also the untreated SGTF groups. The analysis also 
explored any adjusted differences between the groups with an interaction for IQ test, results 
remained non-significant (p = .224). 
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Figure 20: Graph of mean drop in intelligent quotient (IQ) over time for the treated 
Suboptimal Gestational Thyroid Function (SGTF) group  
IQs 1 = Verbal Comprehension IQ, 2 = Perceptual Reasoning IQ, 3 = Full Scale IQ. IQ test 1 = 
Wechsler Preschool and Primary Scale of Intelligence-third edition, UK, 2 = Wechsler 
Intelligence Scale for Children-fourth edition, UK. X axis=IQ test, Y axis=estimated marginal 
means of the IQ domains per IQ test.  
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Figure 21: Graph of mean drop in intelligent quotient (IQ) over time for the untreated 
Suboptimal Gestational Thyroid Function (SGTF) group  
IQs 1 = Verbal Comprehension IQ, 2 = Perceptual Reasoning IQ, 3 = Full Scale IQ. IQ test 1 = 
Wechsler Preschool and Primary Scale of Intelligence-third edition, UK, 2 = Wechsler 
Intelligence Scale for Children-fourth edition, UK. X axis=IQ test, Y axis=estimated marginal 
means of the IQ domains per IQ test. 
 
2.2.6. Discussion 
The aim of the current chapter was to explore the associations between ages 3 (WPPSI-III) 
and 9 (WISC-IV) IQ scores from those in the treated and untreated SGTF groups from the 
CATS sample. The first hypothesis was to explore whether there would be a weak-moderate 
association between the IQs (based on previous literature (480, 486, 488, 490)). This was 
confirmed by the partial correlations, between the groups they were all positive and 
significant (p’s < .008) and were weak to strong associations (r’s = .293-.684). The second 
hypothesis was that the age 3 IQ would be significantly different to the age 9 IQ (based on 
the literature of younger age IQs not being stable (465, 484-488)). The main analysis 
confirmed this and revealed, from an adjusted repeated measures MANCOVA, that the VCIQ 
(p = .033) and FSIQs (p < .001) were significantly different between the two time points.  
The correlations identified in the results section were all positive relationships. The analysis 
in this chapter needed to extend beyond correlation calculations as they only informed the 
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direction of the IQs, i.e. if a child had a lower age 3 IQ they would also have a lower age 9 IQ. 
This trend did not indicate how the statistics had changed overtime. It was clear from the 
means in Table 40 that the WPPSI-III scores were much higher than the WISC-IV, which was 
also why a repeated measured MANCOVA was implemented. The weakest associations for 
the treated SGTF group were between the WPPSI-III PRIQ and WISC-IV VCIQ, for the 
untreated SGTF group it was between the WPPSI-III VCIQ and WISC-IV PRIQ. A reason for this 
may have been because these were separate domains and thus measuring two types of 
cognitive functioning. The strongest relationship for the treated SGTF group was between 
the FSIQs, as a representation of g; this being the most stable over the 6 year period it 
contradicted other findings that found no association over childhood (487). As can be seen 
by the treated (Table 41) and untreated (Table 42) SGTF group correlations, the covariates 
had an effect on all of the interactions and reduced the strength of all the associations.  
The comparative study in the WISC-IV manual ((78), pp. 64) found positive strong and very 
strong significant associations, these were more highly correlated than the current results. A 
reason for this could be due to the fact the WISC-IV was administered prior to its publication, 
and in CATS II, the WISC-IV was administered around ten years post publication (i.e. a decade 
post standardisation). However, the means for the WISC-IV were around the proposed 
population mean of 100, and subsequently were not subject to the Flynn Effect, which 
proposed a gain of around three IQ points (217-223). It appeared to be the WPPSI-III means 
that were much higher than the population. The WPPSI-III was published in 2003 and was 
used in CATS I during 2006-2010, so the Flynn Effect could explain the high means of 106-
109 (page 41). Further investigation of calculated means in the sample being higher than 
those measured earlier in the study would be an interesting reflection. The reversal of the 
Flynn Effect (474-477) may be having an effect on the IQs, as it was proposed that more 
recently, Western countries previously measured increases in IQ (due to the Flynn effect), 
were now slowly decreasing. This phenomenon has not been widely reported yet, so it is 
difficult to generalise the hypothesis here, especially when considering the sample in the 
current analysis were not from the normal GTF group.  
As well as the correlations from the study conducted during the validation testing of the 
WISC-IV providing a baseline comparison ((78), pp. 64), the significance of the difference 
between the scores on the tests were also calculated, revealing a non-significant difference 
which contradicted the main findings here, apart from the PRIQ domain. The WISC-IV 
findings (chapter 1.4., Intelligence measured at age 9; CATS II data) previously reported this 
higher PRIQ compared to the other domains of VC, WM and PS, which have been confirmed 
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by other literature (222, 297-300). The graphs for the treated (Figure 20) and untreated 
(Figure 21) display how the PRIQs dropped over time, as with the VC and FSIQs, but this 
decrease was nowhere near as substantial. Comparative study findings found that the 
WPPSI-III and WISC-IV were extremely similar in results (FSIQ results were 0.2 points 
different with the WISC-IV scoring higher), the current analysis revealed a mean difference 
of 8.4 points, but as mentioned, for the treated SGTF group the FSIQs held the strongest 
associations.  
As previously reported (200), the CATS I study was the first in the world to explore the effect 
of treatment on SGTF in an RCT and now also, being the first to explore the effects of SGTF 
whilst following up the offspring. It is difficult to compare the findings as no such similar 
studies have been planned in the UK context at this time. The findings from the repeated 
measures MANCOVA were not significant when calculated for any differences between the 
treated and untreated SGTF groups (p = .378), and also when an interaction was included for 
the two IQ tests (p = .224). These results were anticipated as means between the groups 
were similar at age 3 (see chapter 1.2., Re-analysis of intelligence at age 3; UK CATS I cohort) 
and age 9 (see chapter 1.4., Intelligence measured at age 9; CATS II data). The latter result 
suggests that both groups’ IQs changed equally over time. 
As part of data cleaning of the WISC-IV data in chapter 1.4. (Intelligence measured at age 9; 
CATS II data), an outlier was identified and subsequently removed (see pages 64-71), as the 
individual scored < -3 for z-scores on 4 out of 5 IQs. Upon unblinding, it came to light, that 
this participant was from one of the SGTF groups and had taken part in IQ testing at age 3. 
The participant was excluded from the analysis in the current chapter, due to the WISC-IV IQ 
results being removed, but her data was included in chapter 1.2. (Re-analysis of intelligence 
at age 3; UK CATS I cohort) as her scores obtained were not flagged as being outliers. As 
reported, the WPPSI-III mean scores were on the whole, significantly higher than the WISC-
IV scores. The removed CATS II participant at age 3 scored 116 for verbal IQ, 102 for 
performance IQ and 110 for her FSIQ. The participant’s scores for the WISC-IV were 87 for 
VCIQ (dropped 29 points), 59 for PRIQ (dropped 43 points), (59 for WMIQ, 50 for PSIQ) and 
a FSIQ of 58 (dropped 52 points). Points to consider alongside these reductions are, when 
the WISC-IV assessment had taken place the child may not have wanted to comply with the 
testing which may have resulted in poorer results (284), as well as motivational factors (227-
229), and the child’s anxiety levels (287) (more information can be found on pages 79-81). It 
would be difficult to summarise that this child may have ‘missed’ a diagnosis of having a 
learning difficulty at a young age, if the WPPSI-III results found during CATS I were presented 
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to the school, this stability of the earlier IQ results may be weak and the importance of this 
in relation to SEN placement has been previously discussed (480). However, without a third 
time point it would be challenging to confirm whether the age 3 IQ was not stable compared 
to the age 9 data.  
As the CATS IQs dramatically reduced over the follow-up period, another possible 
explanation for this could be the phenomenon of “regression to the mean”; was the 
regression a true reflection of IQ drops over-time, or was it a product of the reliability of the 
measuring instrument? An early discussion for this phenomenon was that this result could 
be a product of measurement error (495). There was also evidence to suggest that individuals 
with IQ scores in the ‘outer ranges’ of the bell curve (for example, IQs > 130) were more 
‘susceptible’ to this phenomena (496). Veiel and Koopman (497) identified, in a premorbid 
IQ context, that there was a tendency for an estimate of IQ to be low (as measured on 
intelligence tests) if an individual’s true IQ was above the population mean, and the effect 
would be inversed for true IQs below the population mean. This would suggest, that the age 
3 to age 9 IQs in the CATS cohort may be a biased estimate of change of the children’s IQs.  
2.2.6.1. Limitations 
The current analysis included a number of limitations. Firstly, performance IQ from the 
WPPSI-III was compared to the PRIQ on the WISC-IV. The WPPSI-III score may have been a 
broader representation of this domain to encompass as much data as possible in a short 
testing time. On reflection, these two domains may not have been good comparisons of one 
another, although were identified as the best match for this analysis.  
As only the SGTF groups were included in CATS I, only these participants could be included 
in the current analysis. It was unfortunate that the normal GTF were not included in CATS I, 
as this group of participants would have been a better representation of the wider 
population. Overall a third IQ measurement may have generated a better interpretation of 
IQ stability during childhood.   
The comparative study published in the WISC-IV (78) comparing it to the WPPSI-III was useful 
as the identical versions were used in the current analysis, although CATS I and II adopted 
the UK editions. Sample size was similar (the current analysis contained 14 more 
participants), but it could be argued we did not have a ‘typically developing’ sample. 
Furthermore, at time of the WISC-IV data collection, the tool was around a decade out of 
date; also the WPPSI-III will have been out of date for assessments during the latter parts of 
the CATS I data collection. When the comparison study was conducted, the WPPSI-III had just 
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been published (2003) and the WISC-IV was also new, which could account for the similar 
reported IQs.  
2.2.6.2. Conclusions 
This chapter aimed to explore how similar and associated the scores from the WPPSI-III and 
the WISC-IV would be for the treated and untreated SGTF groups. It was found that all scores 
were positivity correlated, and the difference between the PRIQs was not significant (when 
adjusted) between age 3 and age 9. However, the VC and FSIQs were significantly different 
between the two time points. As all of the IQs measured at age 3 were high, it could be 
concluded that IQ measurement around this time (i.e. late infancy to very early childhood), 
does not yield stable results. It was possible that the WPPSI-III may have been subject to the 
Flynn Effect, whereas the WISC-IV may have succumbed to the new phenomena of the 
Reversed Flynn Effect. Also, the phenomenon of “regression to the mean” may have 
contributed to the drop in IQs. If future studies within the CATS cohort were to be conducted, 
a third IQ test may be beneficial to explore whether the age 3 or age 9 results persist as 
significantly different.   
2.2.7. Chapter Summary 
This chapter has discussed the findings from the exploratory analysis into the comparison of 
the age 3 and age 9 IQs of those children from the treated and untreated SGTF groups. All 
IQs were significantly positively correlated with associations ranging from weak to strong. 
Following adjustments for the repeated measures MANCOVA, the VC and FSIQs were 
significantly different between age 3 and 9; PRIQ was not. No differences were identified 
between the two groups, inclusive of group with an interaction of IQ test. The chapter 
covered a literature detailing how intelligence has been evidenced to change over time, how 
stability of IQ tests in very young children may not be best practice, and also a brief review 
of a comparative study. The research aim followed along with two hypotheses which were 
explored in the results section. A discussion with links to the literature closed the chapter. 
The following section is the main discussion for this thesis 
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3. General Discussion 
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3.1. Overview 
This final section of the thesis summarises all the results from the previous eight chapters. 
Overviews of the findings in the first two sections are considered in the context of the 
literature. Implications of the findings are discussed as well as the main limitations of CATS I 
and II. Two possible future studies are discussed with this section closing on final conclusions.  
3.2. Main findings  
This section covers the main findings from all the analyses conducted in the thesis. The aims 
and hypothesis are covered for each chapter, as well as the primary and secondary analyses 
(where relevant). Links are drawn across the findings where applicable, as well as to the CATS 
II analysis. 
3.2.1. Section 1 Overview 
3.2.1.1. Summary of, ‘Re-analysis of intelligence at age 3; UK CATS I cohort’  
This first results chapter presented the analysis I conducted of the UK data from CATS I, 
excluding the Italian sample, an analysis that had not previously been done or presented 
(200). This also acted as the pilot to the analysis I planned to conduct to explore the data I 
had collected for CATS II. Based on the previous published results, it was hypothesised that 
there would be no significant differences between the IQs at age 3 for those from the treated 
and untreated SGTF groups (n = 607).  
As predicted, no difference was identified for mean IQs in the adjusted model (p = .688). The 
exploration of the continuous outcome was different to the CATS I publication by sample, 
and it also controlled for variables which may have had an impact on the scores; child gender, 
mother’s age at time of consent into CATS I, and a measure of the participant’s social 
deprivation. These were not adjusted in CATS I as the study was an RCT and therefore should 
have been free from bias. The data I had collected for CATS II was adjusted for covariates, 
therefore making my own CATS I analysis similar. The results that treatment for SGTF made 
no difference to childhood IQ may have been a first hint that being born to a mother with 
SGTF had no effect on offspring intelligence, if being born to a mother with euthyroid 
function was the same for offspring intelligence as being born to a mother with SGTF, why 
would treatment for SGTF have an impact? This theory of SGTF not having an effect to 
offspring intelligence has been found in Henrichs et al.’s (53) epidemiology study, as well as 
a number of other recent studies (91-93, 95, 96). Also, the finding of treatment having no 
effect on offspring IQ was previously identified in Haddow et al.’s work (54); a study which 
included a small number of women who received treatment (n = 14).  
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The secondary analysis of a binary outcome was conducted so that the work in this thesis 
would be comparable to the published CATS I study (200); odds of IQ ≤ 85 (1 SD below the 
mean of 100). This also included an unadjusted (chi-square) and adjusted model (multinomial 
logistic regression); which again developed the analysis forwards from the original study by 
controlling for variables. It was found that those from the untreated SGTF group were 3.335 
times more likely to score ≤ 85 for FSIQ compared to those from the treated SGTF group. This 
finding was suggestive that treatment, did in-fact, have some benefit to offspring and 
appeared to improve IQ. Caution was advised however, as analysing for binary outcomes has 
been described as not being as valid as continuous analysis (i.e. the primary analysis from 
this chapter) (211-213).  
The CATS I paper (200) also described how the analysis was conducted on an ‘intention to 
treat’ analysis; i.e. those who were originally randomised to the treatment branch of the 
study were kept in the treated SGTF group, even if they were suspected of not complying 
with the levothyroxine medication. For the CATS II study the analysis was executed with an 
‘on-treatment’ plan whereby those that violated the treatment protocol were subsequently 
allocated for analysis purposes to the untreated SGTF group (n = 2); this was based on CATS 
I treated SGTF pregnancy data when the mothers were followed up twice after initial 
consent.   
3.2.1.2. Summary of, ‘Intelligence measured at age 9; CATS II data’ 
This chapter, 1.4., was the first analysis of the cognitive data I had collected for CATS II. This 
chapter would be comparable to CATS II, as described in Hales et al. (280), IQ was the primary 
outcome. The aims were to explore whether there would be any difference between the 
untreated SGTF group and the normal GTF group, based on previous studies it was 
hypothesised that the normal GTF group would perform better (34, 49-57, 90, 91). The 
second aim was to explore the IQ of the treated and untreated SGTF groups at age 9, 
hypothesising that there would be no difference based on chapter 1.2. (Re-analysis of 
intelligence at age 3; UK CATS I cohort) findings and CATS I results (200). Four hundred and 
fifty two participants’ IQ data were used in the analysis. 
The primary analysis for this chapter was comparing the three groups of participants (normal 
GTF, treated and untreated SGTF) in a MANCOVA. The finding at the multivariate level was 
that there were no significant differences of VCIQ, PRIQ, WMIQ, PSIQ or FSIQ between the 
groups (p = .353). Within the sample of CATS II, it can thus be inferred that SGTF did not have 
an impact on childhood intelligence at age 9; which was supported in some studies (53, 56, 
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91-93, 95, 96). As there was no difference between the untreated SGTF and the normal GTF 
group, it could be inferred that treatment of SGTF would not yield any difference, as SGTF 
was reported as not being detrimental for the offspring IQ at age 9. This chapter was also the 
first to introduce the four models of analysis (for continuous outcomes); so that the findings 
from this thesis could be comparable to the cognitive CATS II analysis (see study protocol 
where the models were first proposed (280)).  
The secondary analysis, similar to chapter 1.2. (Re-analysis of intelligence at age 3; UK CATS 
I cohort), was to explore possible differences between the groups based on binary outcomes. 
This was deemed important to execute in the thesis, as the primary outcome for CATS II was 
odds of IQ ≤ 85; therefore binary calculations made this work comparable to CATS II findings. 
I chose continuous variables as my primary outcome, since the validity of binary outcomes 
have been questioned in the literature. Binary outcomes could underestimate the variability 
in a sample and indicate that characteristics are different when in fact they could be similar 
(211-213). The exploratory chi-squares and regressions revealed no significant differences 
between the groups. As a binary difference was identified at age 3 for FSIQ between the 
treated and untreated SGTF groups, and if we accept the regression result as not being a type 
one error (see Austin and Brunner (213) for further details), it could be inferred that any 
differences from treatment may only be apparent in very early childhood.  
3.2.1.3. Summary of, ‘Additional cognitive assessments at age 9; CATS II data’  
As well as IQ data, I also collected additional cognitive data from the CATS II participants. As 
with CATS II, the NEPSY-II assessments were treated as secondary to the main outcome of 
childhood IQ (280). The aims were to explore whether the non-significant differences for IQs 
would extend to the additional cognitive tests; based on previous research it was 
hypothesised that I would fail to reject this null hypothesis (34, 51, 53, 54, 56, 91-96, 111, 
113, 114). The second aim was to explore whether there would be any differences between 
the SGTF groups to the normal GTF group, hypothesising that specifically the untreated SGTF 
would perform less well than the normal GTF group (supported by (10, 32, 49-51, 53-58, 103-
106, 110, 112)). Four hundred and sixteen participants were assessed using the NEPSY-II 
following their WISC-IV assessment.  
The primary analysis from this chapter was to explore the differences between the groups 
by an ANCOVA and MANCOVA. As previously discussed (page 91), LM was analysed 
separately as a reduced number of participants completed the subtest. The LM analysis 
revealed a non-significant difference between the groups (p = .613) as was the case with the 
173 
 
other subtests that were analysed together in a MANCOVA (p = .212). As this persistent lack 
of difference was identified between the SGTF and normal GTF groups, it could be inferred 
that an underactive thyroid during pregnancy does not affect the child’s cognition at age 9; 
which Haddow et al. (54), Willougby et al. (103-105) and Saurez-Rogrigues et al. (51) found 
for similar aged children. With the small CATS II groups, it would have been difficult to have 
the power to identify a mean difference between the groups. As can be seen in Table 21, all 
of the NEPSY-II subtest means were higher in the normal GTF group (similar to the WISC-IV 
findings), which warrants the continued suggestion that with larger groups this difference 
may have been more apparent, or even achieved significance.  
The secondary analysis was assessing odds for binary cut offs. The NEPSY-II data generated 
scaled scores, but similarly the cut-off of ≤ 1 SD was adopted, therefore it was the odds of 
scoring ≤ 7. It was identified that the treated SGTF group were 2.257 times more likely to 
score ≤ 7 compared to the untreated SGTF. Similarly, the normal GTF were 1.899 times less 
likely to score below the threshold compared to the treated SGTF group; we can infer from 
these findings that the treated SGTF performed significantly worse than both groups. 
Conversely, this finding was not evident on any other of the WM tests from the NEPSY-II, nor 
was it identified on the WM domain of the WISC-IV. The exploratory chapter 2.4. (Memory 
score comparisons; data from the WISC-IV and NEPSY-II assessments) investigated 
associations between the WISC-IV and NEPSY-II, and found that for the MD subtest, it was 
only associated to letter-number sequencing. This evidenced how MD was not entirely 
similar to the WISC-IV WM subtests, which may suggest a type one error. This second analysis 
highlighted the challenges from binary outcomes (211-213), and was why the primary 
analyses focused on continuous outcomes in this thesis.  
3.2.1.4. Summary of, ‘Behavioural questionnaires at age 9; CATS II data’  
The final data collection I completed for CATS II was the child behavioural questionnaires 
completed by the mothers. These included the SDQ (assessed general behaviour across five 
domains), the Child ADHD Questionnaire (assessed three different aspects of ADHD-typical 
behaviours) and the SCQ (assessed for ASC traits). The aim of the research was to quantify 
differences between the three groups of participants that might extend beyond cognition. 
The hypothesis, that there would be no differences between the treated and untreated SGTF 
groups, were based upon the chapter 1.4. (Intelligence measured at age 9; CATS II data) and 
chapter 1.5. (Additional cognitive assessments at age 9; CATS II data) findings. It was also 
predicted that the untreated SGTF group would have more behavioural problems as rated 
by the questionnaires compared to those from the normal GTF group; as identified in other 
174 
 
studies (19, 44, 45, 143, 148-151, 170, 175-180). Four hundred and seventy one mothers in 
CATS II completed the questionnaires and were included in the analysis.  
The primary analysis was investigating for differences at the continuous level; MANCOVA. 
Similar to the previous models, a three-staged analysis was executed so that findings would 
be comparable to CATS II results. At the multivariate level a difference was detected (p = 
.006), and from post hoc analysis that was Bonferroni corrected, it was found that the treated 
SGTF group had significantly higher scores on the SCQ (indicating more behaviours indicative 
of ASCs) compared to the untreated SGTF group (p = .047). It was inferred from this finding, 
that within the CATS cohort, treatment of SGTF may increase ASC behaviours as it could be 
seen in the graph of the SCQ means (Figure 16) that the treated SGTF group had, 
undoubtedly, much higher scores compared to the other two groups. As was previously 
discussed (page 120), it may not have been the levothyroxine treatment that incurred the 
higher rating on the SCQ, but some form of psychological effect from taking medication 
during their pregnancies. However, there is new evidence that over-treatment and 
consequently higher levels of T4 during pregnancy could have detrimental effects for the 
offspring (37).  
The secondary analysis was centred on binary outcomes. The SCQ finding was replicated 
during this analysis with the normal GTF being 4.132 times less likely to score above the 
threshold (≥ 15 [SCQ published cut-off to warrant further investigating for a diagnosis of ASCs 
(233)]) compared to the treated SGTF group. It was interesting that the comparison was not 
between the treated and untreated SGTF groups similar to the continuous outcomes 
analysis, but this added validity to the idea that binary outcomes may increase the risk of a 
false positive result (213). Following adjustments for the multinomial logistic regressions, 
two more significant differences were identified; the normal GTF group were less likely to 
score ≥ 1 SD (indicating more behavioural difficulties) compared to the treated SGTF group 
for Overactivity and Impulsivity (2.027 OR and 2.060 OR, respectively). These findings were 
not replicated from the primary analysis, but suggest that treatment for SGTF incurred higher 
scoring for offspring (indicating less desirable behaviour) on the questionnaires. Offspring 
cognition at age 9 and the behaviour questionnaires could be a future analysis to explore 
within this cohort.  
Additional analyses (appendix 10) identified that there was an over-treatment of 
levothyroxine in the treated SGTF group; this was evident from the mean T4 scores compared 
to current ‘normal reference ranges’. Mothers with high T4 values (identified as T4 > 97.5th 
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percentile of the complete UK CATS I cohort = 17.7 pmol/L) were found to have offspring 
with higher mean scores and scores > 2 SDs compared to the rest of the CATS II cohort and 
the normal GTF sub-group (respectively). This finding identified a need for clinicians to 
closely monitor levothyroxine dosage throughout pregnancy. 
3.2.2. Section 2 Overview 
3.2.2.1. Summary of, ‘Significant effects from the covariates; CATS II data’ 
This chapter was the first exploratory analysis conducted on the CATS II data. The aims were 
to explore whether any of the six covariates (child gender, whether the mother breastfed 
over one month, the age of the mother at time of consent into CATS I, where the child was 
assessed, language at the child’s school and home and social deprivation) had significant 
effects on the dependent variables of CATS II; WISC-IV, NEPSY-II and child behaviour 
questionnaires. The hypotheses were based on the literature discussed in the chapter and 
the following paragraphs will discuss the findings in light of the data collection tools. The 
number of ‘groups’ for each covariate (for example, gender had two- male or female) 
dictated whether the exploratory analysis was to be a t-test or MANOVA. The initial 
significant effects of covariates were identified from the final model of analyses for the WISC-
IV, NEPSY-II and questionnaires. The participant sizes were identical to those found in the 
respective results chapters for the tools; for the WISC-IV see chapter 1.4. (Intelligence 
measured at age 9; CATS II data), NEPSY-II see chapter 1.5. (Additional cognitive assessments 
at age 9; CATS II data) and for the behavioural questionnaires see chapter 1.6. (Behavioural 
questionnaires at age 9; CATS II data). Participants were kept in one group for the analyses 
in this chapter.  
Further details of the hypotheses for the WISC-IV in respect of the covariates can be found 
in Table 31. The alternate hypothesis proposed by Goldbeck et al. (333) that males would 
outperform females for VCIQ, was rejected following analysis. For PRIQ, WMIQ and FSIQ it 
was predicted that there would be no differences between males and females (332, 335), 
whereas for PSIQ females were anticipated to perform significantly better (328, 332). The 
analysis identified that females performed significantly better than males for WMIQ, FSIQ 
and PSIQ; yielding the biggest difference. For the effects of breastfeeding, based on the 
literature it was hypothesised that those who were breastfed over one month would achieve 
higher IQs compared to those who were not (as widely investigated by: (380-384, 386-390, 
402, 403)). The older the mother was at time of pregnancy, it was predicted the offspring IQs 
would be higher at age 9 (360, 361, 363, 364), and also the higher the social deprivation score 
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(indicating less social deprivation), the higher the IQs would be (439-442). These three 
alternate hypotheses were confirmed in the analysis from this chapter. This added validity 
to the study demonstrating that the sample for CATS II was somewhat representative of the 
general population. The place of the WISC-IV assessment was anticipated to have a 
significant effect on the results (216, 230, 250), this hypothesis was rejected based upon the 
findings (p = .095). The final covariate was for the child’s language of school and home, it was 
hypothesised that VCIQ of bilingual children would be lower compared to those who were 
monolingual (420-422, 433, 434), this was not identified by the results. Furthermore, the 
bilingual children would perform better on PRIQ compared to the monolingual children (420, 
423-427, 433, 434), which was also not apparent in the results. A possible reason for this 
finding was that the groups were underpowered to see these effects. As can be seen in table 
13 in chapter 1.4. (Intelligence measured at age 9; CATS II data), 77.7-87.1% of children in 
each of the participant groups attended English speaking schools and also spoke English at 
home. Therefore the number of monolingual children vastly outweighed the number of 
bilingual children for this exploratory analysis. 
Specific to the NEPSY-II, child gender, child’s language at school and home, and social 
deprivation rating had a significant effect on subtest scores. The gender finding contradicted 
the proposed null hypothesis (332), again it was identified that females out performed males. 
The social deprivation rating alternate hypothesis was confirmed; those from more socially 
deprived backgrounds performed worse compared to those from a less socially deprived 
background (442, 446-448). The null hypothesis of language having an effect was adopted as 
no effects were found for NM subtest in the literature (435-437); this was unfounded in the 
current data. The hypotheses that mother age would have a significant effect on the scores 
(360, 361, 363, 364), as well as breastfeeding (380-384, 386-390, 402, 403) and where the 
NESPY-II assessment took place (216, 230, 250), were not confirmed in this chapter’s 
analysis. Further details of the hypotheses that were adopted for the analysis can be found 
in Table 32.  
Finally, the behaviour questionnaires were analysed with respect to the covariates; excluding 
where the child was assessed and language at school and home, as these were considered 
not to affect ongoing childhood behaviour. The only null hypothesis devised was for SDQ, 
except for males scoring higher on peer problems based on the literature (338, 339). For the 
Child ADHD Questionnaire and SCQ, males were predicted to score higher compared to 
females (128, 341-345, 347-350). The analysis revealed that males performed worse (with 
higher scores) on all of the questionnaire domains (p’s < .023). Social deprivation score was 
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the only other covariate to have a significant effect on the questionnaires. The findings 
confirmed the hypothesis that the lower the rating, the higher the scores would be 
(indicating ‘worse’ behaviour) (449, 450, 454). It was anticipated that breastfeeding over one 
month would have an effect on the questionnaires as it was widely reported in the literature 
(404, 410, 412-414); however this was not confirmed in the CATS II sample. The final 
covariate of maternal age yielded two hypotheses; for SDQ and Child ADHD Questionnaires, 
the younger the mother was the higher the mean scores would be (361, 365-367, 370), with 
the effect reversed for ASC traits (371-376). Both alternate hypotheses were rejected based 
on the findings. Further details of the hypotheses that were adopted for the analysis can be 
found in Table 33. 
The covariate of gender had the biggest effect on the offspring scores for WISC-IV, NEPSY-II 
and the child behaviour questionnaires. Upon reflection, the widest literature available was 
on gender differences, and is something, I predict, that will continue to be reported upon for 
many decades to come. A number of the hypotheses were confirmed which supported past 
studies and aided the generalisability of the current research. Conversely, some of the 
hypotheses were not confirmed. One of the reasons for this may be that the exploratory 
analyses were on the grouped data set, i.e. the normal GTFs were mixed with the SGTF 
groups. With around 50% of the sample being in the SGTF groups, it could be argued that 
these individual’s may not necessarily be ‘typically developing’ and therefore were not 
comparable to those individuals included in the studies discussed in the Introduction section 
of the chapter 2.1. (Significant effects from the covariates; CATS II data); although we have 
no evidence that the SGTF group were not ‘typically developing’. However, with the initial 
identification of the covariates having an effect on the dependent variables being derived 
from the final model MANCOVAs, splitting the participants into their respective groups may 
have incurred difficulties associated with multiple testing.  
3.2.2.2. Summary of, ‘IQ comparison between ages 3 and 9; children from the CATS 
sample’ 
The aim of this chapter was to explore the associations between the WPPSI-III and WISC-IV 
IQ assessments that were administered to children in the treated and untreated SGTF 
groups. Age 3 IQs were again calculated in their ‘uncorrected’ form, and not by the corrected 
IQs around 100 that were presented in the CATS I paper (200). Previous literature discussing 
cognitive measures conducted on very young children concluded that they do not make good 
predictions for later life outcomes (465, 484, 485). Key studies supporting this literature have 
found significant drops in IQ overtime (Yang et al. (488)), infancy to middle childhood IQs not 
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being associated (Anderson (487)) and increasing correlations of IQ scores with age (Honzik 
et al. (486)). Based on this, it was hypothesised that there would be a weak-moderate 
positive significant association between the IQs (VCIQ, PRIQ and FSIQ), but that age 3 IQs 
would be significantly different to those measured at age 9. One hundred and six 
participants’ data was used for this chapter’s analysis. 
To explore the first hypothesis, Pearson and partial correlations were calculated for both of 
the groups. The adjusted correlations took account of four of the six covariates, excluding 
place of assessment and child’s language at school and home. The predicted weak-moderate 
significant associations were based on a number of studies (480, 486, 488, 490). This was 
confirmed between the groups with all associations being positive and significant (p’s < .008), 
and weak to strong associations reported (r’s = .293-.684). It was inferred from these findings 
that the two Wechsler scales included similar constructs. Furthermore, the associations were 
apparent despite only those from the SGTF groups being included in the analysis, i.e. it could 
be argued that these may be ‘atypically developing’ children.  
The second analysis was quantifying the differences between the two IQ scores by repeated 
measures MANOVA and an adjusted MANCOVA. As mentioned, an alternate hypothesis was 
anticipated based on previous literature confirming IQ from young children being unstable 
(465, 484-488). Both models confirmed these findings, reporting that the age 9 IQs had 
significantly decreased from age 3; PRIQ lost significance following adjustments. VCIQ had 
decreased by 11.11 points (p = .033) and FSIQ by 8.4 points (p < .001) (see Table 40 for further 
information on the means). This reported decline in IQs overtime was attributed as possibly 
being reflective of either the Flynn Effect, or the phenomena of “regression to the mean”. 
The WPPSI-III may have been subject to the Flynn Effect of increasing IQs over time (217-
223), whilst the WISC-IV results could be attributed to the new found phenomena of the 
Reversal Flynn Effect recently found to occur in European countries (474-477). The regression 
to the mean in the age 9 IQ results may have been a product of bias in the estimate of change, 
or a measurement error. This latter phenomenon highlights how there may have been a bias 
with the CATS II sample.   
One of the main draw backs of this analysis was that the data available was only for those 
from the SGTF groups. None of the normal GTF offspring were assessed at age 3, and these 
participants would have been most relevant when generalising the results. However, no 
WISC-IV or NEPSY-II differences were found between the three groups at age 9 so it would 
be unclear how different the results of those from the normal GTF group might have been. 
179 
 
The repeated measures MANCOVA found no differences between the IQ tests of the SGTF 
groups, which confirmed chapter 1.2. (Re-analysis of intelligence at age 3; UK CATS I cohort) 
and chapter 1.4. (Intelligence measured at age 9; CATS II data) findings of there being no 
differences between these two groups.  
3.2.3. Conclusions  
The outcome from CATS II was that there were no cognitive differences between the normal 
GTF and both SGTF groups. For behaviour however, the MANCOVA identified that the 
treated SGTF group had significantly higher SCQ means compared to the untreated SGTF 
group; inferring that the treated SGTF were more likely to present behaviours related to 
ASCs. This finding could be critiqued as the evidence was based upon a mother-completed 
questionnaire, but the sustained effect of treatment on behaviour from maternal gestational 
thyroid function was measured around 9 years post-partum; therefore a long time since the 
exposure to the treatment for SGTF.  
3.3. Limitations 
3.3.1. Challenges from CATS I 
In critiquing CATS II and the research in this thesis, challenges presented by wave one of the 
study also need to be discussed. A recurring theme throughout this thesis was the somewhat 
broad definition of SGTF; including those with either TSH above the 97.5th percentile of the 
cohort (GSH), or T4 below the 2.5th percentile (gestational hypothyroxinaemia), or both 
(overt hypothyroidism). Nearly all the studies in the ‘General introduction’ (chapter 1.1.), 
used different reference ranges to define an underactive thyroid during pregnancy. One such 
example that was different to CATS, was Klein et al. (90) that identified GSH as having a TSH 
in the 99.85th percentile of the cohort. This more stringent GSH definition could have been 
why Klein and colleagues identified a difference compared to those with normal thyroid 
function. For intelligence, the literature has tended to explore either a high TSH or low T4; 
those that have found an effect (49, 54, 56, 90, 91) and no effect (53, 56) of GSH, and 
maternal hypothyroxinaemia (evidence of there being an effect to offspring intelligence (34, 
49-53) and no effect (91, 92, 94-96)).  
The percentile cut-offs were adjusted throughout the recruitment stage of CATS I as more 
participants joined the study; this was a pragmatic approach based on the population. This 
led to the untreated SGTF classification being ‘more hypothyroid’ than the treated SGTF 
group. This was because those who initiated treatment and were recruited at the beginning 
of the study will have started their levothyroxine therapy immediately based upon percentile 
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ranges of a smaller cohort. Within CATS II, this subsequently lead to participants from the 
normal GTF group being moved into the untreated SGTF group, to help make the percentile 
ranges more comparable between the groups; 30 participants were moved.  
As discussed in the CATS I paper (200), participants were recruited during their first visit to 
the antenatal clinic in hospital; which generally fell towards the end of the first trimester 
(median of 13 weeks and three days). Soon after this, the foetus’ thyroid has been reported 
to work independently (5). It could be inferred, that a more ‘critical time’ of the foetus being 
dependent on the mothers circulating thyroid hormones, would be during the first trimester; 
i.e. before treatment for SGTF was initiated in CATS I. Therefore, CATS may have been 
challenged to measure any benefits of treatment from the outset because treatment was 
initiated too late. 
The treated SGTF group were followed up during pregnancy at six weeks post initial consent 
and at 30 weeks gestation. The starting dose was 150 µg per day of levothyroxine, and the 
follow up appointments were to track any fluctuations in the mothers TSH and T4; an 
indication that dose may have needed to been adjusted. It would have been difficult to 
categorically conclude that mothers took their medication every day. Within the supporting 
documents in the CATS I paper, graphs of the mean changes in T4 and TSH were presented 
to show that change towards more euthyroid function did occur (200). Compliance was 
explored, as a few participants (two of which continued with CATS into wave two) were 
suspected of not initiating therapy.  CATS I analysed data on an ‘intention to treat’ model, 
and an exploratory analysis did remove those who were suspected of non-compliance but 
no difference was identified (200).  
Further to treatment, the levothyroxine drug itself was not given to participants from the 
study, but a prescription for it. The make of the levothyroxine drug was not investigated in 
CATS I and this may have been a potential confounder as absorption rates of T4 have been 
demonstrated to vary between brands (498). Caffeine has also been recently evidenced to 
affect absorption rates of levothyroxine (499, 500), which was unknown when CATS I began 
recruitment and data collection.  
As previously discussed, an opportunity may have been overlooked by not assessing the 
normal GTF offspring in wave one. This would have made CATS I more comparable to other 
studies that could not identify a link between underactive thyroid function during pregnancy 
and euthyroid function (i.e. the comparison would be between the untreated SGTF and the 
normal GTF groups) (53, 56, 91-93, 95, 96). The CATS I findings identified no difference for 
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treatment of SGTF, but if the normal GTF were found to have similar IQs in wave one as in 
CATS II, it may have been concluded treatment was no benefit to the offspring, but SGTF 
made no difference to cognition either.  
3.3.2. Challenges from CATS II 
Recruitment for CATS II was a challenge from the beginning of the data collection period.  
From August 2011 to the end of 2012, recruitment was low at an average of around four 
participants per month. In 2013 (when the cognitive assessments began) this rate doubled, 
2014 saw an average of 12 participants per month, and in the final year of recruitment the 
rate was around 18 per month. This increase of recruitment could have been due to a 
number of factors; there were changes within the CATS II recruitment team from August 
2014, a Facebook page was developed which was another mode of communication for the 
participants, the option of home visits were introduced in September 2013, and also the 
Welsh Demographics Service was latterly introduced which enabled the team to ‘prompt’ 
responses from participants after initial invitation to the research by telephone calls. 
Importantly, the Patient Data Register was used which ensured up-to-date addresses for the 
participants; this was only adopted for the SGTF groups, utilisation of these services required 
amendments to ethical approval. If all of these alterations were in place from the start of 
CATS II, the recruitment target of 480 for cognitive assessments may have been surpassed.  
Once participants were booked in for their appointment at the research centre or at their 
homes, there was the further issue of appointments not being kept. This posed a time issue 
in respect of the home visits, particularly if the participants lived far from the research centre. 
The team attempted to overcome this issue by the text reminders, which also offered a 
simple method of cancelling the appointment. As can be seen in the demographic tables on 
pages 70, 90 and 108, the untreated SGTF group were the most challenging to revisit; 
specifically their attendance to the research centre was much lower than the treated SGTF 
and normal GTF groups. In retrospect, it would have been interesting to have kept track of 
participants cancelling appointments and explored if there was a group bias involved.  
To gain a better perspective on what motivated participants to take part, a follow-up 
questionnaire could have been given to participants at the end of their 
appointments/following the return of their postal pack. This could have also generated 
feedback on how the structure of the study could have been improved, which may have 
helped recruitment. Also exploring what motivated individuals to participate may have 
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identified a possible confounder of participants taking part because they may have believed 
something to be ‘wrong’ developmentally/behaviourally with their child.  
Specific to the cognitive assessments, the environments were not considered ideal, although 
these were the best options for the study to keep things feasible for participants. For 
research centre visits, the assessments occurred at the end of the visit. A higher performance 
may have been scored if the assessments were conducted earlier in the visits as the child 
would have not have fatigued from proceeding demands i.e. giving a blood or saliva sample, 
waiting for his/her mother to complete the informed consent and medical history with a 
clinician or from lying still for the bone density scans. However, as discussed in Table 8, there 
was a time constraint and the only feasible time to have the assessments was at the end of 
the visit. This was similar to the difficulties of the home assessments, as achieving the ideal 
‘distraction free environment’ (216) was challenging in someone’s home.  
As research centre visits occurred during one visit, it was natural that the cognitive 
assessments were also completed during one visit. In retrospect, perhaps the cognitive 
assessments could have been completed on separate days to the initial research centre visits 
(i.e. collecting consent, blood/saliva samples, and bone scans etc.), or the WISC-IV and the 
NEPSY-II assessments could have been divided by a defined break of, for example, collecting 
a saliva sample. Fatigue of the child was something I was constantly aware of as the 
examiner, and was most frequently listed as a reason for not commencing with the additional 
NEPSY-II tests (in total 36/452 [8%] did not complete any of the NEPSY-II, see page 88 for 
further details). Placing the NEPSY-II straight after the WISC-IV was the correct decision, as 
the mean scores for the NEPSY-II were not below the standardised means of ten (230); it 
could be argued that no ‘underperformance’ was apparent. A sensitivity analysis of those 
who did not complete the NEPSY-II compared to those who did, of IQs may have been 
interesting. Commonly, the child was fatigued due to a long testing time of the WISC-IV, 
which could have indicated a superior performance on the IQ test (78), it could therefore be 
hypothesised that the more intelligent children in the CATS II cohort did not complete the 
NEPSY-II.  
As previously discussed on page 80, administering different intelligence tests could produce 
a range of results (289, 290), thus perhaps by only adopting one it may not be a true 
representation of that individual’s functioning.  For the measure of intelligence of the 
offspring in CATS II, the WISC-IV could have been perhaps used in conjunction with other 
data. For example, data from the National Pupil Database could have been explored as this 
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was routine data collected by schools which would have captured the child’s ongoing 
performance, behaviour and sociability; this data would have avoided any potential bias of 
maternal reporting. With the increasing recruitment of CATS II, and time cost of home visits 
and scoring data, this data would have been difficult for me to gather during the data 
collection phase of the CATS II study. However, having this educational attainment 
information may have been useful to explore the correlation to the child’s IQ. In retrospect, 
attainment information could have been collected post hoc by the proposed ‘follow-up’ 
questionnaires mentioned above.  
Specific to the analysis of the cognitive data, one MANCOVA could have been executed for 
the WISC-IV and NEPSY-II data instead of two separate analyses. From a statistical 
standpoint, this may have been preferable as it would have reduced multiple testing. If this 
thesis was not going to be comparable to the CATS II results, this analysis may have been 
different; as the planned analysis was for separate comparisons between the WISC-IV and 
NEPSY-II (280). However, one MANCOVA would have meant smaller participant groups as 
the LM NEPSY-II subtest was not completed by many. 
Throughout all analyses (except for significant effects of the covariates’ investigations), 
adjustments were made to try and control for any extraneous effects. Randomisation from 
the CATS I study was inevitably compromised, for example some of the normal GTF group 
were recruited based upon their proximity to the research centre, similarly those from the 
SGTF groups who had moved further than three hours away were difficult to follow-up in 
CATS II. The age of the children in the normal GTF group were significantly older than those 
from the SGTF groups, which was indicative of this broken randomisation; on average they 
were around 0.235 years older, which is equivalent to just under three months. The social 
deprivation score as a covariate could have been collated better by the ‘General CATS 
Questionnaire’, for example collecting information on parental education, whether their 
home was bought, income levels etc. (see Appendix 8: Revised CATS general questionnaire, 
this could not be used unfortunately as it was devised too close to the end of the study).  
3.4. Future studies 
 CATS 0 
To overcome many of the limitations discussed above, a restart on the entire project could 
be considered. One of the main benefits of this would be that serum samples to test thyroid 
function would be collected earlier in pregnancy, and also treatment could be initiated 
earlier. This could occur by recruiting local surgeries into the project so that when women 
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visit their general practitioner to confirm the pregnancy, samples could be collected here. 
The SGTF definition could be split into exploring GSH and maternal hypothyroxinaemia, with 
clear defined reference ranges based on the most up-to-date UK/European guidelines 
available. 
Tracking the mothers’ diet and when levothyroxine was taken during the day could be 
conducted; including caffeine consumption. Also, following the offspring’s development and 
cognition throughout childhood would be interesting, as well as following the development 
of those born to the normal GTF group. Data from the National Pupil Database could be 
utilised as well as perhaps using the teacher version of the SDQ to minimise any bias from 
maternal reporting. CATS 0 could administer questionnaires and cognitive assessments 
electronically to aid speed of scoring, electronic questionnaire could be designed to ‘flag’ 
unanswered questions to the mother to ensure high completion rates.  
Clear targets of how many participants need to be assessed per month might aid numbers, 
also allowing for participants not attending visits would be beneficial.  More contact with 
participants could be established between waves of the study which would help with 
attrition rates; e.g. news leaflets, birthday cards, information on relevant study publications. 
Finally, use of social media could also be adopted, as well as a Facebook page for the 
mothers; one could also be developed for the children in addition to using other social 
network avenues.  
More information about the participants ‘general home life’ would be beneficial when 
considering adjustments for analyses. For example, information on diet (specific for the 
physical aspects of CATS II), information on parental education, as well as the child’s 
educational attainments would be useful. As mentioned, a follow-up questionnaire could be 
used to help develop and improve the project.  
 CATS III; brain imaging 
Thyroid hormone action in the developing brain is dependent on an important gene called 
deiodinase 2 (D2), as well as the mother’s thyroid hormone levels (25). D2 is involved in the 
deiodination of T4 to T3, and is expressed in the brain (and also the pituitary, thyroid gland 
and skeletal muscle) (6). Rodent studies have shown how exposure to low thyroid hormone 
in utero may lead to hypo-myelination of white matter tracts (501, 502); but exploration in 
humans is limited. In the exploratory analysis for CATS II, it was found that children carrying 
a common variant of the D2 gene (homozygous for Thr92Ala) and who were also born to 
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mothers with low T4, were at an increased risk of FSIQ ≤ 85 and treatment appeared to 
alleviate some of these lower IQs.  
At time of submission of this thesis, a small grant had been awarded to conduct 12 magnetic 
resonance imaging scans on the CATS children. These scans will be conducted on six children 
from the untreated SGTF (i.e. low maternal T4) homozygous for Thr92Ala, compared to six 
children from the normal GTF without the specific genotype. This small study only planned 
to scan males to reduce any gender effects, and would act as a pilot for a much larger study. 
An application for this larger study was also submitted at time of completion of this thesis. 
This study proposed 80 scans; 40 children born to mothers with low T4, 20 with the 
homozygous Thr92Ala genotype and 20 without, would be compared to 40 children born to 
mothers with normal T4 levels, again 20 with the Thr92Ala genotypes and 20 without. Repeat 
cognitive testing was also planned to ensure contemporaneous capture with the 
neuroimaging readouts. It was planned that the children would undergo characterisation of 
white matter microstructure in vivo; which would generate a quantification of their 
myelination. This potential third wave of the study was planned to occur around age 11 of 
the children to avoid any potential confounders from puberty.  
The research aims of this planned future study are to explore: 
i. Whether differences would exist between children exposed to gestational low 
thyroid hormone or not; if so, whether these would be restricted to the adverse D2 
genotype? 
ii. Whether any differences in cognition were attributable to differences in white 
matter microstructure; if so, were they specific to myelin metrics and in which 
anatomical pathways? 
iii. Whether any differences identified would be alleviated by maternal thyroxine 
supplementation.  
3.5. Final conclusions and summary 
The work described in this thesis failed to generate evidence for SGTF having a negative 
impact on offspring’s cognition at age 9 years. Treatment of SGTF also had no effect to 
cognition, but was shown to ‘worsen’ behaviour as measured by questionnaires completed 
by the mothers. Whilst the exploratory analyses generated interesting findings of the 
significant effects of the covariates and how the IQs significantly changed between wave one 
and two, no further evidence was identified between the three main groups in the study.  
CATS was the first RCT in the world to explore the effect of treatment in a large cohort, 
further large studies exploring underactive thyroid function during pregnancy are needed to 
determine whether universal screening and treatment should be sought during pregnancy 
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or not. With the finding from the behavioural questionnaires, additional exploration is 
needed to better quantify whether treatment for SGTF could be detrimental for the child’s 
behaviour.  
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Appendix 1: Timeline of the CATS project 
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2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
 
 
1. Women recruited during their pregnancy (mean 12 weeks 
gestation) 
2. Offspring born 
3. Cognitive tests (IQ) for offspring (mean age 3 years) 
4. CATS I paper published (Lazarus et al NEJM) 
5. CATS II recruitment (data collected: DXA scans, DNA, behavioural 
questionnaires) 
6. CATS II cognitive assessments (IQ and 
additional tests) 
Timeline of the CATS project 
KEY 
  
 
CATS I 
CATS II 
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Appendix 2: The decision process for additional tests for CATS II 
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Summary of the decision process for the additional tests to be used in CATS II 
 
Literature has suggested that as well as IQ impairments for children who have been born to 
mothers with an underactive thyroid, there may be further deficits that require testing. This 
document is a summary of how the CATS II research team came to decide which tests to 
administer, alongside the WISC-IV.  
 
Memory Tests 
1) Memory for Patterns Delayed 
2) Narrative Recall 
A memory deficit has been proposed by Willoughby et al. (2013), Gilbert et al. (2012) and 
Riva and Naranjo (2007). Willoughby et al. identified a difficulty with episodic memory which 
resulted from hippocampal damage to the fetus from a lack of thyroxin. As episodic memory 
is one of the long term memory systems, choosing a delayed memory task seemed highly 
appropriate. ‘Narrative Recall’ does not investigate possible deficits in long term memory per 
se, but will examine memory for organised verbal material. Along with the working memory 
tests from the WISC, this recall task could provide further evidence for any results found. 
 
Motor Test 
3) Fingertip Tapping 
Li et al. (2010) and Haddow et al. (1999) investigated MHT and the effects it may have on the 
developing child; their results displayed evidence for a fine motor deficit. Li et al. and Zoeller 
and Rovet (2004) identified a gross motor deficit, however within the CATS II protocol this 
would be difficult to investigate. The ‘Fingertip Tapping’ test is quick and easy to administer 
and was chosen as the fine motor assessment as it could be easily added onto a WISC-IV 
assessment.  
 
Deficits that are identified in the literature, but are not to be investigated in CATS II 
 Visual Perception 
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Visual perception deficits of children who experience MHT are sparsely reported upon. 
Haddow et al. (2009) did identify this as a problem in such children, and Zoeller and Rovet 
(2004) have reported upon this difficulty. However, such a deficit has been disproved by 
Oken et al. (2009) who tested children at age three. As the WISC-IV and additional subtests 
from the NEPSY could take up to 90 minutes to administer, following through on this line of 
enquiry was discounted.  
 Hearing 
The literature has suggested hearing difficulties to be a possible line of enquiry (Haddow et 
al., 1999; Crofton, 2004). Tests of phonological and auditory awareness were examined but 
none were suitable enough; age restrictions and time to administer were some of the 
problems encountered with the proposed hearing tests (see below). On these grounds, 
investigating hearing as a deficit was cut.  
o PHaB – Phonological Assessment Battery 
 30-40 minutes to administer 
o CTOPP – Comprehensive Test of Phonological Processing 
 30 minutes to administer 
o PAT - Phonological Abilities Test 
 30-40 minutes to administer 
o Test of Phonological Awareness 
 Tests only up to age 8 
o TAAS – Test of Auditory Analysis Skills 
 Tests only up to age 8 
 Language difficulties 
Haddow et al. (1999) identified this as a deficit and this will be looked at, but only so far as 
looking at differences between verbal and perceptual reasoning IQs on the WISC-IV. There is 
not enough time available to administer separate tests to thoroughly investigate a possible 
language difficulty.  
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Appendix 3: CATS II General Questionnaire 
DATE:___________________________ 
 
MOTHER - GENERAL 
Name  
DOB  
No. of pregnancies  
No. of live children (with ages)  
Child’s Paternal height  
Occupation (or details of last job)  
Child’s Paternal Occupation  
Cigarette smoker (per day) pls tick Never  Present 0-10  10-20  20+  
Ethnicity pls tick White  Asian  African  Other  
MEDICAL 
Previous illnesses/pls give date: 
 
 
 
 
Operations/pls give date: 
 
 
 
 
Family History of Thyroid Disease? Yes/No  (pls delete as appropriate) 
Previous Thyroid Hormone 
Treatment/pls give date(s): 
 
Current Thyroid Hormone Treatment Yes/No    Dose: 
Other current drug therapy Name               Dose Date started 
   
   
   
   
   
Other current illnesses  
 
 
 
OTHER COMMENTS:  
 
 
 
CHILD 
DOB  M/F  
Birth Weight  
Child’s Handedness Right  Left  
Language of School English  Welsh  Other  
Language Spoken at Home English  Welsh  Other  
Gestational age Full term (37-40 
wks 
 Preterm (32-37 wks)  Very Preterm 
(<32 weeks) 
 
Mode of Delivery Normal  Caesarean  
Medical complications in pregnancy Diabetes Yes/No 
High BP Yes/No 
Pre eclampsia Yes/No 
Anaemia Yes/No 
Other: 
Breast fed for more than 1 mth Yes  No  
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Appendix 4: Initial contact pack  
1. Cover letter 
2. Information for the mother 
3. Information for the child 
4. Response form 
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1. Cover letter 
 
Dear «returned_forename» «returned_surname» 
 
Between 2004 and 2006 when you were attending antenatal clinic you 
may remember agreeing to take part in a study called CATS (Controlled 
Antenatal Thyroid Screening) which was a research project looking at the 
effects of maternal thyroid functioning in pregnancy: At that time you 
kindly agreed to an extra blood test, then three years later you may have 
been part of a much smaller group of women who were contacted and 
their children took part in an assessment at their home.   
Many thanks to each and every one of you who agreed to take part in 
CATS which was the largest study of its type in the world at the time, and 
which is now complete and has been published. 
We would like to invite you to join CATS II, a study led by Professor 
Marian Ludgate, following up on the progress of the mothers and children 
from CATS.  
Enclosed is a Patient Information Leaflet for CATS II which we hope 
explains the study clearly and in more detail. We have also enclosed a 
response form for you to complete and return to us in the stamped 
addressed envelope when you have made your decision. You are certainly 
not obliged to take part.    
As you can imagine many people will have changed address since 2004 – 
we have been working with the Welsh Demographic Service and the 
Patient Data registry to update our information, as approved by South 
East Wales Research Ethics Committee and the local Health Boards. We 
hope we have the correct address for you but if not please let us know. 
We look forward to receiving your response form and please get in touch 
if you have any questions. 
Yours sincerely, 
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Professor John Lazarus. 
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2. Information for the mother 
PARTICIPANT INFORMATION LEAFLET (initial) 
 V5, 1 April 2014 
 
PART 1  
1. Title of study 
 
Controlled Antenatal Thyroid Screening Study II (CATS 2) 
 
2. Introduction 
We would like to invite you to take part in our research 
study. Before you decide we would like you to 
understand why the research is being done and what it 
would involve for you. Talk to others about the study if 
you wish.  
(Part 1 tells you the purpose of this study and what will 
happen to you if you take part.  
Part 2 gives you more detailed information about the 
conduct of the study).  
Please ask us if there is anything that is not clear. 
3. What is the purpose of this study? 
Following on from your participation in the original CATS study, 
scientists and doctors at the University Hospital of Wales are 
hoping to arrange further studies to investigate how thyroid 
hormone levels during pregnancy may affect the development 
of the proportions of fat, muscle and general development in a 
child.  They will assess your child’s abilities in a range of areas, 
such as verbal and non-verbal skills, memory and speed of 
processing with an IQ test.  They will also investigate whether 
there is any effect on fat and bone development in the mother 
and/or any influence on their general wellbeing. 
 
4. Why have I been invited? 
It is only those involved in the previous study that will be able 
to help us with our ongoing investigations. 
We really appreciated your involvement in the CATS 1 study on 
thyroid hormone levels in pregnancy, and how variations in this 
might affect your child. The results of this study should be 
available later this year (we are planning a meeting to let you 
know the results) and will prove useful in understanding these 
effects and help to improve the care of pregnant women and 
their children.  
 
5. Do I have to take part? 
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It is up to you to decide whether or not to take part. If you are 
interested in continuing your involvement with the CATS study 
by taking part in CATS II, there are two different levels of 
involvement detailed below.  It is up to you which you would 
like to be involved in. If you choose not to take part, that is fine 
by us, you do not have to give us reasons why and this decision 
will not have any implications for your future medical care. 
 
If you decide to take part you will be asked to sign a consent 
form. You are still free to withdraw at any time and without 
giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care 
you receive. 
6. What will happen to me if I take part? 
The study will involve either: 
 
1) Completing questionnaires about your child’s general 
development, your mood and obtaining saliva or mouth 
swabs and urine samples from you and/or your child for 
genetic studies. The saliva or mouth swabs will provide 
us with a sample of DNA which will be analysed for 
variations in the genes which influence e.g. control of 
thyroid function or mood disorders. These will need to be 
returned to us in an envelope provided, along with the 
completed consent forms confirming you are happy for 
us to analyze these questionnaires and samples.  
 
Or,  
 
2) We would like to invite you to attend an appointment at 
the University Hospital of Wales for a morning to: 
 
1.  Measure height and weight in you and your child. 
2.  Measure blood pressure and assess the blood 
flow in the blood vessels of you and your child’s arm 
with a probe put on the skin in you and your child.  
3.  Complete questionnaires with you about 
your mood and your child’s social and educational 
development and progress. 
4.  Perform a DEXA scan to measure the 
proportion of fat and muscle in you (providing 
you are not pregnant at the time) and your child 
(this would involve lying still on the scan table for 
a minute or two whilst the scan is performed and 
does not hurt). DEXA is a simple, rapid and non-
invasive technique which is used routinely in 
clinical practice to measure bone density. This 
scan does involve exposure to a small amount of 
radiation (no more than experienced during a day 
walking around outside in the UK) but the risk is 
negligible. 
5.  Take a blood sample from you and your 
child (approximately 6 teaspoonfuls), to measure 
thyroid hormone levels, aspects of the control of 
bone and fat tissues and variations in the genes 
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which influence the different aspects that we will 
measure in the study. Some of the tests need for 
you and your child to have fasted since the night 
before; we will provide breakfast as soon as 
possible after you arrive. If you or your child 
prefers not to have a blood test we would still 
like to take saliva or mouth swabs for genetic 
studies.  
6. For your child to undertake an intelligence test 
called Weschler Intelligence Scale for Children 
(Fourth UK Edition (WISC-IVuk). and sections 
from the Neuropsychological Assessment Second 
Edition.  This usually takes about 1-1½ hours and 
would generate an IQ score, which would 
represent your child’s intelligence.  You can of 
course be present during the test, but some 
children do not perform as well if their parents 
are there as they are distracted.  You will be able 
to have a copy of the report if you wish. If you 
prefer we could arrange for our research 
assistant to make an appointment for this test to 
be done in your home. 
7. Take a urine sample from you and your child. 
7. Expenses and payments  
If you wish we will be able to reimburse any travelling expenses 
/ car parking fees incurred while attending for the study visit. 
8. What do I have to do? 
If you are interested in taking part or you would like more 
information about the study, please complete the response form 
by putting your initials in the appropriate box and we will be in 
touch with you very soon. 
If you have any hesitation and would like more information, you 
may contact Professor John Lazarus (phone: 02920 742938 
email lazarus@cf.ac.uk). Professor Lazarus set up the original 
CATS study in which you were involved but is now retired. 
However, he has kindly agreed to act as an advisor with expert 
understanding of the issues involved in our proposed study and 
would be happy to provide you with any advice you might 
require.  
 
9. What are the alternatives for diagnosis or treatment?  
 
At present, the thyroid function of women who are pregnant is 
not tested at all. Our studies will help to decide whether it is 
advisable for this to be done, either because of benefits to the 
child, the mother or both. 
 
10.  What are the possible disadvantages and risks of taking 
part? 
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Other than possible discomfort (temporary pain, swelling, 
bruising and rarely infection) caused by the collection of blood, 
no other side effects are anticipated from the study procedures. 
A DEXA scan does involve exposure to a small amount of 
radiation but the risk is negligible. It is possible that the blood 
tests or DEXA scan could by chance pick up an unsuspected 
abnormality, in which case you will be given an opportunity to 
discuss these findings further with the doctors.  
These investigations will only be performed once we have 
explained in detail what will be involved, you have given us your 
consent and your child has agreed to take part. You or your 
child may decide to undergo some but not all of the tests. It is 
possible that you decide to participate but your child prefers not 
too, or vice versa. 
 
11. What are the side effects of any treatment received when 
taking part? 
 
The new study (CATS II) does not involve you taking any 
medication or receiving any treatment. In CATS I, you may 
have received tablets containing thyroid hormone which is 
exactly the same as produced naturally by your thyroid and so 
does not have any side effects.  
 
12. Exposure to radiation or ionising radiation 
As mentioned above, you and/or your child may agree to have 
a DEXA scan. This involves exposure to a small amount of 
radiation but no more than experienced walking around outside 
for 1 day in the UK. 
13. Harm to the unborn child 
None of the investigations to be performed have any negative 
effect on an unborn child EXCEPT the DEXA scan. With your 
permission, we will perform a pregnancy test and if you it is 
positive you will not receive the DEXA scan. None of the 
investigations will affect you or your child if you are breast 
feeding.  
14. What are the potential benefits of taking part? 
We cannot promise the study will help you but the information 
we get from this study will help improve the future care of 
pregnant women with consequent benefit to their children. 
15. What happens when the research study stops? 
Since no treatment is involved, there are no special 
considerations to take into account. However, with your 
permission, we will store samples and this is explained in part 
2. 
16. What if something goes wrong? 
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Any complaint about the way you have been dealt with during 
the study or any possible harm you might suffer will be 
addressed. The detailed information on this is given in Part 2.  
17. Will my taking part in this study be kept confidential 
Yes. We will follow ethical and legal practice and all information 
about you will be handled in confidence. The details are included 
in Part 2.  
 
This completes Part 1.  
 
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision.  
 
PART 2 
1. What if relevant new information becomes available? 
Sometimes we get new information about treatments, in this 
case we are measuring the effects of treatment you may have 
received when you were pregnant and not during this new 
study.   
2. What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, with your permission, we will 
keep any samples, and use any data collected up to your 
withdrawal. A decision to withdraw at any time will not affect 
the standard of care you receive.   
Similarly in the event of your loss of capacity, with your 
permission, we will keep any samples, and use any data 
collected prior to this. 
 
3. What if there is a problem? 
If you have a concern about any aspect of this study, you should 
ask to speak to the researchers who will do their best to answer 
your questions (phone 02920 745457 or 02920 745002).  This 
study is being indemnified by Cardiff University. If you are 
harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated during the course of 
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this study, the normal National Health Service complaints 
mechanisms should be available to you.  
4. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course 
of the research will be kept strictly confidential. No personally 
identifiable information will be held on NHS or University 
computers although storage of study data on both systems will 
occur in an anonymised form. These computers are held by 
Professor Ludgate, Dr Rees and other members of the study 
team and are stored in locked rooms (rooms 254 & 261, 2nd 
Floor C block, University Hospital of Wales). The computers are 
password protected and no identifiable data will be transferred 
electronically, though final analysis of the anonymised study 
data may require email transfer to Professor Newcombe in the 
Department of Primary Care and Public Health who may provide 
statistical advice.  
5. Involvement of your general practitioner/family doctor 
With your permission your GP will be informed of your 
participation in this study.  
6. What will happen to any samples I give? 
The blood and urine samples (6 teaspoons) for this study will 
be collected and stored securely for later analysis in the Centre 
for Endocrine and Diabetes Sciences at the University Hospital 
of Wales. Only immediate members of the research team will 
have access to these samples. With your permission, we also 
plan to test the samples we collected during CATS I.  It is most 
likely that the samples will be destroyed (by incineration) at the 
end of the study, in this case, all identifiable information will be 
removed. Should we decide to store the samples, we will apply 
for additional Research Ethics Committee approval before CATS 
II is complete and request your permission. 
7. Will any genetic tests be done? 
With your permission, we will obtain blood samples, saliva or 
mouth swabs from you and/or your child to test genes involved 
in controlling the production of thyroid hormone. Because 
changes in genes can be inherited, if you are discovered to have 
such a change it is possible that other members of your family 
might also be affected. We will therefore ask for your 
permission to contact your immediate family members 
(parents, brothers/sisters, children) to see whether they also 
wish to be tested.  
8. What will happen to the results of the research study? 
The results of the research study will be prepared for publication 
in appropriate medical journals together with presentation at 
medical conferences. People participating in the study will be 
able to obtain a copy of the results after they have been 
published in the relevant journal(s). Participants will not be 
identified in any report/publication.  
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We will also organise a meeting at the end of the study to let 
you know about the results. 
9. Who is organising and funding the research?  
The study is being organised by Professor Marian Ludgate, Dr 
Aled Rees, Professor John Gregory and Professor John Lazarus 
from the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. Funding for the study is provided 
by the Charles Wolfson Charitable Trust. The doctors conducting 
the research are not being paid for including and looking after 
women and children in the study. 
10. Who has reviewed the study? 
The Cardiff & Vale University Health Board Research & 
Development Office and by the South East Wales Research 
Ethics Committee. 
11.  Future Studies 
It is possible that further research may be carried out related 
to the CATS studies.  If this happens, we may contact you again 
at some time in the future to ask if you would be prepared to 
be involved in future studies. 
12. Further information and contact details 
Should you have any further queries regarding this research 
study, then please do not hesitate to contact us on 02920 
745457 or 02920 5002. You can also contact us via e-mail on 
ludgate@cf.ac.uk or reesda@cf.ac.uk  
 
Thank you for considering taking part in this study. 
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3. Information for the child 
 
Child Information Sheet,  V4, 1 April 2014 (Initial) 
 
Study title  
 
Testing how the thyroid gland affects the growth and health of mothers and their 
children.  
 
What is research? Why is this project being done?  
 
Research is a way we try to find out the answers to questions. When your 
mother was expecting you she took part in some tests and may have taken 
some medicine until you were born. You might remember that when you were 3, 
you did some puzzles for us in your house. Now that you are growing up, we 
would like you to help us find out more. We want to look at how much fat and 
muscle there is in your body, and how a gland in your neck called the thyroid 
gland can affect this.  
 
Why have I been asked to take part?  
 
There is nothing wrong with you, and everybody has this gland, but you have 
been specially chosen because your mother was tested before.  
Did anyone else check the study is OK to do?  
 
Before any research is allowed to happen, it has to be checked by a group of 
people called a Research Ethics Committee. They make sure that the research is 
fair. Your project has been checked by the South East Wales Research Ethics 
Committee.  
 
Do I have to take part?  
 
You do not have to take part, it is completely your choice. Even if you do decide 
to join in you do not have to have all of the tests if you prefer not to. 
 
What will happen to me if I take part in the research?  
 
You and your mother might prefer to help us from home. In this case, your 
mother will complete some forms explaining how you are getting on in school 
and with your friends. We will also ask you to scrape the inside of your cheek 
with a special stick (it won’t hurt) or spit into a tube. We will use this to find out 
whether you have inherited anything from your mum which alters how your 
thyroid works.  
 
If you agree to come to the hospital with your mother to have some tests, it will 
take all morning and you may miss school. On the day that you come for the 
tests, you should not have breakfast because we will provide that for you. You 
will have the same tests as your mother. 
We will see how much you weigh, check how tall you are, and measure your 
heart beat.  We will ask you for a urine sample.  We will also ask your mother 
some questions about you. We will also take a picture of you with a special 
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camera, to see how much bone and muscle you have and give you a copy to 
show your friends.  
Also, if you will let us, and your parents say it is OK, we will take a small amount 
of blood (6 teaspoonfuls) to see how the gland in your neck is working. If you 
don’t want a blood test we will ask for a scrape from inside your cheek (it won’t 
hurt) or spit into a tube. We will use this to find out whether you have inherited 
anything from your mother which alters how your thyroid works. 
We would also like for you to take part in a test that will take about 1-1½ 
hours, which will check your learning and concentration.  The test will 
involve puzzles, answering questions and remembering certain things.   
Might anything about the research upset me? 
  
Most of the tests will not hurt at all. If you agree for us to take some blood, to 
prevent this from hurting, we can put some special cream on your skin before 
the blood test which helps to stop you from feeling it.  
Will joining in help me?  
 
We cannot promise the study will help you but the information we get might 
help treat mothers who have a problem with their thyroid, especially when they 
are pregnant, and their children. 
 
What happens when the research stops? 
 
The study does not involve you taking any medicine so there will be no change 
for you. 
 
What if something goes wrong during the project? 
 
This is very unlikely since we are doing tests to find out if medicine your mother 
may have taken before is having an effect. 
 
Will my medical details be kept private if I take part? Will anyone else 
know I’m doing this? 
 
Only the doctors involved in the study will know about you taking part. 
 
What if I don’t want to do the research anymore?  
 
If at any time you don‘t want to do any of the tests, just tell your parents, 
doctor or nurse. They will not be cross with you.  
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4. Response form 
CATS II 
 
Response form V, V3, 1 April 2014 
Please complete and return in the envelope provided. 
Name:………………………………………………………….…………..………… 
(Previous name if recently married): 
…………………..……………………………… 
Address:……………………………………………………………….……………… 
Post Code: ………………………….........................DOB: ………………………… 
Contact No.:………………………………………………………………… 
Email Address: ………………….…………………………………………   
(Please place a star next to desired mode of contact) 
Child’s Name:……………………………… DOB:………….……………… 
Please initial to indicate your preference. 
□ Before deciding to participate or not, I wish to obtain further information and would 
like to talk to the patient adviser (Professor John Lazarus). I give my permission for 
you to contact me by telephone. 
□ I am interested in participating by providing a DNA and a urine sample from myself 
and my child and completing some questionnaires at home. I give my permission for 
you to provide me with the required information, kits and questionnaires by post. 
□ I am interested in participating by having a home visit in which my child will be 
evaluated using tests of cognition, by providing a DNA and a urine sample from 
myself (using the provided kits) and my child and my completing some questionnaires. 
□ I am interested in participating and am prepared to attend at the University Hospital 
of Wales, Heath Park, Cardiff, with my child, for a half day for a range of non-invasive 
tests. I give my permission for you to contact me by telephone to organise a convenient 
time and date to attend. 
□ I give my permission for you to inform my GP about the study. 
Thank you for your time. 
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Appendix 5: Information sheets from the post pack 
1. Information for the mother 
2. Information for the child 
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1. Information for the mother 
 
1. Heading       PARTICIPANT INFORMATION LEAFLET (Remote)  
V4(ii), 6 February 2012 
 
PART 1  
2. Title of study 
Controlled Antenatal Thyroid Screening Study II (CATS 2) 
3. Introduction 
Thank you for taking the time to read this leaflet. You have 
indicated that you are prepared to take part in the CATS 2 
study. Before you confirm that you wish to become involved it 
is important that you understand why the research is being 
done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you 
wish 
Part 1 reminds you of the purpose of this study and what will 
happen if you take part. 
Part 2 gives you more detailed information about the conduct 
of the study. 
Please do not hesitate to ask us if there is anything that is not 
clear or if you would like more information.  
Take time to consider whether or not you still wish to take part. 
4. What is the purpose of this study? 
Following on from your participation in the original CATS study, 
scientists and doctors at the University Hospital of Wales are 
hoping to arrange further studies to investigate how thyroid 
hormone levels during pregnancy may affect the development 
of the proportions of fat, muscle and general development in a 
child. They will also investigate whether there is any effect on 
fat and bone development in the mother and/or any influence 
on their general wellbeing. It is only those involved in the 
previous study that will be able to help us with our ongoing 
investigations. 
 
5. Why have I been chosen? 
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It is only those involved in the previous study that will be able 
to help us with our ongoing investigations. 
We really appreciated your involvement in the CATS 1 study on 
thyroid hormone levels in pregnancy, and how variations in this 
might affect your child. The results of this study should be 
available later this year and will prove useful in understanding 
these effects and help to improve the care of pregnant women 
and their children.    
 
6. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you 
choose not to take part, that is fine by us, you do not have to 
give us reasons why and this decision will not have any 
implications for your future medical care. If you decide to take 
part you will be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason. A decision 
to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
7. What will happen to me if I take part? 
You and/or your child have opted to participate from home, this 
will involve completing some questionnaires and obtaining 
mouth swabs or saliva samples from you and your child for 
genetic studies. These will provide us with a sample of DNA 
which will be analyzed for variations in genes. These will need 
to be returned to us, along with the completed consent forms 
confirming you are happy for us to analyse these questionnaires 
and samples. 
 
8. Expenses and payments 
 
There should not be any expense incurred by you since we have 
provided envelopes with the postage paid for you to return the 
samples and questionnaires. 
 
9. What do I have to do? 
1.  Complete the questionnaires in your own time.  
There are 4 of these labelled: 
 
 ADHD, this provides information about your child’s 
social behaviour. 
 SCQ, this provides information about your child’s 
activity level. 
 SDQ, this indicates how your child is progressing. 
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 General, this contains information which is useful to 
us about you and your child. 
2.  Use the kits provided to obtain saliva or a sample 
from the inside of your and your child’s mouth. There 
are instructions in the box but please contact us on 
02920 745457, if you need more information. We will 
use the samples to obtain DNA to look for variations 
in the genes which influence the different aspects 
that we will measure in the study. If you need more 
information, you may contact Dr Marian Ludgate 
(02920 745457) or Dr Aled Rees (02920 745002).   
3.  Please return all completed questionnaires, samples 
and signed consent forms in the stamped addressed 
containers provided. 
 
10. What are the alternatives for diagnosis or treatment?  
 
At present, the thyroid function of women who are pregnant is 
not tested at all. Our studies will help to decide whether it is 
advisable for this to be done, either because of benefits to the 
child, the mother or both. 
 
11.  What are the possible disadvantages and risks of taking 
part? 
No side effects are anticipated from the study procedures.  
12. What are the side effects of any treatment received when 
taking part? 
 
The new study (CATS II) does not involve you taking any 
medication or receiving any treatment. In CATS I, you may 
have received tablets containing thyroid hormone which is 
exactly the same as produced naturally by your thyroid and so 
does not have any side effects.  
 
13. Exposure to radiation or ionising radiation 
None. 
14. Harm to the unborn child 
 
None of the investigations to be performed have any negative 
effect on an unborn child or will affect you or your child if you 
are breast feeding.  
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15. What are the potential benefits of taking part? 
We cannot promise the study will help you but the information 
we get from this study will help improve the future care of 
pregnant women with consequent benefit to their children. 
16. What happens when the research study stops? 
Since no treatment is involved, there are no special 
considerations to take into account. However, with your 
permission, we will store samples and this is explained in part 
2. 
17. What if something goes wrong? 
Any complaint about the way you have been dealt with during 
the study or any possible harm you might suffer will be 
addressed. The detailed information on this is given in Part 2.  
18. Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information 
about you will be handled in confidence. The details are included 
in Part 2.  
 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision. 
 
PART 2 
1. What if relevant new information becomes available? 
Sometimes we get new information about treatments, in this 
case we are measuring the effects of treatment you may have 
received when you were pregnant and not during this new 
study.   
2. What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, with your permission, we will 
keep any samples, and use any data collected up to your 
withdrawal. A decision to withdraw at any time will not affect 
the standard of care you receive.   
 
Similarly in the event of your loss of capacity, with your 
permission, we will keep any samples, and use any data 
collected prior to this. 
3. What if there is a problem? 
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If you have a concern about any aspect of this study, you should 
ask to speak to the researchers who will do their best to answer 
your questions (phone 02920 745457 or 02920 745002).  This 
study is being indemnified by Cardiff University. If you are 
harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated during the course of 
this study, the normal National Health Service complaints 
mechanisms should be available to you.  
4. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course 
of the research will be kept strictly confidential. No personally 
identifiable information will be held on NHS or University 
computers although storage of study data on both systems will 
occur in an anonymised form. These computers are held by Drs 
Ludgate, Rees and other members of the study team and are 
stored in locked rooms (rooms 254 & 261, 2nd Floor C block, 
University Hospital of Wales). The computers are password 
protected and no identifiable data will be transferred 
electronically, though final analysis of the anonymised study 
data may require email transfer to Professor Newcombe in the 
Department of Primary Care and Public Health who may provide 
statistical advice.  
5. Involvement of your general practitioner/family doctor 
With your permission your GP will be informed of your 
participation in this study. 
6. What will happen to any samples I give? 
The DNA samples for this study will be collected and stored 
securely for later analysis in the Centre for Endocrine and 
Diabetes Sciences at the University Hospital of Wales. Only 
immediate members of the research team will have access to 
these samples.  
With your permission, we also plan to test the samples we 
collected during CATS 1.  
It is most likely that the samples will be destroyed (by 
incineration) at the end of the study, in this case, all identifiable 
information will be removed. Should we decide to store the 
samples, we will apply for additional LREC approval before CATS 
II is complete and request your permission. 
7. Will any genetic tests be done? 
With your permission, we will obtain mouth swabs from you 
and/or your child to test genes involved in controlling the 
production of thyroid hormone. Because changes in genes can 
be inherited, if you are discovered to have such a change it is 
possible that other members of your family might also be 
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affected. We will therefore ask for your permission to contact 
your immediate family members (parents, brothers/sisters, 
children) to see whether they also wish to be tested.  
8. What will happen to the results of the research study? 
The results of the research study will be prepared for publication 
in appropriate medical journals together with presentation at 
medical conferences. People participating in the study will be 
able to obtain a copy of the results after they have been 
published in the relevant journal(s). Participants will not be 
identified in any report/publication.  
We will also organise a meeting at the end of the study to let 
you know about the results. 
9. Who is organising and funding the research?  
The study is being organised by Dr Marian Ludgate, Dr Aled 
Rees, Professor John Gregory and Professor John Lazarus from 
the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. Funding for the study is provided 
by the Charles Wolfson Charitable Trust. The doctors conducting 
the research are not being paid for including and looking after 
women and children in the study. 
10. Who has reviewed the study? 
The Cardiff & Vale University Health Board Research & 
Development Office and by the South Wales Research Ethics 
Committee. 
11.  Future studies 
It is possible that further research may be carried out related 
to the CATS studies.  If this happens, we may contact you again 
at some time in the future to ask if you would be prepared to 
be involved in future studies. 
12. Further information and contact details 
Should you have any further queries regarding this research 
study, then please do not hesitate to contact us on 02920 
745457 or 02920 5002. You can also contact us via e-mail on 
ludgate@cf.ac.uk or reesda@cf.ac.uk  
 
Thank you for considering taking part in this study. 
2. Information for the child 
 
 
Child Information Sheet, V4(i), 6 February 2012  (Remote ) 
 
 
Study title  
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Testing how the thyroid gland affects the growth and health of mothers and their 
children. 
 
What is research? Why is this project being done?  
 
Research is a way we try to find out the answers to questions. When your 
mother was expecting you she took part in some tests and may have taken 
some medicine until you were born. You might remember that when you were 3, 
you did some puzzles for us in your house. Now that you are growing up, we 
would like you to help us find out more. We want to look at how much fat and 
muscle there is in your body, and how a gland in your neck called the thyroid 
gland can affect this.  
 
Why have I been asked to take part?  
 
There is nothing wrong with you, and everybody has this gland, but you have 
been specially chosen because your mother was tested before.  
Did anyone else check the study is OK to do?  
 
Before any research is allowed to happen, it has to be checked by a group of 
people called a Research Ethics Committee. They make sure that the research is 
fair. Your project has been checked by the South East Wales Research Ethics 
Committee.  
 
Do I have to take part?  
 
You do not have to take part, it is completely your choice. Even if you do decide 
to join in you do not have to have all of the tests if you prefer not to. 
 
What will happen to me if I take part in the research?  
 
You and your mother prefer to help us from home. Your mother will complete 
some forms explaining how you are getting on in school and with your friends. 
We will also ask you to scrape the inside of your cheek with a special stick (it 
won’t hurt) or spit into a tube. We will use this to find out whether you have 
inherited anything from your mum which alters how your thyroid works.  
 
Might anything about the research upset me?  
 
None of the tests will hurt at all.  
 
Will joining in help me?  
 
We cannot promise the study will help you but the information we get might help 
treat mothers who have a problem with their thyroid, especially when they are 
pregnant, and their children. 
 
What happens when the research stops? 
 
The study does not involve you taking any medicine so there will be no change for 
you. 
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What if something goes wrong during the project? 
 
This is very unlikely since we are doing tests to find out if medicine your mother may 
have taken before is having an effect. 
 
Will my medical details be kept private if I take part? Will anyone else know 
I’m doing this? 
 
Only the doctors involved in the study will know about you taking part. 
 
What if I don’t want to do the research anymore?  
 
If at any time you don‘t want to do any of the tests, just tell your parents, doctor or 
nurse. They will not be cross with you.  
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Appendix 6: Appointment letters 
1. Remote/home visit 
a. Cover letter 
b. Information for mother 
c. Information for child 
d. Copy of consent form 
2. Research centre visit 
a. Cover letter 
b. Information for mother 
c. Information for child 
d. Copy of consent form 
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1. Remote/home visit 
a. Cover letter 
 
 
>>ADDRESS<< 
 
Dear >>NAME<<, 
 
Further to your conversation with my colleague on the >>DATE<<, I have enclosed some 
information letters and a copy of the consent form for my visit at your home.  
 
I look forward to meeting you and >>CHILD NAME<< on >>APPOINTMENT DATE AND 
TIME<<. If you have any problems with the appointment, please ring or text: 07908 243 142. 
 
Yours sincerely, 
 
 
 
Charlotte Hales 
  
261 
 
b. Information for mother 
1. Heading       PARTICIPANT INFORMATION LEAFLET (Remote)  
 V6, 1 April 2014 
PART 1  
2. Title of study 
Controlled Antenatal Thyroid Screening Study II (CATS 2) 
3. Introduction 
Thank you for taking the time to read this leaflet. You have 
indicated that you are prepared to take part in the CATS 2 
study. Before you confirm that you wish to become involved it 
is important that you understand why the research is being 
done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you 
wish. 
Part 1 reminds you of the purpose of this study and what will 
happen if you take part. 
Part 2 gives you more detailed information about the conduct 
of the study. 
Please do not hesitate to ask us if there is anything that is not 
clear or if you would like more information.  
Take time to consider whether or not you still wish to take part. 
4. What is the purpose of this study? 
Following on from your participation in the original CATS study, 
scientists and doctors at the University Hospital of Wales are 
hoping to arrange further studies to investigate how thyroid 
hormone levels during pregnancy may affect the development 
of the proportions of fat, muscle and general development in a 
child. They will also investigate whether there is any effect on 
fat and bone development in the mother and/or any influence 
on their general wellbeing. It is only those involved in the 
previous study that will be able to help us with our ongoing 
investigations. 
 
5. Why have I been chosen? 
 
It is only those involved in the previous study that will be able 
to help us with our ongoing investigations. 
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We really appreciated your involvement in the CATS 1 study on 
thyroid hormone levels in pregnancy, and how variations in this 
might affect your child. The results of this study should be 
available later this year and will prove useful in understanding 
these effects and help to improve the care of pregnant women 
and their children.    
 
6. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you 
choose not to take part, that is fine by us, you do not have to 
give us reasons why and this decision will not have any 
implications for your future medical care. If you decide to take 
part you will be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason. A decision 
to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
7. What will happen to me if I take part? 
You and/or your child have opted to participate from home, this 
will involve completing some questionnaires, providing a urine 
sample from you and your child and obtaining mouth swabs or 
saliva samples from you and your child for genetic studies. 
These will provide us with a sample of DNA which will be 
analyzed for variations in genes. These will need to be returned 
to us, along with the completed consent forms confirming you 
are happy for us to analyse these questionnaires and samples. 
 
If you and your child agree, your child would also undertake an 
intelligence test called Weschler Intelligence Scale for Children 
(Fourth UK Edition (WISC-IVuk) . and sections from the 
Neuropsychological Assessment Second Edition.  Our research 
assistant will arrange an appointment to visit your home. The 
test usually takes about 1-1½ hours and would generate an IQ 
score, which would represent your child’s intelligence.  You can 
of course be present during the test, but some children do not 
perform as well if their parents are there as they are distracted.  
You will be able to have a copy of the report if you wish. 
 
8. Expenses and payments 
 
There should not be any expense incurred by you since we have 
provided envelopes with the postage paid for you to return the 
samples and questionnaires. 
 
9. What do I have to do? 
1.  Complete the questionnaires in your own time.  
There are 4 of  these labelled: 
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 ADHD, this provides information about your child’s 
social behaviour. 
 SCQ, this provides information about your child’s 
activity level. 
 SDQ, this indicates how your child is progressing. 
 General, this contains information which is useful to 
us about you and your child. 
3. Use the kits provided to obtain urine sample and saliva or 
a sample from the inside of your and your child’s mouth. 
There are instructions in the box but please contact us on 
02920 745457, if you need more information. We will use 
the samples to obtain DNA to look for variations in the 
genes which influence the different aspects that we will 
measure in the study. If you need more information, you 
may contact Professor Marian Ludgate (02920 745457) or 
Dr Aled Rees (02920 745002).   
4. Please return all completed questionnaires, samples and 
signed consent forms in the stamped addressed containers 
provided. Or if you have agreed, give these to the research 
assistant who visits your home to conduct the IQ test on your 
child. 
5. If you and your child have agreed to the IQ test, if possible 
please make a quiet space available with a table, but don’t 
worry if this is difficult. 
 
 
10. What are the alternatives for diagnosis or treatment?  
 
At present, the thyroid function of women who are pregnant is 
not tested at all. Our studies will help to decide whether it is 
advisable for this to be done, either because of benefits to the 
child, the mother or both. 
 
11.  What are the possible disadvantages and risks of taking 
part? 
No side effects are anticipated from the study procedures.  
12. What are the side effects of any treatment received when 
taking part? 
 
The new study (CATS II) does not involve you taking any 
medication or receiving any treatment. In CATS I, you may 
have received tablets containing thyroid hormone which is 
exactly the same as produced naturally by your thyroid and so 
does not have any side effects.  
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13. Exposure to radiation or ionising radiation 
None. 
14. Harm to the unborn child 
None of the investigations to be performed have any negative 
effect on an unborn child or will affect you or your child if you 
are breast feeding.  
15. What are the potential benefits of taking part? 
We cannot promise the study will help you but the information 
we get from this study will help improve the future care of 
pregnant women with consequent benefit to their children. 
16. What happens when the research study stops? 
Since no treatment is involved, there are no special 
considerations to take into account. However, with your 
permission, we will store samples and this is explained in part 
2. 
17. What if something goes wrong? 
Any complaint about the way you have been dealt with during 
the study or any possible harm you might suffer will be 
addressed. The detailed information on this is given in Part 2.  
18. Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information 
about you will be handled in confidence. The details are included 
in Part 2.  
 
This completes Part 1.  
If the information in Part 1 has interested you and you 
are considering participation, please read the additional 
information in Part 2 before making any decision.  
 
PART 2 
1. What if relevant new information becomes available? 
Sometimes we get new information about treatments, in this 
case we are measuring the effects of treatment you may have 
received when you were pregnant and not during this new 
study.   
2. What will happen if I don’t want to carry on with the study? 
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If you withdraw from the study, with your permission, we will 
keep any samples, and use any data collected up to your 
withdrawal. A decision to withdraw at any time will not affect 
the standard of care you receive.   
Similarly in the event of your loss of capacity, with your 
permission, we will keep any samples, and use any data 
collected prior to this. 
3. What if there is a problem? 
If you have a concern about any aspect of this study, you should 
ask to speak to the researchers who will do their best to answer 
your questions (phone 02920 745457 or 02920 745002).  This 
study is being indemnified by Cardiff University. If you are 
harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated during the course of 
this study, the normal National Health Service complaints 
mechanisms should be available to you.  
4. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course 
of the research will be kept strictly confidential. No personally 
identifiable information will be held on NHS or University 
computers although storage of study data on both systems will 
occur in an anonymised form. These computers are held by 
Professor Ludgate, Dr Rees and other members of the study 
team and are stored in locked rooms (rooms 254 & 261, 2nd 
Floor C block, University Hospital of Wales). The computers are 
password protected and no identifiable data will be transferred 
electronically, though final analysis of the anonymised study 
data may require email transfer to Professor Newcombe in the 
Department of Primary Care and Public Health who may provide 
statistical advice.  
5. Involvement of your general practitioner/family doctor 
With your permission your GP will be informed of your 
participation in this study.  
6. What will happen to any samples I give? 
The urine and DNA samples for this study will be collected and 
stored securely for later analysis in the Centre for Endocrine and 
Diabetes Sciences at the University Hospital of Wales. Only 
immediate members of the research team will have access to 
these samples.  
With your permission, we also plan to test the samples we 
collected during CATS 1.  
It is most likely that the samples will be destroyed (by 
incineration) at the end of the study, in this case, all identifiable 
information will be removed. Should we decide to store the 
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samples, we will apply for additional Research Ethics Committee 
approval before CATS II is complete and request your 
permission. 
7. Will any genetic tests be done? 
With your permission, we will obtain mouth swabs from you 
and/or your child to test genes involved in controlling the 
production of thyroid hormone. Because changes in genes can 
be inherited, if you are discovered to have such a change it is 
possible that other members of your family might also be 
affected. We will therefore ask for your permission to contact 
your immediate family members (parents, brothers/sisters, and 
children) to see whether they also wish to be tested.  
8. What will happen to the results of the research study? 
The results of the research study will be prepared for publication 
in appropriate medical journals together with presentation at 
medical conferences. People participating in the study will be 
able to obtain a copy of the results after they have been 
published in the relevant journal(s). Participants will not be 
identified in any report/publication.  
We will also organise a meeting at the end of the study to let 
you know about the results. 
9. Who is organising and funding the research?  
The study is being organised by Professor Marian Ludgate, Dr 
Aled Rees, Professor John Gregory and Professor John Lazarus 
from the Centre for Endocrine and Diabetes Sciences at the 
University Hospital of Wales. Funding for the study is provided 
by the Charles Wolfson Charitable Trust. The doctors conducting 
the research are not being paid for including and looking after 
women and children in the study. 
10. Who has reviewed the study? 
The Cardiff & Vale University Health Board Research & 
Development Office and by the South East Wales Research 
Ethics Committee 
11.  Future studies 
It is possible that further research may be carried out related 
to the CATS studies.  If this happens, we may contact you again 
at some time in the future to ask if you would be prepared to 
be involved in future studies. 
12. Further information and contact details 
 
Should you have any further queries regarding this research 
study, then please do not hesitate to contact us on 02920 
745457 or 02920 5002. You can also contact us via e-mail on 
ludgate@cf.ac.uk or reesda@cf.ac.uk  
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Thank you for considering taking part in this study.  
 
  
268 
 
c. Information for the child 
 
 
Child Information Sheet,  V6, 1 April 2014 (Remote ) 
 
 
Study title  
 
Testing how the thyroid gland affects the growth and health of mothers and their 
children. 
 
What is research? Why is this project being done?  
 
Research is a way we try to find out the answers to questions. When your 
mother was expecting you she took part in some tests and may have taken 
some medicine until you were born. You might remember that when you were 3, 
you did some puzzles for us in your house. Now that you are growing up, we 
would like you to help us find out more. We want to look at how much fat and 
muscle there is in your body, and how a gland in your neck called the thyroid 
gland can affect this.  
 
Why have I been asked to take part?  
 
There is nothing wrong with you, and everybody has this gland, but you have 
been specially chosen because your mother was tested before.  
Did anyone else check the study is OK to do?  
 
Before any research is allowed to happen, it has to be checked by a group of 
people called a Research Ethics Committee. They make sure that the research is 
fair. Your project has been checked by the South East Wales Research Ethics 
Committee.  
 
Do I have to take part?  
 
You do not have to take part, it is completely your choice. Even if you do decide 
to join in you do not have to have all of the tests if you prefer not to. 
 
What will happen to me if I take part in the research?  
 
You and your mother prefer to help us from home. Your mother will complete 
some forms explaining how you are getting on in school and with your friends. 
We will also ask you to scrape the inside of your cheek with a special stick (it 
won’t hurt) or spit into a tube. We will use this to find out whether you have 
inherited anything from your mum which alters how your thyroid works.  We will 
also ask you for a urine sample.  
 
If you and your mother agree, we would also like for you to take part in a test 
that will take about 1-1½ hours, which will check your learning and 
concentration.  The test will involve puzzles, answering questions and 
remembering certain things.   
 
Might anything about the research upset me?  
 
269 
 
None of the tests will hurt at all.  
 
Will joining in help me?  
 
We cannot promise the study will help you but the information we get might help 
treat mothers who have a problem with their thyroid, especially when they are 
pregnant, and their children. 
 
What happens when the research stops? 
 
The study does not involve you taking any medicine so there will be no change for 
you. 
 
What if something goes wrong during the project? 
 
This is very unlikely since we are doing tests to find out if medicine your mother may 
have taken before is having an effect. 
 
Will my medical details be kept private if I take part? Will anyone else know 
I’m doing this? 
 
Only the doctors involved in the study will know about you taking part. 
 
What if I don’t want to do the research anymore?  
 
If at any time you don‘t want to do any of the tests, just tell your parents, doctor or 
nurse. They will not be cross with you.  
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d. Copy of consent form 
Participant Consent Form: Involvement in Controlled Antenatal Thyroid 
Screening II (CATS 2) Study,  V7, 1 April 2014 (Remote participants) 
Name of Study: CATS 2 
Researchers: Dr Marian Ludgate, Dr Aled Rees, Professor John Gregory, 
Professor John Lazarus 
I, (full name)……………………………………………………….     Date of Birth………………….…... 
(address)…………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………………… 
as the mother of……………………………………………………………(full name of child)   
agree to myself       and/or my child       being involved in the above study.  
I have read the accompanying information leaflet and understand that 
involvement in the study is voluntary, and that non-involvement in the study will 
not affect the medical treatment of me or my child in any way, and that I will be 
free to withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.  
The data will be analysed in accordance with the study protocol and remain 
confidential. I understand that if any abnormality is discovered in the tests 
carried out that I will be informed of this and I will be directed to the appropriate 
clinical services.  
The aspects of the study that I specifically agree to participate in are (please 
initial):  
collection of my child ’s DNA from a mouth swab or from saliva sample to 
test for variations within genes that affect the different aspects that we 
will measure in the study.  After testing the sample will probably be 
destroyed but it is possible that they may be used in a related project.   
collection of my DNA from a mouth swab or saliva sample to test for 
variations within genes that affect the different aspects that we will 
measure in the study.  After testing the sample will probably be destroyed 
but it is possible that they may be used in a related project.   
Collection of my urine sample. 
Collection of a urine sample from my child. 
I give permission for the study team to contact my immediate family 
members (parents, brothers/sisters, children) to see whether they also 
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wish to have mouth testing carried out to test genes involved in 
controlling the production of thyroid hormone. 
 My completion of the Strengths and Difficulties, ADHD & SCQ 
Questionnaires with respect to my child and the Edinburgh Postnatal 
Depression Scale with respect to myself; 
I give my permission for my child to take part in the Weschler Intelligence 
Scale for children (this will involve 1-1½ hour test) and sections from the 
Neuropsychological Assessment Second Edition.   
In the event of my loss of capacity, I give you my consent to retain and 
use the samples and data you have collected from me. 
I give my consent for you to inform my GP of my participation in the 
study. 
  I am happy for my contact details to be retained by Cardiff University 
Research Team to  consider whether I would be suitable to take part in any 
future related studies and am  happy to be contacted about such studies. 
 
 
____________________ ______________ ____________________ 
Name of participant   Date   Signature 
 
___________________ _____________ ____________________ 
Researcher    Date   Signature 
___________________ _____________ ____________________ 
Name of person taking consent Date   Signature 
(if different from researcher) 
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2. Research centre visit 
a. Cover letter 
 
Department of Medicine 
 
Dear >>NAME<<, 
Further to your telephone conversation with my colleague, thank you for agreeing to 
take part in the CATS II Study.  We would be grateful if you and your 
>>SON/DAUGHTER<< could attend the Clinical Research Facility at the University 
Hospital of Wales on >>DATE AND TIME OF APPOINTMENT<<, a map with directions to 
the Clinical Research Facility is enclosed. 
 
Please could we remind you that it is important that you attend having fasted since 
the night before.  You can drink as much water as you like and we will provide 
breakfast as soon as possible after you arrive. 
 
If you have any queries, please do not hesitate to contact us one of our dedicated 
CATS mobiles: 07908 243142 or  07866 980039. 
Yours sincerely, 
 
 
 
Dr Aled Rees 
Senior Lecturer and Honorary Consultant 
Centre for Endocrine & Diabetes Sciences 
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b. Information for the mother 
PARTICIPANT INFORMATION LEAFLET (UHW attenders) 
V5, 1 April 2014 
 
PART 1  
 
1. Title of study 
Controlled Antenatal Thyroid Screening Study II (CATS 2) 
 
2. Introduction 
Thank you for taking the time to read this leaflet. You have indicated 
that you are prepared to take part in the CATS 2 study. Before you 
confirm that you wish to become involved it is important that you 
understand why the research is being done and what it will involve. One 
of our team will go through the information sheet with you and answer 
any questions you have, this should take about 5 minutes. Please take 
time to read the following information carefully and discuss it with others 
if you wish. 
Part 1 reminds you of the purpose of this study and what will happen if 
you take part. 
Part 2 gives you more detailed information about the conduct of the 
study. 
Please do not hesitate to ask us if there is anything that is not clear or 
if you would like more information.  
Take time to consider whether or not you still wish to take part. 
3. What is the purpose of this study? 
Following on from your participation in the original CATS study, scientists 
and doctors at the University Hospital of Wales are hoping to arrange 
further studies to investigate how thyroid hormone levels during 
pregnancy may affect the development of the proportions of fat, muscle 
and general development in a child.  They will assess your child’s abilities 
in a range of areas, such as verbal and non-verbal skills, memory and 
speed of processing with an IQ test.  They will also investigate whether 
there is any effect on fat and bone development in the mother and/or 
any influence on their general wellbeing.  
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4. Why have I been chosen?  
 
It is only those involved in the previous study that will be able to help 
us with our ongoing investigations.  We really appreciated your 
involvement in the CATS 1 study on thyroid hormone levels in 
pregnancy, and how variations in this might affect your child. The results 
of this study should be available later this year and will prove useful in 
understanding these effects and help to improve the care of pregnant 
women and their children. 
5. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you choose not 
to take part, that is fine by us, you do not have to give us reasons why 
and this decision will not have any implications for your future medical 
care. If you decide to take part you will be asked to sign a consent form. 
You are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive.   
 
6. What will happen to me if I take part? 
As you and your child have opted to attend the University Hospital of 
Wales (UHW) this will involve some or all (depending on your wishes) of 
the following tests and could take most of the morning: 
 
 1) Measure height and weight in you and your child. 
2) Measure blood pressure and assess the blood flow in the 
blood vessels of you and your child’s arm with a probe put 
on the skin in you and your child. 
3) Complete questionnaires with you about your mood and 
your child’s social and educational development and 
progress. 
4) Perform a DEXA scan to measure the proportion of fat and 
muscle in you (providing you are not pregnant at the time) 
and your child (this would involve lying still on the scan 
table for a minute or two whilst the scan is performed and 
does not hurt).  DEXA is a simple, rapid and non-invasive 
technique which is used routinely in clinical practice to 
measure bone density.  This scan does involve exposure 
to a small amount of radiation (no more than experienced 
during a day walking around outside in the UK) but the 
risk is negligible. 
5) Take a blood sample from you and your child (about 6 
teaspoons), to measure thyroid hormone levels, aspects 
of the control of bone and fat tissues and variations in the 
genes which influence the different aspects that we will 
measure in the study.  Some of the tests need for you and 
your child to have fasted since the night before; we will 
provide breakfast as soon as possible after you arrive.  If 
you or your child prefers not to have a blood test we would 
still like to take saliva samples or mouth swabs for genetic 
studies. 
6. For your child to undertake an intelligence test called 
Weschler   Intelligence Scale for Children (Fourth UK 
Edition (WISC-IVuk) and sections from the 
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Neuropsychological Assessment Second Edition..  This 
usually takes about 1-1½ hours and would generate an IQ 
score, which would represent your child’s intelligence.  
You can of course be present during the test, but some 
children do not perform as well if their parents are there 
as they are distracted.  You will be able to have a copy of 
the report if you wish. 
7. Ask you and your child to provide a urine sample. 
 
7. Expenses and payments  
 
If you wish, we will be able to reimburse any traveling expenses/car 
parking fees incurred while attending for the study visit.  
 
8. What do I have to do?  
 
Please decide which of the tests (if any) you are willing to undertake. 
Please also discuss with your child which tests (if any) he/she is willing 
to undertake. Please feel free to ask for more information from the staff 
in CRF before signing the consent form indicating which tests you and 
your child will undertake. 
 
9. What are the alternatives for diagnosis or treatment?  
 
At present, the thyroid function of women who are pregnant is not tested 
at all. Our studies will help to decide whether it is advisable for this to 
be done, either because of benefits to the child, the mother or both. 
 
10.  What are the possible disadvantages and risks of taking part? 
Other than possible discomfort (temporary pain, swelling, bruising and 
rarely infection) caused by the collection of blood, no other side effects 
are anticipated from the study procedures. A DEXA scan does involve 
exposure to a small amount of radiation but the risk is negligible. It is 
possible that the blood tests or DEXA scan could by chance pick up an 
unsuspected abnormality, in which case you will be given an opportunity 
to discuss these findings further with the doctors.  
These investigations will only be performed once we have explained in 
detail what will be involved, you have given us your consent and your 
child has agreed to take part. You or your child may decide to undergo 
some but not all of the tests. It is possible that you decide to participate 
but your child prefers not too, or vice versa. 
 
11. What are the side effects of any treatment received when taking 
part? 
 
The new study (CATS II) does not involve you taking any medication or 
receiving any treatment. In CATS I, you may have received tablets 
containing thyroid hormone which is exactly the same as produced 
naturally by your thyroid and so does not have any side effects.  
 
12. Exposure to radiation or ionising radiation 
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As mentioned above, you and/or your child may agree to have a DEXA 
scan. This involves exposure to a small amount of radiation but no more 
than experienced walking around outside for 1 day in the UK. 
13. Harm to the unborn child 
None of the investigations to be performed have any negative effect on 
an unborn child EXCEPT the DEXA scan. With your permission, we will 
perform a pregnancy test and if you it is positive you will not receive the 
DEXA scan. None of the investigations will affect you or your child if you 
are breast feeding.  
14. What are the potential benefits of taking part? 
We cannot promise the study will help you but the information we get 
from this study will help improve the future care of pregnant women 
with consequent benefit to their children. 
15. What happens when the research study stops? 
Since no treatment is involved, there are no special considerations to 
take into account. However, with your permission, we will store samples 
and this is explained in part 2. 
16. What if something goes wrong? 
Any complaint about the way you have been dealt with during the study 
or any possible harm you might suffer will be addressed. The detailed 
information on this is given in Part 2.  
17. Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about 
you will be handled in confidence. The details are included in Part 2.  
 
This completes Part 1.  
 
If the information in Part 1 has interested you and you are 
considering participation, please read the additional information 
in Part 2 before making any decision.  
 
PART 2 
1. What if relevant new information becomes available? 
Sometimes we get new information about treatments, in this case we 
are measuring the effects of treatment you may have received when you 
were pregnant and not during this new study.   
2. What will happen if I don’t want to carry on with the study? 
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If you withdraw from the study, with your permission, we will keep any 
samples, and use any data collected up to your withdrawal. A decision 
to withdraw at any time will not affect the standard of care you receive.   
Similarly in the event of your loss of capacity, with your permission, we 
will keep any samples, and use any data collected prior to this. 
3. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions 
(phone 02920 745457 or 02920 745002).  This study is being 
indemnified by Cardiff University. If you are harmed by taking part in 
this research project, there are no special compensation arrangements. 
If you are harmed due to someone’s negligence, then you may have 
grounds for a legal action but you may have to pay for it. Regardless of 
this, if you wish to complain, or have any concerns about any aspect of 
the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms 
should be available to you.  
4. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the 
research will be kept strictly confidential. No personally identifiable 
information will be held on NHS or University computers although 
storage of study data on both systems will occur in an anonymised form. 
These computers are held by Professor Ludgate, Dr Rees and other 
members of the study team and are stored in locked rooms (rooms 254 
& 261, 2nd Floor C block, University Hospital of Wales). The computers 
are password protected and no identifiable data will be transferred 
electronically, though final analysis of the anonymised study data may 
require email transfer to Professor Newcombe in the Department of 
Primary Care and Public Health who may provide statistical advice.  
5. Involvement of your general practitioner/family doctor 
With your permission your GP will be informed of your participation in 
this study.  
 
6. What will happen to any samples I give? 
The blood and urine samples (6 teaspoons) for this study will be collected 
and stored securely for later analysis in the Centre for Endocrine and 
Diabetes Sciences at the University Hospital of Wales. Only immediate 
members of the research team will have access to these samples.  
With your permission, we also plan to test the samples we collected 
during CATS I. 
It is most likely that the samples will be destroyed (by incineration) at 
the end of the study, in this case, all identifiable information will be 
removed. Should we decide to store the samples, we will apply for 
additional Research Ethics Committee approval before CATS II is 
complete and request your permission. 
7. Will any genetic tests be done? 
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With your permission, we will obtain blood samples, saliva or mouth 
swabs from you and/or your child to test genes involved in controlling 
the production of thyroid hormone. Because changes in genes can be 
inherited, if you are discovered to have such a change it is possible that 
other members of your family might also be affected. We will therefore 
ask for your permission to contact your immediate family members 
(parents, brothers/sisters, children) to see whether they also wish to be 
tested.  
 
8. What will happen to the results of the research study? 
The results of the research study will be prepared for publication in 
appropriate medical journals together with presentation at medical 
conferences. People participating in the study will be able to obtain a 
copy of the results after they have been published in the relevant 
journal(s). Participants will not be identified in any report/publication.  
We will also organise a meeting at the end of the study to let you know 
about the results. 
 
9. Who is organising and funding the research?  
The study is being organised by Professor Marian Ludgate, Dr Aled Rees, 
Professor John Gregory and Professor John Lazarus from the Centre for 
Endocrine and Diabetes Sciences at the University Hospital of Wales. 
Funding for the study is provided by the Charles Wolfson Charitable 
Trust. The doctors conducting the research are not being paid for 
including and looking after women and children in the study. 
10. Who has reviewed the study? 
The Cardiff & Vale University Health Board Research & Development 
Office and by the South East Wales Research Ethics Committee. 
11.  Future Studies 
It is possible that further research may be carried out related to the CATS 
studies.  If this happens, we may contact you again at some time in the 
future to ask if you would be prepared to be involved in future studies. 
 
12. Further information and contact details 
Should you have any further queries regarding this research study, then 
please do not hesitate to contact us on 02920 745457 or 02920 5002. 
You can also contact us via e-mail on ludgate@cf.ac.uk or 
reesda@cf.ac.uk  
 
Thank you for considering taking part in this study. 
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c. Information for the child 
Department of Medicine 
 
Child Information Sheet,  V5, 1 April 2014 (UHW attenders ) 
 
Study title  
Testing how the thyroid gland affects the growth and health of mothers and their 
children. 
 
What is research? Why is this project being done?  
Research is a way we try to find out the answers to questions. When your 
mother was expecting you she took part in some tests and may have taken 
some medicine until you were born. You might remember that when you were 3, 
you did some puzzles for us in your house. Now that you are growing up, we 
would like you to help us find out more. We want to look at how much fat and 
muscle there is in your body, and how a gland in your neck called the thyroid 
gland can affect this.  
 
Why have I been asked to take part?  
There is nothing wrong with you, and everybody has this gland, but you have 
been specially chosen because your mother was tested before.  
Did anyone else check the study is OK to do?  
Before any research is allowed to happen, it has to be checked by a group of 
people called a Research Ethics Committee. They make sure that the research is 
fair. Your project has been checked by the South East Wales Research Ethics 
Committee.  
 
Do I have to take part?  
You do not have to take part, it is completely your choice. Even if you do decide 
to join in you do not have to have all of the tests if you prefer not to. 
 
What will happen to me if I take part in the research?  
If you agree to come to the hospital with your mother to have some tests, it will 
take all morning and you may miss school. On the day that you come for the 
tests, you should not have breakfast because we will provide that for you. You 
will have the same tests as your mother. We will see how much you weigh, 
check how tall you are, and measure your heart beat.  We will ask you for a 
urine sample.  We will also ask your mother some questions about you. We will 
also take a picture of you with a special camera, to see how much bone and 
muscle you have and give you a copy to show your friends. Also, if you will let 
us, and your parents say it is OK, we will take a small amount of blood (about 6 
teaspoonfuls) to see how the gland in your neck is working. If you don’t want a 
blood test we will ask for a scrape from inside your cheek (it won’t hurt) or ask 
you to spit into a tube. We will use this to find out whether you have inherited 
anything from your mum which alters how your thyroid works. 
We would also like for you to take part in a test that will take about 1-1½ 
hours, which will check your learning and concentration.  The test will involve 
puzzles, answering questions and remembering certain things.   
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Might anything about the research upset me?  
Most of the tests will not hurt at all. If you agree for us to take some blood, to 
prevent this from hurting, we can put some special cream on your skin before the 
blood test which helps to stop you from feeling it.  
Will joining in help me?  
We cannot promise the study will help you but the information we get might help 
treat mothers who have a problem with their thyroid, especially when they are 
pregnant, and their children. 
 
What happens when the research stops? 
The study does not involve you taking any medicine so there will be no change for 
you. 
 
What if something goes wrong during the project? 
This is very unlikely since we are doing tests to find out if medicine your mother may 
have taken before is having an effect. 
 
Will my medical details be kept private if I take part? Will anyone else know 
I’m doing this? 
Only the doctors involved in the study will know about you taking part. 
 
What if I don’t want to do the research anymore? 
If at any time you don‘t want to do any of the tests, just tell your parents, doctor 
or nurse.  They will not be cross with you. 
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d. Copy of the consent form 
 
Participant Consent Form: Involvement in Controlled Antenatal Thyroid 
Screening II (CATS 2) Study. V6,  1 April 2014, (UHW attenders) 
Name of Study: CATS 2 
Researchers: Dr Marian Ludgate, Dr Aled Rees, Professor John Gregory, 
Professor John Lazarus 
I, (full name)……………………………………………………Date of Birth…….…………... 
(address)………………………………………………………………………………………… 
as the mother of……………………………………………………………(full name of child)   
agree to myself        and/or my child       being involved in the above study.  
I have read the accompanying information leaflet and understand that 
involvement in the study is voluntary, and that non-involvement in the study will 
not affect the medical treatment of me or my child in any way, and that I will be 
free to withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.  
The data will be analysed in accordance with the study protocol and remain 
confidential. I understand that if any abnormality is discovered in the tests 
carried out that I will be informed of this and I will be directed to the appropriate 
clinical services.  
The aspects of the study that I specifically agree to participate in are (please 
initial):  
 
 measurement of my child’s height, weight and hip/waist circumference; 
  
 measurement of my height, weight and waist/hip circumference; 
  
 measurement of my child’s blood pressure, heart rate and blood flow  
 (involves being attached to a machine but does not hurt); 
  
 measurement of my blood pressure, heart rate and blood flow; 
  
 measurement of my child’s proportion of fat, bone and muscle by DEXA scan 
 (Involves lying flat on a scan table for a few minutes and does not hurt); 
  
 measurement of my proportion of fat, bone and muscle by DEXA scan 
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 (providing I am not pregnant); 
  
 pregnancy test; 
  
 for me to provide a urine sample 
  
for my child to provide a urine sample 
  
 blood sampling  (6 teaspoons) for collection of my child’s DNA to test for genes, 
and variations within genes that affect the different aspects that we will measure 
in the study.  After testing the sample will probably be destroyed but it is possible 
that they may be used in a related project.  I also agree that the blood may be 
tested for the functioning of the thyroid gland, for salts in the blood, and for lipids 
and cholesterol; 
 
 
 blood sampling  (6 teaspoons) for collection of my DNA to test for genes and 
variations  within genes that affect the different aspects that we will measure in the 
study, and nothing else.  After testing the sample will be destroyed.  I also agree 
that the blood may be tested for the functioning of the thyroid gland, for salts in the 
blood, and for lipids and cholesterol; 
 
 collection of my DNA from a mouth swab or saliva sample to test for genes and 
variations within genes that affect the development of the thyroid gland and the 
production of thyroid hormones, and nothing else.  After testing the sample will be 
destroyed; 
 
 
 I give permission for the study team to contact my immediate family members 
(parents, brothers/sisters, children) to see whether they also wish to have mouth 
testing carried out to test genes involved in controlling the production of thyroid 
hormone. 
 
 collection of my child’s DNA from a mouth swab or saliva sample to test for genes 
and variations within genes that affect the development of the thyroid gland and the 
production of thyroid hormones, and nothing else.  After testing the sample will be 
destroyed; 
my completion of the Strengths and Difficulties, ADHD & ADI Questionnaires 
with respect to my child and the Edinburgh Postnatal Depression Scale with respect 
to myself; 
 
  
 I give permission for my child to take part in the Weschler Intelligence Scale for  
 Children and sections from the Neuropsychological Assessment Second Edition. 
 (this will involve 1-1½ hour test) 
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 I give my consent for you to inform my GP of my participation in the study. 
  
 In the event of my loss of capacity, I give you my consent to retain and use  
the samples and data you have collected from me.   
  
 I am happy for my contact details to be retained by the Cardiff University 
 Research Team to consider whether I would be suitable to take part in any future 
related studies and am happy to be contacted about such studies 
 
 
 
___________________ _____________ ____________________ 
Name of participant   Date    Signature 
 
____________________ _____________ ____________________ 
Researcher    Date    Signature 
 
____________________ _____________ ____________________ 
Name of person taking consent Date    Signature 
(if different from researcher) 
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Appendix 7: Behavioural questionnaires, additional regression models 
1. Strengths and difficulties, emotion 
2. ADHD, overactivity 
3. ADHD, impulsivity 
4. Social communication questionnaire 
 
Tables are only displayed for significant interactions.  
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1. Strength and difficulties, emotion 
 
 
Table A1 
Linear Regression Model Fitting Information for the Strengths 
and Difficulties Questionnaire Emotion Above the ‘High’ 
Classification 
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
397.687 
   
Final 381.540 16.147 7 .024 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
Table A2 
Main Output from Multinomial Logistic Regression, Strengths and Difficulties 
Questionnaire (SDQ) Emotion Above the ‘High’ Classification 
SDQ emotion ≤ High B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept 1.806 1.760 1.053 1 .305    
Child Gender -.416 .264 2.478 1 .115 .660 .393 1.107 
Child Age -.037 .174 .044 1 .833 .964 .685 1.357 
Breast Fed .273 .273 1.007 1 .316 1.315 .771 2.243 
Mother Age .087 .128 .460 1 .498 1.090 .849 1.400 
Social Deprivation .259 .092 7.904 1 .005* 1.296 1.082 1.553 
[Normal GTF] -.465 .354 1.727 1 .189 .628 .314 1.257 
[Treated SGTF] -.459 .398 1.325 1 .250 .632 .290 1.380 
[Untreated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ High. *Significance < .05. B=beta, df=degrees 
of freedom, SGTF=suboptimal gestational thyroid function. 
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Table B1 
Linear Regression Model Fitting Information for the Strengths 
and Difficulties Questionnaire Emotion Above the ‘High’ 
Classification 
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
318.075 
   
Final 298.795 19.280 6 .004 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
Table B2 
Main Output from Multinomial Logistic Regression, Strengths and Difficulties 
Questionnaire (SDQ) Emotion Above the ‘High’ Classification 
SDQ emotion ≤ High B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept 2.953 2.016 2.145 1 .143    
Child Gender -.700 .303 5.333 1 .021 .497 .274 .899 
Child Age -.180 .204 .778 1 .378 .836 .561 1.245 
Breast Fed .287 .304 .890 1 .345 1.332 .734 2.416 
Mother Age .058 .142 .166 1 .683 1.060 .802 1.400 
Social Deprivation .330 .104 10.055 1 .002* 1.390 1.134 1.705 
[Normal GTF] .050 .318 .025 1 .874 1.052 .563 1.963 
[Treated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ High. *Significance < .05. B=beta, df=degrees 
of freedom, SGTF=suboptimal gestational thyroid function. 
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2. ADHD, overactivity 
 
 
Table C1 
Linear Regression Model Fitting Information for the Child 
Attention Deficit Hyperactivity Questionnaire, Overactivity 
Domain above one Standard Deviation  
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
332.589 
   
Final 305.344 27.245 6 .000 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
 
Table C2 
Main Output from Multinomial Logistic Regression, Child Attention Deficit Hyperactivity 
(ADHD) Questionnaire, Overactivity Domain above one Standard Deviation (SD) 
ADHD Overactivity ≤ 1 SD B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept -5.257 1.902 7.637 1 .006    
Child Gender .774 .301 6.621 1 .010* 2.168 1.203 3.910 
Child Age .457 .190 5.793 1 .016 1.579 1.088 2.289 
Breast Fed .296 .300 .974 1 .324 1.345 .747 2.422 
Mother Age .100 .142 .494 1 .482 1.105 .837 1.458 
Social Deprivation .144 .103 1.966 1 .161 1.155 .944 1.412 
[Normal GTF] .707 .295 5.737 1 .017* 2.027 1.137 3.615 
[Treated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ 1 SD. *Significance < .05. B=beta, df=degrees 
of freedom, SGTF=suboptimal gestational thyroid function. 
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Table D1 
Linear Regression Model Fitting Information for the Child 
Attention Deficit Hyperactivity Questionnaire, Overactivity 
Domain above one Standard Deviation  
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
448.405 
   
Final 413.029 35.377 7 .000 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
 
Table D2 
Main Output from Multinomial Logistic Regression, Child Attention Deficit Hyperactivity 
(ADHD) Questionnaire, Overactivity Domain above one Standard Deviation (SD) 
ADHD Overactivity ≤ 1 SD B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept -4.512 1.614 7.809 1 .005    
Child Gender .755 .251 9.073 1 .003* 2.128 1.302 3.478 
Child Age .379 .157 5.810 1 .016* 1.461 1.073 1.990 
Breast Fed .374 .256 2.141 1 .143 1.454 .881 2.401 
Mother Age .111 .121 .841 1 .359 1.117 .882 1.416 
Social Deprivation .168 .087 3.775 1 .052 1.184 .999 1.403 
[Normal GTF] .567 .306 3.418 1 .064 1.762 .966 3.213 
[Treated SGTF] -.155 .323 .230 1 .632 .856 .454 1.614 
[Untreated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ 1 SD. *Significance < .05. B=beta, df=degrees 
of freedom, SGTF=suboptimal gestational thyroid function. 
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3. ADHD, Impulsivity 
 
 
Table E1 
Linear Regression Model Fitting Information for the Child 
Attention Deficit Hyperactivity Questionnaire, Impulsivity 
Domain above one Standard Deviation  
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
319.575 
   
Final 296.949 22.626 7 .002 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
 
Table E2 
Main Output from Multinomial Logistic Regression, Child Attention Deficit 
Hyperactivity (ADHD) Questionnaire, Impulsivity Domain above one Standard 
Deviation (SD) 
ADHD Impulsivity ≤ 1 (SD) B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept -1.484 1.964 .571 1 .450    
Child Gender .258 .305 .713 1 .398 1.294 .712 2.353 
Child Age .223 .194 1.321 1 .250 1.250 .854 1.828 
Breast Fed .718 .315 5.195 1 .023* 2.051 1.106 3.804 
Mother Age .302 .154 3.851 1 .050* 1.353 1.000 1.830 
Social Deprivation .053 .106 .248 1 .619 1.054 .856 1.299 
[Normal GTF] .094 .407 .053 1 .817 1.098 .495 2.438 
[Treated SGTF] -.652 .412 2.505 1 .113 .521 .232 1.168 
[Untreated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ 1 SD. *Significance < .05. B=beta, 
df=degrees of freedom, SGTF=suboptimal gestational thyroid function. 
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Table F1 
Linear Regression Model Fitting Information for the Child 
Attention Deficit Hyperactivity Questionnaire, Impulsivity 
Domain above one Standard Deviation  
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
250.467 
   
Final 229.956 20.512 6 .002 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
  
 
Table F2 
Main Output from Multinomial Logistic Regression, Child Attention Deficit Hyperactivity 
(ADHD) Questionnaire, Impulsivity Domain above one Standard Deviation (SD) 
ADHD Impulsivity ≤ 1 (SD) B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept -2.305 2.262 1.039 1 .308    
Child Gender .186 .350 .283 1 .595 1.204 .607 2.391 
Child Age .255 .228 1.247 1 .264 1.291 .825 2.019 
Breast Fed .761 .354 4.625 1 .032* 2.140 1.070 4.282 
Mother Age .369 .175 4.440 1 .035* 1.447 1.026 2.040 
Social Deprivation .003 .122 .000 1 .982 1.003 .789 1.275 
[Normal GTF] .723 .348 4.311 1 .038* 2.060 1.041 4.075 
[Treated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ 1 SD. *Significance < .05. B=beta, df=degrees 
of freedom, SGTF=suboptimal gestational thyroid function. 
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4. Social communication questionnaire  
 
 
Table G1 
Linear Regression Model Fitting Information for the Social 
Communication Questionnaires, scores above cut off ≥15 
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
94.879 
   
Final 86.702 8.177 6 .225 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
 
Table G2 
Main Output from Multinomial Logistic Regression, the Social Communication 
Questionnaires (SCQ), scores above cut off ≥15 
SCQ ≤ 15 B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept .425 4.105 .011 1 .917    
Child Gender .517 .661 .611 1 .434 1.677 .459 6.125 
Child Age .106 .412 .067 1 .796 1.112 .496 2.491 
Breast Fed -.307 .676 .207 1 .650 .736 .196 2.766 
Mother Age -.220 .308 .513 1 .474 .802 .439 1.466 
Social Deprivation .368 .213 2.979 1 .084 1.446 .951 2.196 
[Normal GTF] 1.419 .657 4.665 1 .031* 4.132 1.140 14.974 
[Treated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ 15. *Significance < .05. B=beta, df=degrees of 
freedom, SGTF=suboptimal gestational thyroid function. 
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Table H1 
Linear Regression Model Fitting Information for the Social 
Communication Questionnaires, scores above cut off ≥15 
Model Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-Square df Sig. 
Intercept 
Only 
107.875 
   
Final 96.758 11.117 7 .134 
Note. See improved figure of -2 log likehood. Df=degrees of 
freedom.  
 
 
 
Table H2 
Main Output from Multinomial Logistic Regression, the Social Communication 
Questionnaires (SCQ), scores above cut off ≥15 
SCQ ≤ 15 B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for 
Exp(B) 
Lower 
Bound 
Upper 
Bound 
Intercept 2.917 4.201 .482 1 .488    
Child Gender .608 .637 .910 1 .340 1.837 .527 6.405 
Child Age .007 .408 .000 1 .986 1.007 .453 2.239 
Breast Fed -.147 .633 .054 1 .816 .863 .250 2.984 
Mother Age -.143 .296 .234 1 .629 .867 .486 1.547 
Social Deprivation .397 .205 3.764 1 .052 1.488 .996 2.222 
[Normal GTF] -.632 1.130 .313 1 .576 .532 .058 4.873 
[Treated SGTF] -2.032 1.090 3.475 1 .062 .131 .015 1.110 
[Untreated SGTF] 0 . . 0 . . . . 
Note. The reference category was scores ≥ 15. *Significance < .05. B=beta, df=degrees of 
freedom, SGTF=suboptimal gestational thyroid function. 
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Appendix 8: Revised CATS general questionnaire 
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CATS GENERAL QUESTIONNAIRE 
 
Please answer- 
Section A: MOTHER-   General information about you. 
Section B: MEDICAL- Medical history, please answer if you HAVE NOT attended 
the Heath Hospital for a morning. 
Section C: CHILD-   General information about your child in the study. 
Section A: MOTHER  
A1. Name  
A2. DOB  
A3. No. of pregnancies  
A4. No. of live children (with ages)  
A5. Education; pls tick all that apply None  GCSE or 
equivalent  
 A Level or equivalent  
Degree  Other (please 
specify) 
  
A6. Occupation (or details of last job)  
A7. Cigarette smoker (per day) pls 
tick 
Never  Present 0-10  10-20  20+  
A8. Ethnicity pls tick White  Asian  African  Other  
 
Section B: MEDICAL (please answer if you HAVE NOT attended the Heath Hospital for a morning) 
B1. Previous illnesses/pls give date: 
 
 
 
 
B2. Operations/pls give date: 
 
 
 
 
B3. Family history of thyroid disease? Yes/No  (pls delete as appropriate) 
B4. Previous thyroid hormone 
treatment/pls give date(s): 
 
B5. Current thyroid hormone 
treatment 
Yes/No    Dose: 
B6. Other current drug therapy 
 
Name Dose Date started 
   
   
   
   
   
B7. Other current illnesses 
 
 
 
 
B8. Other comments  
Please turn over 
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Section C: CHILD 
C1. Name  
C2. DOB  
C3. Sex  
C4. Birth weight  
C5. Gestational age Full term (37-40 
wks 
 Preterm (32-36 
wks) 
 Very Preterm 
(<32 weeks) 
 
C6. Mode of delivery Normal  Caesarean  
C7. Medical complications in pregnancy Diabetes Yes/No 
High BP Yes/No 
Pre-eclampsia Yes/No 
Anaemia Yes/No 
Other: 
C8. Breast fed for more than 1 mth Yes  No  
C9. Child’s handedness Right  Left  
C10. Language of school English  Welsh  
C11. Language spoken at home English  Welsh  Other  
C12. Child’s biological father’s 
occupation (if known) 
 
C13. Child’s biological father’s height (if 
known) 
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Appendix 9: Supplementary CATS I IQ statistics 
For the following statistics, with a 5% two-sided significance level and 80% power, a sample 
of 50 from both the treated and untreated SGTF groups allowed a detection of a difference 
of 7.5 IQ points in mean IQ; and with a Cohen’s d of 0.5 for the effect size. 
The following analyses address different ranges of T4 and TSH. All analyses were of 
continuous data and were multivariate with unadjusted and adjusted means presented; 
controlled for child gender, mother age at time of consent into CATS I, and social deprivation.  
Overt Hypothyroidism  
This analysis explored IQ results of children born to women who had abnormal T4 and TSH 
between those who were treated and untreated during their pregnancies; this was classified 
as any maternal T4 <2.5th percentile, and also having TSH >97.5th percentile. There were 37 
participants in this category (18 from the untreated SGTF group). More recent guidelines 
indicate that overt hypothyroidism should also be diagnosed if an individual presents a TSH 
> 10 mIU/L with normal T4 levels (1). Within the CATS I cohort, this occurred in five 
individuals, two from the untreated SGTF group.  
In total, with the above overt hypothyroidism classification, there were 22 from the treated 
SGTF group, and 20 from the untreated SGTF group populating this subgroup. CATS I IQs 
were compared to explore whether treatment for overt hypothyroidism had any impact on 
childhood cognition at age 3. Descriptive statistics are presented firstly (table 1) and means 
were compared for verbal, performance and full scale IQ by a MANOVA and MANCOVA to 
take account adjustments. 
Table 1 
Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK at Age 3 in the those classified as having Overt 
Hypothyroidism 
 CATS GROUP Adjusted Data* 
N Mean 
WPPSI Verbal IQ Treated SGTF 20 106.23 
(11.75) 
Untreated SGTF 22 108.10 
(14.43) 
WPPSI 
Performance IQ 
Treated SGTF 20 105.64 
(12.44) 
Untreated SGTF 22 108.25 
(13.39) 
WPPSI Full scale IQ Treated SGTF 20 106.91 
(11.96) 
Untreated SGTF 22 109.45 
(12.73) 
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Note. *Adjusted for child gender, mother age at time of consent into CATS I, 
and social deprivation quintile. Standard deviations appear in parentheses 
below means.  
 
The unadjusted MANOVA identified no significant results between the groups; ROY = .012, 
F (3, 38) = .157, p = .924, p2 = .012. The adjusted MANCOVA also identified no significant IQ 
results between the groups; ROY = .015, F (3, 35) = .178, p = .910, p2 = .015.  
From the results in this supplementary analysis, treatment of overt hypothyroidism was of 
no benefit to offspring IQ at age 3. Rates of miscarriage were explored in the treated and 
untreated SGTF groups, none were recorded; although 49 occurred in those with normal 
thyroid function during pregnancy.  
Subclinical hypothyroidism  
Within the CATS I UK cohort, there were a total of 267 mothers with subclinical 
hypothyroidism; T4 measurements at consent > 2.5th percentile and with a TSH > 97.5th 
percentile (untreated SGTF = 117, treated SGTF = 150). See table 2 for further descriptive 
details. 
Table 2 
Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK at Age 3 in the those classified as having 
Subclinical Hypothyroidism 
 CATS GROUP Adjusted Data* 
N Mean 
WPPSI Verbal IQ Treated SGTF 
150 
110.87 
(10.81) 
Untreated SGTF 
116 
108.57 
(12.63) 
WPPSI 
Performance IQ 
Treated SGTF 
150 
107.75 
(14.33) 
Untreated SGTF 
116 
106.96 
(14.44) 
WPPSI Full scale IQ Treated SGTF 
150 
110.70 
(12.17) 
Untreated SGTF 
116 
109.00 
(13.54) 
Note. *Adjusted for child gender, mother age at time of consent into CATS I, 
and social deprivation quintile. Standard deviations appear in parentheses 
below means.  
 
The unadjusted MANOVA identified a non-significant difference between the treated and 
untreated SGTF subclinical hypothyroid group; ROY = .018, F (3, 263) = 1.570, p = .197, p2 
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= .018. The adjusted MANCOVA was also non-significant; ROY = .019, F (3, 259) = 1.624, p 
= .184, p2 = .018.  
Within this subclinical hypothyroid group, there were some participants with T4 in the lower 
ranges (2.5-10th percentiles), of which 25 were from the untreated SGTF and 30 from the 
treated SGTF group. See table 3 for further descriptive statistics. 
Table 3 
Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK at Age 3 in the those classified as having 
Subclinical Hypothyroidism with low T4 
 CATS GROUP Adjusted Data* 
N Mean 
WPPSI Verbal IQ Treated SGTF 
30 
112.57 
(11.49) 
Untreated SGTF 
25 
107.20 
(13.60) 
WPPSI 
Performance IQ 
Treated SGTF 
30 
109.47 
(15.98) 
Untreated SGTF 
25 
109.88 
(12.54) 
WPPSI Full scale IQ Treated SGTF 
30 
112.83 
(13.61) 
Untreated SGTF 
25 
109.88 
(12.65) 
Note. *Adjusted for child gender, mother age at time of consent into CATS I, 
and social deprivation quintile. Standard deviations appear in parentheses 
below means.  
 
The unadjusted MANOVA identified a non-significant difference between the treated and 
untreated SGTF subclinical hypothyroid, low T4, group; ROY = .064, F (3, 51) = 1.091, p = 
.362, p2 = .060. The adjusted MANCOVA was also non-significant; ROY = .074, F (3, 48) = 
1.181, p = .327, p2 = .069.  
These exploratory statistics revealed, that within the CATS I UK cohort, treatment made no 
benefit to IQ scores at age 3 of offspring born to mothers with subclinical hypothyroidism. 
Hypothyroxinemia 
Hypothyroxinemia was also explored in the CATS I cohort. When exploring T4 < 10th 
percentile with TSH < 97.5th percentile, 259 participants populated this group (untreated 
SGTF = 125, treated SGTF = 134). See table 4 for further descriptive statistics.  
Table 4 
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Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK at Age 3 in the those classified as having 
Hypothyroxinemia 
 CATS GROUP Adjusted Data* 
N Mean 
WPPSI Verbal IQ Treated SGTF 
134 
106.62 
(10.69) 
Untreated SGTF 
125 
106.20 
(12.65) 
WPPSI 
Performance IQ 
Treated SGTF 
134 
104.76 
(12.73) 
Untreated SGTF 
125 
104.39 
(13.94) 
WPPSI Full scale IQ Treated SGTF 
134 
106.55 
(11.09) 
Untreated SGTF 
125 
106.10 
(13.01) 
Note. *Adjusted for child gender, mother age at time of consent into CATS I, 
and social deprivation quintile. Standard deviations appear in parentheses 
below means.  
 
The unadjusted MANOVA identified a non-significant difference between the treated and 
untreated SGTF hypothyroxinemic group (T4 <10th percentile); ROY = .001, F (3, 255) = .034, 
p = .992, p2 = .001. The adjusted MANCOVA was also non-significant; ROY = .001, F (3, 252) 
= .060, p = .981, p2 = .001.  
T4 < 2.5th percentile in the hypothyroxinemic group identified a reduced dataset of 237 
(untreated SGTF 116, treated SGTF = 121). See table 5 for further descriptive details.  
Table 5 
Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK at Age 3 in the those classified as having 
Hypothyroxinemia with T4 < 2.5th percentile 
 CATS GROUP Adjusted Data* 
N Mean 
WPPSI Verbal IQ Treated SGTF 
121 
106.92 
(10.63) 
Untreated SGTF 
116 
105.97 
(12.78) 
WPPSI 
Performance IQ 
Treated SGTF 
121 
104.93 
(12.73) 
Untreated SGTF 
116 
104.17 
(14.19) 
WPPSI Full scale IQ Treated SGTF 
121 
106.81 
(11.32) 
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Untreated SGTF 
116 
105.86 
(13.24) 
Note. *Adjusted for child gender, mother age at time of consent into CATS I, 
and social deprivation quintile. Standard deviations appear in parentheses 
below means.  
 
 
The unadjusted MANOVA identified a non-significant difference between the treated and 
untreated SGTF hypothyroxinemic group (T4 <2.5th percentile); ROY = .002, F (3, 233) = 
.186, p = .906, p2 = .002. The adjusted MANCOVA was also non-significant; ROY = .003, F 
(3, 230) = .218, p = .884, p2 = .003.  
These exploratory statistics revealed, that within the CATS I UK cohort, treatment made no 
benefit to IQ scores at age 3 of offspring born to mothers with hypothyroxinemia. 
Sub-group of CATS I; subclinical hypothyroidism and hypothyroxinemia 
A large sub-group comprised of hypothyroxinemia (T4 < 10th percentile and TSH < 97.5th 
percentile) and subclinical hypothyroidism (T4 2.5-10th percentile and TSH > 97.5th 
percentile) was populated by 314 participants (untreated SGTF = 150, treated SGTF = 164). 
This sub-group had age 3 IQs compared by unadjusted (MANOVA) and adjusted (MANCOVA) 
multivariate statistics; adjustments were made for child gender, mother age at time of 
consent into CATS I, and social deprivation. Descriptive statistics were presented firstly in 
table 6.  
Table 6 
Intelligent Quotient (IQ) Means for Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI)-III, UK at Age 3 in the sub-group in CATS I UK data 
 CATS GROUP Adjusted Data* 
N Mean 
WPPSI Verbal IQ Treated SGTF 164 107.71 
(11.04) 
Untreated SGTF 150 106.37 
(12.77) 
WPPSI 
Performance IQ 
Treated SGTF 164 105.62 
(13.45) 
Untreated SGTF 150 105.31 
(13.83) 
WPPSI Full scale IQ Treated SGTF 164 107.70 
(11.80) 
Untreated SGTF 150 106.73 
(12.99) 
Note. *Adjusted for child gender, mother age at time of consent into CATS I, 
and social deprivation quintile. Standard deviations appear in parentheses 
below means.  
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The unadjusted MANOVA identified a non-significant difference between the treated and 
untreated SGTF sub-group; ROY = .003, F (3, 310) = .359, p = .782, p2 = .003. The adjusted 
MANCOVA was also non-significant; ROY = .005, F (3, 307) = .466, p = .706, p2 = .005.  
Conclusion 
The exploratory analyses of difference reference ranges of T4 and TSH did not reveal any 
statistically significant results between those that were treated or untreated for underactive 
thyroid function during pregnancy. As no control group of normal thyroid function during 
pregnancy was tested at age 3, I am unable to conclude whether overt hypothyroidism, 
subclinical hypothyroidism or hypothyroxinemia had an effect on offspring IQ in the CATS I 
UK cohort. Haddow et al. (2) included a sub-group of women who were treated for 
gestational subclinical hypothyroidism, and compared to those that were untreated, there 
were no cognitive difference between the offspring. Willoughby et al. (3, 4) also included 
participants who were treated for gestational subclinical hypothyroidism, but these 
individuals were compared to participants with normal thyroid function; therefore, I am 
unable to compare results here.  
These findings support the CATS I publication (5) and the continuous mean analyses in 
chapter 1.2., as further exploration into the SGTF groups revealed no significant differences 
for differing reference ranges of T4 and TSH.  
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Appendix 10: Supplementary CATS II behavioural questionnaire statistics 
This supplementary analysis explored the effect of treatment during gestation in the treated 
SGTF group who participated in CATS II. Firstly, I analysed how the T4 and TSH changed over 
the three time points; consent into CATS I, 6 weeks post consent, and 30 weeks gestation. 
Descriptive statistics for T4 and TSH were presented firstly, followed by a repeated measures 
ANOVA to identify any differences between the three time points. Women from the treated 
SGTF group were identified as over-treated during their pregnancies if their T4 values were 
> 97.5th of the entire CATS cohort (T4 > 17.7 pmol/L) following initiation of levothyroxine 
therapy; i.e. at either 6 weeks post consent, or at 30 weeks gestation. These over-treated 
individuals were compared to the rest of the CATS II cohort for behavioural questionnaire 
scores.  
Thyroid function results during pregnancy 
Table 1 displays the current reference ranges for thyroid function per trimester. CATS I took 
blood samples at the end of the first trimester, six weeks post this point (arguably in the 
second trimester), and at 30 weeks consent (third trimester). There is no data available for 
reference ranges at this time, however, as CATS was such a large cohort study, any reference 
ranges available would have been based on smaller cohorts (around 100 women).  
Table 43 
Current Reference Ranges 
Thyroid  Pregnancy Normal range 
T4 1st trimester 10.5-18.3 
 2nd trimester 9.5-15.9 
 3rd trimester 8.6-13.7 
TSH 1st trimester 0.09-2.84 
 2nd trimester 0.18-2.81 
 3rd trimester 0.30-2.92 
 
T4 
Table 2 displays the descriptive statistics of T4 during pregnancy for the treated SGTF group. 
Table 3 summarises the results from the repeated measure ANOVA and identified that all 
three time points were significantly different from one another. Figure 1 is a boxplot of the 
mean T4 values at the three time points, with the current T4 trimester normal references 
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ranges in red. This boxplot highlights how at the second and third CATS I time points, women 
were potentially over-treated with levothyroxine.  
Table 2 
Descriptive Statistics of T4 Throughout the Treated SGTF 
Mothers’ Pregnancies 
Time point Mean Std. Deviation N 
T4 measurement taken at 
consent into CATS I 
(1) 
11.9243 1.93103 115 
T4 measurement taken 6 
weeks following consent  
(2) 
16.2800 2.94631 115 
T4 measurement taken at 
30 weeks gestation  
(3) 
15.4800 2.33024 115 
 
Table 3 
Pairwise Comparisons of T4 at the Three Time Points Throughout the Treated SGTF Mothers’ 
Pregnancies 
(I) factor1 (J) factor1 Mean 
Difference (I-J) 
Std. Error Sig.** 95% Confidence Interval for 
Difference 
Lower Bound Upper Bound 
1 
2 -4.356* .297 .001 -5.077 -3.635 
3 -3.556* .258 .001 -4.182 -2.929 
2 
1 4.356* .297 .001 3.635 5.077 
3 .800* .236 .003 .227 1.373 
3 
1 3.556* .258 .001 2.929 4.182 
2 -.800* .236 .003 -1.373 -.227 
Note. Based on estimated marginal means. *The mean difference is significant at the .05 level. 
**Adjustment for multiple comparisons: Bonferroni. 1= T4 measurement taken at consent into 
CATS I. 2= T4 measurement taken 6 weeks following consent. 3= T4 measurement taken at 30 
weeks gestation. 
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Figure 1 
Boxplot of T4 Values during Pregnancy of the Treated SGTF Group 
 
Note. Red bars display the current reference ranges per trimester for T4 values.  
TSH 
Table 4 displays the descriptive statistics of TSH during pregnancy for the treated SGTF group. 
Table 5 summarises the results from the repeated measure ANOVA and identified that only 
TSH at time of consent into CATS I was significantly different to time point 2 and 3; this 
indicates that TSH was corrected and reduced with levothyroxine therapy. As time points 2 
and 3 were not significantly different, this displays how any adjustments to levothyroxine 
therapy at this time did not have a substantial effect on TSH; however, T4 did significantly 
change. Figure 2 displays the means of TSH presented by a box plot with normal current TSH 
reference ranges plotted; time points 2 and 3 in CATS I indicate women to be in the lower 
portion of the reference range. This suggests that dosage of levothyroxine was centred on 
TSH levels, rather than T4. 
  
18.3 
8.6 
13.7 
9.5 
15.9 
10.5 
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Table 4 
Descriptive Statistics of TSH Throughout the Treated SGTF 
Mothers’ Pregnancies 
Time point Mean Std. Deviation N 
TSH measurement taken 
at consent into CATS  
(1) 
4.218522 3.9876989 115 
TSH measurement taken 
6 weeks following 
consent  
(2) 
.693478 .8730035 115 
TSH measurement taken 
at 30 weeks gestation  
(3) 
.615565 .8741725 115 
 
Table 5 
Pairwise Comparisons of TSH at the Three Time Points Throughout the Treated SGTF Mothers’ 
Pregnancies 
(I) factor1 (J) factor1 Mean 
Difference (I-J) 
Std. Error Sig.** 95% Confidence Interval for 
Difference 
Lower Bound Upper Bound 
1 
2 3.525* .342 .001 2.694 4.356 
3 3.603* .344 .001 2.767 4.439 
2 
1 -3.525* .342 .001 -4.356 -2.694 
3 .078 .066 .714 -.082 .238 
3 
1 -3.603* .344 .001 -4.439 -2.767 
2 -.078 .066 .714 -.238 .082 
Note. Based on estimated marginal means. *The mean difference is significant at the .05 level. 
**Adjustment for multiple comparisons: Bonferroni. 1= T4 measurement taken at consent into 
CATS I. 2= T4 measurement taken 6 weeks following consent. 3= T4 measurement taken at 30 
weeks gestation. 
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Figure 2 
Boxplot of TSH Values during Pregnancy of the Treated SGTF Group 
 
 
Note. As shown in the repeated measures ANOVA, there is no sig. difference between 6wks 
and 30wks. Red bars display the current reference ranges per trimester for T4 values.   
Over-treatment in CATS 
Those who were over-treated during their pregnancies (T4 > 17.7 pmol/L at 6 weeks post 
consent and 30 weeks gestation) were compared by a MANCOVA to the rest of the CATS II 
cohort and secondly to the rest of the treated SGTF group; adjustments were made for child 
gender, mother age at time of consent into CATS I, whether the mother breastfed over one 
month, and social deprivation. 
There were 33 (28%) of the treated SGTF group that were over-treated during their 
pregnancies at 6 weeks post consent. Those offspring with maternal T4 > 17.7 pmol/L were 
compared to the rest of the CATS II cohort and were found to have significantly higher ADHD 
Overactivity scores (p = .008 [95% CI: 0.322, 2.103]), and SCQ total score was not significantly 
0.09 
2.84 2.81 
0.18 
2.92 
0.30 
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different (p = .269) (see table 6 for adjusted means and SDs). When comparing maternal T4 
> 17.7 pmol/L within the treated SGTF group for ADHD Overactivity and SCQ total, the 
MANCOVA was not significant (Roy’s largest root = .023, F (2,112) = 1.280, p = .282, p2 = 
.022); see table 7 for adjusted means and SDs.  
 
Table 6 
Mean scores of selected CATS II questionnaires; maternal T4 > 17.7 
pmol/L at 6 weeks post initiation of levothyroxine therapy compared to 
the rest of the CATS II cohort  
 T4 > 17.7 pmol/L* Mean N 
SCQ Mean 
no** 
4.42 
(3.74) 
432 
yes 
5.09 
(4.86) 
33 
Total 
4.47 
(3.83) 
465 
ADHD Overactivitity 
Mean 
no 
2.29 
(2.52) 
432 
yes 
3.50 
(3.50) 
33 
Total 
2.38 
(2.62) 
465 
Note. *At six weeks post initiation of levothyroxine therapy. **No=rest 
of CATS II study group. Standard deviations appear in parenthesis 
below means. SCQ= Social Communication Questionnaire. 
 
Table 7 
Mean scores of selected CATS II questionnaires; maternal T4 > 17.7 
pmol/L at 6 weeks post initiation of levothyroxine therapy within in the 
treated SGTF group  
 T4 > 17.7 pmol/L* Mean N 
SCQ Mean 
no** 
5.15 
(4.63) 
86 
yes 
5.09 
(4.86) 
33 
Total 
5.13 
(4.68) 
119 
ADHD 
Overactivitity 
Mean 
no 
2.68 
(2.86) 
86 
yes 
3.50 
(3.50) 
33 
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Total 
2.90 
(3.06) 
119 
Note. *At six weeks post initiation of levothyroxine therapy. **No=rest 
of CATS II study group. Standard deviations appear in parenthesis 
below means. SCQ= Social Communication Questionnaire. 
 
At 30 weeks gestation, 21 (18%) of the treated SGTF group were over-treated; 13 of which 
were also over-treated from 6 weeks post consent. ADHD Overactivity was significantly 
higher in the over-treated group compared to the rest of the CATS II cohort (p = .004, [95% 
CI: 0.542, 2.746]), SCQ total score was not (p = .241); see table 8 for means and SDs. At the 
multivariate level, SCQ total score and ADHD Overactivity were not significantly different 
between those who were over-treated during pregnancy at 30 weeks gestation, and the rest 
of the treated SGTF group (Roy’s largest root = .033, F (2,112) = 1.866, p = .160, p2 = .032); 
see table 9 for means and SDs.  
Table 8 
Mean scores of selected CATS II questionnaires; maternal T4 > 17.7 
pmol/L at 30 weeks gestation compared to the rest of the CATS II cohort
  
 T4 > 17.7 pmol/L* Mean N 
SCQ Mean 
no** 
4.43 
(3.74) 
444 
yes 
5.31 
(5.40) 
21 
Total 
4.47 
(3.83) 
465 
ADHD 
Overactivitity 
Mean 
no 
2.30 
(2.54) 
444 
yes 
4.00 
(3.67) 
21 
Total 
2.38 
(2.62) 
465 
Note. *At 30 weeks post initiation of levothyroxine therapy. **No=rest 
of CATS II study group. Standard deviations appear in parenthesis 
below means. SCQ= Social Communication Questionnaire. 
 
Table 9 
Mean scores of selected CATS II questionnaires; maternal T4 > 17.7 
pmol/L at 30 weeks post initiation of levothyroxine therapy within in 
the treated SGTF group  
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 T4 > 17.7 pmol/L* Mean N 
SCQ Mean 
no** 
5.05 
(4.53) 
99 
yes 
5.53 
(5.44) 
20 
Total 
5.13 
(4.68) 
119 
ADHD Overactivitity 
Mean 
no 
2.65 
(2.87) 
99 
yes 
4.15 
(3.70) 
20 
Total 
2.90 
(3.06) 
119 
Note. *At 30 weeks post initiation of levothyroxine therapy. **No=rest 
of CATS II study group. Standard deviations appear in parenthesis 
below means. SCQ= Social Communication Questionnaire. 
 
ADHD Overactivity prevalence 
The prevalence of ADHD Overactivity was explored in this section. This included exploring 
scores > 1 SD and 2 SDs in participants from the treated SGTF group with maternal T4 > 17.7, 
compared to the untreated SGTF group, and selected individuals from the normal GTF group 
with T4 and TSH within the 10-90th percentiles. 
Scores between these three groups were explored firstly by a chi-square, and significant 
differences were analysed by a logistic regression; this also allowed adjustment for the four 
covariates listed above. Following these analyses, mean scores of these three identified 
groups were explored by a ANOVA and ANCOVA; any significant difference identified were 
explored by a Bonferroni correction.  
ADHD Overactivity; prevalence >1SD 
Table 10 displays the chi-square results of offspring who scored > 1 SD for ADHD overactivity 
in CATS II. An unadjusted significant difference (p = .030) was identified between the three 
groups. This was explored further by regressions. Table 11 displays the model fitting data for 
the sub-group of the normal GTF compared to the T4 > 17.7 treated SGTF group; regression 
results following table 12, there was no significant difference between the groups. Table 13 
displays the model fitting data for the T4 > 17.7 treated SGTF group compared to the 
untreated SGTF group; the regression results in table 14 identified a non-significant 
difference for ADHD Overactivity scores > 1 SD. A possible reason that there was a significant 
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difference for the chi-square, and not the regressions, was that the regressions took account 
of adjustments.  
Table 10 
ADHD Overactivity scores > 1 SD per study group 
 ADHD Overactivity > 1 SD (%) 
Treated SGTF*  
(n =33) 
9  
(27%) 
Untreated SGTF  
(n = 106) 
26  
(24%) 
Normal GTF** 
(n = 189) 
26 
(14%) 
Pearson Chi-Square p=.030*** 
Note. Scores were from the Child ADHD Questionnaire. Percentages of 
scores per group are appear in parentheses below totals. *only those with 
T4 > 17.7. **only those with T4 and TSH between the 10-90th percentile. 
***Significance < .05.  SGTF=suboptimal gestational thyroid function. 
 
 
Table 11 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
119.517 
   
Final 110.761 8.756 5 .119 
Note. See improved figure for -2 Log Likelihood. Df=degrees 
of freedom. 
 
Table 12 
Main Output from Multinomial Logistic Regression, ADHD Overactivity > 1 SD; sub-group 
of the normal GTF compared to the T4 > 17.7 pmol/L treated SGTF 
ADHD 
Overactivity 
> 1 SD 
B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
       Lower Upper 
Gender -.626 .391 2.565 1 .109 .535 .249 1.150 
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Breastfed 
>1mns 
-.427 .393 1.185 1 .276 .652 .302 1.408 
Mother age .050 .185 .074 1 .785 1.052 .732 1.510 
Social 
deprivation 
-.132 .143 .853 1 .356 .876 .662 1.160 
[Normal 
GTF*] 
-.879 .462 3.616 1 .057 .415 .168 1.027 
[Treated 
SGTF**] 
0 . . 0 . . . . 
Note. The reference category was ADHD Overactivity < 1 SD. *sub-group of the normal 
GTF (10-90th percentile). **only those with T4 > 17.7 pmol/L. SGTF=suboptimal gestational 
thyroid function, B=beta, df=degrees of freedom. 
 
Table 13 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
121.058 
   
Final 111.314 9.744 5 .083 
Note. See improved figure for -2 Log Likelihood. Df=degrees 
of freedom. 
 
Table 14 
Main Output from Multinomial Logistic Regression, ADHD Overactivity > 1 SD; T4 > 17.7 
pmol/L treated SGTF compared to the untreated SGTF  
ADHD 
Overactivity 
> 1 SD 
B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
       Lower Upper 
Gender -.617 .401 2.362 1 .124 .540 .246 1.185 
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Breastfed 
>1mns 
-.749 .440 2.896 1 .089 .473 .200 1.120 
Mother age -.035 .205 .029 1 .864 .966 .647 1.442 
Social 
deprivation 
-.215 .148 2.118 1 .146 .807 .604 1.077 
[Treated 
SGTF*] 
.244 .480 .259 1 .611 1.277 .498 3.272 
[Untreated 
SGTF] 
0 . . 0 . . . . 
Note. The reference category was ADHD Overactivity < 1 SD. *only those with T4 > 17.7 
pmol/L. ***Significance < .05. SGTF=suboptimal gestational thyroid function, B=beta, 
df=degrees of freedom. 
 
Those from the treated SGTF group with T4 > 17.7 pmol/L at 6 weeks post initiation of 
levothyroxine therapy had the highest percentage of offspring scoring > 1 SD for ADHD 
Overactivity. Scores were significantly different between groups however, following 
adjustments there was no difference.  
ADHD Overactivity; prevalence >2SD 
Table 15 displays the chi-square results of offspring who scored > 2 SD for ADHD overactivity 
in CATS II. An unadjusted significant difference (p = .023) was identified between the three 
groups. This was explored further by regressions. Table 16 and 17 display the model fitting 
data and regression for the sub-group of the normal GTF compared to the T4 > 17.7 treated 
SGTF group. The regression revealed that the T4 > 17.7 treated SGTF group were 1.59 times 
more likely to score > 2 SD compared to the sub-group normal GTF group (p = .015). Table 
18 and 19 display the model fitting data for the T4 > 17.7 treated SGTF group compared to 
the untreated SGTF group and the regression results; which were non-significant.  
Table 15 
ADHD Overactivity scores > 2 SD per study group 
 ADHD Overactivity > 2 SD (%) 
Treated SGTF*  
(n =33) 
5  
(15%) 
Untreated SGTF  
(n = 106) 
5  
(5%) 
Normal GTF** 
(n = 189) 
7 
(4%) 
Pearson Chi-Square p=.023*** 
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Note. Scores were from the Child ADHD Questionnaire. Percentages of 
scores per group are appear in parentheses below totals. *only those with 
T4 > 17.7 pmol/L. **only those with T4 and TSH between the 10-90th 
percentile. ***Significance < .05.  SGTF=suboptimal gestational thyroid 
function. 
 
Table 16 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
68.624 
   
Final 58.877 9.747 5 .083 
Note. See improved figure for -2 Log Likelihood. Df=degrees 
of freedom. 
 
Table 17 
Main Output from Multinomial Logistic Regression, ADHD Overactivity > 2 SD; sub-group 
of the normal GTF compared to the T4 > 17.7 pmol/L treated SGTF 
ADHD 
Overactivity 
> 2 SD 
B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
       Lower Upper 
Gender 1.198 .709 2.855 1 .091 3.314 .826 13.298 
Breastfed 
>1mns 
.287 .647 .197 1 .657 1.332 .375 4.737 
Mother age .018 .310 .003 1 .954 1.018 .554 1.870 
Social 
deprivation 
.101 .232 .191 1 .662 1.106 .702 1.743 
[Normal 
GTF*] 
1.588 .656 5.866 1 .015*** 4.896 1.354 17.703 
[Treated 
SGTF**] 
0 . . 0 . . . . 
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Note. The reference category was ADHD Overactivity < 2 SD. *sub-group of the normal 
GTF (10-90th percentile). **only those with T4 > 17.7 pmol/L. ***Significance < 0.05. 
SGTF=suboptimal gestational thyroid function, B=beta, df=degrees of freedom. 
 
Table 18 
Table Displaying the Regression Model’s Fit for the Data 
Model Model 
Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log 
Likelihood 
Chi-
Square 
df Sig. 
Intercept 
Only 
59.849 
   
Final 50.221 9.629 5 .086 
Note. See improved figure for -2 Log Likelihood. Df=degrees 
of freedom. 
 
Table 19 
Main Output from Multinomial Logistic Regression, ADHD Overactivity > 2 SD; T4 > 17.7 
pmol/L treated SGTF compared to the untreated SGTF  
ADHD 
Overactivity 
> 2 SD 
B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 
Interval for Exp(B) 
       Lower Upper 
Gender .472 .686 .472 1 .492 1.603 .418 6.151 
Breastfed 
>1mns 
.757 .789 .920 1 .338 2.132 .454 10.017 
Mother age .638 .425 2.253 1 .133 1.893 .823 4.356 
Social 
deprivation 
.024 .252 .009 1 .924 1.024 .625 1.679 
[Treated 
SGTF*] 
-1.199 .702 2.915 1 .088 .302 .076 1.194 
[Untreated 
SGTF] 
0 . . 0 . . . . 
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Note. The reference category was ADHD Overactivity < 2 SD. *only those with T4 > 17.7 
pmol/L. ***Significance < .05. SGTF=suboptimal gestational thyroid function, B=beta, 
df=degrees of freedom. 
 
Those from the treated SGTF group with T4 > 17.7 pmol/L at 6 weeks post initiation of 
levothyroxine therapy had the highest percentage of offspring scoring > 2 SD for ADHD 
Overactivity; around three times more participants meet the 2 SD threshold compared to the 
sub-group of the normal GTF and the untreated SGTF groups. The regressions identified that 
the T4 > 17.7 pmol/L treated SGTF group were significantly more likely to meet the threshold 
compared to the sub-group normal GTF; interactions to the untreated SGTF group were non-
significant.  
Over-treated SGTF group mean ADHD Overactivity scores  
As discussed in the main body of the thesis, binary outcomes are susceptible to type-1 errors, 
therefore I also explored continuous mean scores for significant differences between the T4 
> 17.7 pmol/L treated SGTF, untreated SGTF and also the sub-group normal GTF group. 
Descriptive statistics of means and SDs are presented firstly (table 20), followed by the 
unadjusted ANOVA, and adjusted ANCOVA for ADHD Overactivity scores.  
Table 20 
Mean scores for ADHD Overactivity in CATS II 
 CATS GROUP N Mean 
ADHD Overactivity 
Mean 
Treated SGTF* 33 3.50 
(3.50) 
Untreated SGTF 105 2.48 
(2.69) 
Normal GTF** 189 2.12 
(2.38) 
Note. *Only including those with T4 > 17.7 pmol/L at 6 weeks post initiation 
of levothyroxine therapy. **sub-group of the normal GTF; only including 
those with T4 and TSH between the 10-90th percentiles. Standard deviations 
appear in parentheses below means.  
 
The unadjusted ANOVA revealed a significant difference between the groups for mean ADHD 
Overactivity score; F (2, 325) = 4.061, p = .018, p2 = .024.  Post hoc analysis (Bonferroni 
corrected) identified that the treated SGTF (only those with T4 > 17.7 pmol/L at 6 weeks post 
initiation of levothyroxine therapy) was significantly higher than the normal GTF sub-group; 
p = .017 (95% CI [.184, 2.231]); all other group interactions were p > .05. The adjusted 
ANCOVA was also significant; F (2, 320) = 4.100, p = .017, p2 = .025. Similar to the ANOVA, 
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post hoc analysis revealed it was the treated SGTF to normal GTF sub-groups that had 
significantly different results; with the treated SGTF scoring higher (p = .014, 95% CI [.214, 
2.538]), see table 21 for further details.  
Table 21 
Pairwise comparisons of adjusted ANCOVA exploring ADHD Overactivty mean scores 
between groups. 
  Mean 
Difference  
Std. 
Error 
Sig.** 95% Confidence 
Interval for Difference 
Lower 
Bound 
Upper 
Bound 
normal GTF 
treated SGTF -1.376 .483 .014* -2.538 -.214 
untreated SGTF -.297 .312 1.000 -1.048 .453 
treated SGTF 
normal GTF 1.376 .483 .014* .214 2.538 
untreated SGTF 1.078 .509 .105 -.147 2.304 
untreated SGTF 
normal GTF .297 .312 1.000 -.453 1.048 
treated SGTF -1.078 .509 .105 -2.304 .147 
Note. *The mean difference is significant at the .05 level. SGTF=suboptimal gestational 
thyroid function. **Adjustment for multiple comparisons: Bonferroni. 
 
These statistics support the logistic regression exploring ADHD Overactivity scores > 2 SDs, 
as significant differences persistently appeared between the T4 > 17.7 pmol/L treated SGTF 
and the normal GTF sub-groups. 
Conclusion 
Overall, we have identified within the CATS II cohort that treatment for underactive thyroid 
function during pregnancy has resulted in offspring having more ADHD Overactivity and 
autism-type behaviours, though not clinically significant. One of the reasons could be that 
just under a third of the mothers in CATS II were over-treated with levothyroxine during their 
pregnancies, which identifies a need for clinicians to closely monitor dosage levels during the 
gestation period.  
